<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cervical-pregnancy">Cervical pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cervical-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Cervical pregnancy often presents as the cervical stage of a spontaneous miscarriage. Occasionally, it is possible to remove the conceptus by curettage but haemorrhage can be severe, and in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of cases it is necessary to proceed to hysterectomy to obtain adequate haemostasis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="trophoblastic-disease">TROPHOBLASTIC DISEASE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#trophoblastic-disease" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Abnormality of early trophoblast may arise as a developmental anomaly of placental tissue, and results in the formation of a mass of oedematous and avascular villi. There is usually no fetus but the condition can be found in the presence of a fetus. The placenta is replaced by a mass of grapelike vesicles known as a hydatidiform mole (Fig. 18.10).</p>
<p>Invasion of the myometrium without systemic spread occurs in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>16</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">16 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">16%</span></span></span></span></span> of cases of benign mole, and is known as invasive mole or chorioadenoma destruens. Frankly malignant change occurs in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2.5%</span></span></span></span></span> of cases, and is known as choriocarcinoma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="incidence">Incidence<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#incidence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The overall prevalence of this condition is about 1.5 in 1000 pregnancies in the UK, but is much higher in Asia and South-east Asia. It is relatively more common at the extremes of reproductive age.</p>
<p><img src="assets/images/image-20251213-fa727896.jpeg" alt="img-200.jpeg"></p>
<p>Fig. 18.10 Vesicles of a hydatiform mole.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pathology">Pathology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pathology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Molar pregnancy is thought to arise from fertilization by two sperm, and can be diploid with no female genetic material (complete mole) or it may exhibit triploidy (partial mole). Benign mole remains confined to the uterine cavity and decidua. The histopathology exhibits a villous pattern, which is also found in the invasive. However, invasive molar tissue penetrates the myometrium deeply and may result in serious haemorrhage. Choriocarcinoma comprises plexiform columns of trophoblastic cells without villous patterns. Widespread blood-borne metastases are a feature of this disease which, until recent years, carried a very high mortality rate. Metastases may occur locally in the vagina but most commonly appear in the lungs. Theca lutein cysts occur in about one-third of all cases as a result of high circulating levels of hCG. These regress spontaneously with removal of the molar tissue. Fifty percent of cases of choriocarcinoma are not associated with molar pregnancy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-presentation">Clinical presentation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-presentation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Molar pregnancy most commonly presents as bleeding in the first half of pregnancy, and spontaneous miscarriage often occurs at about 20 weeks gestation. Occasionally, the passage of a grape-like villus heralds the presence of a mole. The uterus is larger than dates in about half the cases, but this is not a reliable sign as it may sometimes be small for dates. Severe hyperemesis, pre-eclampsia and unexplained anaemia are all factors suggestive of this disorder. The diagnosis can be confirmed by ultrasound scan and by the presence of very high levels of hCG in the blood or urine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management">Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Once the diagnosis is established, the pregnancy is terminated by suction curettage. Adequate replacement of
blood loss is essential. Although there is an increased risk of blood loss there is a theoretical concern over the routine use of oxytocic agents because of the potential to disseminate trophoblastic tissue through the venous system. If possible these should be commenced once the evacuation has been completed. Occasionally repeat evacuation may be required if there is persistent bleeding or a raised serum hCG, but routine second evacuation is not helpful. All cases of molar pregnancy in the UK should be registered with one of the trophoblastic disease screening centres who will arrange follow up. Serial estimations of hCG are followed for a period of 6 months or 2 years, initially every 2 weeks. If hCG levels reach normal within 8 weeks of evacuation of the mole follow-up will be for 6 months, otherwise follow-up will be for 2 years but in the second samples are collected at intervals of 3 months.</p>
<p>If the histological evidence shows malignant change, chemotherapy with methotrexate and actinomycin D is employed and produces good results. In the UK, management of these cases is concentrated in specialized centres.</p>
<p>It must be remembered that choriocarcinoma sometimes can occur following a miscarriage or a normal term intrauterine pregnancy.</p>
<p>Pregnancy is contraindicated until 6 months after the serum hCG levels fall to normal. Oestrogen-containing oral contraceptives and HRT can be used as soon as hCG levels are normal. The risk recurrence in subsequent pregnancies is 1 in 74 and serum hCG levels should be checked 6 weeks after any subsequent pregnancy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vomiting-in-early-pregnancy">VOMITING IN EARLY PREGNANCY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vomiting-in-early-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Nausea and vomiting are common symptoms in early pregnancy (affecting <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of women, respectively) usually starting between 4 and 10 weeks gestation, and resolving before 20 weeks. Symptoms persist beyond 20 weeks in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>13</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">13 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">13%</span></span></span></span></span> of cases but new symptoms appearing after the 12th week should not be attributed to hyperemesis. Hyperemesis gravidarum is defined as persistent pregnancy-related vomiting associated with weight loss of more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> of body mass and ketosis. Affecting <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mo>−</mo><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.3-3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> of all pregnant women, this is associated with dehydration, electrolyte imbalance and thiamine deficiency.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="trophoblastic-disease">Trophoblastic disease<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#trophoblastic-disease" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A 27-year-old primigravid woman attended the clinic with a history of 12 weeks of amenorrhoea, complaining of bright vaginal blood loss and lower abdominal discomfort. Abdominal examination revealed that the uterine fundus was 16 weeks in size. There was fresh blood in the vagina, and the cervical os was closed. There was a high titre of hCG in the urine, and an ultrasound scan showed a snowstorm appearance with the uterine cavity filled with echoes but no evidence of fetal parts (Fig. 18.11). Suction evacuation of molar tissue was performed the following day, and recovery was uneventful.
<img src="assets/images/image-20251213-b14b66bf.jpeg" alt="img-201.jpeg"></p>
<p>Fig. 18.11 Hydatiform mole. The typical snowstorm appearance of molar tissue is apparent.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="aetiology">Aetiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aetiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The aetiology of hyperemesis is uncertain, with multifactorial causes such as endocrine, gastrointestinal and psychological factors proposed. Hyperemesis occurs more often in multiple pregnancy and hydatidiform mole, suggesting an association with the level of hCG. Although transient abnormalities of thyroid function are common this does not require treatment in the absence of other clinical features of hyperthyroidism. Infection with Helicobacter pylori, the organism implicated in gastric ulcers, may also contribute. Women with a previous history of hyperemesis are likely to experience it in subsequent pregnancies.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="diagnosis">Diagnosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diagnosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is important to ask about the frequency of vomiting, trigger factors and whether any other members of the family have been affected. A history of vomiting in a previous pregnancy or outside pregnancy should be sought. Smoking and alcohol can both exacerbate symptoms, and should be enquired of. If this pregnancy resulted from fertility treatment or there is a close family history of twins, a multiple pregnancy is more likely. Early pregnancy bleeding or a past history of trophoblastic disease may point to a hydatidiform mole.</p>
<p>The clinical features of dehydration include tachycardia, hypotension and loss of skin turgor. Causes of vomiting not due to pregnancy, such as thyroid problems, urinary tract infection or gastroenteritis, need to be excluded so the abdomen should be palpated for areas of tenderness, especially in the right upper quadrant, hypogastrium and renal angles. A dipstick analysis of the urine for ketones, blood or protein should be performed.</p>
<p>Routine investigations should include full blood count, electrolytes, liver and thyroid function tests. Elevated haematocrit, alterations in electrolyte levels and ketonuria are associated with dehydration. Urine should be sent for culture to exclude infection and an ultrasound arranged to look for multiple pregnancy or gestational trophoblastic disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management">Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>If the vomiting is mild to moderate and not causing signs of dehydration, then usually reassurance and advice will be all that is necessary.</p>
<p>Simple measures include:</p>
<ul>
<li>Taking small, carbohydrate meals and avoiding fatty foods.</li>
<li>Powdered ginger root or pyridoxine (vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>6</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{6}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ).</li>
<li>Avoiding large volume drinks, especially milk and carbonated drinks.</li>
<li>Raising the head of the bed if reflux is a problem.
A history of persistent, severe vomiting with evidence of dehydration requires admission to hospital for assessment and management of symptoms.</li>
</ul>
<p>Hypovolaemia and electrolyte imbalance should be corrected by intravenous fluids. These should be balanced electrolyte solutions or normal saline.</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<p>Thromboprophylaxis with compression stockings and low-molecular weight heparin should be considered. Most women will settle in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>24</mn><mo>−</mo><mn>48</mn></mrow><annotation encoding="application/x-tex">24-48</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">24</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">48</span></span></span></span></span> hours with these supportive measures. Once the vomiting has ceased, small amounts of fluid and eventually food can be re-introduced.</p>
<p>Anti-emetic therapy is reserved for those women who do not settle on supportive measures, or who persistently relapse. The use of anti-emetics in pregnancy received widespread publicity when links were found between thalidomide and severe malformations of children born to mothers who had taken the drug for morning sickness. Currently antihistamines are the recommended pharmacological for first-line treatment for nausea and vomiting, no anti-emetic being approved for treatment. Dopamine antagonists (metoclopramide) and phenothiazines (prochloperazine) have not been shown to be teratogenic in humans (though metoclopramide is in animals). 5HT-selective serotonin antagonists such as ondansetron has been used although patient safety data is limited, because it can be given as a wafer and provides an alternative to parenteral administration in patients unable to tolerate other oral therapy.</p>
<p>Vitamin supplements including thiamine should be given, particularly where hyperemesis has been prolonged. If vomiting continues, and the history is suggestive of
severe reflux or ulcer disease, endoscopy can be very valuable. It is a safe technique in pregnancy. If severe oesophagitis is confirmed then appropriate treatment with alginates and metoclopramide can be given. Ulcer disease will require H 2 antagonist treatment (ranitidine) or if very severe, omeprazole, though there is limited experience of this in pregnancy.</p>
<p>Very occasionally, women do not settle with a combination of the above measures. Some of these women may improve with steroid therapy, though trials are still ongoing. Women in whom there is liver function derangement may benefit particularly. H 2 antagonists must be given in conjunction with the steroid treatment. Parenteral nutrition is necessary for some that develop severe protein/ calories malnutrition. Specialized nutrition units can be very helpful in this setting.</p>
<p>If hyperemesis is left untreated the mother's condition worsens. Wernicke's encephalopathy is a complication associated with a lack of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">B_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (thiamine). Coma and death have been reported because of hepatic and renal involvement. Termination of pregnancy may reverse the condition and has a place in preventing maternal mortality. Hyperemesis persisting into the third trimester should be further investigated as it may be symptomatic of serious illness such as acute fatty liver of pregnancy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="essential-information">Essential information<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#essential-information" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="miscarriage">Miscarriage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscarriage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Pregnancy loss before 24 weeks</li>
<li>Complicates 10-20% of pregnancies</li>
<li>Commonly associated with chromosome abnormalities</li>
<li>Does not always require surgical treatment</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="recurrent-miscarriage">Recurrent miscarriage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#recurrent-miscarriage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Defined as 3 consecutive pregnancy losses</li>
<li>Investigations should include screening for antiphospholipid antibodies, chromosome abnormalities and PCOS</li>
<li>Chances of successful subsequent pregnancy more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> without any treatment</li>
<li>Women with antiphospholipid antibodies should be offered treatment with low dose aspirin and heparin</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ectopic-pregnancy">Ectopic pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ectopic-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> of pregnancies are ectopic</li>
<li>Most important cause of maternal death in early pregnancy</li>
<li>Atypical presentations are common</li>
<li>Commonest site for ectopic pregnancy is the ampullary region of the Fallopian tube</li>
<li>Can be accurately diagnosed by a combination of ultrasound and hCG measurement</li>
<li>Laparoscopic treatment is associated with lower morbidity</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="trophoblastic-disease">Trophoblastic disease<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#trophoblastic-disease" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Affects 1 in 650 pregnancies in the UK</li>
<li>Partial moles are triploid, complete moles diploid</li>
<li>Treated initially by surgical evacuation of the uterus</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of choriocarcinomas occur without a history of molar pregnancy</li>
<li>Requires follow-up with serial hCG measurement</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hyperemesis-gravidarum">Hyperemesis gravidarum<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hyperemesis-gravidarum" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Persistent vomiting starting before 20 weeks in pregnancy associated with weight loss and ketosis</li>
<li>Usually resolves in second trimester</li>
<li>May lead to encephalopathy, renal and hepatic failure</li>
<li>Hospital admission is indicated where there is evidence of dehydration or electrolyte imbalance</li>
</ul>
<p>This page intentionally left blank</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sexual-and-reproductive-health">Sexual and reproductive health<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sexual-and-reproductive-health" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Roger Pepperell</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="learning-outcomes">Learning outcomes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#learning-outcomes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter you should be able to:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="knowledge-criteria">Knowledge criteria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#knowledge-criteria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Describe the methods of contraception in terms of efficiency, benefits, risks and side effects</li>
<li>Describe the surgical and medical options for termination of pregnancy</li>
<li>Discuss the ethical and legal issues relating to fertility control</li>
<li>Describe the aetiology, diagnosis, prevention and management of the common sexually transmitted infections including HIV</li>
<li>Describe the aetiology, investigation and management of the common disorders of male and female sexual dysfunction</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-competencies">Clinical competencies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-competencies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Take a history in relation to contraceptive and sexual health needs</li>
<li>Explain the benefits, risks and side effects of different forms of contraception</li>
<li>Counsel a woman about using the combined oral contraceptive pill</li>
<li>Counsel a woman and her partner about permanent contraception</li>
<li>Counsel a women about emergency contraception</li>
<li>Plan appropriate investigation of men and women presenting with genital tract infections</li>
<li>Counsel a client about safe sexual behaviour</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="professional-skills-and-attitudes">Professional skills and attitudes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#professional-skills-and-attitudes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Reflect on the sexual health care needs of vulnerable groups, e.g. the young, commercial sex workers and drug abusers</li>
<li>Reflect on the psychosocial impact of sexually transmitted infections and unplanned pregnancy</li>
<li>Recognize the need to respect cultural and religious beliefs as well as sexual diversity</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraception-and-termination-of-pregnancy">CONTRACEPTION AND TERMINATION OF PREGNANCY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraception-and-termination-of-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The ability to control fertility by reliable artificial methods has transformed both social and epidemiological aspects of human reproduction. Family size is determined by a number of factors, including social and religious customs, economic aspirations, knowledge of contraception and the availability of reliable methods to regulate fertility.</p>
<p>Artificial methods of contraception act predominantly by the following pathways:</p>
<ul>
<li>inhibition of ovulation</li>
<li>prevention of implantation of the fertilized ovum</li>
<li>barrier methods of contraception, whereby the spermatozoa are physically prevented from gaining access to the cervix.
The effectiveness of any method of contraception is measured by the number of unwanted pregnancies that occur during 100 women years of exposure, i.e. during 1 year in 100 women who are normally fertile and are having regular coitus. This is known as the 'Pearl index' (Table 19.1).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="barrier-methods-of-contraception">Barrier methods of contraception<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#barrier-methods-of-contraception" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These techniques involve a physical barrier that reduces the likelihood of spermatozoa reaching the female upper genital tract. Barrier methods also offer protection against sexually transmitted infection (STIs). The relative risk of an STI-induced pelvic inflammatory disease (PID) is 0.6 for women using these methods. Women who use another method of contraception to prevent pregnancy are often advised to use a condom as well to reduce an otherwise increased risk of STI.</p>
<p>Table 19.1 Failure rates per 100 women for different methods of contraception</p>
<table><thead><tr><th style="text-align: center;"></th><th style="text-align: center;">USA data used by WHO: &lt;br&gt; % of women having an unintended pregnancy within the first year of use <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>a&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {a }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">a&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></th><th style="text-align: center;"></th><th style="text-align: center;">Oxford/FPA Study (all women married and aged above 25) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>b&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {b }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">b&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></th><th style="text-align: center;"></th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;">Typical use <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>a&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">^{\text {a }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">a&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Perfect use <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">†</mo></msup></mrow><annotation encoding="application/x-tex">^{\dagger}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">†</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Overall (any duration)</td><td style="text-align: center;">Age 25-34 ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≤</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">\leq 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≤</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> years use)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;Age&nbsp;</mtext><mn>35</mn><mo>+</mo></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mo stretchy="false">(</mo><mo>≤</mo><mn>2</mn><mtext>&nbsp;years&nbsp;use&nbsp;</mtext><mo stretchy="false">)</mo></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; \text { Age } 35+ \\ &amp; (\leq 2 \text { years use }) \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;Age&nbsp;</span></span><span class="mord">35</span><span class="mord">+</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mopen">(</span><span class="mrel">≤</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord">2</span><span class="mord text"><span class="mord">&nbsp;years&nbsp;use&nbsp;</span></span><span class="mclose">)</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Sterilization &lt;br&gt; Male (after azoospermia) &lt;br&gt; Female (Filshie clip)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.15</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.5</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 0.15 \\ &amp; 0.5 \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.15</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.5</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.1</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.5</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 0.1 \\ &amp; 0.5 \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.1</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.5</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.02</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.13</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 0.02 \\ &amp; 0.13 \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.02</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.13</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.08</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.45</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 0.08 \\ &amp; 0.45 \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.08</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.45</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.08</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.08</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 0.08 \\ &amp; 0.08 \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.08</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.08</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Subcutaneous implant Nexplanon <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>®&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {® }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9852em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9852em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord accent mtight"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8889em;"><span style="top: -2.7em;"><span class="pstrut" style="height: 2.7em;"></span><span class="mord mtight"><span class="mord">R</span></span></span><span style="top: -2.8944em;"><span class="pstrut" style="height: 2.7em;"></span><span class="accent-body accent-full" style="left: 0em; top: 0.2em;"><span class="mord mtight">◯</span></span></span></span></span></span></span><span class="mord mtight">&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">0.05</td><td style="text-align: center;">0.05</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Injectable (DMPA)</td><td style="text-align: center;">3</td><td style="text-align: center;">0.3</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Combined pills &lt;br&gt; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> oestrogen &lt;br&gt; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>50</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;50 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> oestrogen</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>8</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>8</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 8 \\ &amp; 8 \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">8</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">8</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.3</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.3</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 0.3 \\ &amp; 0.3 \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.3</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.3</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.16</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.27</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 0.16 \\ &amp; 0.27 \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.16</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.27</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.25</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.38</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 0.25 \\ &amp; 0.38 \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.25</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.38</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.17</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.23</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 0.17 \\ &amp; 0.23 \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.17</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.23</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Evra <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>®&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {® }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9852em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9852em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord accent mtight"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8889em;"><span style="top: -2.7em;"><span class="pstrut" style="height: 2.7em;"></span><span class="mord mtight"><span class="mord">R</span></span></span><span style="top: -2.8944em;"><span class="pstrut" style="height: 2.7em;"></span><span class="accent-body accent-full" style="left: 0em; top: 0.2em;"><span class="mord mtight">◯</span></span></span></span></span></span></span><span class="mord mtight">&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> patch</td><td style="text-align: center;">8</td><td style="text-align: center;">0.3</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">NuvaRing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>®&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {® }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9852em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9852em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord accent mtight"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8889em;"><span style="top: -2.7em;"><span class="pstrut" style="height: 2.7em;"></span><span class="mord mtight"><span class="mord">R</span></span></span><span style="top: -2.8944em;"><span class="pstrut" style="height: 2.7em;"></span><span class="accent-body accent-full" style="left: 0em; top: 0.2em;"><span class="mord mtight">◯</span></span></span></span></span></span></span><span class="mord mtight">&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">8</td><td style="text-align: center;">0.3</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Cerazette <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>®&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {® }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9852em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9852em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord accent mtight"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8889em;"><span style="top: -2.7em;"><span class="pstrut" style="height: 2.7em;"></span><span class="mord mtight"><span class="mord">R</span></span></span><span style="top: -2.8944em;"><span class="pstrut" style="height: 2.7em;"></span><span class="accent-body accent-full" style="left: 0em; top: 0.2em;"><span class="mord mtight">◯</span></span></span></span></span></span></span><span class="mord mtight">&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> progestogen-only pill</td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>0.17</mn><mo lspace="0em" rspace="0em">†</mo></msup></mrow><annotation encoding="application/x-tex">0.17^{\dagger}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">0.1</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">†</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Old-type POP</td><td style="text-align: center;">8</td><td style="text-align: center;">0.3</td><td style="text-align: center;">1.2</td><td style="text-align: center;">2.5</td><td style="text-align: center;">0.5</td></tr><tr><td style="text-align: center;">IUD &lt;br&gt; Levonorgestrel-releasing intrauterine system (LNG-IUS)</td><td style="text-align: center;">0.2</td><td style="text-align: center;">0.2</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">T-Safe <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>®&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {® }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9852em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9852em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord accent mtight"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8889em;"><span style="top: -2.7em;"><span class="pstrut" style="height: 2.7em;"></span><span class="mord mtight"><span class="mord">R</span></span></span><span style="top: -2.8944em;"><span class="pstrut" style="height: 2.7em;"></span><span class="accent-body accent-full" style="left: 0em; top: 0.2em;"><span class="mord mtight">◯</span></span></span></span></span></span></span><span class="mord mtight">&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> Cu 380 A Other <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>300</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;300 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">300</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> copper-wire IUDs (Nova-T 380 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>®&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {® }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9852em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9852em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord accent mtight"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8889em;"><span style="top: -2.7em;"><span class="pstrut" style="height: 2.7em;"></span><span class="mord mtight"><span class="mord">R</span></span></span><span style="top: -2.8944em;"><span class="pstrut" style="height: 2.7em;"></span><span class="accent-body accent-full" style="left: 0em; top: 0.2em;"><span class="mord mtight">◯</span></span></span></span></span></span></span><span class="mord mtight">&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span>, Multiload <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>®&nbsp;</mtext></msup><mn>375</mn></mrow><annotation encoding="application/x-tex">{ }^{\text {® }} 375</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9852em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9852em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord accent mtight"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8889em;"><span style="top: -2.7em;"><span class="pstrut" style="height: 2.7em;"></span><span class="mord mtight"><span class="mord">R</span></span></span><span style="top: -2.8944em;"><span class="pstrut" style="height: 2.7em;"></span><span class="accent-body accent-full" style="left: 0em; top: 0.2em;"><span class="mord mtight">◯</span></span></span></span></span></span></span><span class="mord mtight">&nbsp;</span></span></span></span></span></span></span></span></span></span><span class="mord">375</span></span></span></span></span>, Flexi-T <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>®&nbsp;</mtext></msup><mn>300</mn></mrow><annotation encoding="application/x-tex">{ }^{\text {® }} 300</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9852em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9852em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord accent mtight"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8889em;"><span style="top: -2.7em;"><span class="pstrut" style="height: 2.7em;"></span><span class="mord mtight"><span class="mord">R</span></span></span><span style="top: -2.8944em;"><span class="pstrut" style="height: 2.7em;"></span><span class="accent-body accent-full" style="left: 0em; top: 0.2em;"><span class="mord mtight">◯</span></span></span></span></span></span></span><span class="mord mtight">&nbsp;</span></span></span></span></span></span></span></span></span></span><span class="mord">300</span></span></span></span></span> )</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.8</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mo>≈</mo><msup><mn>1</mn><mo lspace="0em" rspace="0em">†</mo></msup></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 0.8 \\ &amp; \approx 1^{\dagger} \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3.0591em; vertical-align: -1.2796em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.7796em;"><span style="top: -3.8387em;"><span class="pstrut" style="height: 2.8991em;"></span><span class="mord"></span></span><span style="top: -2.2796em;"><span class="pstrut" style="height: 2.8991em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.2796em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.7796em;"><span style="top: -3.9396em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.8</span></span></span><span style="top: -2.3804em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">≈</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8991em;"><span style="top: -3.113em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">†</span></span></span></span></span></span></span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.2796em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>0.6</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mo>≈</mo><msup><mn>1</mn><mo lspace="0em" rspace="0em">†</mo></msup></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 0.6 \\ &amp; \approx 1^{\dagger} \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3.0591em; vertical-align: -1.2796em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.7796em;"><span style="top: -3.8387em;"><span class="pstrut" style="height: 2.8991em;"></span><span class="mord"></span></span><span style="top: -2.2796em;"><span class="pstrut" style="height: 2.8991em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.2796em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.7796em;"><span style="top: -3.9396em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">0.6</span></span></span><span style="top: -2.3804em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">≈</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8991em;"><span style="top: -3.113em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">†</span></span></span></span></span></span></span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.2796em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mo>−</mo></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mo>−</mo></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; - \\ &amp; - \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">−</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">−</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mo>−</mo></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mo>−</mo></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; - \\ &amp; - \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">−</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">−</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mo>−</mo></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mo>−</mo></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; - \\ &amp; - \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">−</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">−</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Male condom</td><td style="text-align: center;">15</td><td style="text-align: center;">2</td><td style="text-align: center;">3.6</td><td style="text-align: center;">6.0</td><td style="text-align: center;">2.9</td></tr><tr><td style="text-align: center;">Female condom</td><td style="text-align: center;">21</td><td style="text-align: center;">5</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Diaphragm (all caps believed similar, not all tested)</td><td style="text-align: center;">16</td><td style="text-align: center;">6</td><td style="text-align: center;">1.9</td><td style="text-align: center;">5.5</td><td style="text-align: center;">2.8</td></tr><tr><td style="text-align: center;">Withdrawal</td><td style="text-align: center;">27</td><td style="text-align: center;">4</td><td style="text-align: center;">6.7</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Spermicides alone</td><td style="text-align: center;">29</td><td style="text-align: center;">18</td><td style="text-align: center;">11.9</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Fertility awareness &lt;br&gt; Standard days method &lt;br&gt; Ovulation (mucus) method &lt;br&gt; Persona &lt;br&gt; No method, young women &lt;br&gt; No method at age 40 &lt;br&gt; No method at age 45 &lt;br&gt; No method at age 50 (if still having menses)</td><td style="text-align: center;">25</td><td style="text-align: center;">5</td><td style="text-align: center;">15.5</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>6</mn><mo lspace="0em" rspace="0em">†</mo></msup></mrow><annotation encoding="application/x-tex">6^{\dagger}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">†</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>90</mn></mrow><annotation encoding="application/x-tex">80-90</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">90</span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">40-50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn></mrow><annotation encoding="application/x-tex">10-20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">20</span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0</mn><mo>−</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">0-5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr></tbody></table>
<p>Sources: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span> Trussell J (2007) Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL, et al. (eds). Contraceptive technology: nineteenth revised edition. Ardent Media, New York.
Other Notes (1) Note influence of age: all the rates in the fifth column being lower than those in the fourth column. Lower rates still may be expected above age 45. (2) Much better results also obtainable in other states of relative infertility, such as lactation. (3) Oxford/fpa users were established users at recruitment - greatly improving results for barrier methods (Qs 1.19, 4.9). (4) The Nexplanon, Cerazette and Persona results come from pre-marketing studies by the manufacturer, giving an estimate of the Pearl 'method-failure' rate.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>b&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {b }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">b&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> Vessey M, Lawless M, Yeates D (1982) Efficacy of different contraceptive methods. Lancet 1(8276):841-842.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span> Typical use: Among typical couples who initiate use of the method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">†</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{\dagger}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">†</span></span></span></span></span></span></span></span></span></span></span></span></span> Perfect use: Among typical couples who initiate use of the method (not necessarily for the first time), and who then use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>d&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {d }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">d&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> Data not available from Trussell, so best alternative data given, e.g. from manufacturer's studies.
(This Table was published in Guillebaud J, MacGregor A (2013) Contraception 6e. OEleveler. Reproduced from Trussell J, Wyn LL (2008) Reducing unintended pregnancy in the United States. Contraception 77(1): 1-5, with permission.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="male-condoms">Male condoms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#male-condoms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The basic condom consists of a thin, stretchable latex film, which is moulded into a sheath, lubricated and packed in a foil wrapper. The sheath has a teat end to collect the ejaculate. The disadvantages of sheaths are that they need to be applied before intercourse and that they reduce the level of sensation for the male partner. The advantages are that they are readily available, are without side effects for the female partner and provide a degree of protection against infection. They have an efficiency of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>97</mn><mo>−</mo><mn>98</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">97-98 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">97</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">98%</span></span></span></span></span> with careful use, although typical failure rates can be as high as 15 pregnancies per 100 women years. Common reasons for failure are leakage of sperm when the penis is withdrawn, putting the condom on after genital contact, use of lubricants that cause the latex to break and mechanical damage. Condoms should be unrolled completely on to the penis before genital contact occurs and held when the penis is withdrawn to avoid leakage. The penis needs to be withdrawn from the vagina before the erection is lost, or sperm will inevitably be lost from it.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="female-condoms">Female condoms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#female-condoms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Female condoms are less widely used than the male equivalent, but have a similar failure rate and give similar protection against infection. They are made of polyurethane and, like the male condom, are suitable for a single episode of intercourse only.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="diaphragms-and-cervical-caps">Diaphragms and cervical caps<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diaphragms-and-cervical-caps" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The modern vaginal diaphragm consists of a thin latex rubber dome attached to a circular metal spring. These diaphragms vary in size from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>45</mn><mo>−</mo><mn>100</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">45-100 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">45</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> in diameter. The size of the diaphragm required is ascertained by
examination of the woman. The size and position of the uterus are determined by vaginal examination and the distance from the posterior vaginal fornix to the pubic symphysis is noted. The appropriate measuring ring, usually between 70 mm and 80 mm , is inserted. When in the correct position the anterior edge of the ring or diaphragm should lie behind the pubic symphysis and the lower posterior edge should lie comfortably in the posterior fornix (Fig. 19.1).</p>
<p>The woman should be advised to insert the diaphragm either in the dorsal position or in the kneeling position while bending forwards. The diaphragm can be removed by simply hooking an index finger under the rim from below and pulling it out. The diaphragm should be smeared on both sides with a contraceptive cream, and it is usually advised that it should be inserted dome down. However, some women prefer to insert the diaphragm with the dome upwards.</p>
<p>The diaphragm must be inserted prior to intercourse and should not be removed until at least 6 hours later. The main advantage of this technique is that it is free of side effects to the woman, apart from an occasional reaction to the contraceptive cream. The main disadvantages are that the diaphragm must be inserted before intercourse and typical failure rates are between 6 and 16 pregnancies per 100 women years. The main reason for failure is probably that the diaphragm size chosen is actually too small and when orgasm occurs in the woman, when the vaginal size can increase dramatically, the diaphragm no longer fits adequately.</p>
<p>There are a variety of vault and cervical caps, which are of much smaller diameter than the diaphragm. These are suitable for women with a long cervix or with some degree of prolapse, but otherwise have no particular advantage over the diaphragm.
<img src="assets/images/image-20251213-1faa17de.jpeg" alt="img-202.jpeg"></p>
<p>Fig. 19.1 Insertion of a vaginal diaphragm to cover the cervix and anterior vaginal wall.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="spermicides-and-sponges">Spermicides and sponges<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#spermicides-and-sponges" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Spermicides are only effective, in general, if used in conjunction with a mechanical barrier. Pessaries or suppositories have a water-soluble or wax base and contain a spermicide. They must be inserted approximately 15 minutes before intercourse. Common spermicides are nonoxynol-9 and benzalkonium. Creams consist of an emulsified fat base and tend not to spread. Care in insertion is essential so that the spermicide covers the cervix.</p>
<p>Jellies or pastes have a water-soluble base that spreads rapidly at body temperature. They therefore have an advantage over creams, as they spread throughout the vagina.</p>
<p>Foam tablets and foam aerosols contain bicarbonate of soda so that carbon dioxide is released on contact with water. The foam spreads the spermicide throughout the vagina. Pregnancy rates vary with different agents, but average around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>9</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">9-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">9</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> per 100 women years.</p>
<p>Sponges consist of polyurethane foam impregnated with nonoxynol-9. The failure rate is between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">9%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>32</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">32 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">32%</span></span></span></span></span>, and their use in isolation is therefore not recommended. They are inserted at least 15 minutes before intercourse and can be left in for a maximum of 12 hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="intrauterine-contraceptive-devices">Intrauterine contraceptive devices<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#intrauterine-contraceptive-devices" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Intrauterine contraception is used by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>8</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6-8 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">8%</span></span></span></span></span> of women in the UK. A wide variety of intrauterine devices (IUDs) have been designed for insertion into the uterine cavity (Fig. 19.2). These devices have the advantage that, once inserted, they are retained without the need to take alternative contraceptive precautions. It seems likely that they act mainly by preventing fertilization. This is a result of a reduction in the viability of ova and the number of viable sperm reaching the tube.</p>
<p>The first device to be widely used was the Graefenberg ring, which was made of a silver-copper alloy. Introduced in the 1930s, it ran into considerable difficulties with haemorrhage, infection, miscarriages and uterine perforation. Later, inert plastic devices such as the Lippes loop were associated with a significant increase in menstrual blood flow in many users. The development of copper IUDs has been associated with improved contraceptive efficacy and a lessening of excess menstrual blood loss.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="types-of-devices">Types of devices<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#types-of-devices" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The devices are either inert or pharmacologically active.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="inert-devices">Inert devices<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inert-devices" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Lippes loops, Saf-T-coils and Margulis spirals are plastic or plastic-coated devices. They have a thread attached that protrudes through the cervix and allows the woman to check that the device is still in place. Inert devices tend to
be relatively large. They are not now available but may still be found in situ in some older users.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacologically-active-devices">Pharmacologically active devices<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacologically-active-devices" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The addition of copper to a contraceptive device produces a direct effect on the endometrium by interfering with endometrial oestrogen-binding sites and depressing uptake of thymidine into DNA. It also impairs glycogen storage in the endometrium. Examples of such devices are the Copper-T <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> or Copper-7 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> (first generation), the Multiload <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> Copper-250 (second generation) and the Copper-T <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> 380 (third generation).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="devices-containing-progestogen">Devices containing progestogen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#devices-containing-progestogen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The levonorgestrel-releasing intrauterine system or Mirena <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> contains 52 mg of levonorgestrel (Fig. 19.2) which suppresses the normal build up of the endometrium so that, unlike most IUDs, it causes a reduction in menstrual blood loss. However, there is a high incidence of irregular scanty bleeding in the first 3 months after insertion of the device. Unlike previous progestogencontaining devices it does not appear to be associated with a higher risk of ectopic pregnancy. The superior efficacy of
<img src="assets/images/image-20251213-8e3a3421.jpeg" alt="img-203.jpeg"></p>
<p>Fig. 19.2 Some intrauterine contraceptive devices; on the right the levonorgestrel intrauterine system.</p>
<p>third-generation copper IUDs and the levonorgestrelreleasing system means that these are now considered the devices of choice.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="life-span-of-devices">Life span of devices<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#life-span-of-devices" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The Copper-T 380 is licensed for 8 years in the UK and Australia (and 13 in the USA). Other copper devices and the Mirena are licensed for 5 years. However, IUDs do not need to be replaced in women over the age of 40 years. They should be left in place until 2 years after the menopause if this occurs under 50 and 1 year otherwise.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="insertion-of-devices">Insertion of devices<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#insertion-of-devices" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The optimal time for insertion of the device is in the first half of the menstrual cycle. With postpartum women, the optimal time is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> weeks after delivery. Insertion at the time of therapeutic abortion is safe and can be performed when motivation is strong. It is unwise to insert IUDs following a miscarriage because of the risk of infection. Devices may be inserted within a few days of delivery but there is a high expulsion rate.</p>
<p>Ideally, the woman should be placed in the lithotomy position. A cervical smear should be taken, and a swab taken for culture if there is any sign of infection. The uterus is examined bimanually and its size, shape and position are ascertained. The cervix is swabbed with an antiseptic solution and a vulsellum can be applied to the anterior lip of the cervix, although this is not essential and may cause discomfort.</p>
<p>The passage of a uterine sound will indicate the depth and direction of the uterine cavity and the dimensions of the cavity may be assessed by devices known as cavimeters, which measure its length and breadth. Many IUDs are available in different sizes, and cavimeters help to choose the appropriate IUD.</p>
<p>Insertion devices vary in construction but generally consist of a stoppered plastic tube containing a plunger to extrude the device, which may be linear or folded. The device is inserted in the plane of the lumen of the uterus and care must be taken not to push it through the uterine fundus.</p>
<p>Attempts at insertion of a device where the cervical canal is tight may result in vagal syncope. Acute pain following insertion may indicate perforation of the uterus. The woman should be instructed to check the loop strings regularly and to notify her doctor immediately if the strings are not palpable.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="complications">Complications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The complications of IUDs are summarized in Figure 19.3.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pregnancy-rates">Pregnancy rates<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pregnancy-rates" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Pregnancy rates vary according to the type of device used, from 2-6/100 women years for non-medicated IUDs and
<img src="assets/images/image-20251213-d78d521f.jpeg" alt="img-204.jpeg"></p>
<p>Fig. 19.3 Complications of IUDs.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>2</mn><mi mathvariant="normal">/</mi><mn>100</mn></mrow><annotation encoding="application/x-tex">0.5-2 / 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2/100</span></span></span></span></span> for early generation copper devices to less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mi mathvariant="normal">/</mi><mn>100</mn></mrow><annotation encoding="application/x-tex">0.3 / 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.3/100</span></span></span></span></span> women years for third-generation copper and levonorgestrel IUDs. If pregnancy does occur with an IUD in situ and its strings are easily grasped, it is sensible to remove it to reduce the incidence of a septic miscarriage, there being a high incidence of miscarriage in such pregnancies. If the strings are not accessible, the IUD should be left and removed at the time of delivery, although the risk of a miscarriage or premature rupture of the membranes would be increased. The risk of failure of the IUD diminishes with each year after insertion.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="perforation-of-the-uterus">Perforation of the uterus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#perforation-of-the-uterus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mo>−</mo><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1-1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> of devices perforate the uterus. In many cases, partial perforation occurs at the time of insertion and later migration completes the perforation. If the woman notices that the tail of the device is missing, then it must be assumed that one of the following has occurred:</p>
<ul>
<li>The device has been expelled.</li>
<li>The device has turned in the uterine cavity and drawn up the strings.</li>
<li>The device has perforated the uterus and lies either partly or completely in the peritoneal cavity.
If there is no evidence of pregnancy, an ultrasound examination of the uterus should be performed. If the device is located within the uterine cavity (Fig. 19.4A), unless part of the loop or strings is visible, it will generally be necessary to remove the device with formal dilatation of the cervix under general or local anaesthesia. If the device is not found in the uterus, a radiograph of the abdomen will reveal the site in the peritoneal cavity (Fig. 19.4B). It is advisable to remove all extrauterine devices by either laparoscopy or laparotomy. Inert devices can probably be left with impunity, but copper devices promote considerable peritoneal irritation and should certainly be removed.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pelvic-inflammatory-disease">Pelvic inflammatory disease<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pelvic-inflammatory-disease" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Pre-existing PID is a contraindication to this method of contraception. There is a small increase in the risk of acute</p>
<p><img src="assets/images/image-20251213-4321273b.jpeg" alt="img-205.jpeg"></p>
<p>Fig. 19.4 (A) Ultrasound diagnosis of a plastic IUD. (B) Radiography of the abdomen showing an IUCD and a full-term pregnancy.</p>
<p>PID in IUD users, but this is largely confined to the first 3 weeks after insertion. If PID does occur, antibiotic therapy is commenced and, if the response is poor, the device should be removed. If the infection is severe, it is preferable to complete 24 hours of antibiotic therapy before removing the device. It is not uncommon to find evidence of Actinomyces organisms in the Pap smear routinely collected in an asymptomatic woman who has an IUD in place. This is generally not due to an actinomycotic pelvic infection, but due to the presence of these organisms on
the surface of the IUD. There is no absolute consensus of what should be done if such organisms are found in the Pap smear. Some would remove the IUD, repeat the smear in 3 months and reinsert another IUD if the smear is clear, whereas others would leave the IUD in place but give a 2 week course of penicillin therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="abnormal-uterine-bleeding">Abnormal uterine bleeding<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#abnormal-uterine-bleeding" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Increased menstrual loss occurs in most women with an inert or copper IUD, but this can be tolerated by the majority. However, in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> of such women it is sufficiently severe to necessitate removal of the device. It can be controlled by drugs such as tranexamic acid or mefenamic acid. Intermenstrual bleeding may also occur, but if the loss is slight it does not constitute a reason for IUD removal. Amenorrhoea occurs in at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of women using the Mirena and average menstrual blood loss is reduced by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pelvic-pain">Pelvic pain<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pelvic-pain" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Pain occurs either in a chronic low-grade form or as severe dysmenorrhoea. The incidence is widely variable, with up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of women suffering some pain. However, the pain may be acceptable if it is not severe, and this is a decision that has to be made by the patient in relation to the convenience of the method.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vaginal-discharge">Vaginal discharge<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vaginal-discharge" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Vaginal discharge may be due to infection but most women with an IUD develop a slight watery or mucoid discharge.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ectopic-pregnancy">Ectopic pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ectopic-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Compared with women having unprotected intercourse, the incidence of pregnancy is lower in women with an IUD in situ ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.2</mn><mi mathvariant="normal">/</mi><mn>100</mn></mrow><annotation encoding="application/x-tex">1.2 / 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.2/100</span></span></span></span></span> women years). However, should pregnancy occur, there is a higher risk ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> ) of the pregnancy being extrauterine. It is therefore essential to think of this diagnosis in any woman presenting with abdominal pain and irregular vaginal bleeding who has an IUD in situ.</p>
<p>Ectopic pregnancy should be excluded in any woman who conceives with an IUD in situ.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hormonal-contraception">Hormonal contraception<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hormonal-contraception" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Oral contraception is given as a combination of oestrogen and progestogen, as a combined pill, or as progestogen only.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="combined-pill">Combined pill<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#combined-pill" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Most of the current combined pills contain <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>30</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-30 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of ethinyl oestradiol and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mo>−</mo><mn>4000</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">150-4000 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">150</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4000</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of progestogen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-19-1-progestogen-content-of-contraceptive-pills">Box 19.1 Progestogen content of contraceptive pills<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-19-1-progestogen-content-of-contraceptive-pills" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="combined">Combined<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#combined" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Norethisterone
Norgestrel
Levonorgestrel
Desogestrel
Gestodene
Cyproterone
Drospirenone
Dienogest</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="progestogen-only">Progestogen only<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#progestogen-only" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Norethisterone
Levonorgestrel</p>
<p>The progestogens used are derived from 17hydroxyprogesterone or 19-norsteroids (Box 19.1).</p>
<p>The pill is usually taken for 21 days, followed by a 7-day pill-free interval during which there is a withdrawal bleed. Everyday (ED) preparations include seven placebo pills that are taken instead of a pill-free week. The concentration of the hormones may be the same throughout the 21 days (monophasic preparations) or vary across the cycle (biphasic and triphasic preparations) in order to reduce breakthrough bleeding.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="progestogen-only-pill">Progestogen-only pill<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#progestogen-only-pill" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Progestogen-only pills contain either norethisterone or levonorgestrel and are taken continuously on the basis of one tablet daily. Because of the low dose, they should be taken at the same time every day.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mode-of-action-of-the-contraceptive-pills">Mode of action of the contraceptive pills<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mode-of-action-of-the-contraceptive-pills" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Combined and triphasic pills act by suppressing gonadotrophin-releasing hormone (GnRH) and gonadotrophin secretion and, in particular, suppressing the luteinizing hormone peak, and thus inhibiting ovulation. The endometrium also becomes less suitable for nidation and the cervical mucus becomes hostile. Progesterone-only pills act predominantly to reduce the amount and character of the cervical mucus, although they do alter the endometrial maturation as well. Ovulation is completely suppressed in only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of women.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications">Contraindications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are various contraindications to the pill, some being more absolute than others.</p>
<p>The absolute contraindications include pregnancy, previous pulmonary embolism or deep vein thrombosis, sickle-cell disease, porphyria, current active liver disease or</p>
<p>Table 19.2 Minor side effects of combined oral contraception</p>
<table><thead><tr><th style="text-align: left;">Oestrogenic effects</th><th style="text-align: left;">Progestogenic effects</th></tr></thead><tbody><tr><td style="text-align: left;">Fluid retention and oedema</td><td style="text-align: left;">Premenstrual depression</td></tr><tr><td style="text-align: left;">Premenstrual tension and</td><td style="text-align: left;">Dry vagina</td></tr><tr><td style="text-align: left;">irritability</td><td style="text-align: left;">Acne, greasy hair</td></tr><tr><td style="text-align: left;">Increase in weight</td><td style="text-align: left;">Increased appetite with</td></tr><tr><td style="text-align: left;">Nausea and vomiting</td><td style="text-align: left;">weight gain</td></tr><tr><td style="text-align: left;">Headache</td><td style="text-align: left;">Breast discomfort</td></tr><tr><td style="text-align: left;">Mucorrhoea, cervical erosion</td><td style="text-align: left;">Cramps of the legs and</td></tr><tr><td style="text-align: left;">Menorrhagia</td><td style="text-align: left;">abdomen</td></tr><tr><td style="text-align: left;">Excessive tiredness</td><td style="text-align: left;">Decreased libido</td></tr><tr><td style="text-align: left;">Vein complaints</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Breakthrough bleeding</td><td style="text-align: left;"></td></tr></tbody></table>
<p>previous cholestasis (particularly where it is associated with a previous pregnancy), migraine associated with an aura or carcinoma of the breast. It is necessary to maintain a high level of vigilance in women with varicose veins, diabetes, hypertension, renal disease and chronic heart failure but none of these conditions constitutes an absolute contraindication and, in some cases, the adverse effects of a pregnancy may substantially outweigh any hazard from the pill. Women who smoke and are also over the age of 35 years have a significantly increased risk of coronary artery and thromboembolic disease.</p>
<p>The occurrence of migraine for the first time, severe headaches or visual disturbances, or transient neurological changes are indications for immediate cessation of the pill. There are a series of minor side effects that may sometimes be used to advantage or may be offset by using a pill with a different combination of steroids (Table 19.2).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-therapeutic-uses">Other therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Therapeutic uses other than contraception include the treatment of menorrhagia, premenstrual syndrome, endometriosis and dysmenorrhoea.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="major-side-effects">Major side effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#major-side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The risk of venous thrombosis is increased from 5/100 000 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">/</mi><mn>100000</mn></mrow><annotation encoding="application/x-tex">15 / 100000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15/100000</span></span></span></span></span> women per year and is further increased in smokers and women with a previous history of venous thrombosis. This compares to a risk in pregnancy and the puerperium of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">/</mi><mn>100000</mn></mrow><annotation encoding="application/x-tex">60 / 100000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">60/100000</span></span></span></span></span> women. Several studies have suggested that so-called 'third and fourth-generation' combined pills containing desogestrel, gestodene or drospirenone, are associated with a twofold greater risk of venous thrombosis than those containing other progestogens, although the risk of venous thrombosis was lower in these studies than had previously been reported.</p>
<p>There is an increase in arterial disease, with a 1.6 to 5.4fold increase in stroke and 3 to 5 -fold increase in myocardial infarction (although there is no significant increase in women under 25 or in non-smokers). However, both these conditions are rare in women under the age of 35 years so the overall risk remains low, with deaths from venous thrombosis attributable to the combined pill of no more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1-2 /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2/</span></span></span></span></span> million women years.</p>
<p>Although some reports have suggested there is a small increase in the relative risk of breast (relative risk 1.24) and cervical cancer (relative risk 1.5-2) in pill users, especially if it is commenced before a first pregnancy, the breast cancer increased risk is not definitely proven, and the cervical cancer risk is probably due to the incidence of wart virus infection and not the taking of the oral contraceptive pill (OCP).</p>
<p>There is an increase in gallstone formation and cholecystitis and an increase in glucose intolerance.</p>
<p>The progestogen-only pill has a higher failure rate and is more likely to be associated with irregular bleeding. If it fails there is a higher risk of ectopic pregnancy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="beneficial-effects">Beneficial effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beneficial-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In addition to the prevention of unwanted pregnancy, the use of the combined pill is associated with a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> reduction in blood loss at menstruation, a lower incidence of ectopic pregnancy <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.4</mn><mi mathvariant="normal">/</mi><mn>1000</mn><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(0.4 / 1000)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.4/1000</span><span class="mclose">)</span></span></span></span></span> and some protection against PID and benign ovarian cysts. Pill users also have a reduced risk of both endometrial and ovarian cancer of up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>, depending on the length of use with this benefit lasting for up to 10 years after the OCP therapy has been ceased.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a8c-practical-patient-care-of-a-patient-requesting-to-use-the-combined-ocp">A8C Practical patient care of a patient requesting to use the combined OCP<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a8c-practical-patient-care-of-a-patient-requesting-to-use-the-combined-ocp" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is important to obtain a complete general history and examination before prescribing the pill, and also to perform annual check-ups and cervical cytology. There are a large number of compounds commercially available, and some pills are marketed by different companies but contain the same compounds at the same concentrations. The history taken must exclude the contra-indications detailed above. Examination should include breast examination, blood pressure assessment and, except in women who have never been sexually active, speculum examination, Pap smear testing, and PV assessment. An appropriate pill for that particular patient should then be chosen, and counselling then given along the following lines.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="which-pill-should-you-choose">Which pill should you choose?<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#which-pill-should-you-choose" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In general a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> ethinyl oestradiol-containing pill is usually chosen first because of its effectiveness and low cost. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> containing preparations are much more expensive but preferred by many women, and the side effects are usually less, except that breakthrough bleeding during the first few months of treatment is more common. If the woman had evidence of androgen excess, hirsutism or clinical PCOS, the OCP Diane 35 should be given because its progestogen is cyproterone acetate, an anti-androgen. If the woman has fluid retention problems, an OCP containing drospirenone is usually advisable.</p>
<p>If the woman has used the OCP previously and had major problems with breakthrough bleeding, has conceived when taking the pill correctly, or is on treatment with an anti-epileptic medication, it is safer to advise them to take an OCP containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of ethinyl oestradiol.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="when-should-it-be-commenced">When should it be commenced?<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#when-should-it-be-commenced" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is best commenced on day <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> of the next period but can be commenced at any time. Many combined pills include 7 days of placebo ('sugar') tablets so that the user takes a pill every day of the month and so reduces the risk of forgetting when to restart the pill after the normal 7 'pill free' days each cycle (sometimes labelled 'ED' or everyday preparations). Each tablet including the placebos are labelled with a day of the week in these calendar packs with the placebos being a different colour (Fig. 19.5) With these pills a woman should start taking the pill on the first day of her next period starting with the inactive tablet corresponding to the current day of the week. When changing from a higher to a lower dose pill preparation women should be advised to start taking the active tablets of the new pill immediately on completing the last tablet of her previous pill, omitting the normal 7 day gap.
<img src="assets/images/image-20251213-dc9657cd.jpeg" alt="img-206.jpeg"></p>
<p>Fig. 19.5 The ED combined oral contraceptive pill.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="when-will-it-achieve-its-contraceptive-effect">When will it achieve its contraceptive effect?<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#when-will-it-achieve-its-contraceptive-effect" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When 7 active hormone tablets have been taken on successive days.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="what-to-do-if-a-pill-is-missed-or-nausea-vomiting-or-diarrhoea-occurs">What to do if a pill is missed or nausea, vomiting or diarrhoea occurs?<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#what-to-do-if-a-pill-is-missed-or-nausea-vomiting-or-diarrhoea-occurs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>If the missed pill is not discovered until more than 12 hours after it was meant to be taken, that pill should not be taken, but the original course continued and alternative contraception used for the next 7 days. If discovered <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">&lt;12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hours after the time it was meant to have been taken, take that pill now, and continue the cycle taking the next one at the appropriate time. When the missed pill is close to the time the hormone tablets were due to be ceased and sugar tablets given, the original course can be stopped and a new pack commenced about 5-6 days later. There is no need for additional contraception under such circumstances.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="what-are-the-potential-side-effects-including-the-common-ones-of-break-through-bleeding-and-what-to-do-if-such-bleeding-occurs">What are the potential side effects, including the common ones of break through bleeding, and what to do if such bleeding occurs?<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#what-are-the-potential-side-effects-including-the-common-ones-of-break-through-bleeding-and-what-to-do-if-such-bleeding-occurs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The main nuisance side effect is breakthrough bleeding where generally light bleeding occurs despite the hormone tablets still being taken. This usually settles spontaneously within 3 months of starting the OCP, but if it persists a higher dose pill should be given.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="when-is-further-review-needed-and-why">When is further review needed and why?<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#when-is-further-review-needed-and-why" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>She should be reviewed in 2-3 months to check if any problems have occurred and to check that blood pressure has not become elevated. Further reviews, when blood pressure, breast examination and gynaecological assessment including Pap smear testing should be done, are generally done annually.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interaction-between-drugs-and-contraceptive-steroids">Interaction between drugs and contraceptive steroids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interaction-between-drugs-and-contraceptive-steroids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Many drugs affect the contraceptive efficacy of the pill, and therefore additional precautions should be taken (Table 19.3). Vomiting and diarrhoea also result in loss of the pill and hence the return of fertility - particularly with the low-dose pills now widely in use. Progestogen-only pills must be taken every day if they are to be effective.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="failure-rates">Failure rates<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#failure-rates" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The failure rate of combined pills is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.27</mn><mo>−</mo><mn>5</mn><mi mathvariant="normal">/</mi><mn>100</mn></mrow><annotation encoding="application/x-tex">0.27-5 / 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.27</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5/100</span></span></span></span></span> women years. The failure rate for progestogen-only preparations is higher and varies between 0.3 and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mi mathvariant="normal">/</mi><mn>100</mn></mrow><annotation encoding="application/x-tex">8 / 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">8/100</span></span></span></span></span> women years.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-pill-and-surgery">The pill and surgery<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-pill-and-surgery" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The pill increases the risk of deep vein thrombosis and should therefore be stopped at least 6 weeks before major surgery. It should not be stopped before minor procedures - particularly before laparoscopic sterilization procedures. The risk of an unwanted pregnancy occurring before admission is substantially greater than the risk of thromboembolism.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-pill-and-lactation">The pill and lactation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-pill-and-lactation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Combined preparations tend to inhibit lactation and are therefore best avoided. The pill of choice at this time is the progestogen-only pill as it has minimal effect on lactation and may indeed promote it.</p>
<table><thead><tr><th style="text-align: left;">Table 19.3 Interaction of various drugs with oral &lt;br&gt; contraceptives</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">Interacting drug</td><td style="text-align: left;">Effects of interaction</td></tr><tr><td style="text-align: left;">Analgesics</td><td style="text-align: left;">Possible increased sensitivity to &lt;br&gt; pethidine</td></tr><tr><td style="text-align: left;">Anticoagulants</td><td style="text-align: left;">Possible reduction of effect of &lt;br&gt; anticoagulant - increased &lt;br&gt; dosage of anticoagulant may &lt;br&gt; be necessary</td></tr><tr><td style="text-align: left;">Anticonvulsants</td><td style="text-align: left;">Possible decrease in contraceptive &lt;br&gt; reliability</td></tr><tr><td style="text-align: left;">Tricyclic &lt;br&gt; antidepressants</td><td style="text-align: left;">Reduced antidepressant response; &lt;br&gt; increase in antidepressant &lt;br&gt; toxicity</td></tr><tr><td style="text-align: left;">Antihistamines</td><td style="text-align: left;">Possible decrease in contraceptive &lt;br&gt; reliability</td></tr><tr><td style="text-align: left;">Antibiotics</td><td style="text-align: left;">Possible decrease in contraceptive &lt;br&gt; reliability &lt;br&gt; Possibility of breakthrough &lt;br&gt; bleeding (this is most likely &lt;br&gt; with rifampicin)</td></tr><tr><td style="text-align: left;">Hypoglycaemic &lt;br&gt; agents</td><td style="text-align: left;">Control of diabetes may be &lt;br&gt; reduced</td></tr><tr><td style="text-align: left;">Antiasthmatics</td><td style="text-align: left;">Asthmatic condition may be &lt;br&gt; exacerbated by concomitant &lt;br&gt; oral contraceptive</td></tr><tr><td style="text-align: left;">Systemic &lt;br&gt; corticosteroids</td><td style="text-align: left;">Increased dosage of steroids may &lt;br&gt; be necessary</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="injectable-compounds">Injectable compounds<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#injectable-compounds" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are currently two main types - Depo-Provera <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> and Implanon <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span>. Depo-Provera contains 150 mg of medroxyprogesterone acetate and is given as a 3-monthly intramuscular injection. Implanon is a single Silastic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> rod containing etonogestrel that is inserted subdermally in the upper arm and is effective for up to 3 years. An earlier type of implant, the levonorgestrel-releasing Nor-plant <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> Silastic rod, has been discontinued but some women may still have this in place. Each of these injectable preparations works by making the cervical mucus hostile, the endometrium hypotrophic and by also suppressing ovulation.</p>
<p>Failure rates are low, at less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">/</mi><mn>100</mn></mrow><annotation encoding="application/x-tex">0.1 / 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.1/100</span></span></span></span></span> women years in the first year rising to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.9</mn><mi mathvariant="normal">/</mi><mn>100</mn></mrow><annotation encoding="application/x-tex">3.9 / 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.9/100</span></span></span></span></span> over 5 years. Failures mostly relate to women already pregnant at the time of injection of the Depo-Provera or insertion of the Implanon device, so it is essential that these methods are commenced at the time of a pregnancy termination or within the first 5 days of menstruation.</p>
<p>Parenteral progestogen-only contraceptives are longacting but easily reversible, effective, avoid first-pass effect liver metabolism, require minimal compliance and avoid the side effects associated with oestrogens. However, they may cause irregular bleeding or amenorrhoea, which can be a source of anxiety because of the possibility of pregnancy. Removal of the implants may be difficult and should only be carried out by a doctor trained in the procedure. Some women will experience systemic progestogenic effects such as mood changes and weight gain or develop symptoms of oestrogenic deficiency</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="newer-methods-of-hormonal-contraception">Newer methods of hormonal contraception<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#newer-methods-of-hormonal-contraception" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In the last few years combined hormone transdermal patches and a vaginal contraceptive ring have been introduced. Each of these is as effective as the combined OCP and there is good evidence that the actual hormone levels achieved with either of these is less variable than that seen with oral therapy, and lower overall. The transdermal contraceptive patches are changed weekly for 3 weeks and the fourth week is then patch free. For the NuvaRing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span>, the device is left in the vagina for 3 weeks, then removed for 1 week, then a new vaginal ring inserted. With each of these methods, as with the OCP, the period occurs during the hormone free week.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="emergency-contraception">Emergency contraception<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#emergency-contraception" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After unprotected intercourse, missed combined pill or a burst condom, a single 750 mg levonorgestrel tablet is taken within 72 hours of intercourse, followed by a second dose exactly 12 hours later. The levonorgestrel-only method has fewer side effects than the previously used
combined method and, in some countries, is available to women over the age of 16 years directly from pharmacists. Side effects include mild nausea, vomiting (an additional pill should be taken if vomiting occurs within 2-3 hours of the first dose) and bleeding. The woman should be advised that:</p>
<ul>
<li>Her next period might be early or late.</li>
<li>She needs to use barrier contraception until then.</li>
<li>She needs to return if she has any abdominal pain or if the next period is absent or abnormal.
If the next period is more than 5 days overdue, pregnancy should be excluded. Emergency contraception prevents <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">85 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">85%</span></span></span></span></span> of expected pregnancies. Efficacy decreases with time from intercourse.
If the woman concerned does not attend until more than 72 hours after the sexual activity occurred, levonorgestrel therapy is ineffective, however an IUD can be inserted if it is still before the time implantation of any embryo produced would have occurred.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="non-medical-methods-of-contraception">Non-medical methods of contraception<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#non-medical-methods-of-contraception" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The most fertile phase of the menstrual cycle occurs at the time of ovulation. In a 28-day cycle, this occurs on day 13 or 14 of the cycle. The fertile phase is associated with changes in cervical mucus that a woman can learn to recognize by self-examination and hormone changes that can be measured by home urine testing kits. Avoidance of the fertile period can be an extremely effective method in wellmotivated couples.</p>
<p>Natural methods of family planning include the following:</p>
<ul>
<li>
<p>The rhythm method: Avoiding intercourse mid-cycle and for 6 days before ovulation and 2 days after it. The efficacy of this method depends on being able to predict the time of ovulation. If a regular 28 day cycle occurs, ovulation is predicted for day 14 , and abstinence should be from days 8 to 16 . If the cycles are very variable, varying between 24 and 32 days, the earliest ovulation would be on day 10 and the latest on day 18 , so abstinence would be required between days 4 and 20.</p>
</li>
<li>
<p>The ovulation method: This method takes into account the ability of a woman to recognize the increase in vaginal wetness due to cervical mucus production in the phase before ovulation, and abstaining from sex during that time and for 2 days after the peak wetness has been observed. This method is much better than the rhythm method, but many women only get 4 days advanced warning of the time of ovulation, so intercourse on the preceding 2 days can result in a pregnancy.</p>
</li>
<li>
<p>Coitus interruptus (withdrawal): A traditional and still widely used method of contraception that relies on withdrawal of the penis before ejaculation. It is not a particularly reliable method of contraception, because the best sperm often reach the tip of the penis before the male experiences the imminent ejaculation, or he forgets in the 'heat' of the moment.</p>
</li>
<li>
<p>Lactational amenorrhoea method: Breastfeeding has historically been the most important means of family 'spacing'. Ovulation resumes on average 4-6 months later in women who continue to breastfeed. During the first 6 months after birth this is an effective method of contraception in mothers providing they are fully breastfeeding, not giving the baby any non-breast milk or other food, AND have remained amenorrhoeic, with failure rates as low as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>100</mn></mrow><annotation encoding="application/x-tex">1 / 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/100</span></span></span></span></span> women being seen.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sterilization">Sterilization<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sterilization" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Contraceptive techniques have the major advantage that they are easily reversible and provide a high level of protection against pregnancy. They have the disadvantage that they require a conscious act on behalf of the individual before intercourse. When family size is complete or there is a specific medical contraindication to continuing fertility, sterilization becomes the contraceptive method of choice. Around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of couples use sterilization for contraception and this increases to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> in those aged over the age of 40 years.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="counselling">Counselling<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#counselling" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is essential to counsel both partners about the nature of the procedures and their implications and to discuss whether it is better for the male or female partner to be sterilized. In many cases, only one partner will be seeking sterilization, in which case only one point of view needs to be considered. It is important, however, to ensure that there is a full discussion of the alternatives.</p>
<p>Counselling should include reference to the intended method, its risks and failure rates ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>200</mn></mrow><annotation encoding="application/x-tex">1 / 200</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/200</span></span></span></span></span> for female sterilization, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2000</mn></mrow><annotation encoding="application/x-tex">1 / 2000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2000</span></span></span></span></span> for male sterilization). Women should be warned of the increased risk of ectopic pregnancy in the event of failure.</p>
<p>Remember the reported failure rate for third-generation/levonorgestrel IUDs is comparable to that of sterilization but male sterilization has a significantly lower failure rate.</p>
<p>With the improvements brought about by microsurgery, it is no longer acceptable to say that sterilization is irreversible and the patient should be counselled according to the technique to be used. The partner to be sterilized will be a matter of choice and motivation. If one partner has a reduced life expectancy from chronic illness, then that partner should be sterilized.</p>
<p>Women should be advised to continue to use other contraception until the period occurs following the sterilization procedure. Men should be advised to use alternative contraception until they have had two consecutive semen analyses showing azoospermia 2-4 weeks apart, with these analyses not done until at least 10 ejaculations have occurred.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="timing-of-sterilization">Timing of sterilization<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#timing-of-sterilization" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The operation can be performed at any time in the menstrual cycle, but is best done in the follicular phase of the cycle. A pregnancy test should be performed preoperatively if a woman has a late or missed period or thinks she may be pregnant.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="techniques">Techniques<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#techniques" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="female-sterilization">Female sterilization<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#female-sterilization" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The majority of procedures involves interruption of the Fallopian tubes but may vary from the application of clips on the tubes to total hysterectomy. In general terms, the more radical the procedure the less likely there is to be a failure. However, very low failure rates can now be achieved using methods with high reversibility prospects and these should be the methods of choice.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="laparoscopic-sterilization">Laparoscopic sterilization<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#laparoscopic-sterilization" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The use of the laparoscope for sterilization procedures has substantially reduced the duration of hospital stay. This is the method of choice in most developed countries, but an open approach through a mini-laparotomy may be more appropriate in countries where endoscopic facilities or training are limited.</p>
<ul>
<li>Tubal clips. This is the most widely used method of sterilization in the UK and Australia. The clips are made of plastic and inert metals and are locked on to the tube (Fig. 19.6). They have the advantage of causing minimal damage to the tube, but their disadvantage is a higher failure rate. Failures may be due to application on the wrong structure, extrusion of the tube from the clip, recanalization or fracture of the clip so that it falls off the tube. The Filshie clip, which has a titanium frame lined by silicone rubber, has the lowest failure rate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.5</mn><mi mathvariant="normal">%</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(0.5 \%)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.5%</span><span class="mclose">)</span></span></span></span></span> and is easier to apply. Yoon or Fallope rings are applied over a loop of tube and are similar to a Madlener procedure (see below). This technique is associated with</li>
</ul>
<p><img src="assets/images/image-20251213-89a61f63.jpeg" alt="img-207.jpeg"></p>
<p>Fig. 19.6 Sterilization by clip occlusion. (A) The right Fallopian tube is grasped with the clip. (B) The clip is closed and the tube is crushed. (C) The Filshie clip is closed and locked across the Fallopian tube.
<img src="assets/images/image-20251213-b3a34aa1.jpeg" alt="img-208.jpeg"></p>
<p>Fig. 19.7 Sterilization by tubal ligation.
considerably greater abdominal pain postoperatively, and the failure rates vary between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.3%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span>. The rings are not suitable for application to the tubes in the puerperium when the tube is swollen and oedematous.</p>
<ul>
<li>Tubal coagulation and division. Sterilization is effected by either unipolar or bipolar diathermy of the tubes in two sites <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> from the uterotubal junction. A considerable amount of tube can be destroyed with this technique. Division of the diathermied tube is said to reduce the risk of ectopic pregnancy. The failure rate depends on the length of tube destroyed. Because of the risk of thermal bowel injury with subsequent leakage and faecal peritonitis, diathermy should not be used as the primary method of sterilization unless mechanical methods of tubal occlusion are technically difficult or fail at the time of the procedure.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="tubal-ligation-fig-19-7">Tubal ligation (Fig. 19.7)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tubal-ligation-fig-19-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These procedures are usually performed through a small abdominal incision (mini-laparotomy) or at the time of caesarean section. They are less widely used with the increase in laparoscopic procedures. Even when laparoscopy is contraindicated for some reason it is still more common now to use clips to occlude the tubes.</p>
<p>The most basic form of the procedure involving simple ligation of the tube is known as the Madlener procedure but the failure rate may be up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.7</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3.7 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3.7%</span></span></span></span></span>. The Pomeroy technique is the same, but the loop of tube is excised and absorbable suture material is used for the ligation. There are several variations of this technique, including the separation of the cut ends of the tubes on contralateral sides of the broad ligament. The excised segments should be examined histologically to confirm that the tube has been excised.
<img src="assets/images/image-20251213-ca48377d.jpeg" alt="img-209.jpeg"></p>
<p>Burial of tubal stumps</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a7d180b4">The Essure <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> procedure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a7d180b4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This procedure consists of insertion of a small device into each tube at the time of a hysteroscopic examination, with this device resulting in fibrosis and ultimate occlusion of the tube on each side. This insertion can often be done without anaesthesia and does not require a laparoscopy. The device has a stainless steel coil, which holds the device in position in the proximal portion of the tube, and inner polyethylene terephthalate fibres which induce the benign fibrotic reaction over the succeeding 3 months. Adequacy of tubal blockage is often checked by the performance of a hysterosalpingogram.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="complications">Complications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Apart from the complications of laparoscopy, if it was performed to enable sterilization, the longer-term complications of any tubal sterilization are tubal recanalization and pregnancy, ectopic pregnancy, menstrual irregularity and loss of libido.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vasectomy">Vasectomy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vasectomy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This procedure is generally performed under local anaesthesia. Two small incisions are made over the spermatic cord and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">3-4 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> of the vas deferens is excised (Fig. 19.8). The advantage of the technique is its simplicity. The disadvantages are that sterility is not immediate and should not be assumed until all spermatozoa have disappeared from the ejaculate. On average, this takes at least 10 ejaculations.</p>
<p>The procedure is more difficult to reverse than most forms of female sterilization and, even when satisfactory re-anastomosis is achieved, only about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of patients will sire children, because of the adverse effect of the
<img src="assets/images/image-20251213-84c0716b.jpeg" alt="img-210.jpeg"></p>
<p>Fig. 19.8 Vasectomy involves excision of a segment of the vas deferens.
production of sperm-immobilizing and spermagglutinating antibodies. The failure rate is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2000</mn></mrow><annotation encoding="application/x-tex">1 / 2000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2000</span></span></span></span></span>.</p>
<p>Failures may follow spontaneous recanalization and excision of an inadequate length of vas deferens. The excised segments should always be examined histologically to confirm that the vas has been excised. Complications of the operation include haematoma formation, wound infection and epididymitis. Also a painful granuloma may form at the cut end of the vas as a result of a foreign body reaction induced by spermatozoa.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="psychological-implications-of-sterilization">Psychological implications of sterilization<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#psychological-implications-of-sterilization" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Sterilization in women has acquired the reputation of leading to psychiatric problems and a deterioration in sexual function. Modern studies do not confirm this reputation. Apart from the fact that modern studies tend to use prospective standardized methodologies, the population being sterilized in the 21 st century is very different to that of 40 years ago. Sterilization used to be performed predominantly on older women in poor gynaecological health, with large numbers of children and living in conditions of social adversity. It was carried out on medical recommendation, frequently shortly after childbirth, abortion or some other gynaecological procedure. Nowadays, sterilization is a widely accepted form of contraception used by women of all ages and social classes. They are, therefore, more representative of the population as a whole. Sterilization usually takes place at the request of the woman as an interval procedure unrelated to either childbirth or abortion. Women being sterilized have fewer children and are in better general health than previously.
The rate of psychiatric disorder following sterilization is, in general, no higher than that in the general female population. However, for women who are sterilized immediately following childbirth, there is an increased risk of suffering from postnatal depression. A previous psychiatric history and ambivalence or uncertainty about sterilization are risk factors for psychiatric disorder. Postpartum status, previous psychiatric history, ambivalence and marital discord are also risk factors for deterioration of psychosexual functioning and regret. Some authors have also suggested that, in cultures where femininity is strongly associated with fertility and where there is guilt and shame about contraception, great care should be exercised to ensure that patients are properly prepared for sterilization. Regret, often measured by a request for reversal of sterilization, appears to be most strongly predicted by marital breakdown and subsequent remarriage.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="termination-of-pregnancy">Termination of pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#termination-of-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In the UK this is carried out in approved centres under the provisions of the Abortion Act 1967. This requires that two doctors agree that either continuation of the pregnancy</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-19-2-indications-for-termination">Box 19.2 Indications for termination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-19-2-indications-for-termination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Risk to the life of the mother would be greater if the pregnancy continues
B. To prevent permanent harm to mental or physical health of the mother
C. Risk to mother's health greater* if the pregnancy continues
D. Risk to other children in the family* if the pregnancy continues
E. Risk of serious disability in the child
*Only if less than 24 weeks.
would involve greater risk to the physical or mental health of the mother or her other children than termination, or that the fetus is at risk of an abnormality likely to result in it being seriously handicapped (Box 19.2). The most recent amendment to the Act (1991) set a limit for termination under the first of these categories at 24 weeks, although in practice the majority of terminations are carried out prior to 20 weeks.</p>
<p>All terminations carried out in the UK must be notified. Annual abortion numbers peaked in the UK in 1990 at 170000 and declined after that until the scare over the risk of venous thrombosis with the 'third-generation' pills in 1996.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="methods">Methods<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#methods" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>All women undergoing termination of pregnancy should be screened for STIs and/or offered antibiotic prophylaxis. Following termination, anti-D immunoglobulin should be given to all rhesus negative women. All women should be offered a follow-up appointment to check that there are no physical problems and that contraceptive measures are in place.</p>
<p>The rate of infection with Chlamydia spp. is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">12 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">12%</span></span></span></span></span> of women requesting termination of pregnancy. In these women there is a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> risk of PID if appropriate antibiotic treatment is not given at the time of a surgical termination.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="surgical-termination">Surgical termination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#surgical-termination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is the method most commonly used in the first trimester or pregnancy. The cervix is dilated by a number of millimetres equivalent to the gestation in weeks and the conceptus is removed using a suction curette. A
variation involving piecemeal removal of the larger fetal parts with forceps (dilatation and evacuation) allows the method to be used for later second trimester pregnancies. Although most procedures are carried out under general anaesthesia in the UK, local anaesthesia is widely used in many countries for terminations before 10 weeks and reduces the time the patient needs to stay in the hospital or clinic.</p>
<p>Cervical dilation can be made easier by administration of prostaglandin pessaries before the operation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medical-termination">Medical termination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medical-termination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is the method most commonly used for pregnancies after 14 weeks and is increasingly being offered as an alternative to surgical termination in first trimester pregnancies up to 9 weeks gestation. The standard regimens for first-trimester termination use the progesterone antagonist mifepristone (RU 486) given orally, followed 36-48 hours later by prostaglandins administered as a vaginal pessary. There are several different regimens, but all have a success rate of greater than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span>. Second trimester terminations can also be performed using vaginal prostaglandins given 3-hourly or as an extra-amniotic infusion through a balloon catheter passed through the cervix. Pretreatment with mifepristone significantly reduces the time interval from induction to abortion. After delivery of the fetus, an examination under general anaesthetic may be necessary to remove the placenta.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="complications">Complications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Early complications include bleeding, uterine perforation (with possible damage to other pelvic viscera), cervical laceration, retained products and sepsis. All the procedures also have a small failure rate (overall rate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.7</mn><mi mathvariant="normal">/</mi><mn>1000</mn></mrow><annotation encoding="application/x-tex">0.7 / 1000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.7/1000</span></span></span></span></span> ). Late complications include infertility, cervical incompetence, isoimmunization and psychiatric morbidity. Adequate counselling (supported by written information) and explanation of the procedures and their risks are essential.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="psychological-sequelae-of-termination">Psychological sequelae of termination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#psychological-sequelae-of-termination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The majority of women who find themselves with an unwanted pregnancy are very distressed. Despite this, evidence shows that the majority of women do not experience medium- to long-term psychological sequelae, nor is there any evidence of an increase in the rate of psychiatric morbidity. The available evidence is that the rate of</p>
<p>psychiatric morbidity following termination of pregnancy is less than if the pregnancy was allowed to proceed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="risk-factors-for-adverse-sequelae-of-first-trimester-abortion">Risk factors for adverse sequelae of first-trimester abortion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#risk-factors-for-adverse-sequelae-of-first-trimester-abortion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Being married and having children prior to a termination can lead to problems of guilt and regret. Women in such circumstances need careful counselling before proceeding with the termination. Ambivalence, coercion, previous termination of pregnancy, past psychiatric history and termination associated with sterilization are risk factors for psychiatric morbidity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="later-terminations-of-pregnancy">Later terminations of pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#later-terminations-of-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The number of women having terminations of pregnancy after 12 weeks for psychosocial reasons is falling. Second trimester terminations now account for fewer than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">8 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">8%</span></span></span></span></span> of all therapeutic terminations of pregnancy. A minority of these women are having a therapeutic abortion for psychosocial reasons; the majority for fetal abnormality.</p>
<p>Unlike first trimester abortions, later terminations of pregnancy are associated both with marked psychological distress and an increased rate of psychiatric disorder. Some <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>39</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">39 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">39%</span></span></span></span></span> of women having an abortion for fetal abnormality are depressed at 3-9 months, although the rates fall to normal at 1 year. For women undergoing this procedure for psychosocial reasons, the cause for the increased rate of distress and morbidity is likely to be found in the delay in presenting for termination. The very young, the mentally handicapped and the chronically mentally ill may be found in this group, as well as those who have experienced marked ambivalence about their pregnancies.</p>
<p>The situation for women having a termination of pregnancy because of fetal abnormality is different. These are usually older women who have a much wanted pregnancy and whose problem has been diagnosed either because of a previous experience or as the result of screening. The decision to terminate the pregnancy is usually reached only after much thought and anguish. The consequence of termination is, therefore, very much like the spontaneous loss of a more advanced pregnancy, that is to say, a grief reaction. Their psychosocial recovery may be assisted by granting them the dignity of a naming and burial. Most late terminations of pregnancy involve the induction of labour and a prolonged process of giving birth. This can be a distressing and traumatic experience, and psychological recovery will be improved by sensitive and compassionate handling by the doctor and nursing staff.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraception-following-termination">Contraception following termination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraception-following-termination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Referral for termination should also be an opportunity to discuss future contraception and to ensure that adequate
provision is made for this after the termination. The procedure can be combined with sterilization. This has the advantage of preventing further terminations for the woman who is certain that she has completed her family. There is little evidence that this is associated with an increase in the rate of complications or later contraceptive failure. However, because of the increase in the 'regret rate' for the sterilization, an interval procedure is generally recommended. IUD insertion can be carried out at the same time as termination and is not associated with an increased risk of perforation or failure. If the oral contraceptive is being used, this can be started on the same or following day.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="criminal-abortion">Criminal abortion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#criminal-abortion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Miscarriage induced by a variety of techniques makes up a substantial percentage of miscarriage in some countries. Where the indications for legal miscarriage are liberal, criminal abortion is infrequent but in many countries it contributes to a high percentage of apparently spontaneous miscarriages. The World Health Organization estimates that 250000 women per year in the world die as a result of abortions, most of which are illegal. Mortality from abortion in the UK has fallen from a rate of 37/million maternities to 1.4/million since 1967. There have been no deaths from illegal abortion in the UK since 1982 .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="genital-tract-infections">GENITAL TRACT INFECTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#genital-tract-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The female genital tract provides direct access to the peritoneal cavity. Infection may extend to any level of the tract and, once it reaches the Fallopian tubes, is usually bilateral.</p>
<p>The genital tract has a rich anastomosis of blood and lymphatic vessels that serve to resist infection, particularly during pregnancy.</p>
<p>There are other natural barriers to infection:</p>
<ul>
<li>The physical apposition of the pudendal cleft and the vaginal walls.</li>
<li>Vaginal acidity - the low pH of the vagina in the sexually mature female provides a hostile environment for most bacteria; this resistance is weakened in the prepubertal and postmenopausal female.</li>
<li>Cervical mucus that acts as a barrier in preventing the ascent of infection.</li>
<li>The regular monthly shedding of the endometrium.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-b-c-taking-a-sexual-history">A B C Taking a sexual history<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-b-c-taking-a-sexual-history" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Taking an accurate sexual history is essential to the management of genital tract infections, and aspects of sexual history are relevant to a range of other presentations including subfertility, pelvic pain and disorders of sexual function. A concise sexual history will help to:</p>
<ul>
<li>identify specific risk behaviours</li>
<li>assess symptoms to guide examination and testing</li>
<li>identify anatomical sites for testing based on risk</li>
<li>assess other related sexual health issues such as pregnancy risk and contraceptive needs</li>
<li>inform the counselling process, health education required and contact tracing.
Patients (and students!) are often anxious so it is important to create a relaxed and friendly environment and have a respectful and a non-judgemental attitude. Introducing self and role, maintaining eye contact and having appropriate body language are important aspects of good communication when obtaining a sexual history. The confidential nature of the consultation should be explained. It is important etc to use language that is understandable and does not use labels or make judgements. Ask general questions first, using open ended questions. Move on to the exploration of reasons for presentation and more closed ended questions (see below). Explain there are some 'universal' questions that are explicitly asked of everyone to assess risk and avoid making assumptions about sexual orientation based on appearance.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="specific-questions">Specific questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specific-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Reason for attendance: the problem/issue, including symptoms
Direct questions about symptoms may include:</p>
<ul>
<li>duration and severity of symptoms</li>
<li>urethral and vaginal discharge: amount, colour, odour, character</li>
<li>abnormal vaginal or rectal bleeding</li>
<li>genital and extra genital rashes, lumps or sores</li>
<li>itching and/or discomfort in the perineum, peri-anal and pubic region</li>
<li>lower abdominal pain or dyspareunia</li>
<li>difficulties/pain with micturition, defecation or during intercourse</li>
</ul>
<p>Sexual behaviour risk assessment:</p>
<ul>
<li>last sexual intercourse (LSI)</li>
<li>history of unprotected intercourse</li>
<li>number and gender of sexual contacts in last 3 to 12 months (all men should be asked if they have ever had sex with another man in the past)</li>
<li>type of sexual activity practised (oral, anal, vaginal, toys)</li>
<li>STI prevention used and whether consistently used and remained intact (condoms)</li>
<li>relationship with sexual contacts (regular, casual, known, unknown)</li>
<li>have any recent sexual contacts had any symptoms or infections
STI and blood-borne virus (BBV) risk assessment: additional questions to assess timing of tests and other risks to inform testing and management planning:</li>
<li>date and results of previous STI and BBV testing</li>
<li>current or past history of injecting drug use, sharing of needles, syringes or of body piercing and/or tattoos including country, when done and whether sterile equipment used</li>
<li>whether they have had sex overseas other than with the person they are travelling with</li>
<li>sex industry worker or sexual contact with a sex worker</li>
<li>vaccination history including Hepatitis A, B and HPV
Other relevant information: to identify issues that may be associated with or influence client management:</li>
<li>current or recent medications</li>
<li>history of allergies especially adverse reaction to penicillin</li>
<li>contraceptive and reproductive health history, including contraceptive use and compliance and last menstrual period (LMP)</li>
<li>cervical cytology history including date of last test and result, past abnormal cytology</li>
<li>past medical and surgical history (including any overseas medical treatment and transfusions)</li>
<li>alcohol, tobacco and other drug use
(Reproduced from NSW Sexually Transmissible Infections Programs Unit 2011. NSW Health Sexual Health Services Standard Operating Procedures Manual 2011.)</li>
</ul>
<p>Lower genital tract infections</p>
<p>The commonest infections of the genital tract are those that affect the vulva and vagina. Infections that affect the vagina also produce acute and chronic cervicitis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="symptoms">Symptoms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#symptoms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Swelling and reddening of the vulval skin is accompanied by soreness, pruritus and dyspareunia. When the infection is predominantly one of vaginitis, the symptoms include vaginal discharge, pruritus, dyspareunia and often dysuria.</p>
<p>Cervicitis is associated with purulent vaginal discharge, sacral backache, lower abdominal pain, dyspareunia and dysuria. The proximity of the cervix to the bladder often results in coexistent trigonitis and urethritis, particularly in the case of gonococcal infections.</p>
<p>Chronic cervicitis is present in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50-60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of all parous women. In many cases, the symptoms are minimal. There may be a slight mucopurulent discharge, which is not sufficient to trouble the woman and may simply present as an incidental finding that does not justify active treatment. In the more severe forms of the condition, there is profuse vaginal discharge, chronic sacral backache, dyspareunia and occasionally postcoital bleeding. Bacteriological culture of the discharge is usually sterile. The condition may cause subfertility because of hostility of the cervical mucus to sperm invasion.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="signs">Signs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#signs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These will depend on the cause. The appearance of the vulval skin is reddened, sometimes with ulceration and excoriation. In the sexually mature female, the vaginal walls may become ulcerated, with plaques of white monilial discharge adherent to the skin or, in protozoal infections, the discharge may be copious with a greenish-white, frothy appearance.</p>
<p>Bartholin's glands are sited between the posterior part of the labia minora and the vaginal walls, and these two glands secrete mucus as a lubricant during coitus. Infection of the duct and gland results in closure of the duct and formation of a Bartholin's cyst or abscess. The condition is often recurrent and causes pain and swelling of the vulva. Bartholinitis is readily recognized by the site and nature of the swelling.</p>
<p>In cervicitis the cervix appears reddened and may be ulcerated, as with herpetic infections, and there is a mucopurulent discharge as the endocervix is invariably involved. The diagnosis is established by examination and taking cervical swabs for culture.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="common-organisms-causing-lower-genital-tract-infections">Common organisms causing lower genital tract infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#common-organisms-causing-lower-genital-tract-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vaginal-candidiasis">Vaginal candidiasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vaginal-candidiasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Candida albicans is a yeast pathogen that occurs naturally on the skin and in the bowel. Infection may be asymptomatic or associated with an increased or changed vaginal discharge associated with soreness and itching in the vulva area. There is no evidence of male to female sexual transmission. White curd-like collections attached to the vaginal epithelium may be seen on speculum examination, although these are not present in all cases.</p>
<p>Candidal infections are particularly common during pregnancy, in women taking the contraceptive pill and in underlying conditions involving immunosuppression,
e.g. HIV infection, diabetes or long-term steroids. In each instance, vaginal acidity is increased above normal and bacterial growth in the vagina is inhibited in such a way as to allow free growth of yeast pathogens, which thrive well in a low-pH environment. Candida hyphae and spores can also be seen in a wet preparation and can be cultured.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="trichomoniasis">Trichomoniasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#trichomoniasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Trichomonas vaginalis is a flagellated single-celled protozoal organism that may infect the cervix, urethra and vagina. In the male the organism is carried in the urethra or prostate and infection is sexually transmitted. The organisms are often seen on the Pap smear even in the absence of symptoms. The commonest presentation is with abnormal vaginal bleeding, but other symptoms include vaginal soreness and pruritus. The vaginal pH is usually raised above 4.5. A fresh wet preparation in saline of vaginal discharge will show motile trichomonads (Fig. 19.9). The characteristic flagellate motion is easily recognized and the organism can be cultured.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="genital-herpes">Genital herpes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#genital-herpes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The condition is caused by herpes simplex virus (HSV) type 2 and, less commonly, type 1. It is a sexually transmitted disease. Primary HSV infection is usually a systemic infection with fever, myalgia and occasionally meningism. The local symptoms include vaginal discharge, vulval pain, dysuria and inguinal lymphadenopathy. The discomfort may be severe enough to cause urinary retention. Vulval lesions include skin vesicles and multiple shallow skin ulcers (Fig. 19.10). The infection is also associated with an increased risk of cervical dysplasia. Partners may be asymptomatic and the incubation period is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>14</mn></mrow><annotation encoding="application/x-tex">2-14</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">14</span></span></span></span></span> days.</p>
<p>The diagnosis is made by sending fluid from vesicles for viral culture or antigen detection. After the initial infection the virus remains latent in the sacral ganglia. Recurrences may be triggered by stress, menstruation or intercourse,
<img src="assets/images/image-20251213-ad1e3db5.jpeg" alt="img-211.jpeg"></p>
<p>Fig. 19.9 Trichomonas vaginalis.</p>
<p><img src="assets/images/image-20251213-86826a4e.jpeg" alt="img-212.jpeg"></p>
<p>Fig. 19.10 Herpetic vulvitis. Lesions can also occur in the cervix and in the perivulvar region.
but are normally of shorter duration and less severe than the primary episode. Serum antibodies are raised in wellestablished lesions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="bacterial-vaginosis">Bacterial vaginosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bacterial-vaginosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is due to an overgrowth of a number of anaerobic organisms including Gardnerella spp. It is not sexually transmitted. It may be asymptomatic or cause a smelly vaginal discharge and vulval irritation. It is associated with an increased risk of PID, urinary tract infection and puerperal infection. Diagnosis is made by finding three of the following:</p>
<ul>
<li>An increase in vaginal pH of more than 4.5 .</li>
<li>A typical thin homogenous vaginal discharge.</li>
<li>A fishy odour produced when <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> potassium hydroxide is added to the discharge.</li>
<li>Clue cells on Gram-stained slide of vaginal fluid (Fig.19.11).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="gonococcal-and-chlamydial-vulvovaginitis">Gonococcal and chlamydial vulvovaginitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gonococcal-and-chlamydial-vulvovaginitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These organisms can result in extensive pelvic infection (see below) but may also be asymptomatic or indicated merely by vaginal discharge and dysuria. Chlamydia is the commonest sexually transmitted infection seen today.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="syphilis">Syphilis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#syphilis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The initial lesion appears 10-90 days after contact with the spirochaete Treponema pallidum. The primary lesion or chancre is an indurated, firm papule, which may become
<img src="assets/images/image-20251213-cc7109b0.jpeg" alt="img-213.jpeg"></p>
<p>Fig. 19.11 Clue cells in bacterial vaginosis. These are epithelial squamous cells with multiple bacteria adherent to their surface.
ulcerated and has a raised firm edge. This lesion most commonly occurs on the vulva but may also occur in the vagina or cervix. The primary lesion may be accompanied by inguinal lymphadenopathy. The chancre heals spontaneously within <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">2-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> weeks.</p>
<p>Some 6 weeks after the disappearance of the chancre, the manifestations of secondary syphilis appear. A rash develops which is maculopapular and is often associated with alopecia. Papules occur, particularly in the anogenital area and in the mouth, and give the typical appearance known as condylomata lata.</p>
<p>Swabs taken from either the primary or secondary lesions are examined microscopically under dark-ground illumination, and the spirochaetes can be seen. The serological tests have been described in Chapter 7.</p>
<p>The disease then progresses from the secondary phase to a tertiary phase. It may mimic almost any disease process and affect every system in the body, but the common long-term lesions are cardiovascular and neurological.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="genital-warts-condylomata-acuminata">Genital warts (condylomata acuminata)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#genital-warts-condylomata-acuminata" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Vulval and cervical warts (Fig. 19.12) are caused by a human papilloma virus (HPV). The condition is commonly, although by no means invariably, transmitted by sexual contact. The incubation period is up to 6 months. The incidence has risen significantly over the last 15 years, particularly in women aged 16-25 years.</p>
<p>The warts have an appearance similar to those seen on the skin in other sites, and in the moist environment of the vulval skin are often prolific - particularly during pregnancy. There is frequently associated pruritus and vaginal discharge. The lesions may spread to the perianal region, and in some cases become confluent and subject to secondary infection. Diagnosis is usually made by clinical examination.</p>
<p><img src="assets/images/image-20251213-b07c187c.jpeg" alt="img-214.jpeg"></p>
<p>Fig. 19.12 Papilloma virus infection of the cervix: condylomata acuminata.</p>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Vaginal discharge in a child may also be associated with the presence of a foreign body, and this possibility should always be excluded.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment-of-lower-genital-tract-infections">Treatment of lower genital tract infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-lower-genital-tract-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When the diagnosis has been established by examination and bacteriological tests, the appropriate treatment can be instituted. The treatment for Chlamydia and gonorrhoea is discussed below under infections of the upper genital tract. Whenever a diagnosis of sexually transmitted infection is made, it is essential to screen patients (and their partners) for other infections.</p>
<p>Vulval and vaginal monilial infections can be treated by topical or oral preparations. These include a single dose of clotrimazole given as a pessary or fluconazole taken orally. Recurrent infections can be treated by oral administration of ketoconazole and fluconazole. The patient's partner should be treated at the same time, and any predisposing factors such as poor hygiene or diabetes should be corrected.</p>
<p>Trichomonas infections and bacterial vaginosis are treated with metronidazole 400 mg taken twice a day for 5 days, which must be taken by both sexual partners if recurrence of the infection is to be avoided. Metronidazole may be administered as a single dose of 2 g , but high-dose therapy should be avoided in pregnancy. Topical treatment with metronidazole gel or clindamycin cream is also effective for bacterial vaginosis.</p>
<p>If a patient is asymptomatic and there is no evidence of vaginitis on clinical examination, but trichomonal or monilial organisms are identified in a routine Pap smear, treatment of these patients is usually not required.</p>
<p>Non-specific vaginal infections are common and are treated with vaginal creams, including hydrargaphen, povidone-iodine, di-iodohydroxyquinoline or sulphonamide creams.</p>
<p>Syphilis is treated in the first instance with penicillin and, if this fails, for example in the case of coinfection, with penicillin-resistant strains of the gonococcus, doxycycline hydrochloride or other antibiotics can be used.</p>
<p>Infections of the vagina associated with menopausal atrophic changes are treated by the appropriate hormone replacement therapy using an oral or vaginal oestrogen preparation, or lactic acid pessaries when oestrogens are contraindicated. The same therapy may be used, with the local application of oestrogen creams, in juvenile vulvovaginitis.</p>
<p>Infections of Bartholin's gland are treated with the antibiotic appropriate to the organism. If abscess formation has occurred, the abscess should be 'marsupialized' by excising an ellipse of skin and sewing the skin edges to result in continued open drainage of the abscess cavity (Fig. 19.13). This reduces the likelihood of recurrence of the abscess.</p>
<p>Vulval warts are treated with either physical or chemical diathermy using podophyllin applied directly to the surface of the warts. Any concurrent vaginal discharge should also receive the appropriate therapy.</p>
<p>Herpetic infections are notoriously resistant to treatment and highly prone to recurrence. The best available treatment is aciclovir administered in tablet form 200 mg five times daily for 5 days or locally as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> cream.</p>
<p>Acute cervicitis usually occurs in association with generalized infection of the genital tract and is diagnosed and treated according to the microbiology. Medical treatment is rarely effective in chronic cervicitis because it is difficult to identify an organism and antibiotics do not penetrate the chronic microabscesses of the cervical glands. If the cervical swab is negative, the next most effective management is diathermy of the endocervix under general anaesthesia. Following diathermy, an antibacterial cream should be placed in the vagina and the woman should be advised that the discharge may increase in amount for 2-3 weeks but will then diminish. She should also be advised to avoid intercourse for 3 weeks as coitus may cause a secondary haemorrhage.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="upper-genital-tract-infections">Upper genital tract infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#upper-genital-tract-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Acute infection of the endometrium, myometrium, Fallopian tubes and ovaries are usually the result of ascending infections from the lower genital tract causing PID.</p>
<p>However, infection may be secondary to appendicitis or other bowel infections, which sometimes give rise to a pelvic abscess. Perforation of the appendix with pelvic sepsis remains a common cause of tubal obstruction and subfertility. Pelvic sepsis may also occur during the puerperium and after pregnancy termination or after operative procedures on the cervix. Retained placental tissue and blood provide an excellent culture medium for organisms from the bowel, including Escherichia coli, Clostridium</p>
<p><img src="assets/images/image-20251213-c9f1cab6.jpeg" alt="img-215.jpeg"></p>
<p>Fig. 19.13 Marsupialization of a Bartholin's cyst or abscess. The incision is made over the medial aspect of the cyst (left) and the lining is sutured to the skin (right).
welchii or C. perfringens, Staphylococcus aureus and Streptococcus faecalis.</p>
<p>PID affects approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.7</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.7 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1.7%</span></span></span></span></span> of women between 15 and 35 years of age per year in the developed world. Up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of women with PID will have a further episode within 2 years. The disease is most common between the ages of 15 and 24 years, and particular risk factors include multiple sexual partners and procedures involving transcervical instrumentation. PID is an important cause of infertility. After a first episode <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">8 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">8%</span></span></span></span></span> of women will have evidence of tubal infertility; subsequent episodes approximately double this figure. Women with a past history of PID are 4 times more likely to have an ectopic pregnancy when they conceive.</p>
<p>40% of women who have had three or more episodes of PID have tubal damage.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="symptoms-and-signs">Symptoms and signs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#symptoms-and-signs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The symptoms of acute salpingitis include:</p>
<ul>
<li>Acute bilateral lower abdominal pain: Salpingitis is almost invariably bilateral; where the symptoms are unilateral, an alternative diagnosis should be considered</li>
<li>Deep dyspareunia</li>
<li>Abnormal menstrual bleeding</li>
<li>Purulent vaginal discharge.</li>
</ul>
<p>The signs include:</p>
<ul>
<li>Signs of systemic illness with pyrexia and tachycardia.</li>
<li>Signs of peritonitis with guarding, rebound tenderness and often localized rigidity. (It should be noted that guarding and rigidity rarely are seen if blood is in the peritoneal cavity, such as due to an ectopic pregnancy, whereas tenderness and release tenderness are seen even in the absence of peritonitis.)</li>
<li>On pelvic examination, acute pain on cervical excitation and thickening in the vaginal fornices, which may be associated with the presence of cystic tubal swellings due to pyosalpinges or pus-filled tubes; fullness in the pouch of Douglas suggests the presence of a pelvic abscess (Fig. 19.14).</li>
<li>An acute perihepatitis occurs in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10-25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of women with chlamydial PID, which may cause right upper quadrant abdominal pain, deranged liver function tests and multiple filmy adhesions between the liver surface and the parietal peritoneum, and is known as the Fitz-Hugh-Curtis syndrome.</li>
<li>A pyrexia of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>38</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">38^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">3</span><span class="mord"><span class="mord">8</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> or more, sometimes associated with rigors.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="common-organisms">Common organisms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#common-organisms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Pelvic inflammatory disease is thought to be the result of polymicrobial infection with primary infection by Chlamydia trachomatis or Neisseria gonorrhoeae (or both) allowing opportunistic infection with other aerobic bacteria and anaerobes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chlamydia">Chlamydia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chlamydia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>C. trachomatis is an obligate intracellular Gramnegative bacterium. It is the commonest bacterial sexually</p>
<p><img src="assets/images/image-20251213-1cd1740e.jpeg" alt="img-216.jpeg"></p>
<p>Fig. 19.14 Acute salpingitis: the tubes are swollen and engorged.
<img src="assets/images/image-20251213-30d4cd39.jpeg" alt="img-217.jpeg"></p>
<p>Fig. 19.15 Neisseria gonorrhoeae.
transmitted infection in Europe, Australia and North America and is thought to be the causative agent in at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of cases of PID in those areas. Prevalence rates vary from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mo>−</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">11-30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">11</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> in women attending genitourinary medicine clinics, with the peak incidence in the UK in women aged <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>24</mn></mrow><annotation encoding="application/x-tex">20-24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">24</span></span></span></span></span> years. The main sites of infection are the columnar epithelium of the endocervix, urethra and rectum, but many women remain asymptomatic. Ascent of infection to the upper genital tract occurs in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of women with cervical infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="gonorrhoea">Gonorrhoea<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gonorrhoea" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>N. gonorrhoeae is a Gram-negative intracellular diplococcus (Fig. 19.15). Infection is commonly asymptomatic or associated with vaginal discharge. In cases of PID it spreads across the surface of the cervix and endometrium and causes tubal infection within 1-3 days of contact. It is the principal cause for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>14</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">14 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">14%</span></span></span></span></span> of cases of PID and occurs in combination with Chlamydia in a further <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">8 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">8%</span></span></span></span></span>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="differential-diagnosis">Differential diagnosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#differential-diagnosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is often difficult to establish the diagnosis of acute pelvic infection with any degree of certainty. The predictive value
of clinical signs and symptoms when compared to laparoscopic diagnosis is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">65-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">65</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>. The differential diagnosis includes the following:</p>
<ul>
<li>Tubal ectopic pregnancy: Initially pain is unilateral in most cases. There may be syncopal episodes and signs of diaphragmatic irritation with shoulder tip pain. The white cell count is normal or slightly raised but the haemoglobin level is likely to be low depending on the amount of blood lost, whereas in acute salpingitis the white cell count is raised and the haemoglobin concentration is normal.</li>
<li>Acute appendicitis: The most important difference in the history lies in the unilateral nature of this condition. Pelvic examination does not usually reveal as much pain and tenderness but it must be remembered that the two conditions sometimes coexist, particularly where the infected appendix lies adjacent to the right Fallopian tube.</li>
<li>Acute urinary tract infections: These may produce similar symptoms but rarely produce signs of peritonism and are commonly associated with urinary symptoms.</li>
<li>Torsion or rupture of an ovarian cyst.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="investigations">Investigations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#investigations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When the diagnosis of acute salpingitis is suspected, the woman should be admitted to hospital. After completion of the history and general examination, swabs should be taken from the vaginal fornices and cervical canal and sent to the laboratory for culture and antibiotic sensitivity. A midstream specimen of urine should also be sent for culture to exclude a possible urinary tract infection. An additional endocervical swab should be taken for detection of Chlamydia by enzyme-linked immunoassay (ELISA) or, preferably, polymerase chain reaction (PCR). Urethral swabs may identify chlamydial infection not detected by endocervical swabs. PCR assays of urine samples have a similar of better sensitivity ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ) compared to genital tract swabs and offer a potential means for screening for chlamydial infection in asymptomatic women.</p>
<p>Examination of the blood for differential white cell count, haemoglobin estimation and C-reactive protein may help to establish the diagnosis. Blood culture is indicated if there is a significant pyrexia. The diagnosis of mild to moderate degrees of PID on the basis of history and examination findings is unreliable and, where the diagnosis is in doubt, laparoscopy is indicated.</p>
<p>Negative swabs do not exclude the possibility of PID.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management">Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When the patient is unwell and exhibits peritonitis, highgrade fever, vomiting or a pelvic inflammatory mass, she should be admitted to hospital and managed as follows:</p>
<ul>
<li>Fluid replacement by intravenous therapy - vomiting and pain often result in dehydration.</li>
<li>When PID is clinically suspected, antibiotic therapy should be commenced. Antibiotic therapy initially prescribed for clinically diagnosed PID should be effective against C. trachomatis, N. gonorrhoeae and the anaerobes characterizing bacterial vaginosis. If the woman is acutely unwell, treatment should be started with an antibiotic such as cefuroxime and metronidazole given intravenously with oral doxycycline until the acute phase of the infection begins to resolve. Treatment with oral metronidazole and doxycycline should then be continued for 7 and 14 days, respectively.</li>
<li>Pain relief with non-steroidal anti-inflammatory drugs.</li>
<li>If the uterus contains an intrauterine device, it should be removed as soon as antibiotic therapy has been commenced.</li>
<li>Bed rest - immobilization is essential until the pain subsides.</li>
<li>Abstain from intercourse.</li>
</ul>
<p>Women who consulted after 3 days of symptoms had an almost threefold increased risk of impaired infertility after PID compared with those who consulted promptly.</p>
<p>Patients who are systemically well can be treated as outpatients, with a single dose of azithromycin and a 7 -day course of doxycycline, reviewed after 48 hours.</p>
<p>In all cases of confirmed sexually transmitted infection, it is important to treat the partner and arrange appropriate contact tracing.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indications-for-surgical-intervention">Indications for surgical intervention<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications-for-surgical-intervention" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In most cases, conservative management results in complete remission. Laparotomy is indicated where the condition does not resolve with conservative management and where there is a pelvic mass.
In most cases, the mass will be due to a pyosalpinx or tubo-ovarian abscess. This can either be drained or a salpingectomy can be performed.
<img src="assets/images/image-20251213-fd372a32.jpeg" alt="img-218.jpeg"></p>
<p>Fig. 19.16 Chronic pelvic inflammatory disease: a sheet of fine adhesions covering the tubes and ovary, which is buried beneath the tube.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chronic-pelvic-infection">Chronic pelvic infection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chronic-pelvic-infection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Acute pelvic infections may progress to a chronic state with dilatation and obstruction of the tubes forming bilateral hydrosalpinges with multiple pelvic adhesions (Fig.19.16).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="symptoms-and-signs">Symptoms and signs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#symptoms-and-signs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Symptoms are varied but include:</p>
<ul>
<li>chronic pelvic pain</li>
<li>chronic purulent vaginal discharge</li>
<li>epimenorrhagia and dysmenorrhoea</li>
<li>deep-seated dyspareunia, or just</li>
<li>infertility.</li>
</ul>
<p>Chronic salpingitis is also associated with infection in the connective tissue of the pelvis known as parametritis.</p>
<p>On examination, there can be a purulent discharge from the cervix. The uterus is often fixed in retroversion, and there is thickening in the fornices and pain on bimanual examination.</p>
<p>Chronic pelvic pain occurs in 25-75% of women with a past history of PID.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management">Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Conservative management of this condition is rarely effective and the problem is only eventually resolved by clearance of the pelvic organs. Women with a history of PID are 8 times more likely to have a hysterectomy than the general population. If the problem is mainly infertility due to tubal disease, the best treatment is IVF. Tubal removal prior to IVF is usually indicated if hydrosalpinges are present because this improves the pregnancy rate achieved.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="human-immunodeficiency-virus">Human immunodeficiency virus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#human-immunodeficiency-virus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Human immunodeficiency virus (HIV)-1 and HIV-2 are RNA retroviruses characterized by their tropism for the human CD4 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>(helper) T lymphocyte. The proportion of cells infected is initially low and there is a prolonged latent phase between infection and clinical signs. Transmission occurs by sex, infected blood products, shared needles, breastfeeding and at the time of delivery. Risk groups include intravenous drug abusers and their partners, the partners of bisexual men, haemophiliacs, prostitutes and immigrants from high-risk areas. Although HIV infection is more common in men in the developed world, anonymous testing shows that <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.3%</span></span></span></span></span> of pregnant women in London are infected and it is now the most common cause of death in African American females aged 24-35 years in the US. In parts of sub-Saharan Africa, 20-30% of all pregnant women are HIV positive. Vertical transmission rates can be reduced from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> to less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> by antenatal treatment with the modern antiretroviral drugs, delivery by elective caesarean section and avoidance of breastfeeding. Although HIV infection was a life-ending sentence for most people in the past as most developed acquired immunodeficiency syndrome (AIDS) as an end result within a few years of becoming infected with the HIV, with modern continuous therapy most are able to be controlled and progression to AIDS is much less common.</p>
<p>The main clinical states can be identified as:</p>
<ul>
<li>a 'flu-like' illness 3-6 months after infection, associated with seroconversion</li>
<li>asymptomatic impaired immunity</li>
<li>persistent generalized lymphadenopathy</li>
<li>AIDS-related complex with pathognomonic infections or tumours.
Common opportunistic infections include Candida, HSV, HPV, Mycobacterium spp., Cryptosporidium spp., Pneumocystis carinii and cytomegalovirus. Non-infective manifestations include weight loss, diarrhoea, fever, dementia, Kaposi's sarcoma and an increased risk of cervical cancer.</li>
</ul>
<p>The diagnosis is made by detecting antibodies to the virus, although these may take up to 3 months to appear.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="disorders-of-female-sexual-function">DISORDERS OF FEMALE SEXUAL FUNCTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#disorders-of-female-sexual-function" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Disorders of sexual function are reported by up to a third of women. Sometimes they are accompanied by awareness of the underlying disturbance but often, as with other emotional difficulties, the link between cause and effect is obscure even to the sufferer. Sexual problems may therefore appear in the guise of mental or physical illness or disturbances of behaviour and relationships, and thus form a part of the working experience not only of doctors
but of anyone in the 'caring' professions. Lack of knowledge about sex and the anatomy of the genital tract remain common and a source of anxiety.</p>
<p>The commonest complaints are:</p>
<ul>
<li>painful sex (dyspareunia)</li>
<li>vaginismus</li>
<li>loss of desire (libido)</li>
<li>orgasmic dysfunction.</li>
</ul>
<p>Pay attention to the non-verbal communication during the consultation and examination.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dyspareunia">Dyspareunia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dyspareunia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Dyspareunia is defined as painful intercourse. It is predominantly but not exclusively a female problem. The aetiology is divided on the basis of whether the problem is superficial (at the entrance to the vagina) or deep (only occurs with deep penile insertion) and it is therefore particularly important to obtain a concise history.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="superficial-dyspareunia">Superficial dyspareunia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#superficial-dyspareunia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Pain felt on penetration is generally associated with a local lesion of the vulva or vagina from one of the following causes:</p>
<ul>
<li>Infection: Local infections of the vulva and vagina commonly include monilial and trichomonal vulvovaginitis. Infections involving Bartholin's glands also cause dyspareunia.</li>
<li>Narrowing of the introitus may be congenital, with a narrow hymenal ring or vaginal stenosis. It may sometimes be associated with a vaginal septum. The commonest cause of narrowing of the introitus is the over-vigorous suturing of an episiotomy wound or vulval laceration or following vaginal repair of a prolapse.</li>
<li>Menopausal changes: Atrophic vaginitis or the narrowing of the introitus and the vagina from the effects of oestrogen deprivation may cause dyspareunia. Atrophic vulval conditions such as lichen sclerosus can also cause pain.</li>
<li>Vulvodynia: This is a condition of unknown aetiology characterized by persisting pain over the vulva.</li>
<li>Functional changes: Lack of lubrication associated with inadequate sexual stimulation and emotional problems will result in dyspareunia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="deep-dyspareunia">Deep dyspareunia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#deep-dyspareunia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Pain on deep penetration is often associated with pelvic pathology. Any woman who develops deep dyspareunia after enjoying a normal sexual life should be considered</p>
<p>to have an organic cause for her pain until proved otherwise. The common causes of deep dyspareunia include:</p>
<ul>
<li>Acute or chronic pelvic inflammatory disease: including cervicitis, pyosalpinx and salpingooophoritis (Fig. 19.16). The uterus may become fixed. Ectopic pregnancy must also be considered in the differential diagnosis in this group.</li>
<li>Retroverted uterus and prolapsed ovaries: If the ovaries prolapse into the pouch of Douglas and become fixed in that position, intercourse is painful on deep penetration.</li>
<li>Endometriosis: Both the active lesions and the chronic scarring of endometriosis may cause pain.</li>
<li>Neoplastic disease of the cervix and vagina: At least part of the pain in this situation is related to secondary infection.</li>
<li>Postoperative scarring: This may result in narrowing of the vaginal vault and loss of mobility of the uterus. The stenosis commonly occurs following vaginal repair and, less often, following repair of a high vaginal tear. Vaginal scarring may also be caused by chemical agents such as rock salt, which, in some countries, is put into the vagina in order to produce contracture.</li>
<li>Foreign bodies: Occasionally, a foreign body in the vagina or uterus may cause pain in either the male or female partner. For example, the remnants of a broken needle or partial extrusion of an intrauterine device may cause severe pain in the male partner.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="apareunia">Apareunia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#apareunia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Apareunia is defined as the 'absence' of intercourse or the inability to have intercourse at all. The common causes are:</p>
<ul>
<li>congenital absence of the vagina</li>
<li>imperforate hymen.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment">Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Accurate diagnosis is dependent on careful history taking and a thorough pelvic examination. The treatment will therefore be dependent on the cause. Congenital absence of the vagina can be successfully treated by surgical correction (vaginoplasty) and removal of the imperforate hymen is effective.</p>
<p>Medical treatment for deep dyspareunia includes the use of antibiotics and antifungal agents for pelvic infection, and the use of local or oral hormone therapy for post-menopausal atrophic vaginitis. Treatment for endometriosis is discussed in Chapter 17. Surgical treatment includes correction of any stenosis, excision of painful scars where appropriate, and reassurance and sexual counselling is necessary in functional disorders.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vaginismus">Vaginismus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vaginismus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Vaginismus is the symptom resulting from spasm of the pelvic floor muscles and adductor muscles of the thigh, which prevents or results in pain on attempted penile penetration. A physical barrier may be present but is not necessarily causative. The woman may be unable to allow anyone to touch the vulva. Primary vaginismus is usually due to fear of penetration. Secondary vaginismus is more likely to be the result of an experience of pain with intercourse after infection, sexual assault, a difficult delivery or surgery. Even after the condition has improved, fear of further pain may lead to involuntary contraction of the vaginal muscles, which is in itself painful, completing the vicious circle. Encouraging the patient to explore her own vagina and feel for herself that there is no abnormality or pain can help break this cycle. Resort to surgery is likely to confirm the patient's fears of abnormality and often leaves the presenting problem unchanged</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="loss-of-libido">Loss of libido<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#loss-of-libido" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Loss of desire is the commonest symptom in women complaining of sexual dysfunction. If it has always been present it may be a result of a repression of sexual thoughts as a result of upbringing or religious belief or a feeling that sex is dirty or unsuitable in some way. It may represent differences between the expectations of the couple. Loss of desire in a relationship that was previously satisfactory is more likely to be due to:</p>
<ul>
<li>major life events - marriage, pregnancy</li>
<li>being ill, depressed or grieving</li>
<li>endocrine or neurological disorders</li>
<li>pain on intercourse</li>
<li>medication (Box 19.3)</li>
<li>menopause</li>
<li>fear of pregnancy or infection</li>
<li>stress or chronic anxiety.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment">Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Helping the couple to look at the underlying reasons involved helps to identify what they might do to correct the situation. Relationship therapy may be an option for suitably motivated couples. Where loss of libido is a</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-19-3-drugs-that-may-impair-libido">Box 19.3 Drugs that may impair libido<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-19-3-drugs-that-may-impair-libido" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Antiandrogens - cyproterone</li>
<li>Anti-oestrogens - tamoxifen and some contraceptives</li>
<li>Cytotoxic drugs</li>
<li>Sedatives</li>
<li>Narcotics</li>
<li>Antidepressants</li>
<li>Alcohol and illegal drug misuse</li>
</ul>
<p>feature of menopausal symptoms this will occasionally respond to low dose testosterone therapy, along with conventional oestrogen hormone replacement therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="orgasmic-dysfunction">Orgasmic dysfunction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#orgasmic-dysfunction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>About 5-10% of women have not experienced orgasm by the age of 40 years. Orgasmic dysfunction is often linked to myths about it being the responsibility of the man to bring the woman to orgasm. The problem can be helped by breaking down inhibitions about self-stimulation and encouraging better communication during foreplay and intercourse.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="disorders-of-male-sexual-function">DISORDERS OF MALE SEXUAL FUNCTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#disorders-of-male-sexual-function" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Normal male sexual function is largely mediated through the autonomic nervous system. Erection occurs as a result of parasympathetic (cholinergic) outflow causing vasocongestion. Orgasm and ejaculation are predominantly sympathetic (adrenergic). Emission occurs by the sequential expulsion of fluid from the prostate gland, vas deferens and seminal vesicles into the posterior urethra. Emission and closure of the vesical neck are mediated by alphaadrenergic systems, while opening of the external sphincter (to allow antegrade ejaculation) is mediated through the somatic efferent of the pudendal nerve. Ejaculation is stimulated by the dorsal nerve of the penis and involves contractile activity of the bulbocavernous and ischiorectal muscles as well as the posterior urethra. These responses are easily inhibited by cortical influences or by impaired hormonal, neural or vascular mechanisms.</p>
<p>The principal features of sexual dysfunction in men are:</p>
<ul>
<li>failure to achieve erection</li>
<li>problems with ejaculation</li>
<li>loss of libido.</li>
</ul>
<p>All or any of these may be present from adolescence or have their onset at any time of life after a period of healthy sexuality. The causes of loss of libido have been previously described above under female sexual dysfunction.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="erectile-dysfunction">Erectile dysfunction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#erectile-dysfunction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Erectile dysfunction or impotence, the inability in the male to achieve erection for satisfactory penetration of the vagina, is the most common problem seen.</p>
<p>It is now recognized that a high proportion (50%) of such men, especially those over the age of 40 years, have an underlying organic cause. Of these diabetes is the commonest as a result of damage to the large and small blood vessels and neuropathy. Neurological impotence may also be caused by injuries to the spinal cord, brain and prostate, and multiple sclerosis. Hyperprolactinaemia is associated
with erectile dysfunction as well as with loss of libido. While androgens are not essential for erection they influence it through their effects on libido and nitrogen oxide release in the cavernosum. Recreational drugs such as alcohol are known to cause erectile failure and more than 200 prescription drugs are known to have it as a side effect. The most common of these are antihypertensive and diuretic agents. Others include antidepressant and sedative medications.</p>
<p>In the younger age group the cause is more likely to be psychogenic. Depression, reactive or endogenous, is an important aetiological or concomitant condition. The stress provoked by timing intercourse with ovulation may result in erectile dysfunction in couples undergoing treatment for infertility.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment">Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Mild psychogenic cases will usually respond to simple measures such as counselling, sex therapy and sensate focusing exercises.</p>
<p>Treatment with bromocriptine may restore sexual function in cases where prolactin levels are raised.</p>
<p>Intracavernous injection of prostaglandin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">E</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{E}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">E</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is effective in patients with both psychogenic and organic causes of erectile dysfunction, although pain and the fear of injection cause some patients to stop treatment. Sildenafil is an effective orally administered alternative, with up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of attempts at intercourse being successful compared with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>22</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">22 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">22%</span></span></span></span></span> with placebo. It promotes erection by potentiating the effect of nitric oxide on vascular smooth muscle, thus increasing blood flow to the penis. Concurrent use in patients taking nitrate therapy for myocardial ischaemic disease causes significant hypotension.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ejaculatory-problems">Ejaculatory problems<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ejaculatory-problems" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Ejaculatory dysfunction encompasses premature, retarded, retrograde and absent ejaculation. Anejaculation and premature ejaculation are more often seen in younger patients. Retrograde ejaculation is often a result of an organic cause or after surgery, e.g. prostate operations. The diagnosis is usually made on the presenting history.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment">Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>For premature ejaculation the squeeze technique described by Masters and Johnson involves application of pressure to the top of the penis. This diminishes the urge to ejaculate, although the success rate is poor. Alternative approaches include the use of a local anaesthetic and selective serotonin-reuptake inhibitors. Anejaculation and retarded ejaculation can be treated by teaching masturbation techniques, couple counselling and sensate focus exercises. Retrograde ejaculation is regarded mainly as a fertility problem. Treatment may involve surgery or drug therapy with alpha-adrenoceptor agonists.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="essential-information">Essential information<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#essential-information" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="intrauterine-devices">Intrauterine devices<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#intrauterine-devices" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Prevent implantation and fertilization</li>
<li>Inert or pharmacologically active</li>
<li>Best for older multiparous women</li>
<li>Can be inserted at time of delivery</li>
<li>Replace after 3-5 years</li>
<li>Failure rate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><mo>−</mo><mn>0.8</mn><mi mathvariant="normal">/</mi><mn>100</mn></mrow><annotation encoding="application/x-tex">0.2-0.8 / 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.8/100</span></span></span></span></span> women years</li>
<li>Complications: perforation, pelvic inflammatory disease, abnormal bleeding, ectopic pregnancy</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="combined-oral-contraceptive-pill">Combined oral contraceptive pill<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#combined-oral-contraceptive-pill" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Suppress gonadotrophins, but have other effects as well</li>
<li>Oestradiol and progestogen</li>
<li>Pregnancy, thromboembolism and liver disease contraindicate</li>
<li>1.3/100 000 mortality</li>
<li>Failure rate 0.3/100 women years</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sterilization">Sterilization<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sterilization" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>1/200 failure rate (female)</li>
<li>Increased risk of ectopic pregnancy if procedure fails</li>
<li>Permanence</li>
<li>Risks of surgery</li>
<li>Alternatives</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="termination-of-pregnancy">Termination of pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#termination-of-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Methods:</li>
<li>surgical</li>
<li>medical</li>
<li>Complications:</li>
<li>bleeding</li>
<li>infection</li>
<li>infertility</li>
<li>retained tissue</li>
<li>regret</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vulvovaginitis">Vulvovaginitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vulvovaginitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Commonest infection of genital tract</li>
<li>Presents as pruritus, dyspareunia or discharge</li>
<li>Common causes are Trichomonas, bacterial vaginosis and Candida</li>
<li>Predisposing factors include pregnancy, diabetes, contraceptive pill</li>
<li>Can be diagnosed by examination of fresh wet preparation of vaginal discharge</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="herpes-genitalis">Herpes genitalis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#herpes-genitalis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Caused by herpes simplex virus</li>
<li>Presents with pain, bleeding and vesicles or shallow ulcers on the vagina/vulva</li>
<li>Associated with cervical dysplasia</li>
<li>Tends to be recurrent but with decreasing severity</li>
<li>Can be transmitted to the neonate during vaginal delivery if active</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="infections-of-the-cervix">Infections of the cervix<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#infections-of-the-cervix" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Acute (associated with generalized infection) or chronic</li>
<li>Discharge, dyspareunia, low abdominal pain or backache, urinary symptoms and postcoital bleeding</li>
<li>Can cause subfertility</li>
<li>Difficult to isolate an organism when chronic</li>
<li>Treatment includes appropriate antibiotics and cautery</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="upper-genital-tract-infection">Upper genital tract infection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#upper-genital-tract-infection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Usually from ascending lower genital tract infection</li>
<li>Can follow abortion, normal delivery or an operative procedure on the cervix.</li>
<li>Commonly due to C. trachomatis or N. gonorrhoeae when sexually transmitted</li>
<li>Presents as pain, fever, discharge and irregular periods</li>
<li>Bilateral pain on cervical excitation and raised white cell count</li>
<li>Differential diagnosis includes ectopic pregnancy, urinary tract infection and appendicitis</li>
<li>Management includes fluid replacement, antibiotics, analgesia and rest</li>
<li>Surgery (laparoscopy or laparotomy) is indicated to confirm diagnosis if in doubt, for drainage of pelvic mass and to clear pelvis in unresponsive chronic disease</li>
<li>Major cause of infertility worldwide, resulting in tubal obstruction in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of cases after three or more attacks</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hiv-infection">HIV infection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hiv-infection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Retrovirus infection of T-helper cells and central nervous system</li>
<li>Transmitted by sex, blood transfusion or to offspring (delivery or due to breast feeding)</li>
<li>Diagnosis by serology, differential lymphocyte count or opportunistic infection</li>
<li>Can be asymptomatic, cause generalized malaise and lymphadenopathy or AIDS</li>
<li>Rates of vertical transmission can be reduced by drug treatment, elective caesarean section and avoiding breastfeeding</li>
<li>Incidence in heterosexuals increasing</li>
<li>With current retroviral therapy progressing to AIDS is rare</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="disorders-of-sexual-function">Disorders of Sexual Function<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#disorders-of-sexual-function" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Dyspareunia:</li>
<li>often caused by infection, atrophic conditions or lack of lubrication</li>
<li>deep dyspareunia indicates pelvic pathology</li>
<li>Vaginismus and loss of libido are often psychogenic</li>
<li>Failure to achieve erection - organic (50%) or psychogenic</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="gynaecological-oncology">Gynaecological oncology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gynaecological-oncology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hextan Y.S. Ngan and Karen K.L. Chan</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="learning-outcomes">Learning outcomes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#learning-outcomes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter you should be able to:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="knowledge-criteria">Knowledge criteria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#knowledge-criteria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Understand the epidemiology, aetiology, diagnosis, management and prognosis of gynaecological cancer</li>
<li>Describe the aetiology, epidemiology and presentation of the common neoplasms of the female genital tract including:</li>
<li>Vulval and cervical intraepithelial neoplasia</li>
<li>Vulval and vaginal carcinoma</li>
<li>Cervical carcinoma</li>
<li>Endometrial hyperplasia</li>
<li>Endometrial adenocarcinoma</li>
<li>Ovarian epithelial and germ cell tumours</li>
<li>Discuss the role of minor procedures and diagnostic imaging procedures in the management of gynaecological cancers including:</li>
<li>Cervical and endometrial sampling</li>
<li>Ultrasound</li>
<li>Laparoscopy</li>
<li>Hysteroscopy</li>
<li>Magnetic resonance imaging and computerized tomography</li>
<li>List the short- and long-term complications of medical and surgical therapies for gynaecological cancer</li>
<li>Discuss the role of screening and immunization in the prevention of female genital tract malignancy</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-competencies">Clinical competencies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-competencies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Counsel a woman about screening for the preclinical phase of squamous cell carcinoma of the cervix</li>
<li>Plan initial investigation of women presenting with symptoms of genital tract malignancy</li>
<li>Communicate sensitively with a woman and her family about the diagnosis of gynaecological cancer</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="professional-skills-and-attitudes">Professional skills and attitudes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#professional-skills-and-attitudes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Discuss the principles of palliative care in gynaecological cancers</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lesions-of-the-vulva">LESIONS OF THE VULVA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lesions-of-the-vulva" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vulval-intraepithelial-neoplasia">Vulval intraepithelial neoplasia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vulval-intraepithelial-neoplasia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Vulval intraepithelial neoplasia (VIN) is a condition characterized by disorientation and loss of epithelial architecture extending through the full thickness of the epithelium. In the past, the World Health Organization classified VIN into VIN-1, 2 and 3 based on the extent to which normal epithelium is replaced by abnormal dysplastic cells. However, since VIN-1 mainly corresponds with condyloma that is not a precancerous lesion, the term VIN-1 has been abandoned and VIN now refers to the previous VIN-2 and 3 in the latest classification of the International Society for the Study of Vulvar Disease.</p>
<p>VIN is categorized into usual VIN (classic VIN or Bowen's disease) and differentiated VIN (d-VIN) based on the distinctive pathological features (Box 20.1). Usual VIN often occurs in young women between 30-50 years and is associated with cigarette smoking and human papilloma virus (HPV) infection. Patients can be asymptomatic, or they may complain of pruritus, pain, dysuria and ulceration. Lesions can be white, pink or pigmented, in the forms of plaques or papules. They are most frequently found in labia and posterior fourchette; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3-4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span> of usual VIN may progress to invasive disease.
d-VIN occurs in post-menopausal women and accounts for only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2-10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of all VIN. It is associated with squamous hyperplasia, lichen sclerosus and lichen simplex chronicus, and is considered as the precursor of most HPVnegative invasive keratinizing squamous cell carcinomas. Patients have similar symptoms as for lichen sclerosus. Grey, white, red nodules, plaques or ulcers may be found. It is found in up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of adjacent cancer, and has a higher malignant potential than usual VIN. It is hence important to exclude malignancy when d-VIN is found.</p>
<p>Unlike VIN, which arises from squamous epithelium, extramammary Paget's disease arises from apocrine</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-20-1-vulval-intra-epithelial-neoplasia-vin">Box 20.1 Vulval intra-epithelial neoplasia (VIN)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-20-1-vulval-intra-epithelial-neoplasia-vin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Squamous VIN
Usual VIN (formerly classic VIN or Bowen's disease)
Differentiated VIN (formerly 'simplex' VIN)
Non-squamous VIN
Paget's disease
glandular epithelium. The appearance of the lesions is variable, but they are papular and raised, may be white, grey, dull red or various shades of brown, and may be localized or widespread. These conditions are rare, with an incidence of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.53</mn><mi mathvariant="normal">/</mi><mn>100000</mn></mrow><annotation encoding="application/x-tex">0.53 / 100000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.53/100000</span></span></span></span></span>, and commonly occur in women over the age of 50 years. Paget's disease is associated with underlying adenocarcinoma or primary malignancy elsewhere in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of cases, mainly breast and bowel.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management">Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is important to establish the diagnosis by biopsy (Fig. 20.1) and to search for intraepithelial neoplasia in other sites like the cervix and vagina, particularly when usual VIN is found. Treatment of usual VIN includes imiquimod, an immune modifier, laser therapy, and superficial excision of the skin lesion. There is no role for medical treatment in d-VIN, and surgical excision tends to be more radical than that for usual VIN. Recurrence is common and because there is a risk of malignant progression especially in d-VIN, long-term follow-up is essential.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cancers-of-the-vulva">Cancers of the vulva<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cancers-of-the-vulva" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Carcinoma of the vulva accounts for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1-4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span> of female malignancies: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of the lesions are squamous cell carcinomas, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> are adenocarcinomas, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> are basal carcinomas and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> are malignant melanomas. Carcinoma of the vulva most commonly occurs in the sixth and seventh decades.</p>
<p>Vulvar cancer has two distinct histological patterns with two different risk factors. The more common basoloid/ warty types occur mainly in younger women and are associated with usual VIN and HPV infection sharing similar risk factors as cervical cancer. The keratinizing types occur in older women and are associated with lichen sclerosus. As noted above, there may be foci of d-VIN adjacent to the main tumour.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="symptoms">Symptoms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#symptoms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The patient with vulval carcinoma experiences pruritus and notices a raised lesion on the vulva, which may ulcerate and bleed (Fig. 20.2). Malignant melanomas are usually single, hyperpigmented and ulcerated. Vulval carcinoma most frequently develops on the labia majora ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of cases) but may also grow on the prepuce of the
<img src="assets/images/image-20251213-6323ddff.jpeg" alt="img-219.jpeg"></p>
<p>Fig. 20.1 Diagnosis of vulval skin lesions using Keye's punch biopsy under local anaesthetic.
<img src="assets/images/image-20251213-5eb2e836.jpeg" alt="img-220.jpeg"></p>
<p>Fig. 20.2 Ulcerative squamous cell carcinoma of the vulva.</p>
<p>clitoris, the labia minora, Bartholin's glands and in the vestibule of the vagina.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mode-of-spread">Mode of spread<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mode-of-spread" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Spread occurs both locally and through the lymphatic system. The lymph nodes involved are the superficial and deep inguinal nodes and the femoral nodes (Fig. 20.3). Pelvic lymph nodes, except in primary lesions involving the clitoris, have usually only secondary involvement. Vascular spread is late and rare. The disease usually progresses slowly and the terminal stages are accompanied by extensive ulceration, infection, haemorrhage and remote metastatic disease. In some <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of cases, lymph nodes are involved on both sides. Stages are defined by the International Federation of Obstetrics and Gynaecology (FIGO) on the basis of surgical rather than clinical findings (Table 20.1).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment">Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Stage IA disease can be treated by wide local excision. Stage IB lesions that are at least 2 cm lateral to the midline are treated by wide local excision and unilateral groin node dissection. All other stages are treated by wide radical local excisions or radical vulvectomy and bilateral groin node dissection (Fig. 20.4). Sentinel node dissection may replace conventional node dissection in future. Postoperative radiotherapy has a role in patients where the tumour extends close to the excision margin or there is involvement of the
groin nodes. Preoperative radiotherapy may be used in cases of extensive disease to reduce the tumour volume. Complications of radical vulvectomy and groin node dissection include wound breakdown, lymphocyst and lymphoedema (30%), secondary bleeding, thromboembolism, sexual dysfunction and psychological morbidity. Response to chemotherapy (bleomycin) is generally poor. Patients are followed up at intervals of 3-6 months for 5 years.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="prognosis">Prognosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prognosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Prognosis is determined by the size of the primary lesion and lymph node involvement. The overall survival rate in operable cases without lymph node involvement is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> and is up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>98</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">98 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">98%</span></span></span></span></span> where the primary lesion is less than 2 cm in size. This falls to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50-60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> with node involvement and is less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> in patients with bilateral lymph node involvement. Malignant melanoma and adenocarcinoma have a poor prognosis, with a 5-year survival of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="neoplastic-lesions-of-the-vaginal-epithelium">NEOPLASTIC LESIONS OF THE VAGINAL EPITHELIUM<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#neoplastic-lesions-of-the-vaginal-epithelium" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vaginal-intraepithelial-neoplasia">Vaginal intraepithelial neoplasia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vaginal-intraepithelial-neoplasia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Vaginal intraepithelial neoplasia (VAIN) is usually multicentric and tends to be multifocal and associated with similar lesions of the cervix. The condition is
<img src="assets/images/image-20251213-0383350d.jpeg" alt="img-221.jpeg"></p>
<p>Fig. 20.3 Lymphatic drainage of the vulva.</p>
<p><img src="assets/images/image-20251213-2cfb0593.jpeg" alt="img-222.jpeg"></p>
<p>Fig. 20.4 Block dissection of the lymph nodes in surgical treatment of malignant disease of the vulva.</p>
<table><thead><tr><th style="text-align: center;">Stage I</th><th style="text-align: center;">Tumour confined to the vulva: &lt;br&gt; Stage IA: Lesions <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≤</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">\leq 2 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≤</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> in size, confined to the vulva or perineum and with stromal invasion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≤</mo><mn>1.0</mn><msup><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">\leq 1.0 \mathrm{~mm}^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≤</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span>, no nodal metastasis &lt;br&gt; Stage IB: Lesions <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;2 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> in size or with stromal invasion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>1.0</mn><msup><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">&gt;1.0 \mathrm{~mm}^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span>, confined to the vulva or perineum, with negative nodes</th></tr></thead><tbody><tr><td style="text-align: center;">Stage II</td><td style="text-align: center;">Tumour of any size with extension to adjacent perineal structures (lower third of urethra, lower third of vagina, anus) with negative nodes</td></tr><tr><td style="text-align: center;">Stage III</td><td style="text-align: center;">Tumour of any size with or without extension to adjacent perineal structures (lower third of urethra, lower third of vagina, anus) with positive inguinofemoral lymph nodes: &lt;br&gt; Stage IIIA: (i) With 1 lymph node metastasis ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≥</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">\geq 5 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≥</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> ), or (ii) 1-2 lymph node metastasis(es) ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;5 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> ) &lt;br&gt; Stage IIIB: (i) With 2 or more lymph node metastases ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≥</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">\geq 5 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≥</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> ), or (ii) 3 or more lymph node metastases <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mo>&lt;</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(&lt;5 \mathrm{~mm})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mclose">)</span></span></span></span></span> &lt;br&gt; Stage IIIC: With positive nodes with extracapsular spread</td></tr><tr><td style="text-align: center;">Stage IV</td><td style="text-align: center;">Tumour invades other regional (upper two-thirds of urethra, upper two-thirds of vagina), or distant structures: &lt;br&gt; Stage IVA: Tumour invades any of the following: (i) upper urethral and/or vaginal mucosa, bladder mucosa, rectal mucosa, or fixed to pelvic bone, or (ii) fixed or ulcerated inguinofemoral lymph nodes &lt;br&gt; Stage IVB: Any distant metastasis including pelvic lymph nodes</td></tr><tr><td style="text-align: center;">*The depth of invasion is defined as the measurement of the tumour from the epithelial stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion.</td><td style="text-align: center;"></td></tr></tbody></table>
<p>asymptomatic and tends to be discovered because of a positive smear test or during colposcopy for abnormal cytology, often after hysterectomy. There is a risk of progression to invasive carcinoma, but the disease remains superficial until then and can be treated by surgical excision, laser ablation or cryosurgery.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vaginal-adenosis">Vaginal adenosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vaginal-adenosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is the presence of columnar epithelium in the vaginal epithelium and has been found in adult females whose mothers received treatment with diethylstilboestrol during pregnancy. The condition commonly reverts to normal</p>
<p>squamous epithelium, but in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span> of cases the lesion progresses to vaginal adenocarcinoma. It is therefore important to follow these women carefully with serial cytology.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vaginal-malignancy">Vaginal malignancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vaginal-malignancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Invasive carcinoma of the vagina may be a squamous carcinoma or, occasionally, an adenocarcinoma. Primary lesions arise in the sixth and seventh decades, but are rare in the UK. The incidence of adenocarcinoma, typically clear cell, associated with in utero exposure of diethylstilboestrol has declined since this drug was withdrawn from use in pregnancy.</p>
<p>Secondary deposits from cervical carcinoma and endometrial carcinoma are relatively common in the upper third of the vagina and can sometimes occur in the lower vagina through lymphatic spread.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="symptoms">Symptoms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#symptoms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The symptoms include irregular vaginal bleeding and offensive vaginal discharge when the tumour becomes necrotic and infection supervenes. Local spread into the rectum, bladder or urethra may result in fistula formation. The tumour may appear as an exophytic lesion or as an ulcerated, indurated mass.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="method-of-spread">Method of spread<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#method-of-spread" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Tumour spread, as previously stated, occurs by direct infiltration or by lymphatic extension. Lesions involving the upper half of the vagina follow a pattern of spread similar to that of carcinoma of the cervix. Tumours of the lower half of the vagina follow a similar pattern of spread to that of carcinoma of the vulva.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment">Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The diagnosis is established by biopsy of the tumour. Staging is made before commencing treatment (Table 20.2).</p>
<table><thead><tr><th style="text-align: left;">Stage 0</th><th style="text-align: left;">Intraepithelial carcinoma</th></tr></thead><tbody><tr><td style="text-align: left;">Stage I</td><td style="text-align: left;">Limited to the vaginal walls</td></tr><tr><td style="text-align: left;">Stage II</td><td style="text-align: left;">Involves the subvaginal tissue but has &lt;br&gt; not extended to the pelvic wall</td></tr><tr><td style="text-align: left;">Stage III</td><td style="text-align: left;">The tumour has extended to the lateral &lt;br&gt; pelvic wall</td></tr><tr><td style="text-align: left;">Stage IV</td><td style="text-align: left;">The lesion has extended to involve &lt;br&gt; adjacent organs (IVA) or has spread to &lt;br&gt; distant organs (IVB)</td></tr></tbody></table>
<p>The primary method of treatment is by radiotherapy both by external beam therapy and brachytherapy.</p>
<p>Surgical treatment can also be considered in selected patients. For example, radical hysterectomy or vaginectomy and pelvic lymph node dissection can be considered in patients with stage I disease in the upper vagina, radical vulvectomy may be needed in stage I disease in the lower vagina, and pelvic exenteration may be considered in patients with localized metastatic disease to the bladder or rectum without parametrial or lymph node metastasis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="prognosis">Prognosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prognosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Results of treatment depend on the initial staging and on the method of therapy. Stages I and II have a 5-year survival of around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> but this figure falls to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30-40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> for stages III and IV. Adenocarcinoma of the vagina, which often occurs in young females, also responds well to irradiation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lesions-of-the-cervix">LESIONS OF THE CERVIX<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lesions-of-the-cervix" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="screening-for-cervical-cancer">Screening for cervical cancer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#screening-for-cervical-cancer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The aim of cervical screening programmes is to detect the non-invasive precursor of cervical cancer, cervical intraepithelial neoplasia (CIN), in the asymptomatic population in order to reduce mortality and morbidity. The NHS national cervical screening programme was introduced in England and Wales in 1988, and by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>199180</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">199180 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">199180%</span></span></span></span></span> of all women between the ages of 20 and 65 were being tested on a 5 -yearly basis. Since then mortality from cervical cancer has fallen by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">7 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">7%</span></span></span></span></span> a year. Currently all women aged between 25 and 65 are invited for screening every 3-5 years. In Australia screening commences at the age of 18 or 2 years after the start of sexual activity and takes place every 2 years. In taking a cervical cytology, the speculum should be introduced with a minimum of artificial lubricant. Cells are taken from around the cervix from the whole of the transformation zone with a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>360</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">360^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">36</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span> sweep using an Ayres or Aylesbury spatula or a plastic cervical brush and fixed in an appropriate manner (see Chapter 15). Cervical cytology (Figs 20.5 and 20.7) is primarily for screening for squamous lesions and cannot reliably exclude endocervical disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-of-cervical-cytology">Classification of cervical cytology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-cervical-cytology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The terminology used in the UK for reporting cervical smears was introduced by The British Society for Clinical Cytology in 1986 (Table 20.3).</p>
<p>The term dyskaryosis is used to describe those cells that lie between normal squamous and frankly malignant cells</p>
<p><img src="assets/images/image-20251213-83137c58.jpeg" alt="img-223.jpeg"></p>
<p>Fig. 20.5 Normal cervical smear showing superficial (pink) and intermediate (blue/green) exfoliated cervical cells (low power magnification).
<img src="assets/images/image-20251213-1839b996.jpeg" alt="img-224.jpeg"></p>
<p>Fig. 20.6 Cell layers in the stratified squamous epithelium of the cervix and vagina.
and exhibit degrees of nuclear changes before malignancy (Fig. 20.7). Cells showing abnormalities that fall short of dyskaryosis are described as borderline. Atypical glandular cells may represent premalignant disease of the endocervix or endometrium.</p>
<p>Malignant cells show nuclear enlargement at the expense of cytoplasmic mass (Fig. 20.8). The nuclei may assume a lobulated outline. There is increased intensity of staining of the nucleus and an increase in the number of mitotic figures.</p>
<p>The Bethesda system of classification used in the US (Table 20.3) differs by combining moderate and severe dyskaryosis as high-grade squamous intraepithelial lesions
<img src="assets/images/image-20251213-ff50f416.jpeg" alt="img-225.jpeg"></p>
<p>Fig. 20.7 Moderate dyskaryosis. The cells are smaller and the nuclear:cytoplasmic ratio higher when compared with normal cells.</p>
<table><thead><tr><th style="text-align: left;">Table 20.3 Classification of cervical smears</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">UK system</td><td style="text-align: left;">US Bethesda system</td></tr><tr><td style="text-align: left;">Negative</td><td style="text-align: left;">Within normal limits</td></tr><tr><td style="text-align: left;">Borderline nuclear change</td><td style="text-align: left;">ASCUS/ASC-H/possible &lt;br&gt; low-grade SIL</td></tr><tr><td style="text-align: left;">Wart virus change</td><td style="text-align: left;">Low-grade SIL</td></tr><tr><td style="text-align: left;">Mild dyskaryosis</td><td style="text-align: left;">Low-grade SIL</td></tr><tr><td style="text-align: left;">Moderate dyskaryosis</td><td style="text-align: left;">High-grade SIL</td></tr><tr><td style="text-align: left;">Severe dyskaryosis</td><td style="text-align: left;">High-grade SIL</td></tr><tr><td style="text-align: left;">Glandular neoplasia</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Possible invasive cancer</td><td style="text-align: left;">Invasive cancer</td></tr><tr><td style="text-align: left;">Inadequate samples</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">ASCUS, atypical squamous cells of undetermined significance; &lt;br&gt; ASC-H, atypical squamous cells (high-grade), SIL, squamous &lt;br&gt; intraepithelial lesion.</td><td style="text-align: left;"></td></tr></tbody></table>
<p>(HSIL) and using the term atypical squamous cells of undetermined significance (ASCUS) instead of borderline. In the current edition of the classification system, the emphasis is to try and separate out borderline cases that may potentially be a high-grade lesion. This group of borderline lesion is called atypical squamous cells, cannot exclude high-grade intraepithelial lesion (ASC-H). A modified version of this classification is used in Australia and New Zealand with HSIL and low-grade squamous intraepithelial lesions (LSIL) but the term possible lowgrade squamous intraepithelial lesions (PLSIL) and possible high-grade squamous intraepithelial lesions (PHSIL) being used instead of ASCUS and ASC-H, respectively.</p>
<p><img src="assets/images/image-20251213-67573802.jpeg" alt="img-226.jpeg"></p>
<p>Fig. 20.8 Carcinoma cells. Note the large nuclei and abnormal distribution of chromatin.</p>
<p>The correlation between cytology and histological changes in the cervix is poor, with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30-40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of women with mild dyskaryosis having CIN-2 or greater. The overall falsenegative rate varies from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>26</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2-26 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">26%</span></span></span></span></span>. CIN will be detected in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2-3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> of the screened population.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="colposcopy">Colposcopy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#colposcopy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In the UK the presence of dyskaryosis or malignant cells on cytology is an indication for examination by colposcopy. A borderline smear will be repeated after 6 months, and if borderline changes persist in three consecutive tests or if high risk HPV test is positive, colposcopy is required. Women should be referred for colposcopy after one mild dyskaryosis, but it is acceptable to repeat the smear. Women with a test reported as borderline nuclear change in endocervical cells should have colposcopy. In addition, women should have colposcopy if they have one report as moderate or severe dyskaryosis, possible invasion or possible glandular neoplasia. Those with three consecutive inadequate samples should also be referred for colposcopy.</p>
<p>Protocols for referral after Pap smears vary from country to country. In Australia women are referred after a single HSIL or PHSIL or following a LSIL if they are over the age of 35 and have not had a normal smear within the previous 2 years. Women with LSIL or PLSIL will otherwise have a repeat smear after 12 months and be referred only if the second smear is also abnormal.
<img src="assets/images/image-20251213-a10ca276.jpeg" alt="img-227.jpeg"></p>
<p>Fig. 20.9 Colposcopy of CIN-1. The acetowhite appearance of the anterior lip of the cervix indicates the presence of CIN.</p>
<p>Colposcopy is inspection of the cervix using a binocular microscope with a light source. It is usually an outpatient procedure performed using a speculum to expose the cervix. Squamous neoplasia most often occurs in the areas adjacent to the junction of the columnar (velvety red) and squamous (smooth pink) epithelium or the squamocolumnar junction (SCJ). If this cannot be seen in its entirety, CIN cannot be excluded by colposcopic examination and a cone biopsy will be required.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pathophysiology">Pathophysiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pathophysiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The SCJ moves in relation to the anatomical external cervical os. Changes in oestrogen during puberty, pregnancy or while on the combined oral contraceptive pills move the SCJ outwards, exposing columnar epithelium to the lower pH of the vagina. This reacts by undergoing transformation back to squamous epithelium by a process of squamous metaplasia. The area that lies between the current SCJ and that reached as it moves outwards across the ectocervix is the transformation zone and it is here that most preinvasive lesions occur.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="colposcopic-appearances">Colposcopic appearances<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#colposcopic-appearances" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Neoplastic cells have an increased amount of nuclear material in relation to cytoplasm and less surface glycogen than normal squamous epithelium. They are associated with a degree of hypertrophy of the underlying vasculature. When exposed to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> acetic acid the nuclear protein will be coagulated, giving the neoplastic cells a characteristic white appearance (Fig. 20.9). Small blood vessels beneath the epithelium may be seen as dots (punctation) or a crazy paving pattern (mosaicism) due to the increased capillary vasculature. The neoplastic cells do not react with Lugol's iodine (Schiller's test), unlike the normal squamous epithelium that will stain dark brown (Fig. 20.10). The diagnosis is confirmed by biopsies taken from the most abnormal-looking areas. Early invasive cancer is</p>
<p><img src="assets/images/image-20251213-5074ed36.jpeg" alt="img-228.jpeg"></p>
<p>Fig. 20.10 Colposcopic appearances of CIN-2. The abnormal epithelium fails to stain with iodine.
<img src="assets/images/image-20251213-537ff8aa.jpeg" alt="img-229.jpeg"></p>
<p>Fig. 20.11 Colposcopic appearance of invasive carcinoma of the cervix.
characterized by a raised or ulcerated area with abnormal vessels, friable tissue and coarse punctation with marked mosaicism. It feels hard on palpation and often bleeds on contact. In more advanced disease the cervix becomes fixed or replaced by a friable warty looking mass (Fig. 20.11).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="human-papilloma-virus">Human papilloma virus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#human-papilloma-virus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Certain types of HPV are found in association with neoplastic changes in the cervix. Types 6 and 11 are associated with low-grade CIN and condylomata, whereas 14 highrisk serotypes including the more common 16 and 18 are associated with high grades of CIN and carcinoma of the cervix. HPV is considered as the necessary though not sole cause of cervical cancer. It is present in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> of squamous cell cervical cancers and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of adenocarcinomas, but it must be remembered that <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10-30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of normal subjects will also be found to have HPV DNA present in cervical epithelium.</p>
<p>The role of testing for high-risk HPV serotypes in cervical screening has been extensively studied. The sensitivity of these tests for cervical neoplasia is much higher than
<img src="assets/images/image-20251213-7505b193.jpeg" alt="img-230.jpeg"></p>
<p>Fig. 20.12 Histological appearance of CIN-3.
that for conventional cytology, but not all women with high-risk HPV will develop clinical disease. High-risk HPV testing has been used in triaging borderline cytology for colposcopy referral, in the follow-up assessment after treatment of high-grade cervical dysplasia and is being explored as a primary screening tool on its own or as an adjunct to cervical cytology. However, its cost-effectiveness is still under investigation and therefore HPV testing is not routinely performed in the UK and is used only in follow up after treatment in Australia.</p>
<p>In theory, cervical cancer could be reduced by immunization against HPV as the prevention of infection of specific high risk HPV types could prevent development of cervical cancer from those particular types. The prevention of HPV-16 and 18 infections could theoretically prevent more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> cervical cancer. National vaccination programmes against HPV-16 and 18 infections were introduced in the late 2000s offering vaccination to girls aged 12-13 years old, but it will be several years before any decrease in incidence of cervical cancer is likely to be observed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cervical-intraepithelial-neoplasia">Cervical intraepithelial neoplasia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cervical-intraepithelial-neoplasia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is a histological diagnosis, usually made from colposcopic-directed biopsy, of changes in the squamous epithelium characterized by varying degrees of loss of differentiation and stratification and nuclear atypia (Fig. 20.12). It may extend up to 5 mm below the surface of the cervix by involvement of crypt epithelium in the transformation zone, but does not extend beyond the basement membrane. The aetiology is the same as that of invasive disease but with a peak incidence 10 years earlier. In the</p>
<p>UK CIN is graded as mild (CIN-1), moderate (CIN-2) or severe (CIN-3) depending on the proportion of the epithelium replaced by abnormal cells. Twenty-five per cent of CIN 1 will progress to higher grade lesions over 2 years, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30-40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of CIN-3 to carcinoma over 20 years. Around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of low-grade lesions (CIN-1) will regress to normal within 6 months without treatment especially in the younger age group.</p>
<p>Cervical glandular intraepithelial neoplasia is the equivalent change occurring in the columnar epithelium and is associated with the development of adenocarcinoma of the cervix. Two-thirds of cases coexist with CIN. Cervical cytology cannot be used reliably to detect adenocarcinoma of the cervix or CGIN and screening has had no impact on its incidence.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment">Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Low-grade CIN can be managed by cytological and colposcopic surveillance at 6 monthly intervals as progress to invasive disease does not occur within 6 months, or it can be treated as for higher grade lesions (see below).</p>
<p>Higher grade lesions (CIN-2 and 3 and dyskaryotic glandular cells) are an indication for immediate treatment either by excision or destruction of the affected area (usually the whole of the transformation zone).</p>
<p>Destructive therapies include LASER ablation, cryocautery and coagulation diathermy. Ablative techniques are only suitable when the entire transformation zone can be visualized, there is no evidence of glandular abnormality or invasive disease, and there is no major discrepancy between the cytology and histology results. Excision can be carried out using scalpel, LASER or using a diathermy loop wire (large loop excision of the transformation zone, LLETZ; Fig. 20.13). LASER and LLETZ can be carried out under local anaesthetic. Ectocervical lesions can be adequately treated by removing tissue to a depth greater than
<img src="assets/images/image-20251213-493c996b.jpeg" alt="img-231.jpeg"></p>
<p>Fig. 20.13 Large loop excision of the cervix.</p>
<p>7 mm . When the SCJ cannot be seen or a lesion of the glandular epithelium is suspected, a deeper 'cone' biopsy is required to ensure that all of the endocervix is sampled (Fig. 20.14). Patients are advised to abstain from intercourse and not to use tampons for 4 weeks after treatment to reduce the risk of infection. Hysterectomy is rarely indicated for treatment of CIN but may be used if indicated for another reason such as heavy periods.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="complications-of-cone-biopsy">Complications of cone biopsy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complications-of-cone-biopsy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The commonest complication is haemorrhage. This may be primary, i.e. within 12 hours of operation, or secondary, usually between 5 days and 12 days after the operation. Haemorrhage may be profuse but can be controlled by compression with vaginal packing, cauterization or resuturing the cervix. Secondary haemorrhage is commonly associated with infection and the management therefore includes blood transfusion and antibiotic therapy.</p>
<p>Later complications include cervical stenosis with dysmenorrhoea and haematometra. Cone or LLETZ biopsy may also cause cervical incompetence and subsequent second trimester miscarriage, preterm labour or premature preterm rupture of membranes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="follow-up">Follow-up<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#follow-up" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Approximately 5% of women will have persistent or recurrent disease following treatment. Cervical cytology is used to carry out follow-up. In the UK those who have treatment for CIN-2 or III or glandular intraepithelial neoplasia (GIN) should have cervical smears at 6 and 12 months after treatment and then annually for the subsequent 9 years before returning to the normal 3 -yearly screening programme. Patients in Australia can return to normal testing once they have had normal cytology and negative tests for high-risk HPV on two successive occasions a year
<img src="assets/images/image-20251213-10233f76.jpeg" alt="img-232.jpeg"></p>
<p>Fig. 20.14 Cone biopsy of the cervix (left); four mattress sutures are usually adequate to control bleeding from the cervical stump (right).</p>
<p>apart. If the high-grade lesion persists during the follow-up a further excisional treatment is warranted. Those having treatment for low-grade disease require cytology follow up after 6,12 and 24 months before returning to the routine screening programme. If the low-grade lesion persists within 2 years after the first colposcopy referral, at least a biopsy is required.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cervical-cancer">Cervical cancer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cervical-cancer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Cervical cancer is the second commonest female cancer worldwide. In many countries this is the most common cause of death from cancer in women. In the UK the annual incidence in 2007 was <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>9.1</mn><mi mathvariant="normal">/</mi><mn>100000</mn></mrow><annotation encoding="application/x-tex">9.1 / 100000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">9.1/100000</span></span></span></span></span> women with 2276 new cases in 2007 and 759 deaths in 2008. Cervical cancer has a direct relationship to sexual activity. Associated risk factors are early age of first intercourse, number of partners, smoking, low socioeconomic status, infection with HPV and immunosuppression.</p>
<p>In contrast to other gynaecological cancers, cervical cancer affects young women, with a peak incidence at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mo>−</mo><mn>39</mn></mrow><annotation encoding="application/x-tex">35-39</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">35</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">39</span></span></span></span></span> years.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pathology">Pathology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pathology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are two types of invasive carcinoma of the cervix. Approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of lesions are squamous cell carcinoma and 20-30% adenocarcinomas. Histologically, the degree of invasion determines the stage of the disease (Table 20.4).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-spread-of-tumour">The spread of tumour<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-spread-of-tumour" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Cervical carcinoma spreads by direct local invasion and via the lymphatics and blood vessels. Lymphatic spread occurs in approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> of women with stage IA1 disease rising to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> for stage IA2 and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of women with stage II disease. Preferential spread occurs to the external iliac, internal iliac and obturator nodes. Secondary spread may also occur to inguinal, sacral and aortic nodes. Bloodborne metastases occur in the lungs, liver, bone and bowel.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-features">Clinical features<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-features" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Stage IA disease is usually asymptomatic at the time of presentation and is detected at the time of routine cervical</p>
<p>Table 20.4 FIGO classification of cervical cancer (2009)</p>
<table><thead><tr><th style="text-align: center;">Stage I</th><th style="text-align: center;">Carcinoma is strictly confined to the cervix (extension to the corpus would be disregarded): &lt;br&gt; Stage IA: Invasive carcinoma that can be diagnosed only by microscopy, with deepest invasion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≤</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">\leq 5 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≤</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> and largest extension <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≤</mo><mn>7</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">\leq 7 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≤</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> &lt;br&gt; Stage IA1: Measured stromal invasion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≤</mo><mn>3.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">\leq 3.0 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≤</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> in depth and extension of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≤</mo><mn>7.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">\leq 7.0 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≤</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> &lt;br&gt; Stage IA2: Measured stromal invasion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>3.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;3.0 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> and not <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>5.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;5.0 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> with an extension of not <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>7.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;7.0 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> &lt;br&gt; Stage IB: Clinically visible lesions limited to the cervix uteri or preclinical cancers greater than IA* &lt;br&gt; Stage IB1: Clinically visible lesion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≤</mo><mn>4.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">\leq 4.0 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≤</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> in greatest dimension &lt;br&gt; Stage IB2: Clinically visible lesion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>4.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;4.0 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> in greatest dimension</th></tr></thead><tbody><tr><td style="text-align: center;">Stage II</td><td style="text-align: center;">Cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina: &lt;br&gt; Stage IIA: Without parametrial invasion &lt;br&gt; Stage IIA1: Clinically visible lesion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≤</mo><mn>4.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">\leq 4.0 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≤</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> in greatest dimension &lt;br&gt; Stage IIA2: Clinically visible lesion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>4.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;4.0 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> in greatest dimension &lt;br&gt; Stage IIB: With obvious parametrial invasion</td></tr><tr><td style="text-align: center;">Stage III</td><td style="text-align: center;">The tumour extends to the pelvic wall and/or involves lower third of the vagina and/or causes hydronephrosis or non-functioning kidney:** &lt;br&gt; Stage IIIA: Tumour involves lower third of the vagina, with no extension to the pelvic wall &lt;br&gt; Stage IIIB: Extension to pelvic wall and/or hydronephrosis or non-functioning kidney</td></tr><tr><td style="text-align: center;">Stage IV</td><td style="text-align: center;">The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous oedema, as such, does not permit a case to be allotted to stage IV: &lt;br&gt; Stage IVA: Spread of the growth to adjacent organs &lt;br&gt; Stage IVB: Spread to distant organs</td></tr></tbody></table>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-2" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<p>cytology. The common presenting symptoms from invasive carcinoma of the cervix include postcoital bleeding, foul-smelling discharge, which is thin and watery and sometimes blood-stained, and irregular vaginal bleeding when the tumour becomes necrotic. Lateral invasion into the parametrium may involve the ureters, leading eventually to ureteric obstruction and renal failure. Invasion of nerves and bone causes excruciating and persistent pain, and involvement of lymphatic channels may result in lymphatic occlusion with intractable oedema of the lower limbs.</p>
<p>The tumour may also spread anteriorly or posteriorly to involve the bladder or rectum, respectively. Involvement of the bladder produces symptoms of frequency, dysuria and haematuria; if the bowel is involved, tenesmus, diarrhoea and rectal bleeding may occur. The neoplasm may initially grow within the endocervix, producing a cylindrical, barrel-shaped enlargement of the cervix with little external manifestation of the tumour.</p>
<p>The exophytic tumour grows over the vaginal portion of the cervix and appears as a cauliflower-like tumour. The tumour eventually sloughs and replaces the normal cervical tissue and extends on to the vaginal walls.</p>
<p>Death occurs from uraemia following bilateral ureteric obstruction or from sepsis and haemorrhage with generalized cachexia and wasting.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="investigation">Investigation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#investigation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The diagnosis is established histologically by biopsy of the tumour, which should be greater than 5 mm in depth to distinguish between microinvasive and invasive disease. Diagnostic LLETZ may be necessary. Examination under anaesthesia by vaginal and rectal examination with or without cystoscopy is generally recommended except in stage IA1 disease. Magnetic resonance imaging (MRI) of the abdomen and pelvis is performed for assessment of the parametrium and lymph node status. Computed tomography (CT) thorax may also be needed if lung metastasis is suspected. The role of positron-emission tomography (PET)-CT is still under evaluation but may be considered in advanced disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment-of-invasive-carcinoma">Treatment of invasive carcinoma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-invasive-carcinoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Treatment is by surgery or radiotherapy/chemoradiation or a combination of both methods.</p>
<p>Local excision carried out by cone biopsy is an option for patients with stage IA lesions who wish to preserve fertility. Simple hysterectomy suffices for stage IA1 disease for those who have completed family.</p>
<p>Extended hysterectomy or radiotherapy can be used to treat stage IB-IIA. The cure rate is similar for both surgery and radiotherapy, but the former is generally associated with less long-term morbidity from vaginal stenosis. Surgery can also preserve ovarian function for those
pre-menopausal women. Stage II-IV disease is usually treated with chemoradiation with weekly platinum based chemotherapy and intracavity and external beam radiotherapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="surgery-radical-hysterectomy-and-pelvic-lymph-node-dissection">Surgery - radical hysterectomy and pelvic lymph node dissection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#surgery-radical-hysterectomy-and-pelvic-lymph-node-dissection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Radical hysterectomy (Fig. 20.15) includes removal of the uterus, parametrium, and the upper third of the vagina. The ovaries may be conserved. This method of treatment, together with internal and external iliac and obturator lymph node dissection, is appropriate for patients with stage IB1 and early stage IIA1 diseases. Complications include haemorrhage, infection, pelvic haematomas, lymphocyst/lymphoedema, bladder dysfunction and damage to the ureters or bladder, which may result in fistula formation in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2-5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> of cases. However, the incidence of vaginal stenosis is less than after radiotherapy, and so coital function is better preserved, making it the treatment of choice in the younger woman. Radical trachelectomy with pelvic lymph node dissection and prophylactic cervical cerclage can be considered in small stage IB1 tumour (less than 2 cm ) if preservation of fertility is wished.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="radiotherapy-chemoradiation">Radiotherapy/Chemoradiation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#radiotherapy-chemoradiation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is to treat other stages of cervical cancer and those patients with bulky stage IB disease or who are unfit for surgery. Survival stage-for-stage in early forms of the disease is similar to that for surgery. Adjuvant chemoradiotherapy is also used for those patients who have been found to have lymph node involvement at the time of surgery.</p>
<p>Chemotherapy is platinum based and given weekly in conjunction with radiotherapy.</p>
<p>Radiotherapy is administered by local insertion of a source of radium, caesium or cobalt- 60 into the uterine cavity and the vaginal vault and external beam radiation to the pelvic side wall. Complications include the effects of excessive radiation on normal tissues, and may lead to radiation cystitis or proctitis, as well as fistula formation and vaginal stenosis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="prognosis">Prognosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prognosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This depends mainly on the stage at diagnosis and lymph node status. The results for 5-year survival are:</p>
<ul>
<li>stage I: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">85 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">85%</span></span></span></span></span></li>
<li>stage II: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span></li>
<li>stage III: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span></li>
<li>stage IV: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span>.</li>
</ul>
<p>The comparable survival figure for stage IB using radical surgery is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>.</p>
<p>A combination of limited radiation and subsequent radical surgery after 4-6 weeks has produced similar</p>
<p><img src="assets/images/image-20251213-ce5a7f86.jpeg" alt="img-233.jpeg"></p>
<p>Fig. 20.15 Radical hysterectomy involves excision of the uterus, parametrium and upper third of the vagina.
figures, with a 5-year survival in stage I disease of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>77</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">77 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">77%</span></span></span></span></span> and in stage IIA of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>69</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">69 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">69%</span></span></span></span></span>.</p>
<p>Recurrent cervical lesions occur in a third of cases and have a poor prognosis.</p>
<p>Where local recurrence involves the bladder or rectum but does not extend to other structures, curative excision may occasionally be achieved by radical excision or exenteration including total cystectomy and removal of the rectum.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="malignant-disease-of-the-uterus">MALIGNANT DISEASE OF THE UTERUS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#malignant-disease-of-the-uterus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="endometrial-carcinoma">Endometrial carcinoma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#endometrial-carcinoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In developed countries, endometrial adenocarcinoma is one of the commonest female cancers. In the UK, it is the fourth most common female cancer, accounting for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> of all female cancers. The age-standardized incidence has increased by more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> within the past 15 years. It mainly affects postmenopausal women. The incidence peaks in women aged <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>75</mn></mrow><annotation encoding="application/x-tex">60-75</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">75</span></span></span></span></span> years.</p>
<p>There are specific factors associated with an increased risk of corpus carcinoma, such as nulliparity, late menopause, diabetes and hypertension. It can also be hereditary. Women with hereditary non-polyposis colorectal cancer (HNPCC) syndrome have increased risk of endometrial
and ovarian cancers, as well as colorectal cancer. However, the most important risk factors are associated with hyperoestrogen state:</p>
<ul>
<li>Obesity: The ovarian stroma continues to produce androgens after the menopause, which are converted to oestrone in adipose tissue. This acts as unopposed oestrogen on the endometrium, resulting in endometrial hyperplasia and malignancy.</li>
<li>Exogenous oestrogens: Unopposed oestrogen action, particularly as used for hormone replacement therapy in the menopause, is associated with an increased incidence of endometrial carcinoma. The addition of a progestogen for at least 10 days of each month can reduce this risk, and the combined oral contraceptive pill reduces the incidence of the disease.</li>
<li>Endogenous oestrogens: Oestrogen-producing ovarian tumours, such as granulose cell tumours are associated with an increase in the risk of endometrial cancer.</li>
<li>Tamoxifen in breast cancer: Breast cancer patients on tamoxifen have a slightly increased risk of endometrial cancer, but most of these are detected in early stages and have good prognosis.</li>
<li>Endometrial hyperplasia: Prolonged stimulation of the endometrium with unopposed oestrogen may lead to hyperplasia of the endometrium with periods of amenorrhoea followed by heavy or irregular</li>
</ul>
<p><img src="assets/images/image-20251213-0b188415.jpeg" alt="img-234.jpeg"></p>
<p>Fig. 20.16 Endometrial adenocarcinoma. Multiple sections showing a large endometrial carcinoma invading the substance of the myometrium.
bleeding. Endometrial hyperplasia can be classified into simple, complex and atypical hyperplasia. Women with atypical hyperplasia have an up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> chance of concurrent carcinoma and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> chance of future progression to carcinoma. These women are usually treated by hysterectomy and bilateral salpingo-oophorectomy. The risk of carcinoma in those with simple or complex hyperplasia without atypia is much lower ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> ). The majority of these women can be treated conservatively by progestogen therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="symptoms">Symptoms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#symptoms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The commonest symptom is postmenopausal bleeding. However, in the premenopausal woman, endometrial carcinoma is associated with irregular vaginal bleeding and increasingly heavy menses. Endometrial cancer should also be suspected in elderly patients with pyometra. These women usually present with purulent vaginal discharge.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pathology">Pathology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pathology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Endometrial carcinoma can be divided into two types. Type I refers to endometrioid adenocarcinoma. This type is related to the hyperoestrogenic state and hence all the risk factors associated with hyperoestrogenism, such as obesity, diabetes, unopposed oestrogen, etc. Type II represents other histological types, such as serous papillary and clear cell subtypes. These tend to be aggressive tumours with poorer prognosis.</p>
<p>Most endometrial cancer is endometrioid (type I) cancer. The microscopic appearances include changes in the architecture with the development of closely packed
polyhedral cells with dark-staining nuclei and considerable numbers of mitoses.</p>
<p>Endometrial cancer grows locally (Fig. 20.16). The tumour spreads by direct invasion into the myometrium and then transcervically, transtubally and by spillage of carcinomatous material. There can also be lymphatic spread to the pelvic and para-aortic nodes</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="investigations">Investigations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#investigations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Initial investigations include a transvaginal ultrasound scan to assess the endometrial thickness and an endometrial aspirate to obtain endometrial tissue for histological assessment. An endometrial thickness of less than 5 mm on transvaginal ultrasound in a postmenopausal woman indicates a very low risk of endometrial cancer. However, using endometrial thickness is less reliable in a pre- or perimenopausal women because the endometrial thickness varies with the menstrual cycle. In women over 40 years old who have abnormal vaginal bleeding, an endometrial aspirate should be the first line investigation to assess the endometrium. Endometrial aspirate can be done with various endometrial samplers such as the Pipelle sampler. The Pipelle is a transparent plastic cannula with a very small diameter, e.g. 3 mm that can be passed through the cervical os without dilation and can be done in the office without anaesthesia. However, if the endometrial aspirate is unsuccessful or inconclusive or symptoms persist despite a negative endometrial aspirate result, a diagnostic hysteroscopy and biopsy is required. This can be carried out as an outpatient procedure or under general anaesthesia. During a diagnostic hysteroscopy, a hysteroscope, which is a narrow rigid telescope, is passed through the cervical os and the uterine cavity is distended by either</p>
<p>gas or fluid. This allows direct visualization of the uterine cavity and directed biopsies of any endometrial lesions can be taken. The risk of this procedure is small but complications can occur such as uterine perforation, cervical laceration, pelvic infection and reaction to distension media. The diagnosis of endometrial cancer is established histologically by endometrial biopsy result.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment">Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The mainstay of treatment is total hysterectomy and bilateral salpingo-oophorectomy. The value of routine pelvic and para-aortic lymphadenectomy for all patients is controversial. Preoperative investigations include full blood count, renal and liver function test, a chest X-Ray as well as any additional investigations depending on individual health status such as ECG, blood sugar levels, etc. Cancer (or carbohydrate) antigen 125 (CA-125) may be raised in advanced disease and a preoperative baseline value can be useful for subsequent disease monitoring. Risk of extrauterine disease can be assessed preoperatively. These include high-grade lesions, unfavourable histological subtypes, e.g. serous or clear cell histology, tumour size and depth of myometrial invasion. The grading and histological subtypes can be assessed by endometrial biopsy. The tumour size and myometrial invasion can be assessed by preoperative imaging such as ultrasound, CT or MRI. Currently, MRI is the most widely used technique. It helps to assess myometrial invasion, cervical invasion and lymph node involvement. Nonetheless, MRI has limited accuracy and may not be cost-effective for all patients. Total hysterectomy can be done by open laparotomy, laparoscopically or vaginally. Patients should be individually assessed to determine the best route.</p>
<p>Adjuvant radiotherapy is often given to patients with high risk of recurrence. Vaginal brachytherapy can reduce local vault recurrence. Although this has not been shown to improve long-term survival in these patients, it does reduce the risk of vaginal and pelvic recurrence. Patients with advanced disease are treated by debulking the tumour followed by chemotherapy with or without radiotherapy. Cytotoxic drugs such as carboplatin and doxorubicin are used in the treatment of recurrent disease but response rates are low <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>20</mn><mi mathvariant="normal">%</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(20 \%)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">20%</span><span class="mclose">)</span></span></span></span></span>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="prognosis">Prognosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prognosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Endometrial cancer is surgically staged (Table 20.5). Prognosis largely depends on the stage of the disease as well as other prognostic factors that include age, histological subtype and grading. For stage I grade A, the 5 -year survival can be over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> for those with superficial myometrial invasion, but for those with deep myometrial invasion and grade III disease, the 5 -year survival is only about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> even if the disease is still confined to the uterus. For stage</p>
<p>Table 20.5 FIGO staging for endometrial cancer (2009)</p>
<table><thead><tr><th style="text-align: center;">Stage I*</th><th style="text-align: center;">Tumour confined to the corpus uteri: &lt;br&gt; Stage IA: No or less than half myometrial invasion &lt;br&gt; Stage IB: Invasion equal to or more than half of the myometrium</th></tr></thead><tbody><tr><td style="text-align: center;">Stage II*</td><td style="text-align: center;">Tumour invades cervical stroma, but does not extend beyond the uterus**</td></tr><tr><td style="text-align: center;">Stage III*</td><td style="text-align: center;">Local and/or regional spread of the tumour: &lt;br&gt; Stage IIIA: Tumour invades the serosa of the corpus uteri and/or adnexae <span class="math math-inline"><span class="katex-error" title="ParseError: KaTeX parse error: Expected '}', got '#' at position 6: { }^{#̲}" style="color: rgb(204, 0, 0);">{ }^{#}</span></span> &lt;br&gt; Stage IIIB: Vaginal and/or parametrial involvement <span class="math math-inline"><span class="katex-error" title="ParseError: KaTeX parse error: Expected '}', got '#' at position 6: { }^{#̲}" style="color: rgb(204, 0, 0);">{ }^{#}</span></span> &lt;br&gt; Stage IIIC: Metastases to pelvic and/or para-aortic lymph nodes <span class="math math-inline"><span class="katex-error" title="ParseError: KaTeX parse error: Expected '}', got '#' at position 6: { }^{#̲}" style="color: rgb(204, 0, 0);">{ }^{#}</span></span> &lt;br&gt; Stage IIIC1: Positive pelvic nodes &lt;br&gt; Stage IIIC2: Positive para-aortic lymph nodes with or without positive pelvic lymph nodes</td></tr><tr><td style="text-align: center;">Stage IV*</td><td style="text-align: center;">Tumour invades bladder and/or bowel mucosa, and/or distant metastases: &lt;br&gt; Stage IVA: Tumour invasion of bladder and/ or bowel mucosa &lt;br&gt; Stage IVB: Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes</td></tr><tr><td style="text-align: center;">*Either G1, G2, or G3. &lt;br&gt; **Endocervical glandular involvement only should be considered as Stage I and no longer as Stage II. &lt;br&gt; # Positive cytology has to be reported separately without changing the stage.</td><td style="text-align: center;"></td></tr></tbody></table>
<p>II, III and IV diseases, the 5 -year survival is about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span>, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span>, respectively. Serous papillary and clear cell carcinomas have poorer prognosis, with 5 -year survival rates of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span>, respectively.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="malignant-mesenchymal-tumours-of-the-uterus">Malignant mesenchymal tumours of the uterus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#malignant-mesenchymal-tumours-of-the-uterus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Non-epithelial cancers account for only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> of uterine malignancies. In general, they arise from either myometrial smooth muscle (leiomyosarcomas) or stroma of the endometrium (stromal sarcomas). Mixed müllerian duct or carcinosarcomas contain malignant elements from both the endometrial epithelium and stroma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="stromal-sarcomas">Stromal sarcomas<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#stromal-sarcomas" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These tumours, arising from the stroma of the endometrium, account for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> of uterine sarcomas. They</p>
<p><img src="assets/images/image-20251213-abcd1e0e.jpeg" alt="img-235.jpeg"></p>
<p>Fig. 20.17 Large mixed müllerian tumour.
tend to present in a younger age group (45-50 years) than other uterine tumours with vaginal discharge and bleeding. Endometrial stromal sarcoma is found in association with adenomyosis and endometriosis. It can be classified as low or high grade, depending on the number of mitotic figures and similarity to the non-glandular elements of the endometrium. Malignant mixed mesodermal sarcomas contain elements of both smooth muscle and stroma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="6a824c7d">Mixed müllerian tumours (carcinosarcomas)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#6a824c7d" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These tumours (Fig. 20.17) consist of both epithelial and mesenchymal elements. The epithelial elements are usually endometrioid but can be squamous or a mixture. The stromal elements are either heterologous (chondroblastoma, osteosarcoma, fibrosarcoma) or homologous (leiomyosarcoma, presarcoma). The mean age at presentation is 65 years. An enlarged, irregular uterus with tumour protruding through the cervical os is a common finding at examination. Extrauterine spread occurs early and only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of patients have disease limited to the endometrium at the time of diagnosis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="leiomyosarcoma">Leiomyosarcoma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#leiomyosarcoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These smooth muscle tumours arise in the myometrium of the uterus and account for only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1.3%</span></span></span></span></span> of uterine malignancies. They are uncommon <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.7</mn><mi mathvariant="normal">/</mi><mn>100000</mn><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(0.7 / 100000)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.7/100000</span><span class="mclose">)</span></span></span></span></span>, with a peak incidence at the age of 52 years, about 10 years later than the peak incidence for fibroids. Between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> arise in existing fibroids, although the risk of malignant change occurring in a fibroid is small ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mo>−</mo></mrow><annotation encoding="application/x-tex">0.3-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.3</span><span class="mord">−</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.8</mn><mi mathvariant="normal">%</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">0.8 \%)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.8%</span><span class="mclose">)</span></span></span></span></span>. Leiomyosarcomas are classified according to the degree of differentiation. They may present with pain, postmenopausal bleeding or a rapidly growing 'fibroid', but are often asymptomatic and diagnosed following hysterectomy for fibroids. Treatment is by hysterectomy and
bilateral salpingo-oophorectomy. Adjuvant radiotherapy and chemotherapy reduces the risk of local recurrence but does not improve long-term survival.</p>
<table><thead><tr><th style="text-align: left;">Rapid growth of a 'fibroid', especially when</th></tr></thead><tbody><tr><td style="text-align: left;">associated with pain and irregular bleeding,</td></tr><tr><td style="text-align: left;">may indicate malignant change.</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment">Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is by hysterectomy, with removal of as much macroscopic disease as possible, followed by radiotherapy. Prognosis for low-grade stromal sarcomas is similar to that for endometrioid tumours, but poor for others, with a 20 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi><mn>5</mn></mrow><annotation encoding="application/x-tex">40 \% 5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%5</span></span></span></span></span>-year survival.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lesions-of-the-ovary">LESIONS OF THE OVARY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lesions-of-the-ovary" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Ovarian enlargement is commonly asymptomatic, and the silent nature of malignant ovarian tumours is the major reason for the advanced stage of presentation. Ovarian tumours may be cystic or solid, functional, benign or malignant. There are common factors in the presentation and complications of ovarian tumours and it is often difficult to establish the nature of a tumour without direct examination.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="symptoms">Symptoms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#symptoms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Tumours of the ovary that are less than 10 cm in diameter rarely produce symptoms. The common presenting symptoms include:</p>
<ul>
<li>Abdominal enlargement - in the presence of malignant change, this may also be associated with ascites.</li>
<li>Symptoms from pressure on surrounding structures such as the bladder and rectum.</li>
<li>Symptoms relating to complications of the tumour (Fig. 20.18). These include:</li>
<li>Torsion: Acute torsion of the ovarian pedicle results in necrosis of the tumour; there is acute pain and vomiting followed by remission of the pain when the tumour has become necrotic.</li>
<li>Rupture: The contents of the cyst spill into the peritoneal cavity and result in generalized abdominal pain.</li>
<li>Haemorrhage into the tumour is an unusual complication but may result in abdominal pain and shock if the blood loss is severe.</li>
</ul>
<p><img src="assets/images/image-20251213-87dc0066.jpeg" alt="img-236.jpeg"></p>
<p>Fig. 20.18 Common complications of ovarian tumours that precipitate a request for medical advice.</p>
<ul>
<li>Hormone-secreting tumours may present with disturbances in the menstrual cycle. In androgensecreting tumours the patient may present with signs of virilization. Although a greater proportion of the sex-cord stromal type of tumour (see below) are hormonally active, the commonest type of secreting tumour found in clinical practice is the epithelial type.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="signs">Signs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#signs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>On examination, the abdomen may be visibly enlarged. Percussion over the swelling will demonstrate central dullness and resonance in the flanks. These signs may be obscured by gross ascites. Small tumours can be detected on pelvic examination and will be found by palpation in one or both fornices. However, as the tumour enlarges, it assumes a more central position and, in the case of dermoid cysts, is often anterior to the uterus. Most ovarian tumours are not tender to palpation; if they are painful the presence of infection or torsion should be suspected. Benign ovarian tumours are palpable separately from the uterine body and are usually freely mobile.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="benign-ovarian-tumours">BENIGN OVARIAN TUMOURS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#benign-ovarian-tumours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="functional-cysts-of-the-ovary">Functional cysts of the ovary<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#functional-cysts-of-the-ovary" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These cysts occur only during menstrual life and rarely exceed more than 6 cm in diameter.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="follicular-cysts">Follicular cysts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#follicular-cysts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Follicular cysts (Fig. 20.19) are the commonest functional cysts in the ovary and may be multiple and bilateral. The cysts rarely exceed 4 cm in diameter, the walls consisting of layers of granulosa cells and the contents of clear fluid, which is rich in sex steroids. These cysts commonly occur during treatment with clomiphene or human menopausal gonadotrophin (Fig. 20.20). They may produce prolonged
<img src="assets/images/image-20251213-71de3842.jpeg" alt="img-237.jpeg"></p>
<p>Fig. 20.19 (A) Small follicular cyst near mid-cycle. (B) Histological features.
unopposed oestrogen effects on the endometrium, resulting in cystic glandular hyperplasia of the endometrium.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management">Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These cysts regress spontaneously but if they have not involuted after 60 days the diagnosis should be revised.</p>
<p><img src="assets/images/image-20251213-d44eaf67.jpeg" alt="img-238.jpeg"></p>
<p>Fig. 20.20 Pelvic ultrasound showing ovarian hyperstimulation with multiple follicles.</p>
<p>The size and growth of the cysts can be monitored by ultrasound scans.</p>
<p>The prolonged and heavy menstrual loss caused by unopposed oestrogen action can be offset by the administration of a progestogen for 1 week followed by 'medical curettage', or through surgical intervention by cervical dilatation and uterine curettage.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lutein-cysts">Lutein cysts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lutein-cysts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are two types of luteinized ovarian cyst:</p>
<ul>
<li>Granulosa lutein cysts, functional cysts of the corpus luteum, may be <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">4-6 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> in diameter and occur in the second half of the menstrual cycle. Persistent production of progesterone may result in amenorrhoea or delayed onset of menstruation. These cysts often give rise to pain and therefore present a problem in terms of differential diagnosis, as the history and examination findings mimic tubal ectopic pregnancy. Occasionally, haemorrhage occurs into the cyst, which may rupture and lead to a haemoperitoneum. The cysts usually regress spontaneously and require surgical intervention only when they give rise to symptoms of intra-abdominal haemorrhage.</li>
<li>Theca lutein cysts commonly arise in association with high levels of chorionic gonadotrophin and are therefore seen in cases of hydatidiform mole. The cysts may be bilateral and can, on occasion, give rise to haemorrhage if they rupture. Once the cysts have been formed, they can be detected by ultrasound. They usually undergo spontaneous involution but surgical intervention may be necessary if there is significant haemorrhage from the ovaries.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="benign-neoplastic-cysts">Benign neoplastic cysts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#benign-neoplastic-cysts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These tumours may be cystic or solid and arise from specific cell lines in the ovary. The full World Health Organization classification of ovarian tumours illustrates the complexity of tumours arising from the ovary; only the commoner ones will be discussed in this section.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="epithelial-tumours">Epithelial tumours<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#epithelial-tumours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="serous-cystadenomas">Serous cystadenomas<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#serous-cystadenomas" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These cysts, in conjunction with mucinous cystadenomas, form the commonest group of cystic ovarian tumours. The cysts may be unilocular, lined by a layer of cuboidal epithelium, or multilocular with papillary growths extending from both internal and external surfaces of the tumour. It is often difficult to differentiate between benign and malignant appearances. The wall of the tumour sometimes contains calcified granules known as psammoma bodies. The growths may be bilateral and may be large enough to fill the peritoneal cavity.</p>
<p>The tumours often replace all normal ovarian tissue; if this is the case, the whole ovary should be removed. If the tumour is small, it may be possible to perform a local resection and to conserve ovarian tissue. If both ovaries are extensively involved or there is reason to believe that the tumours are malignant, it is better to perform bilateral oophorectomy and hysterectomy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mucinous-cystadenomas">Mucinous cystadenomas<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mucinous-cystadenomas" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These tumours are multilocular and often reach enormous dimensions, with tumours weighing in excess of 100 kg recorded in the literature. The fluid content consists of mucin, and the epithelium lining the cysts presents a</p>
<p>characteristic appearance of a secretory epithelium of tall columnar cells with a pseudostratified appearance. This appearance is similar to the epithelium lining the endocervix. The demarcation between epithelial cells and stroma is sharply defined. There is little tendency to form papillae. These tumours are less likely to become malignant than the serous variety.</p>
<p>The only treatment is to remove the tumour surgically.</p>
<p>Care should be taken to avoid rupture of the cysts because mucinous epithelium may implant in the peritoneal cavity, giving rise to a condition known as pseudomyxoma peritonei. Huge amounts of gelatinous material may accumulate in the peritoneal cavity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="brenner-cell-tumours">Brenner cell tumours<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#brenner-cell-tumours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Brenner cell tumours are commonly solid and occur in women after the age of 50 years. They are only rarely malignant. The histological features of these tumours include nests of epithelial cells surrounded by fibromatous connective tissue groundwork.</p>
<p>The cut surface of the tumour is similar to that of an ovarian fibroma apart from a rather yellowish tinge. The tumours are occasionally bilateral and can be safely treated by local excision.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sex-cord-stromal-tumours">Sex cord stromal tumours<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sex-cord-stromal-tumours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Hormone-secreting tumours of the ovary are a small but important group.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="granulosa-cell-tumours">Granulosa cell tumours<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#granulosa-cell-tumours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Arising from ovarian granulosa cells, these tumours (Fig. 20.21) produce oestrogens and constitute some <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> of all
<img src="assets/images/image-20251213-2c2a0638.jpeg" alt="img-239.jpeg"></p>
<p>Fig. 20.21 Granulosa cell/theca cell tumour. This shows haemorrhagic areas in the solid white surface of the cut tumour.
solid ovarian tumours. Approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> exhibit the characteristics of malignancy. As granulosa cell tumours can present at any age, the symptoms depend on the age of occurrence. Tumours arising before puberty produce precocious sexual development, and in women of the reproductive age, prolonged oestrogen stimulation results in cystic glandular hyperplasia and irregular and prolonged vaginal bleeding. Around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of cases occur after the menopause and present with postmenopausal bleeding. If the tumour is histologically benign, the surgery should be limited to oophorectomy. If there is evidence of malignancy, pelvic clearance is indicated.</p>
<p>Thecomas or theca cell tumours arise from the spindleshaped thecal cells, but are often mixed with granulosa cells and are oestrogen secreting. The presence of a thecoma in one ovary is commonly associated with diffuse thecomatosis in the contralateral ovary.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="arrhenoblastomas-or-androblastomas">Arrhenoblastomas or androblastomas<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#arrhenoblastomas-or-androblastomas" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These are tumours of Sertoli-Leydig cells. They are rare androgen-secreting tumours that occur most frequently in the decade between 20 and 30 years of age. The clinical manifestations include the onset of amenorrhoea, loss of breast tissue, increasing facial and body hirsutism, deepening of the voice and enlargement of the clitoris. The diagnosis is established by the exclusion of virilizing adrenal tumours and the identification of a tumour in one ovary. The condition is treated by excision of the affected ovary. Approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of these tumours are malignant.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="germ-cell-tumours">Germ cell tumours<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#germ-cell-tumours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Tumours of germ cell origin may replicate stages resembling the early embryo.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mature-cystic-teratoma-dermoid-cyst">Mature cystic teratoma (dermoid cyst)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mature-cystic-teratoma-dermoid-cyst" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Benign cystic teratomas account for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>−</mo><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">12-15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> of true ovarian neoplasms. They contain a large number of embryonic elements such as skin, hair, adipose and muscle tissue, bone, teeth and cartilage (Fig. 20.22). Some of the components can be recognized on radiography.</p>
<p>These tumours are often chance findings as they are commonly asymptomatic unless they undergo torsion or rupture, when the release of sebaceous material causes an acute chemical peritonitis. Dermoid cysts tend to be anterior to the uterus. They are bilateral in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">12 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">12%</span></span></span></span></span> of cases, and, although usually benign, become malignant in approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span>. Some specialized elements in these tumours become predominant. The growth of thyroid tissue (struma ovarii) may induce a state of hyperthyroidism.</p>
<p>These cysts should be excised from the ovary with conservation of ovarian tissue. They are frequently bilateral and it is important to examine both ovaries before proceeding to surgical excision.</p>
<p><img src="assets/images/image-20251213-ad6c546d.jpeg" alt="img-240.jpeg"></p>
<p>Fig. 20.22 Dermoid cyst (benign cystic teratoma) containing teeth and hair.</p>
<p>Dermoid cysts are the commonest solid ovarian neoplasm found in young women.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fibromas">Fibromas<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fibromas" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These solid tumours of the ovary are rare. They may be associated with the presence of ascites or hydrothorax - a condition known as Meigs' syndrome.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="tumour-like-conditions">Tumour-like conditions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tumour-like-conditions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This group includes endometriotic cysts, pregnancy luteomas and germinal cell cysts. The treatment depends on the nature of the tumour and normally involves simple excision of the cysts.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="endometriotic-cysts">Endometriotic cysts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#endometriotic-cysts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Endometriomas contain chocolate-coloured fluid representing the accumulation of altered blood, and have a thick fibrous capsule (see Fig. 16. 13). The lining may consist of endometrial cells but in old cysts these may disappear. Management is discussed below.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ovarian-malignancy">OVARIAN MALIGNANCY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ovarian-malignancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Ovarian cancer is the fifth most common cancer in females in the UK and is the fourth most common cause of death from malignant disease in women in the UK. Although it is the second most common gynaecological cancer after endometrial cancer, it is the commonest cause of gynaecological cancer deaths. The life-time risk of developing ovarian cancer is about 1 in 54 women in the UK in 2008. The incidence increases with age, with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> being diagnosed in women over the age of 50 years. The poor survival is partly attributable to late diagnosis as many women present late due to lack of obvious symptoms.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="aetiology">Aetiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aetiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Although the cause of ovarian cancer remains unknown, there are well defined risk factors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="genetic">Genetic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#genetic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> of cases of ovarian cancer occur in women whose families show an autosomal dominant pattern of inheritance of breast and ovarian cancer. Female members of these families have a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> lifetime risk of developing the disease. Many of these women have been shown to have defects in the BRCA1or BRCA2 genes</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="parity-and-fertility">Parity and fertility<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#parity-and-fertility" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Multiparous women are at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> less risk than nulliparous women of developing ovarian cancer, whereas women who have had unsuccessful treatment for infertility seem to be at increased risk. The use of the contraceptive pill may produce up to a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> reduction in the incidence of the disease</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pathology">Pathology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pathology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="primary-ovarian-carcinoma">Primary ovarian carcinoma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#primary-ovarian-carcinoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The distribution of histological types of ovarian cancers is as follows.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="epithelial-type">Epithelial type<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#epithelial-type" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This makes up <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">85 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">85%</span></span></span></span></span> of cases of ovarian malignancy. Epithelial tumours include the following subtypes:</p>
<ul>
<li>Serous cystadenocarcinoma is the most common histological type of ovarian carcinoma ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> ) and is usually unilocular. They may be bilateral. These tumours are more likely to contain solid areas than their benign counterparts.</li>
<li>Mucinous cystadenocarcinomas: These multicystic tumours (Fig. 20.23) are characterized by mucinfilled cysts lined by columnar glandular cells, and may be associated with tumours of the appendix.</li>
<li>Endometrioid cystadenocarcinomas resemble endometrial adenocarcinomas and are associated with uterine carcinomas in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of cases.</li>
<li>Clear-cell cystadenocarcinoma is the most common ovarian malignancy found in association with ovarian endometriosis. The unilocular thin-walled cysts are lined by epithelium with a typical hobnail appearance and clear cytoplasm.</li>
<li>Brenner or transitional cell cystadenocarcinoma is often found in association with mucinous tumours but has a better prognosis than similar tumours arising from the bladder.
Tumours of low malignant or borderline potential account for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10-15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> of primary epithelial carcinomas. They are commonly serous or mucinous tumours. There</li>
</ul>
<p><img src="assets/images/image-20251213-dc00aa20.jpeg" alt="img-241.jpeg"></p>
<p>Fig. 20.23 Bilateral multicystic malignant ovarian tumours.
are cytological changes of malignancy including cellular atypia with increased mitosis and multilayering but without invasion. They have a significantly better prognosis than invasive disease, with a 5 -year survival of more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> for stage I lesions but there is a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10-15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> incidence of late recurrence.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sex-cord-stromal-tumours">Sex cord stromal tumours<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sex-cord-stromal-tumours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These tumours are relatively rare as they make up only 6% of primary ovarian cancers.</p>
<ul>
<li>Granulosa cell tumours: These solid, unilateral, haemorrhagic tumours are the most common oestrogen-secreting lesions. They are characterized histologically by the presence of Call-Exner bodies.</li>
<li>Sertoli-Leydig cell tumours: Approximately 25% of these are malignant, and may present with signs and symptoms of androgen excess.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="germ-cell-tumours">Germ cell tumours<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#germ-cell-tumours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Dysgerminomas: These solid tumours may be small or large enough to fill the abdominal cavity. The cut surface of the tumour has a greyish-pink colour and the microscopically, the tumour consists of large polygonal cells arranged in alveoli or nests separated by septa of fibrous tissue.</li>
<li>Teratomas: The malignant or immature form of teratoma is most commonly solid, unilateral and heterogenous with multiple tissue elements. These tumours may produce human chorionic gonadotrophin, alpha-fetoprotein or thyroxine.</li>
<li>Endodermal sinus or yolk sac tumours. Although these tumours make up only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10-15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> of germ cell tumours, they are the most common germ cell tumour in children. They are solid, encapsulated tumours containing microcysts lined by flat mesothelial cells.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="secondary-ovarian-carcinomas">Secondary ovarian carcinomas<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#secondary-ovarian-carcinomas" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The ovaries are a common site for secondary deposits from primary malignancies in the breast, genital tract, gastrointestinal system and haematopoietic system.</p>
<p>Krukenberg's tumours are metastatic deposits from the gastrointestinal system. They are solid growths that are almost always bilateral. The stroma is often richly cellular and may appear to be myomatous. The epithelial elements occur as clusters of well-marked acini with cells exhibiting mucoid change, known as signet ring cells.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="staging-of-ovarian-carcinoma">Staging of ovarian carcinoma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#staging-of-ovarian-carcinoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Spread of primary ovarian tumours can be by direct extension, lymphatics or via the bloodstream. Staging of ovarian carcinoma (Table 20.6) is important in determining both prognosis and the management. Ideally, it should be staged at the time of laparotomy with inspection and biopsy of the peritoneum and diaphragm, cytological examination of peritoneal fluid and pelvic and para-aortic lymph nodes dissection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="diagnosis">Diagnosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diagnosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Early ovarian carcinomas are mostly asymptomatic. The commonest symptoms are abdominal discomfort or distension. Clinically, a pelvic mass may be detected and there may be ascites. An ultrasound scan can exclude other causes of pelvic mass such as fibroids and show features of malignant change (see below). A chest X-ray should be done to look for pleural effusions. CT or MRI scans (Fig. 20.24) may give an indication of spread. CA-125 is the widely used tumour marker for epithelial ovarian cancer. However, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> of ovarian carcinomas will have normal levels and it is raised in only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of early stage disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management">Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Treatment is based on surgery and chemotherapy. Surgery involves abdominal hysterectomy, bilateral salpingooophorectomy, omentectomy and careful inspection and sampling of peritoneal surfaces and retroperitoneal (pelvic and para-aortic) lymph node dissection. The aim is to remove all macroscopic disease. Subsequent prognosis is proportional to the amount of disease remaining after primary surgery. Surgery is often followed by adjuvant chemotherapy.</p>
<p>Germ cell tumours tend to occur in young women. Fertility sparing surgery, e.g. unilateral salpingo-oophorectomy with preservation of the uterus and the other ovary should be considered even in the presence of metastatic disease because the tumour is highly chemosensitive.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chemotherapy">Chemotherapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Patients with high risk for recurrence, e.g. those with high grade, poor histological subtypes or stage IC or above, are</p>
<table><thead><tr><th style="text-align: left;">Stage I</th><th style="text-align: left;">Growth limited to the ovaries: &lt;br&gt; Stage IA: Growth limited to one ovary, &lt;br&gt; no ascites and no tumour present on &lt;br&gt; the external surface; capsule intact &lt;br&gt; Stage IB: Growth limited to both &lt;br&gt; ovaries, no ascites and no tumour &lt;br&gt; present on the external surface; &lt;br&gt; capsule intact &lt;br&gt; Stage IC: Stage IA or IB where there is &lt;br&gt; tumour on the surface of either &lt;br&gt; ovary; or with ruptured capsules or &lt;br&gt; with ascites containing malignant cells &lt;br&gt; or positive peritoneal washings</th></tr></thead></table>
<p>often given adjuvant chemotherapy. The platinum-based drugs cisplatin and carboplatin are currently the mainstay of treatment. The main side effects are marrow suppression, neurotoxicity and renal toxicity. Carboplatin has now largely replaced cisplatin due to its better side effect profile and it is often combined with paclitaxel, another active agent for ovarian cancer. The overall response rate is up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="borderline-tumours">Borderline tumours<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#borderline-tumours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These can be treated by unilateral oophorectomy in young women wishing to preserve their reproductive capacity, although careful, long-term follow-up is required.
<img src="assets/images/image-20251213-4cc864b7.jpeg" alt="img-242.jpeg"></p>
<p>Fig. 20.24 MRI of a large ovarian cyst. The tumour can be seen distending the uterus and elongating the endometrium.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="germ-cell-tumours">Germ cell tumours<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#germ-cell-tumours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These are more common in young women, and chemotherapy may be curative without hysterectomy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="follow-up-and-treatment-of-recurrence">Follow-up and treatment of recurrence<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#follow-up-and-treatment-of-recurrence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Patients are followed up for any symptoms such as abdominal discomfort, tumour markers and clinical examination. Imaging can be arranged if there is suspicion of recurrence. Chemotherapy is the main-stay of treatment for recurrence. Debulking of the tumour may be feasible if it is localized and there is a long time interval to recurrence. In platinum-sensitive patients, i.e. those that recur after at least 12 months from completion of primary treatment, rechallenge with first-line chemotherapy</p>
<p>Table 20.7 Survival rates for ovarian cancer</p>
<table><thead><tr><th style="text-align: left;">Stage</th><th style="text-align: left;">5-year survival (%)</th></tr></thead><tbody><tr><td style="text-align: left;">Stage I</td><td style="text-align: left;">89</td></tr><tr><td style="text-align: left;">Stage II</td><td style="text-align: left;">66</td></tr><tr><td style="text-align: left;">Stage III</td><td style="text-align: left;">34</td></tr><tr><td style="text-align: left;">Stage IV</td><td style="text-align: left;">18</td></tr></tbody></table>
<p>(carboplatin and paclitaxel) is recommended. Otherwise, there are wide ranges of second-line chemotherapy agents such as liposomal doxorubicin, gemcitabine, etc. but their response rates are only about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20-30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="prognosis">Prognosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prognosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The 5-year survival figures depend on the stage and on whether the tumour has or has not been completely removed (Table 20.7).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="screening-for-ovarian-cancer">Screening for ovarian cancer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#screening-for-ovarian-cancer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Because the prognosis for early stage disease is better than that for advanced disease, overall survival might be improved if the disease could be diagnosed earlier in asymptomatic women. However, the best screening strategy is unclear. The two main methods proposed are ultrasound and CA-125 measurement.</p>
<p>As many cysts in premenopausal women are functional (follicular or corpus luteum) more than one ultrasound examination measurement may be required. Suspicious features are increasing size, internal septa, solid areas within the cyst and increased blood flow (Doppler). Transvaginal ultrasound is sensitive in picking up ovarian masses but it is not accurate enough to differentiate between ovarian cancer and benign ovarian cysts. This leads to many unnecessary operations.</p>
<p>CA-125 is a glycoprotein shed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">85 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">85%</span></span></span></span></span> of epithelial tumours. A cut-off level of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mi mathvariant="normal">u</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">35 \mathrm{u} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">35</span><span class="mord mathrm">u</span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> is commonly used for postmenopausal women. CA-125 lacks specificity if used alone. False positive results occur in other malignancies (liver, pancreas), endometriosis, pelvic inflammatory disease and early pregnancy.</p>
<p>Combining transvaginal ultrasound with serial CA-125 can be a possible screening strategy. Several large multicentre studies randomizing women into screened and unscreened controls are in progress. Such screening methods may be able to detect ovarian cancer at an earlier stage, but whether this would translate to improved overall survival is still not known.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-palliative-care-in-gynaecological-cancer">PRINCIPLES OF PALLIATIVE CARE IN GYNAECOLOGICAL CANCER<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-palliative-care-in-gynaecological-cancer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Despite optimal initial treatment, disease recurrence and progression are inevitable in a certain proportion of women with gynaecological cancer. In many of these situations, a cure is no longer a realistic option but this by no means translates into withdrawal of the input from medical professionals. A multi-disciplinary approach, with strong input from the palliative team to provide supportive care to the individual is crucial. Palliative care aims to provide both physical and emotional support as well as preparation for the eventual outcome of death. Quality of life and patient's autonomy and dignity are the most important aspects in this final phase of life. Good communication and a trusting relationship between the patient and her carers are key to achieving these aims. Ideally, the concept of palliative care should be introduced in good time and not at a clinically critical moment, so that the patient and her family can have time to develop acceptance and realistic expectations. The decision to either continue or stop anticancer treatment needs to take into account for the overall benefit in quality of life, bearing in mind the additional stress and side effects arising from the treatment rather than the disease.</p>
<p>Uncontrolled symptoms can cause severe distress and symptom control is one of the main areas for palliative care. Patients almost inevitably experience pain, which can be a result of the disease or the treatment. Pain is a subjective sensation and therefore, to achieve good control, it is important both to reduce the pain stimulus and to increase the personal pain threshold. Reducing pain stimulus requires careful assessment of the cause by taking a good history. Therapeutic measures can then be targeted at the mechanisms involved, e.g. non-steroidal anti-inflammatory drugs would be appropriate for pain arising from inflammation or antispasmodic agents for bowel spasms, while neuropathic pain can be relieved by tricyclic antidepressant or anticonvulsant drugs such as gabapentin.</p>
<p>Increasing the pain threshold involves good psychological support, possibly with the help of antidepressant and anxiolytics. World Health Organization has developed a three-step 'ladder' for cancer pain relief. Administration of drugs should be in the following order: non-opioids (such as paracetamol and aspirin), mild opioids (codeine), then strong opioids such as morphines. At each step, 'adjuvant' agents can be added. Adjuvants are medications that have a primary indication other than pain control, but can also help to relieve pain in certain situations, such as anticonvulsant and antidepressant agents. Opioids are very effective but they need to be given at the right dose and at the right time. They should be given at regular intervals</p>
<p>and additional doses can be prescribed as required for breakthrough pain. Common opioid side effects include nausea, vomiting and constipation, and therefore antiemetics and regular laxatives should also be prescribed when starting opioids. Patients should be reassured that appropriate use of opioids would not cause addiction.</p>
<p>In women with extensive intra-abdominal disease, such as those in advanced ovarian cancer, bowel obstruction and ascites are common. Symptoms from bowel obstructions are difficult to deal with entirely. Surgical intervention can potentially give the best palliative effect but is often not feasible due to multiple sites of obstructions from extensive disease. Conservative management aims to reduce nausea and vomiting with anti-emetic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> nasogastic tube and maintaining hydration by intravenous fluid. Occasionally, a trial of short-course corticosteroid
drugs to decrease inflammatory oedema around the bowels may be effective in relieving the obstruction. Ascites from peritoneal disease can be effectively relieved by paracentesis, but they tend to re-accumulate and often repeated paracentesis is required. Diuretics such as spironolactone can be tried to reduce the rate of re-accumulation.</p>
<p>Eventually, when the patient is very close to death, care plans should concentrate on providing a peaceful and dignified environment for the patient and her family. Futile medical interventions should be minimized while distressing symptoms should be adequately controlled. Last but not least, it is important to be aware of the individual's cultural and spiritual preferences so that both the patient and her family can feel that she has come to a 'good end'.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="essential-information">Essential information<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#essential-information" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="malignant-vulval-lesions">Malignant vulval lesions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#malignant-vulval-lesions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Commonest in sixth decade</li>
<li>Majority are squamous ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>92</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">92 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">92%</span></span></span></span></span> ) or adenocarcinomas <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>5</mn><mi mathvariant="normal">%</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(5 \%)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">5%</span><span class="mclose">)</span></span></span></span></span></li>
<li>Present with pruritus, bleeding lesions</li>
<li>Spreads by local invasion and via inguinal and femoral nodes</li>
<li>Primary treatment by radical vulvectomy and groin node dissection with individual modification</li>
<li>Good prognosis if confined to vulva at presentation</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="malignant-vaginal-tumours">Malignant vaginal tumours<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#malignant-vaginal-tumours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Primary malignancy rare, squamous carcinomas arising in upper third</li>
<li>Common site for spread from cervix and uterus</li>
<li>Presents as pain, bleeding and fistula formation</li>
<li>Spreads by local invasion and lymphatics</li>
<li>Usually treated by radiotherapy</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cervical-screening-and-vaccination">Cervical screening and vaccination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cervical-screening-and-vaccination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Cytology 3-5 yearly intervals from 25 to 65 years of age</li>
<li>Abnormal cytology requires colposcopy and biopsy</li>
<li>HPV 16 and 18 vaccination in girls aged 12-13 years old</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cervical-cancer">Cervical cancer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cervical-cancer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>More common in lower social class, smokers, early first intercourse and multiple partners</li>
<li>Associated with herpes and human papilloma virus infection</li>
<li>May be asymptomatic or present with vaginal bleeding, pain, and bowel or bladder symptoms</li>
<li>Spreads by local invasion and iliac/obturator nodes</li>
<li>Treatment is radical hysterectomy and pelvic nodes dissection for early stage disease, chemoradiotherapy otherwise</li>
<li>5-year survival varies from 10-90% depending on stage</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="endometrial-carcinoma">Endometrial carcinoma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#endometrial-carcinoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Disease of postmenopausal women</li>
<li>Risk factors include obesity, nulliparity, late menopause, diabetes and unopposed oestrogens</li>
<li>Commonly presents as postmenopausal bleeding</li>
<li>Spreads by direct invasion but tends to remain localized within the uterus initially</li>
<li>Well-differentiated early stage disease can be treated by surgery alone; more advanced lesions require chemotherapy and/or radiotherapy</li>
<li>Has 90% 5-year survival if diagnosed early</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="malignant-ovarian-tumours">Malignant ovarian tumours<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#malignant-ovarian-tumours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Fourth commonest cause of cancer deaths in women in the UK</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> of cases present with advanced disease</li>
<li>Most cases are epithelial in type</li>
<li>Prognosis depends on stage at diagnosis and extent of residual disease after initial surgery</li>
<li>5-year survival 35-40%</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principle-of-palliative-care">Principle of palliative care<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principle-of-palliative-care" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Multidisciplinary approach for symptom control and relief, physical and emotional support</li>
<li>Three step ladder for pain relief with or without adjuvant</li>
<li>Care plan for terminal stage and support to family</li>
</ul>
<p>This page intentionally left blank</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prolapse-and-disorders-of-the-urinary-tract">Prolapse and disorders of the urinary tract<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prolapse-and-disorders-of-the-urinary-tract" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ajay Rane and Jay Iyer</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="learning-outcomes">Learning outcomes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#learning-outcomes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter you should be able to:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="knowledge-criteria">Knowledge criteria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#knowledge-criteria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Describe the normal supports of the uterus and vagina</li>
<li>Describe the normal mechanisms that maintain urinary continence and the physiology of normal micturition</li>
<li>Describe the epidemiology, aetiology and clinical features associated with urinary incontinence, urinary frequency, urinary tract infections and genitourinary prolapse</li>
<li>Evaluate the common surgical and non-surgical treatments used in the management of urinary incontinence and genital prolapse including catheterization, bladder retraining, pelvic floor exercises, medical therapies, vaginal repair with or without hysterectomy, sling procedures and tapes and colposuspension</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-competencies">Clinical competencies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-competencies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Take a history from a woman presenting with urinary tract symptoms or symptoms of prolapse</li>
<li>Perform a pelvic examination to assess genitourinary prolapse and pelvic floor tone</li>
<li>Explain the investigations employed in the assessment of incontinence and prolapse including: microbiology, urodynamics, cystoscopy and imaging</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="professional-skills-and-attitudes">Professional skills and attitudes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#professional-skills-and-attitudes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Consider the impact of urinary incontinence on women and the community</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="uterovaginal-prolapse">UTEROVAGINAL PROLAPSE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#uterovaginal-prolapse" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The position of the vagina and uterus depends on various fascial supports and ligaments derived from specific thickening of areas of the fascial support (Figs 21.1-21.4). There has been a paradigm shift in our understanding of the anatomy of pelvic floor supports and with it the pathophysiology of development of pelvic organ prolapse. There are three levels of pelvic organ support that are clinically relevant and conceptually easier to grasp. The uterosacral ligaments responsible for providing level I support to the upper vagina and the cervix (and by extension to the uterus) have a broad attachment over the second, third and fourth sacral vertebrae arising posteriorly from the junction of the cervix and the upper vagina running on each side lateral to the rectum towards the sacral attachments. The other important structure is the arcus tendineus fasciae pelvis (ATFP; see Figs 21.3 and 21.5) also known as the 'white line' - a condensation of pelvic cellular tissue on the pelvic aspect of the obturator internus muscle. The ATFP runs from the ischial spines to the pubic tubercle and its terminal medial end is known as the iliopectineal ligament (Cooper's ligament), well known to general surgeons that operate on inguinal and femoral hernias. Extending medially from the white lines are condensed sheets of pelvic cellular tissue suspending the anterior and posterior vaginal walls and the organs underlying these, namely the urinary bladder and the rectum providing level II support. The anterior support to the bladder was previously referred to as the pubovesicocervical fascia or 'bladder pillars', whereas the posterior support to the rectum was termed the rectovaginal fascia.</p>
<p><img src="assets/images/image-20251213-f9bfe439.jpeg" alt="img-243.jpeg"></p>
<p>Fig. 21.1 The pelvic diaphragm viewed from below.
<img src="assets/images/image-20251213-d31ce0cf.jpeg" alt="img-244.jpeg"></p>
<p>Fig. 21.2 Muscles of the pelvic floor, lateral view.
<img src="assets/images/image-20251213-4644567c.jpeg" alt="img-245.jpeg"></p>
<p>Fig. 21.3 The lateral attachments of the pubocervical fascia (PCF) and the rectovaginal fascia (RVF) to the pelvic sidewall. Also shown are the arcus tendineus fascia pelvis (ATFP), arcus tendineus fasciae rectovaginalis (ATFRV) and ischial spine (IS).
<img src="assets/images/image-20251213-1eeb8960.jpeg" alt="img-246.jpeg"></p>
<p>Fig. 21.4 Three-dimensional view of the endopelvic fascia. Notice the location of the cervix in the proximal anterior vaginal segment.
<img src="assets/images/image-20251213-e2a9bda7.jpeg" alt="img-247.jpeg"></p>
<p>Fig. 21.5 The endopelvic fascia of a post-hysterectomy patient divided into DeLancey's biomechanical levels: level I, proximal suspension; level II, lateral attachment; level III, distal fusion. (Modified with permission from DeLancey JO (1992) Anatomic aspects of vaginal eversion after hysterectomy. Am J Obstet Gynecol 166:1717. © Elsevier.)</p>
<p>Level III support is provided by the perineal body posteriorly and the pubourethral ligaments anteriorly. The perineal body is a complex fibromuscular mass in to which several structures insert. It is bordered cephalad by the rectovaginal septum (Dennonviller's fascia), caudad by the perineal skin, anteriorly by the wall of the anorectum, and laterally by the ischial rami. The three-dimensional form has been likened to the cone of the red pine (Pinus resinosa) and it forms the keystone of the pelvic floor a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow><mo>×</mo><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">4 \mathrm{~cm} \times 4 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> fibromuscular structure providing support not just to the lower third of the vaginal wall (part of the genital hiatus) anteriorly but also to the external anal sphincter posteriorly. Attaching laterally to the perineal body are the superficial and deep perineal muscles.</p>
<p>The anterior vaginal wall is supported by the pubovesicocervical fascia, which extends from the ATFP on one side</p>
<p>to the ATFP of the other providing a hammock-like level II support. The posterior vaginal wall is supported by the fibrous tissue of the rectovaginal septum that is well defined only in the midline; laterally the hammock-like supports arise from the ATFP.</p>
<p>The uterus is supported indirectly by the supports of the vaginal walls but directly by the uterosacral ligaments. The round and broad ligaments provide weak if any support to the vagina and uterus. Indirect support of the lower third of the vagina and uterus is provided by the intact levator ani (pelvic floor). The role of the latter has always been in doubt, but the puborectalis portion of the levator ani plays a significant role in the distension of the genital hiatus in labour and delivery making it very prone to injury. Injury to this muscle has been postulated to be the cause for vaginal prolapse later in life.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="definitions">Definitions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#definitions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vaginal-prolapse">Vaginal prolapse<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vaginal-prolapse" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Prolapse of the anterior vaginal wall may affect the urethra (urethrocele), and the bladder (cystocele, Fig. 21.6). On examination, the urethra and bladder can be seen to descend and bulge into the anterior vaginal wall and, in severe cases, will be visible at or beyond the introitus of the vagina. An urethrocele is the result of damage to level III (anterior) support, i.e. the pubourethral ligaments. Cystoceles usually result due to a loss of level II support and usually due to a midline defect in pubovesicocervical fascia. A rectocele is formed by a combination of factors: a herniation of the rectum through a defect in the rectovaginal fascia as well as a lateral detachment of the level II
support from the ATFP. This can usually be seen as a visible bulge of the rectum through the posterior vaginal wall. It is often associated with a deficiency and laxity of the perineum. This is the classical level III defect (posterior) affecting the perineal body.</p>
<p>An enterocele is formed by a prolapse of the small bowel through the rectouterine pouch, i.e. the pouch of Douglas, through the upper part of the vaginal vault (Fig. 21.6). The condition may occur in isolation, but usually occurs in association with uterine prolapse. An enterocele may also occur following hysterectomy when there is inadequate support of the vaginal vault. This represents damage to level I support.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="uterine-prolapse">Uterine prolapse<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#uterine-prolapse" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Descent of the uterus, which occurs when level I support is deficient, may occur in isolation from vaginal wall prolapse but more commonly occurs in conjunction with it. First-degree prolapse of the uterus often occurs in association with retroversion of the uterus and descent of the cervix within the vagina. If the cervix descends to the vaginal introitus, the prolapse is defined as second degree. The term procidentia is applied to where the cervix and the body of the uterus and the vagina walls protrude through the introitus. The word actually means 'prolapse' or 'falling' but is generally reserved for the description of total or third-degree prolapse (Fig. 21.7).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="symptoms-and-signs">Symptoms and signs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#symptoms-and-signs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Symptoms generally depend on the severity and site of the prolapse (Table 21.1).
<img src="assets/images/image-20251213-cf354e56.jpeg" alt="img-248.jpeg"></p>
<p>Fig. 21.6 The clinical appearance of vaginal prolapse.</p>
<p>Mild degrees of prolapse are common in parous women and may be asymptomatic.</p>
<p>There are some symptoms that are common to all forms of prolapse; these include:</p>
<ul>
<li>A sense of fullness in the vagina associated with dragging discomfort.
<img src="assets/images/image-20251213-4376c87b.jpeg" alt="img-249.jpeg"></li>
</ul>
<p>Fig. 21.7 Procidentia: a third-degree prolapse of the uterus and vaginal walls.</p>
<ul>
<li>Visible protrusion of the cervix and vaginal walls.</li>
<li>Sacral backache is usually relieved on lying down.</li>
</ul>
<p>Symptoms are often multiple and related to the nature of prolapse. It is important to note that the symptoms (and signs) of prolapse are worse at the end of the day. It is, therefore, of some value, to schedule examination of patients that have typical symptoms of prolapse without its obvious signs a little later in the day.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="urethrocele-and-cystocele">Urethrocele and cystocele<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#urethrocele-and-cystocele" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Typically patients complain of 'something coming down' per vaginum. At times there may be incomplete emptying of the bladder and this will be associated with double micturition, the desire to repeat micturition immediately after apparent completion of voiding. The patient may give a history of having to manually replace the prolapse into the vagina to void. Some patients may get recurrent urinary tract infections as a result of incomplete emptying of the bladder. Occasionally the patient may complain of occult stress incontinence, i.e. the involuntary loss of urine following raised intra-abdominal pressure that is not readily demonstrable on coughing but appears on reducing the prolapse.</p>
<p>The diagnosis is established by examination in the dorsal position. A single bladed Sim's speculum can be used to visualize the anterior vaginal wall. When the patient is asked to strain, the bulge in the anterior vaginal wall can be seen and often appears at the introitus. It is important to culture a specimen of urine to exclude the presence of infection. The differential diagnosis is limited to cysts or tumours of the anterior vaginal wall, and diverticulum of the urethra or bladder.</p>
<p>Table 21.1 Levels of supports, with diagnosis and co-relation with symptoms</p>
<table><thead><tr><th style="text-align: left;">Level of pelvic organ &lt;br&gt; support</th><th style="text-align: left;">Organ affected</th><th style="text-align: left;">Type of prolapse</th><th style="text-align: left;">Symptoms</th></tr></thead><tbody><tr><td style="text-align: left;">Level I - uterosacral &lt;br&gt; ligaments</td><td style="text-align: left;">Uterus/vaginal vault &lt;br&gt; (post-hysterectomy)</td><td style="text-align: left;">Uterocervical/vault &lt;br&gt; prolapse/enterocele</td><td style="text-align: left;">Vaginal pressure, sacral backache, &lt;br&gt; 'something coming down', &lt;br&gt; dyspareunia, vaginal discharge</td></tr><tr><td style="text-align: left;">Level II - arcus tendineus &lt;br&gt; fascia pelvis (ATFP)</td><td style="text-align: left;">Urinary bladder &lt;br&gt; Rectum</td><td style="text-align: left;">Cystocele</td><td style="text-align: left;">'Something coming down', double &lt;br&gt; voiding, occult stress &lt;br&gt; incontinence, recurrent urinary &lt;br&gt; tract infection</td></tr><tr><td style="text-align: left;"></td><td style="text-align: left;">Rectum</td><td style="text-align: left;">Rectocele</td><td style="text-align: left;">'Something coming down', difficult &lt;br&gt; defecation, manual digitation</td></tr><tr><td style="text-align: left;">Level III - anterior &lt;br&gt; (pubourethral ligaments)</td><td style="text-align: left;">Urethra</td><td style="text-align: left;">Urethrocele</td><td style="text-align: left;">'Something coming down', stress &lt;br&gt; incontinence</td></tr><tr><td style="text-align: left;">Level III - posterior &lt;br&gt; (perineal body)</td><td style="text-align: left;">Lower third of the vagina/ &lt;br&gt; vaginal introitus/anal &lt;br&gt; canal</td><td style="text-align: left;">Enlarged genital hiatus</td><td style="text-align: left;">Vaginal looseness, sexual &lt;br&gt; dysfunction, vaginal flatus, &lt;br&gt; needing to apply pressure to the &lt;br&gt; perineum to evacuate faeces</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="rectocele">Rectocele<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rectocele" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The prolapse of the rectum through the posterior vaginal wall is commonly associated with a deficient pelvic floor, disruption of the perineal body and separation of the levator ani. It is predominantly a problem that results from over distension of the introitus and pelvic floor during parturition.</p>
<p>The symptoms of a rectocele include difficulty with evacuation of faeces with an occasional need to 'manually digitate'. Needless to say the awareness of a reducible mass bulging into the vagina and through the introitus is often the presenting symptom.</p>
<p>Examination of the vulva usually shows a deficient perineum (measuring less than 3 cm in length) bringing the posterior fourchette in close apposition with the anterior anal verge. Patients can complain of vaginal looseness and sexual dysfunction as a result of this. Not uncommonly the symptom of vaginal 'flatus' can be uncovered on direct questioning.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="enterocele">Enterocele<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#enterocele" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Herniation of the pouch of Douglas usually occurs through the vaginal vault if the uterus has been removed. It is often difficult to distinguish between a high rectocele and an enterocele as the symptoms of vaginal pressure are identical. Occasionally an examination in the standing position or a bidigital examination may reveal an enterocele in a woman with no obvious signs of prolapse but complains of a dragging sensation in the pelvis or a low backache. Uncommonly the enterocele occurs anterior to the vaginal vault and may mimic a cystocele.</p>
<p>A large enterocele may contain bowel and may be associated with incarceration and obstruction of the bowel.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="uterine-prolapse">Uterine prolapse<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#uterine-prolapse" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Descent of the uterus is initially associated with elongation of the cervix and descent of the body of the uterus. Mostly the affected portion of the cervix is supravaginal, i.e. above the level of the vaginal fornices. The symptoms are those of pressure in the vagina and, ultimately, complete protrusion of the uterus through the introitus. At this stage, the prolapsed uterus may produce discomfort on sitting, and decubitus ulceration may result in bleeding. Sometimes patients with minor degrees of prolapse or with congenital prolapse may have infravaginal cervical elongation, that often leads to confusion in staging the degree of prolapse as it may appear to be in a more advanced stage than it actually is.</p>
<p>Urinary tract infection may occur because of compression of the ureters and consequent hydronephrosis due to incomplete emptying of the bladder. Not unusually, patients experience dyspareunia but are not very forthcoming with this symptom.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="staging-grading-of-prolapse">Staging/grading of prolapse<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#staging-grading-of-prolapse" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="baden-walker-halfway-system">Baden-Walker halfway system<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#baden-walker-halfway-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(Fig. 21.8 and Table 21.2)
This system was developed in an effort to introduce more objectivity into the quantification of pelvic organ prolapse. For example, measurements in centimetres are used instead of subjective grades. Nine specific measurements are recorded as indicated in Figure 21.9.</p>
<p>Table 21.2 Primary and secondary symptoms at each site used in the Baden-Walker halfway system</p>
<table><thead><tr><th style="text-align: left;">Anatomic &lt;br&gt; site</th><th style="text-align: left;">Primary symptoms</th><th style="text-align: left;">Secondary &lt;br&gt; symptoms</th></tr></thead><tbody><tr><td style="text-align: left;">Urethral</td><td style="text-align: left;">Urinary incontinence</td><td style="text-align: left;">Falling out</td></tr><tr><td style="text-align: left;">Vesical</td><td style="text-align: left;">Voiding difficulties</td><td style="text-align: left;">Falling out</td></tr><tr><td style="text-align: left;">Uterine</td><td style="text-align: left;">Falling out, heaviness, etc.</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Cul-de-sac</td><td style="text-align: left;">Pelvic pressure (standing)</td><td style="text-align: left;">Falling out</td></tr><tr><td style="text-align: left;">Rectal</td><td style="text-align: left;">True bowel pocket</td><td style="text-align: left;">Falling out</td></tr><tr><td style="text-align: left;">Perineal</td><td style="text-align: left;">Anal incontinence</td><td style="text-align: left;">Too loose &lt;br&gt; (gas/faeces)</td></tr></tbody></table>
<p>(Reproduced with permission from Baden WF, Walker T (1992) Surgical repair of vaginal defects. Lippincott, Williams &amp; Wilkins, Philadelphia, p. 12.)
<img src="assets/images/image-20251213-efbec02c.jpeg" alt="img-250.jpeg"></p>
<p>Fig. 21.8 Guidelines on how to assign grades in the Baden-Walker halfway system. (Reproduced with permission from Baden WF, Walker T (1992) Surgical repair of vaginal defects. Lippincott, Williams &amp; Wilkins, Philadelphia.)</p>
<p><img src="assets/images/image-20251213-78a655c6.jpeg" alt="img-251.jpeg"></p>
<p>Fig. 21.9 Pelvic organ prolapse quantification system (POP-Q).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pathogenesis">Pathogenesis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pathogenesis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Prolapse may be:</p>
<ul>
<li>Congenital: Uterine prolapse in young or nulliparous women is due to weakness of the supports of the uterus and vaginal vault. There is a minimal degree of vaginal wall prolapse.</li>
<li>Acquired: The commonest form of prolapse is acquired under the influence of multiple factors. This type of prolapse is both uterine and vaginal but it must also be remembered that vaginal wall prolapse can also occur without any uterine descent. Predisposing factors include:</li>
<li>High parity: Uterovaginal prolapse is a condition of parous women. The pelvic floor provides direct and indirect support for the vaginal walls and when this support is disrupted by laceration or over distension it predisposes to vaginal wall prolapse. Instrumental delivery employing forceps/ventouse especially mid-cavity rotational forceps delivery may play a contributory role in the causation of urinary incontinence and prolapse in later life.</li>
<li>Raised intra-abdominal pressure: Tumours or ascites may result in raised intra-abdominal pressure, but a more common cause is a chronic cough and chronic constipation.</li>
<li>Hormonal changes: The symptoms of prolapse often worsen rapidly at the time of the menopause. Cessation of oestrogen production leads to thinning of the vaginal walls and the supports of the uterus. Although the prolapse is generally present before the menopause, it is at this time that
the symptoms become noticeable and the degree of descent visibly worsens. The age at first vaginal childbirth affects the incidence of prolapse and urinary incontinence in later life. It has been postulated that increased maternal age predisposes to levator trauma making these women more prone to developing pelvic floor disorders.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management">Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The management of prolapse can be conservative or surgical.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="prevention">Prevention<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prevention" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Good surgical technique in supporting the vaginal vault at the time of hysterectomy reduces the incidence of later vault prolapse. Avoiding a prolonged second stage of labour and inappropriate or premature bearing down efforts; encouraging pelvic floor exercises after delivery and the judicious use of instrumental delivery with appropriately individualized episiotomies may all help to reduce the risk of prolapse in later life.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="conservative-treatment">Conservative treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#conservative-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span>
Many women have minor degrees of uterovaginal prolapse, which are asymptomatic. If the recognition of the prolapse is a coincidental finding, the woman should be advised against any surgical treatment.</p>
<p>Minor degrees of prolapse are common after childbirth and should be treated by pelvic floor exercises or the use of a pessary. Operative intervention is deferred for at least 6 months after delivery, as the tissues remain vascular and may undergo further spontaneous improvement.</p>
<p>Hormone replacement therapy may be used preoperatively to prepare the tissues, but by itself is of limited benefit in alleviating symptoms.</p>
<p>Where short-term support is required or the general health of the woman makes operative treatment potentially dangerous, then both vaginal wall and uterine prolapse can be treated by using vaginal pessaries. It is, however, necessary to have some pelvic floor support if a pessary is to be retained.</p>
<p>The most widely used pessaries (Fig. 21.10) are:</p>
<ul>
<li>Ring pessary: This pessary consists of a malleable plastic ring, which may vary in diameter from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>105</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">60-105 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">105</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span>. The pessary is inserted in the posterior fornix and behind the pubic symphysis. Distension of the vaginal walls tends to support the vaginal wall prolapse.</li>
</ul>
<p><img src="assets/images/image-20251213-17f1df2a.jpeg" alt="img-252.jpeg"></p>
<p>Fig. 21.10 Various types of vaginal pessary used in the conservative management of uterovaginal prolapse.</p>
<ul>
<li>Hodge pessary: This is a rigid, elongated, curved ovoid which is inserted in a similar way to the ring pessary and is principally useful in uterine retroversion.</li>
<li>Gelhorn pessary: This pessary is shaped like a collar stud and is used in the treatment of severe degrees of prolapse.</li>
<li>Shelf pessary: This is shaped like a coat hook and is used mainly in the treatment of uterine or vaginal vault prolapse.
The main problem with long-term use of pessaries is ulceration of the vaginal vault and rarely a fistula may form, usually between the bladder and the vagina, if the pessary is 'neglected' or 'forgotten'. Pessaries should be replaced every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> months and the vagina should be examined for any signs of ulceration. In postmenopausal women it is considered good practice to prescribe vaginal oestrogen creams/tablets to prevent ulceration.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pelvic-floor-physiotherapy">Pelvic floor physiotherapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pelvic-floor-physiotherapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>See section on Urinary incontinence</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="surgical-treatment">Surgical treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#surgical-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The surgical management of uterovaginal prolapse has seen many changes in recent years. There is an increasing use of graft material and tissue anchors for increasing durability of the prolapse repair. Thus prolapse repairs can be classified into fascial repairs and graft augmented repairs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fascial-repairs">Fascial repairs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fascial-repairs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Classically surgical treatment of a cystocele is by anterior colporrhaphy (Fig. 21.11). The operation consists of
<img src="assets/images/image-20251213-ad7c0816.jpeg" alt="img-253.jpeg"></p>
<p>Fig. 21.11 Anterior fascial repair of cystocele.
dissection of the prolapsed viscus (the urinary bladder) off the vaginal flaps, buttressing the pubovesicocervical fascia with durable delayed absorbable sutures and closure of the vaginal skin. Current practice does not include excision of 'excess vaginal skin' as the vagina is expected to remodel and the perceived laxity all but disappears in 6-8 weeks' time.</p>
<p>Rectocele is repaired by again dissecting the prolapsing viscus (in this case the rectum) off the overlying vaginal skin and effecting a robust repair by apposing the torn ends of the rectovaginal fascia together with delayed absorbable sutures. Sometimes it is possible to identify the tears in the fascia and often a reattachment of the torn ends suffices. Not uncommonly a rectocele is accompanied by a deficient perineal body where the perineal muscles are attenuated or retracted laterally with the patient complaining of 'vaginal laxity' or sexual dysfunction. Intravaginal perineoplasty is the operation designed to treat these symptoms and involves lateral dissection to identify the retracted ends of the perineal muscles, apposing these in the midline and suturing the apposed muscles to the apex of the incision. This procedure helps recreate the perineal body, reduces the size of the genital hiatus thus improving vaginal tone and also corrects the vaginal axis. This operation is an improvement on the perineorraphy where the perineal skin is first incised and later excised but still fails to achieve the objectives stated above.</p>
<p>Where there is an enterocele, the procedure of choice is a McCall's culdoplasty. This involves the placement of delayed absorbable sutures through the cut ends of the</p>
<p>uterosacral ligaments and the intervening peritoneum hitching these successively to the vaginal vault. The aim of this operation is not just to treat the enterocele, but also to prevent occurrence of vault prolapse.
The treatment of choice for uterine prolapse depends on the woman's preference for retaining her reproductive potential. If her family is complete then a vaginal hysterectomy usually with repair of the prolapsed vaginal walls is the preferred approach. If preservation of reproductive function is required, then the uterus can be conserved by simply excising the elongated cervix that is fashioned to an appropriate length with suturing of the cardinal ligaments in front of the cervical stump. This procedure is known as a Manchester or Fothergill repair. The vaginal skin is then sutured into the cervical stump using circumferential sutures. Additionally the operating surgeon may elect to suspend the cervix by means of sutures taken through the sacrospinous ligament called sacrospinous cervicopexy/ hysteropexy.
A similar procedure may be employed to treat vault prolapse occurring after hysterectomy; the procedure is then called sacrospinous colpopexy (colpos Gk: vagina).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="graft-repairs">Graft repairs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#graft-repairs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The earliest repairs using mesh have been to treat vault prolapse (Fig 21.12). The prolapsed vaginal vault is treated by suspending the vaginal vault from the anterior longitudinal ligament of the sacrum using a synthetic mesh. This procedure is known as sacrocolpopexy - a procedure that
<img src="assets/images/image-20251213-78c4fffa.jpeg" alt="img-254.jpeg"></p>
<p>Fig. 21.12 Graft (mesh) used for vaginal prolapse repair (cystocele).
can be performed laparoscopically or through a laparotomy. More recently 'needle driven mesh kits' have become available to treat vaginal prolapse. The first of these kits was called the PERIGEE <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">M</mi></mrow></msup></mrow><annotation encoding="application/x-tex">{ }^{\mathrm{TM}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8413em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8413em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight"><span class="mord mathrm mtight">TM</span></span></span></span></span></span></span></span></span></span></span></span></span></span> used to suspend the prolapsed bladder from one ATFP to its opposite member thus recreating the hammock like arrangement that existed in the pelvis prior to the occurrence of the prolapse. A similar device called the APOGEE <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">M</mi></mrow></msup></mrow><annotation encoding="application/x-tex">{ }^{\mathrm{TM}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8413em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8413em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight"><span class="mord mathrm mtight">TM</span></span></span></span></span></span></span></span></span></span></span></span></span></span> is available to treat large enteroceles and vault prolapses. More recently newer versions called the Anterior and Posterior Elevate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">M</mi></mrow></msup></mrow><annotation encoding="application/x-tex">{ }^{\mathrm{TM}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8413em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8413em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight"><span class="mord mathrm mtight">TM</span></span></span></span></span></span></span></span></span></span></span></span></span></span> have been developed to treat anterior, middle and posterior compartment disorders that are safer to use and employ mesh that is more bio-compatible. These new devices require specialized instruction and training prior to use.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="complications">Complications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Repairs whether fascial or otherwise can result in injury to the viscus being treated, i.e. bladder, small intestines, rectum or anal canal. The sigmoid colon or the ureters may additionally be injured when a McCalls' culdoplasty is performed. The new needle driven devices are known to be rarely associated with damage to the deeper vessels in the pelvis and with more common occurrence of vaginal mesh exposure. Primary, reactionary and secondary hemorrhage may all occur with all of these procedures as may infection. The immediate complications of vaginal hysterectomy includes haemorrhage, haematoma formation, infection and less commonly, urinary retention. The longterm complications are dyspareunia and reduced vaginal capacity especially if vaginal skin is inappropriately excised. Fascial repairs especially of the anterior compartment may recur in about a third of cases. Posterior compartment fascial repairs perform better with only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> recurrence. Inadequate support to the vaginal apex may result in recurrence of the prolapse of the vaginal vault. Mesh repairs are more robust with lower rates of recurrence.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="urinary-tract-disorders">URINARY TRACT DISORDERS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#urinary-tract-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="structure-and-physiology-of-the-urinary-tract">Structure and physiology of the urinary tract<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#structure-and-physiology-of-the-urinary-tract" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The urinary bladder is a hollow muscular organ with an outer adventitial layer, a smooth muscle layer known as the detrusor muscle and an inner layer of transitional epithelium.
The innervation of the bladder contains both sympathetic and parasympathetic components. The sympathetic fibres arise from the lower two thoracic and upper two lumbar segments of the spinal cord, and the parasympathetic fibres from the second, third and fourth sacral segments.</p>
<p>The urethra itself begins outside the bladder wall. In its distal two thirds it is fused with the vagina, with which it shares a common embryologic derivation. From the vesical neck to the perineal membrane, which starts at the junction of the middle and distal thirds of the bladder, the urethra has several layers. An outer, circularly oriented skeletal muscle layer (urogenital sphincter) mingles with some circularly oriented smooth muscle fibres. Inside this layer is a longitudinal layer of smooth muscle that surrounds a very vascular submucosal venous plexus and non-keratinized squamous epithelium that responds to estrogenic stimulation. The continence mechanism is maintained by the urogenital sphincter, aided by the mucosal co-aptation of urethral epithelium and the 'bulking up' effect provided by the submucosal venous plexus.</p>
<p>During micturition, the pressure in the bladder rises to exceed the pressure within the urethral lumen and there is a fall in urethral resistance. The tone of muscle fibres around the bladder neck is reduced by central inhibition of the motor neurons in the sacral plexus. The bladder fills at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>6</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">1-6 \mathrm{~mL} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mL</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>. The intravesical pressure remains low because of compliance of the bladder wall as it stretches and reflex inhibition of the detrusor muscle. At the same time the internal urethral meatus is closed by tonic contraction of the rhabdosphincter and the tone of the urethral mucosa. During rises in intra-abdominal pressure such as coughing or sneezing, continence is maintained by transmission of the pressure rise to the proximal urethra (which lies normally within the intra-abdominal space) and an increase in the levator tone.</p>
<p>The ureter is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>30</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">25-30 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">30</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> long. It runs along the transverse processes of the lumbar spine, anterior to the psoas muscle, is crossed by the ovarian vessels and enters the pelvis anterior to the bifurcation of the common iliac vessels. From there it runs anterior to the internal iliac vessels to the ischial spines where it turns medially to the cervix. It turns again anteriorly 1.5 cm lateral to the vaginal fornix, crossing below the uterine vessels to enter the posterior surface of the bladder.</p>
<p>The ureters are particularly vulnerable to surgical damage at two sites in the pelvis. One is the point at which the ureter enters the pelvis under the lateral origin of the suspensory ligament. At the time of removal of a large ovarian tumour, clamping of the ligament may incorporate the ureter as the tumour is pulled medially and the ureter is lifted off the lateral pelvic wall. Second, during a hysterectomy the ureter may be damaged, by clamping or dissection, at the point where it passes under the uterine artery before entering the bladder.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="common-disorders-of-bladder-function">Common disorders of bladder function<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#common-disorders-of-bladder-function" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The common symptoms of bladder dysfunction include:</p>
<ul>
<li>urinary incontinence</li>
<li>frequency of micturition</li>
<li>dysuria</li>
<li>urinary retention</li>
<li>nocturnal enuresis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="incontinence-of-urine">Incontinence of urine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#incontinence-of-urine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The involuntary loss of urine may be associated with bladder or urethral dysfunction or fistula formation. Types of incontinence are listed below:</p>
<ul>
<li>True incontinence is continuous loss of urine through the vagina; it is commonly associated with fistula formation but may occasionally be a manifestation of urinary retention with overflow.</li>
<li>Stress incontinence is the involuntary loss of urine that occurs during a brief period of raised intraabdominal pressure. It is usually related to injury to the continence mechanism described above and lack of estrogenic stimulation and usually manifests around menopause. Examination reveals the involuntary loss of urine during coughing usually accompanied by a hypermobility of the urethra and a descent of the anterior vaginal wall.</li>
<li>Urge incontinence is the problem of sudden detrusor contraction, with uncontrolled loss of urine. The condition may be due to idiopathic detrusor instability or associated with urinary infection, obstructive uropathy, diabetes or neurological disease. It is particularly important to exclude urinary tract infection.</li>
<li>Mixed urge and stress incontinence occurs in a substantial number of women. Women with urge incontinence also have true stress incontinence and it is particularly important to treat the detrusor instability prior to correcting stress incontinence. Failure to do so may lead to a worsening of the condition.</li>
<li>Overflow incontinence occurs when the bladder becomes dilated or flaccid with minimal or no tone/ function. It is not uncommon after vaginal delivery or when the bladder is 'neglected' after a spinal anaesthetic. A bladder scan usually reveals the presence of a residual of more than half the bladder capacity. The bladder then becomes 'lazy' and empties when it becomes full.</li>
<li>Miscellaneous types of incontinence include infections, medications, prolonged immobilization, cognitive impairment and in certain situations may precipitate incontinence.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="urinary-frequency">Urinary frequency<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#urinary-frequency" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Urinary frequency is an insuppressible desire to void more than seven times a day or more than once a night. If affects <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of women aged between 30 and 64 years, and can be caused by pregnancy, diabetes, pelvic masses, renal failure, diuretics, excess fluid intake or habit, although the most common cause is urinary tract infection. The frequency may be diurnal (daytime) or nocturnal.</p>
<p>However, enhanced bladder contractility may occur without the presence of infection. Reduced bladder capacity may also result in frequency of micturition.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dysuria">Dysuria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dysuria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This symptom results from infection. Local urethral infection or trauma causes burning or scalding during micturition, but bladder infection is more likely to cause pain suprapubically after micturition has been completed. It is always advisable to perform a vaginal examination on any woman who complains of scalding on micturition because urethritis is associated with vaginitis and vaginal infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="urinary-retention">Urinary retention<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#urinary-retention" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Acute urinary retention is less of a problem in women. It can however be seen:</p>
<ul>
<li>after vaginal delivery and episiotomy</li>
<li>following operative delivery</li>
<li>after vaginal repair procedures, particularly those operations that involve posterior vaginal wall and perineum.</li>
<li>in the menopause - spontaneous obstructive uropathy is more likely to occur in menopausal women</li>
<li>in pregnancy - a retroverted uterus may become impacted in the pelvis towards the end of the first trimester</li>
<li>when inflammatory lesions of the vulva are present</li>
<li>as a result of untreated over-distension of the bladder (such as following delivery), neuropathy or malignancy.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nocturnal-enuresis-or-bed-wetting">Nocturnal enuresis or bed-wetting<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nocturnal-enuresis-or-bed-wetting" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is urinary incontinence occurring during sleep and may have a psychological basis to it from childhood.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="diagnosis">Diagnosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diagnosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The diagnosis is initially indicated by the history. Continuous loss of urine indicates a fistula, but not all fistulas leak urine continuously. The fistulous communication usually occurs between the bladder and vagina, vesicovaginal fistula, and the ureter and vagina, ureterovaginal fistula. Fistula formation results from:</p>
<ul>
<li>obstetric trauma associated with obstructed labour</li>
<li>surgical trauma</li>
<li>malignant disease</li>
<li>radiotherapy.</li>
</ul>
<p>There are other types of fistula with communications between bowel and urinary tract and between bowel and vagina, but these are less common.</p>
<p>Rectovaginal fistulas have a similar pathogenesis, with the additional factor of perineal breakdown after a thirddegree tear.</p>
<p>Urinary fistulas are localized by:</p>
<ul>
<li>cystoscopy</li>
<li>intravenous urogram</li>
<li>instillation of methylene blue via a catheter into the bladder; the appearance of dye in the vagina indicates a vesicovaginal fistula.
The differential diagnosis between stress and urge incontinence is more difficult and is often unsatisfactory. Adequate preoperative assessment is important if the correct operation is to be employed or if surgery is to be avoided. It is important to assess patients with a validated patient questionnaire (the Modified Bristol Female Lower Urinary Tract Symptoms Questionnaire is a good example) with a 3-day urinary diary and a pad test. These help the clinician gain an insight into how the symptoms of urinary incontinence affect the patient on a day-to-day basis. The bladder and urethra are assessed in the laboratory by urodynamics. This procedure usually involves three basic steps:</li>
</ul>
<ol>
<li>Uroflowmetry: The patient is asked to pass urine into a specially designed toilet that measures voided volume, maximal and average urinary flow rates. Flow rates of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>15</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">s</mi><mi mathvariant="normal">e</mi><mi mathvariant="normal">c</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;15 \mathrm{~mL} / \mathrm{sec}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mL</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">sec</span></span></span></span></span></span> are considered acceptable and it is expected that a normal bladder will completely empty itself. Flow rates of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>15</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">s</mi><mi mathvariant="normal">e</mi><mi mathvariant="normal">c</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;15 \mathrm{~mL} / \mathrm{sec}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mL</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">sec</span></span></span></span></span></span> are indicative of voiding dysfunction and in the female often indicate a 'functional obstruction' rather than an anatomic one. Occasionally a powerful detrusor may cause the bladder to contract against a closed internal urethral meatus resulting in dysfunctional voiding, a condition termed 'detrusor-sphincter dyssynergia'.</li>
<li>The cystometrogram (Fig 21.13): Pressure is measured intravesically and intravaginally or less commonly intrarectally, because intravaginal pressure represents intra-abdominal pressure and is subtracted from the intravesical pressure to give a measure of detrusor pressure. The volume of fluid in the bladder at which the first desire to void occurs is usually about 150 mL . A strong desire to void occurs at 400 mL in the normal bladder. High detrusor pressure at a lower volume reflects an abnormally sensitive bladder associated with chronic infection. There should be no detrusor contraction during filling, and any contraction that occurs under these</li>
</ol>
<p><img src="assets/images/image-20251213-c4d0ef1d.jpeg" alt="img-255.jpeg"></p>
<p>Fig. 21.13 (A) Bladder flow studies in the investigation of lower urinary tract symptoms. (B) Cystometrogram from a patient with idiopathic detrusor instability.
circumstances indicates detrusor instability. An underactive detrusor shows no contraction on complete filling and indicates an abnormality of neurological control. The average bladder has a capacity of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>550</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">250-550 \mathrm{~mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">550</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mL</span></span></span></span></span></span>, but capacity is a poor index of bladder function. Thus, cystometry is a useful method for assessing detrusor muscle function or detrusor instability, which may result in urge incontinence.</p>
<p>In the presence of urethral incompetence, there is low resting urethral pressure, no voluntary increase in urethral pressure, inability to stop midstream, decreased pressure transmission to the abdominal urethra and large volumes in the frequency/volume measurements. There is not always a clear-cut demarcation between the two conditions, as there may be a mixture of both stress and urge incontinence. Nevertheless, it is important to</p>
<p>differentiate between the predominant influence of bladder neck weakness and stress incontinence, and detrusor instability and urge incontinence.
3. Urethral pressure profile: This is performed at the very end of the cystometry and measures the pressure within the mid-urethra, in particular the maximum urethral closure pressure (MUCP). This is of value in predicting the likelihood of surgical success after an anti-incontinence procedure. Pressures <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>20</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;20 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">20</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><mi mathvariant="normal">O</mi></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{O}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">O</span></span></span></span></span> are predictive of poorer outcomes.
In some units an endoscopic view of the bladder called 'cystoscopy' and an ultrasound scan of the pelvic floor are the additional procedures performed in the evaluation of the incontinent woman.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management">Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="urinary-tract-fistula">Urinary tract fistula<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#urinary-tract-fistula" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In the developed world, most urinary tract fistulas result from surgical trauma. The commonest fistulas are vesicovaginal or ureterovaginal and result from surgical trauma at the time of hysterectomy, or sometimes following caesarean section.</p>
<p>A vesicovaginal fistula will usually become apparent in the first postoperative week. If the fistula is small, closure may be achieved spontaneously.</p>
<p>The patient should be treated by catheterization and continuous drainage. If closure has not occurred after 2-3 months, the fistula is unlikely to close spontaneously and surgical closure is recommended. The timing of further surgery is still a subject of controversy. Until recently, a delay of 6 months was recommended but there is increasing evidence that good results can be obtained with early surgical intervention. However, the fistulous site should be free of infection.</p>
<p>Surgical closure may be achieved vaginally by meticulous separation of the edges of the fistula and closure in layers of the bladder and vagina. Postoperative care includes continuous catheter drainage for 1 week and antibiotic cover. An abdominal approach to the fistula can also be used and has some advantages, allowing the interposition of omentum in cases where there is a large fistula.</p>
<p>Ureterovaginal fistulas are usually treated by reimplantation of the damaged ureter into the bladder.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="stress-incontinence">Stress incontinence<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#stress-incontinence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Stress incontinence should be managed initially by pelvic floor physiotherapy. Surgical treatment is indicated where there is a failure to respond to conservative management. In the presence of anterior vaginal wall prolapse, anterior repair, with the placement of buttressing sutures at the bladder neck, has the virtue of simplicity. It will certainly relieve the prolapse but the results are variable as far as the stress incontinence is concerned, with relief in about
<img src="assets/images/image-20251213-b5b95d32.jpeg" alt="img-256.jpeg"></p>
<p>Fig. 21.14 Mid-urethral sling used in the treatment of stress incontinence.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of cases. It is of no value in the absence of evidence of prolapse.</p>
<p>The following procedures are commonly used:</p>
<ul>
<li>Mid-urethral slings (Fig. 21.14)</li>
<li>Tension-free vaginal tape (TVT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>TM&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {TM }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8413em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8413em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">TM&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> ): Bladder neck elevation can be achieved by the placement of a tension-free vaginal tape. A polypropylene tape is inserted through a sub-urethral vaginal incision and guided via a needle paravesically to exit from the symphysis pubis. This can be carried out under local, regional or general anaesthetic and the tape is placed mid-urethrally in a tensionfree manner. A cystourethroscopy is performed intra-operatively to rule out damage to the bladder and urethra. As this procedure is minimally invasive most women are able to return to normal activity within 1-2 weeks. The long-term success rates are around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span>.</li>
</ul>
<p>In recent times the procedure has become even less invasive than before and now it is possible to perform the procedure by passing needles through the obturator foramina and still site the tape as before, i.e. under the mid-urethra (MONARC <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>TM&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {TM }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8413em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8413em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">TM&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> ). The most recent version of the sling is called the MINIARC <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>TM&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {TM }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8413em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8413em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">TM&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span>. It is the most minimally invasive version of the mid-urethral sling that has the added advantage of not having to be passed through blind spaces like the retropubic space and transobturator foramina.</p>
<ul>
<li>Miscellaneous procedures still in vogue</li>
<li>Laparoscopic Burch colposuspension involves bladder neck elevation by suturing the upper lateral vaginal walls to the iliopectineal ligaments under laparoscopic control. The success rates are around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> and the procedure results in voiding dysfunction in a significant majority of patients. This procedure has more or less been invalidated</li>
</ul>
<p>by the more popular and safer mid-urethral slings.</p>
<ul>
<li>Transurethral injections: Injectable bulking agents can be injected via a cystoscope into the mid-urethra. These are simple procedures with very little perioperative morbidity and have success rates of about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span>. These are useful adjuncts to the mid-urethral slings especially in recurrences and in women with multiple failed operations. The commonest agents employed are collagen (glutaraldehyde cross-linked bovine collagen), silicon (macroparticulate silicon particles), Durasphere <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> (pyrolytic carbon-coated beads), etc.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-unstable-bladder-overactive-bladder-syndrome-oab">The unstable bladder: overactive bladder syndrome (OAB)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-unstable-bladder-overactive-bladder-syndrome-oab" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The features of the unstable bladder are those of frequency of micturition and nocturia, urgency and urge incontinence. When confronted with this history, it is important to obtain some indication of the frequency as related to fluid intake and output. A chart should therefore be kept by the patient to clarify this aspect.</p>
<p>The assessment of predisposing factors includes urine culture, urinary flow rates and urodynamic studies.</p>
<p>Treatment will obviously be directed at the cause, so the presence of urinary tract infection necessitates the administration of the appropriate antibiotic therapy. Postmenopausal women with atrophic vaginal epithelium and symptoms of urgency and frequency often respond to replacement therapy with low-dose oestrogens.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="detrusor-instability-of-unknown-aetiology">Detrusor instability of unknown aetiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#detrusor-instability-of-unknown-aetiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>If the problem arises at a cerebral level, then psychotherapeutic measures are indicated. Bladder drill involves a regime of gradually increasing the voiding interval on a recorded pattern. This is effective in the short term but the relapse rate is high.</p>
<p>The placebo response rate in detrusor instability is more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> and spontaneous remissions occur.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-treatment">Drug treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The alternative approach is to use anticholinergic drugs that act at the level of the bladder wall. These act on the muscarinic receptors on the bladder wall and cause relaxation. Some of these drugs are more specific and act on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">M</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{M}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. The more specific the drug the less likely it is to cause side-effects. The drugs listed in Table 21.3 are in increasing order of specificity and better side-effect profile.</p>
<p>Table 21.3 Drug therapy of overactive bladder</p>
<table><thead><tr><th style="text-align: center;">Drug name</th><th style="text-align: center;">Drug type</th><th style="text-align: center;">Dosage</th><th style="text-align: center;">Available doses</th><th style="text-align: center;">Side effects</th></tr></thead><tbody><tr><td style="text-align: center;">Oxybutynin</td><td style="text-align: center;">Antimuscarinic</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> PO tid</td><td style="text-align: center;">5 mg tablet, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} / \mathrm{mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">mL</span></span></span></span></span></span> syrup</td><td style="text-align: center;">Dry mouth, constipation, dizziness, palpitations, anorexia, nausea, amblyopia</td></tr><tr><td style="text-align: center;">Oxybutynin (transdermal)</td><td style="text-align: center;">See above</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.9</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">3.9 \mathrm{mg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.9</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span>; patch changed twice weekly</td><td style="text-align: center;">36 mg patch</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tolterodine (shortacting)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">M</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{M}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-selective antimuscarinic</td><td style="text-align: center;">1-2 mg PO bid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1,2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tablet</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tolterodine (longacting)</td><td style="text-align: center;">See above</td><td style="text-align: center;">2-4 mg PO once daily</td><td style="text-align: center;">2, 4 mg capsule</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Trospium chloride</td><td style="text-align: center;">Antimuscarinic quaternary amine</td><td style="text-align: center;">20 mg PO bid</td><td style="text-align: center;">20 mg tablet</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Darifenacin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">M</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{M}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-selective antimuscarinic</td><td style="text-align: center;">7.5-15 mg PO daily</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>7.5</mn><mo separator="true">,</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;tablet&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 7.5,15 \mathrm{mg} \\ &amp; \text { tablet } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">7.5</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;tablet&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Solifenacin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">M</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{M}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-selective antimuscarinic</td><td style="text-align: center;">5-10 mg PO once daily</td><td style="text-align: center;">5, 10 mg tablets</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Imipramine hydrochloride</td><td style="text-align: center;">Tricyclic antidepressant, anticholinergic, adrenergic, antihistamine</td><td style="text-align: center;">10-25 mg PO qd-qid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>10</mn><mo separator="true">,</mo><mn>25</mn><mo separator="true">,</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;tablets&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 10,25,50 \mathrm{mg} \\ &amp; \text { tablets } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;tablets&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pelvic-floor-physiotherapy-pelvic-floor-muscle-training">Pelvic floor physiotherapy: pelvic floor muscle training<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pelvic-floor-physiotherapy-pelvic-floor-muscle-training" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In women who have mild to moderate symptoms of urinary incontinence, pelvic floor muscle training (PFMT) may allow improvement if not cure. Also known as Kegel exercises, PFMT entails voluntary contraction of the levator ani muscles. These need to be repeated several times a day up to 50 or 60 times to be of any clinical benefit.</p>
<p>The specifics are a bit variable, being very clinician specific and also dependent on the clinical setting. Most patients find isolating the levator ani muscles most challenging and often contract their abdominal muscles instead. Therefore it is imperative that these exercises be demonstrated by a physiotherapist with a special interest in pelvic floor rehabilitation. To augment efficacy of these exercises, weighted vaginal cones or obturators may be placed into the vagina during Kegel exercises. These provide resistance against which pelvic floor muscles can work.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="electrical-stimulation-interferential-therapy">Electrical stimulation (interferential therapy)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#electrical-stimulation-interferential-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>As an alternative/adjunct to active pelvic floor contraction, a vaginal probe may be used to deliver low-frequency electrical stimulation to the levator ani muscles. Although the mechanism is unclear, electrical stimulation may be used to improve either stress urinary incontinence (SUI) or urge incontinence. With urge incontinence, traditionally a low frequency is applied, whereas higher frequencies are used for SUI.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="biofeedback-therapy">Biofeedback therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#biofeedback-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Many behavioural techniques, often considered together as biofeedback therapy, measure physiological signals such as muscle tension and then display them to a patient in real time. In general, visual, auditory, and/or verbal feedback cues are directed to the patient during these therapy sessions. These cues provide immediate performance evaluation to a patient. Specifically, during biofeedback for PFMT, a sterile vaginal probe that measures pressure changes within the vagina during levator ani muscle contraction is typically used. Readings reflect an estimate of muscle contraction strength. Treatment sessions are individualized, dictated by the underlying dysfunction, and modified based on response to therapy. In many cases, reinforcing sessions at various subsequent intervals may also prove advantageous.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dietary-modifications">Dietary modifications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dietary-modifications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Patients are encouraged to avoid carbonated drinks and caffeine and commence cranberry tablets because these often help with reducing symptoms of urgency and frequency.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="timed-voiding">Timed voiding<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#timed-voiding" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Patients are encouraged to void 'by the clock' in an attempt to limit the waves of urgency that often patients with OAB symptoms experience. Over time the bladder is able to hold successively increasing volumes without resulting in leakage.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vaginal-oestrogen">Vaginal oestrogen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vaginal-oestrogen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Oestrogen has been shown to increase urethral blood flow and increase alpha-adrenergic receptor sensitivity, thereby increasing urethral coaptation and urethral closure pressure. In theory, oestrogen may increase collagen deposition and increase vascularity of the periurethral capillary plexus. These are purported to improve urethral coaptation. Thus, for incontinent women who are atrophic, administration of exogenous oestrogen is reasonable.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="bladder-outlet-obstruction">Bladder outlet obstruction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bladder-outlet-obstruction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Primary bladder neck obstruction in the female probably results from the failure of the vesical neck to open during voiding, and can be treated either with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-adrenergic blocking agents like tamsulosin (Flomax <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> ) or by urethral dilatation. Secondary outlet obstruction is usually associated with previous surgery for incontinence and may respond to urethral dilatation but the results are not particularly good.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-neuropathic-bladder">The neuropathic bladder<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-neuropathic-bladder" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Loss of bladder function may be associated with a variety of conditions that affect the central nervous system. These conditions may also be associated with alteration in bowel function, sexual dysfunction and loss of function of the lower limbs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="presentation">Presentation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#presentation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The neuropathic bladder is a reflection of dyssynergy between the activity of the detrusor muscle and the bladder sphincter. This results in a variety of disorders ranging from the 'automatic bladder' through retention with overflow at high or low pressure to total stress incontinence. It may also be associated with renal failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="aetiology">Aetiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aetiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The causation may be suprapontine, such as a cerebrovascular accident, Parkinson's disease or a cerebral tumour. Infrapontine causes include cord injuries or compression, multiple sclerosis and spina bifida. Peripheral autonomic neuropathies that affect bladder function may be</p>
<p>idiopathic or diabetic and, occasionally, secondary to surgical injury.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="diagnosis">Diagnosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diagnosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The diagnosis is established by a systematic search for the cause involving cystometry, urinary flow rate studies, neurological screening, brain scan, pyelography and renal isotope scans.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management">Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The management clearly depends on establishing the cause, but symptomatically it also involves non-surgical management using absorptive pads and clean intermittent self-catheterization. Anticholinergic drugs also have a place for some patients. Surgical treatment includes the use of artificial sphincters and sacral nerve stimulators.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="essential-information">Essential information<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#essential-information" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="prolapse">Prolapse<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prolapse" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>May involve anterior or posterior vaginal wall with varying degrees of uterine descent</li>
<li>Predisposing factors include high parity, chronically raised intra-abdominal pressure and hormonal changes</li>
<li>Symptoms depend on degree of prolapse and whether bowel or bladder neck involved</li>
<li>May undergo spontaneous improvement up to 6 months postpartum</li>
<li>Treatment of choice is surgical repair <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> hysterectomy</li>
<li>No treatment required for asymptomatic minor degrees of prolapse</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="stress-incontinence">Stress incontinence<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#stress-incontinence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Involuntary loss of urine causing social or hygienic problems and objectively demonstrable</li>
<li>Commonly associated with prolapse of the anterior compartment</li>
<li>Associated with detrusor instability in up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of cases</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="detrusor-instability">Detrusor instability<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#detrusor-instability" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Presents as frequency, urgency, nocturia and incontinence</li>
<li>Usually idiopathic but needs to be distinguished from obstructive uropathy, diabetes, neurological disorders and infection</li>
<li>May present as stress incontinence</li>
<li>Management includes bladder drill, anticholinergics and treatment of infection</li>
</ul>
<p>This page intentionally left blank</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="principles-of-perioperative-care">Principles of perioperative care<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-perioperative-care" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Stergios K. Doumouchtsis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="learning-outcomes">Learning outcomes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#learning-outcomes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter you should be able to:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="knowledge-criteria">Knowledge criteria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#knowledge-criteria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>List the principles of infection control</li>
<li>Describe the appropriate use of blood and blood products</li>
<li>Discuss the general pathological principles of postoperative care</li>
<li>Describe the principles of fluid-electrolyte balance and wound healing</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-competencies">Clinical competencies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-competencies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Plan perioperative care for a patient undergoing the common gynaecological procedures</li>
<li>Recognize normal postoperative course</li>
<li>Interpret relevant postoperative investigations</li>
<li>Recognize symptoms and signs of common postoperative complications</li>
<li>Initiate a management plan for common/serious postoperative complications</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preoperative-care">PREOPERATIVE CARE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preoperative-care" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-counselling-and-consent">Patient counselling and consent<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-counselling-and-consent" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(see also Appendix C)
Selection of the appropriate procedure for the appropriate patient should include detailed counselling and informed consent. The patient should be informed about the proposed procedure and its risks and benefits, adverse events and other procedures that may become necessary, length of hospital stay, anaesthesia, recovery, tissue examination,
storage and disposal, use of multimedia in records, teaching, and alternative therapies available, including no treatment. If there are any procedures that the patient would specifically not wish to be performed, this needs to be documented.</p>
<p>Risks should ideally be presented as a frequency or percentage and estimated according to individual risk factors. Consent should be obtained by someone who is capable of performing the procedure or has experience of the procedure and confirmed by the operating or supervising surgeon.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preoperative-assessment">Preoperative assessment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preoperative-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-history-and-examination">Clinical history and examination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-history-and-examination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Preoperative screening of medical conditions or risk factors should be followed by clinical examination including cardiovascular and respiratory examination to evaluate fitness for anaesthesia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="investigations">Investigations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#investigations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Preoperative blood investigations include full blood count; urea and electrolytes for screening for renal disease in patients with hypertension, diabetes and in women on diuretics; liver function tests for patients with a history of alcohol abuse or liver disease; group and screen prior to procedures with risk of bleeding and cross match if heavy bleeding is anticipated or antibodies are present. The availability of a cell saver should be considered if significant bleeding is anticipated.</p>
<p>Blood glucose tests and HbA1C are indicated to screen for diabetes and assess diabetic control. Routine coagulation screening is not necessary unless the patient has a known bleeding disorder, or has been on medication that causes anticoagulation. A chest X-ray is indicated for</p>
<p>patients with chest disease. A pregnancy test should be undertaken in all women of reproductive age. An electrocardiogram is mandatory preoperatively in patients with cardiac disease, hypertension and advanced age.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medications">Medications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Aspirin should be discontinued 7-10 days before surgery as it inhibits platelet cyclooxygenase irreversibly, so platelet aggregation studies can be abnormal for up to 10 days. Non-steroid anti-inflammatory drugs (NSAIDs) cause inhibition of cyclooxygenase, which is reversible.</p>
<p>Clopidogrel bisulfate, an oral antiplatelet agent, causes a dose-dependent inhibition of platelet aggregation and takes about 5 days after discontinuation for bleeding time to return to normal. Patients on oral anticoagulants need to be converted to low-molecular weight heparin (LMWH). Management of these patients should be undertaken by a multidisciplinary team involving haematologists.</p>
<p>Women with risk factors for venous thromboembolism (VTE) should receive LMWH thromboprophylaxis. The combined oral contraceptive pill should be stopped 4-6 weeks prior to major surgery to minimize the risk of VTE and alternative contraception should be offered. The progesterone-only pill is not known to increase the risk of VTE. Although hormone replacement therapy is a risk factor for postoperative VTE, this risk is small and it is not necessary to stop prior to surgery. On the day of surgery, patients should be advised which of their medications they should take.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preoperative-preparation">Preoperative preparation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preoperative-preparation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management-of-anaemia">Management of anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Iron deficiency anaemia should be treated with iron therapy before surgery. Recombinant erythropoietin (Epo) can be used to increase haemoglobin concentrations. To be effective, iron stores must be adequate and iron should be given before or concurrently with Epo. When significant blood loss is anticipated in women who will not accept blood products, Epo may be used to increase the hemoglobin concentration preoperatively.</p>
<p>Gonadotropin-releasing hormone agonists may be used preoperatively to stop abnormal uterine bleeding and increase hemoglobin concentrations.</p>
<p>Autologous blood donation avoids the risks of human immunodeficiency virus (HIV) or hepatitis infection and transfusion reactions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="antibiotic-prophylaxis">Antibiotic prophylaxis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antibiotic-prophylaxis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Antibiotic prophylaxis should be administered intravenously before the start of the procedure. In prolonged procedures or where the estimated blood loss is excessive, additional doses should be administered. Co-amoxiclav or cephalosporins with metronidazole are the commonly
used antibiotics. For patients with known hypersensitivity, alternative broad-spectrum agents include combinations of clindamycin with gentamicin, ciprofloxacin, or aztreonam, metronidazole with gentamicin, or metronidazole with ciprofloxacin. In patients with known history of MRSA infection or colonization, addition of vancomycin is recommended. Preoperative screening is recommended in women at risk for sexually transmitted infections and antibiotic cover for Chlamydia with doxycycline or azithromycin should be given.</p>
<p>Skin preparation with an antiseptic and a sterile technique reduce the risks of infection. Minor procedures do not require antibiotic prophylaxis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management-of-diabetes">Management of diabetes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-diabetes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Good glucose control in the perioperative period is important for the prevention of diabetic ketoacidosis and healing and infectious complications. Oral hypoglycaemics should be stopped on the day of surgery and replaced by an insulin sliding scale, except for minor procedures in a wellcontrolled patient. Type I diabetics should have a sliding scale commenced on the day of surgery.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="intraoperative-complications">INTRAOPERATIVE COMPLICATIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#intraoperative-complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="regional-and-general-anaesthesia">Regional and general anaesthesia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#regional-and-general-anaesthesia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Complications related to regional and general anaesthesia include fluid overload, electrolyte disturbances and gas embolization.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="local-anaesthesia">Local anaesthesia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#local-anaesthesia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Serious adverse reactions are uncommon, but they are secondary to inadvertent intravascular injection, excessive dose, and delayed clearance. Central nervous system side effects include mouth tingling, tremor, dizziness, blurred vision, seizures, respiratory depression and apnoea. Cardiovascular side effects are those of myocardial depression (bradycardia and cardiovascular collapse).</p>
<p>The adverse events associated with injectable local anaesthetic agents are reduced by attention to total dosage and avoidance of inadvertent intravascular administration.</p>
<p>Topical agents can also be associated with adverse events, secondary to systemic absorption.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="complications-secondary-to-patient-positioning">Complications secondary to patient positioning<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complications-secondary-to-patient-positioning" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="acute-compartment-syndrome">Acute compartment syndrome<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acute-compartment-syndrome" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Compartment syndrome in the legs may occur due to lithotomy position when the pressure in the muscle of an</p>
<p>osteofascial compartment is increased, causing ischaemia followed by reperfusion, capillary leakage from the ischaemic tissue, and further increase in tissue oedema resulting in neuromuscular compromise and rhabdomyolysis. Leg holders, pneumatic compression stockings, high body mass index and prolonged surgical time are risk factors. Decompression techniques and early physiotherapy may reduce long-term sequelae.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="neurological-injury">Neurological injury<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#neurological-injury" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Injury to motor nerves arising from the lumbosacral plexus (femoral, obturator and sciatic nerves) and the sensory nerves (iliohypogastric, ilioinguinal, genitofemoral, pudendal, femoral, sciatic and lateral femoral cutaneous nerves) can occur with lithotomy position and prolonged operative time.</p>
<p>Femoral neuropathy may occur secondary to excessive hip flexion, abduction and external hip rotation, which contribute to nerve compression. The sciatic and peroneal nerves are fixed at the sciatic notch and neck of the fibula respectively. Flexion of the hip with a straight knee, and excessive external rotation of the thighs cause stretch at these points. The sciatic nerve can be traumatized with excessive hip flexion. The common peroneal nerve is also susceptible to compression injury.</p>
<p>Ideal lithotomy positioning requires moderate flexion of the knee and hip, with limited abduction and external rotation. The surgeons and assistants should avoid leaning on the thigh of the patient.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="haemorrhage">Haemorrhage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#haemorrhage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Intraoperative haemorrhage is blood loss of more than 1000 mL or blood loss that requires blood transfusion. Massive haemorrhage is defined as acute loss of more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of the patient's blood volume or a loss that requires a lifesaving intervention.</p>
<p>A loss of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30-40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of the patient's blood volume may result in cardiovascular instability. More than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> blood loss is life threatening. Severe hemorrhage can lead to multiple organ failure and death unless resuscitation takes place within an hour.</p>
<p>The first step is pressure applied to the bleeding area. In laparoscopic surgery, pressure can be applied with an atraumatic laparoscopic grasper. In large vessel bleeding, a laparotomy is usually required.</p>
<p>Diathermy, suturing, or surgical clips can be used to control small vessel bleeding. Vessels should be separated from surrounding structures before ligation, to avoid inadvertent injury.</p>
<p>If initial attempts to arrest bleeding fail, bilateral internal iliac artery ligation should be considered, but only performed by surgeons experienced with this procedure.</p>
<p>Topical haemostatic agents for control of diffuse, lowvolume venous bleeding include Gelfoam <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">{ }^{\circledR} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0976em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span><span class="mord">/</span></span></span></span></span> thrombin
(Pfizer), an absorbable gelatin matrix, Surgicel <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> (Ethicon), made of oxidized regenerated cellulose, FloSeal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> (Baxter), a haemostatic agent made from human plasma and constituted by mixing gelatin and thrombin and Tisseel <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> (Baxter), a mixture of thrombin and highly concentrated human fibrinogen.</p>
<p>The patient's haemodynamic status should be continuously monitored. Fluid replacement and transfusion of blood and blood products should be considered. Assistance of a second senior gynaecologist and anaesthetist, additional nursing and theatre staff and an additional surgeon with expertise in vascular surgery may be necessary. Blood should be cross matched. Haemoglobin, platelet count, PT and aPTT should be checked. If the PT and aPTT exceed 1.5 times the control value, fresh frozen plasma should also be given. The ratio of red blood cells (RBCs) to fresh frozen plasma should be <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>2</mn><mo>:</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">&lt;2: 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span>, as studies on trauma suggest that ratios of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>1.5</mn><mo>:</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">1-1.5: 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.5</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span> are associated with reduced mortality. If fibrinogen is low, cryoprecipitate should be given and a haematologist involved.</p>
<p>Platelet transfusion is indicated if the platelet count is less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50000</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">50000 / \mathrm{mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50000/</span><span class="mord"><span class="mord mathrm">mL</span></span></span></span></span></span>. Acid-base balance and plasma calcium and potassium levels should be monitored.</p>
<p>A systolic blood pressure <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>70</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;70 \mathrm{mmHg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">70</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mmHg</span></span></span></span></span></span>, acidosis, and hypothermia inhibit clotting enzymes and increase the risk of coagulopathy. Large volumes of fluids and transfusion of packed RBCs dilute the clotting factors and platelets and predispose to coagulopathy. Component therapy is used when there is clinical evidence of coagulopathy or microvascular diffuse bleeding.</p>
<p>If other measures fail to control bleeding, a pressure pack may be left in the pelvis for 48 to 72 hours. A pelvic drain will enable monitoring of continued bleeding. An indwelling urinary catheter allows urine output monitoring.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ureteric-and-bladder-injury">Ureteric and bladder injury<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ureteric-and-bladder-injury" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The incidence of ureteric and bladder injury during major gynecologic surgery is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">2-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> per 1000 cases and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">3-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> per 1000 cases, respectively.</p>
<p>Risk factors for bladder injury include endometriosis, infection, bladder over distension and adhesions. In cases with adhesions, it is important to use sharp dissection of the bladder during a hysterectomy, as blunt dissection may result in injury. During laparoscopic surgery, the bladder should be empty to avoid injury with the trocars. Lateral rather than suprapubic trocar insertion will reduce the risk of bladder injury. Bladder thermal injury may be delayed, and clinically manifest several days postoperatively.</p>
<p>Small defects less than 1 cm heal spontaneously and do not need to be repaired. A larger injury is closed in two layers using a running absorbable suture. The integrity of the bladder can be assessed by filling the bladder with indigo carmine or methylene blue dye. Ureteric patency is assessed using indigo carmine intravenously to</p>
<p>demonstrate dye efflux from both ureters or by ureteric stenting. An indwelling catheter should be inserted for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mo>−</mo><mn>14</mn></mrow><annotation encoding="application/x-tex">7-14</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">14</span></span></span></span></span> days.</p>
<p>Ureteric trauma may be caused by transection, crush injury, devascularization or thermal injury. If ureteric injury is suspected, patency can be evaluated by intraoperative cystoscopy with dye or ureteric stenting. If there is doubt an urologist should be consulted and in case of confirmed injury an end-to-end anastomosis or reimplantation, can be undertaken.</p>
<p>Cystoscopy should be performed intraoperatively where possible after all prolapse or incontinence surgery to rule out bladder or ureteric injury. In undiagnosed ureteric injuries, patients present with symptoms of abdominal pain, fever, haematuria, flank pain, and peritonitis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="gastrointestinal-injury">Gastrointestinal injury<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gastrointestinal-injury" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Gastrointestinal (GI) injury during gynecologic surgery occurs in between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.33</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.33 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.33%</span></span></span></span></span> of cases. Intraoperative GI injury has a mortality rate as high as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3.6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3.6%</span></span></span></span></span>. Injury may occur during Veress needle or trocars insertion, adhesiolysis, tissue dissection, devascularization and electrosurgery. Previous abdominal surgery increases the risk of adhesions. In these cases, laparoscopy should be undertaken using an open (Hassan) technique or entry through the left upper quadrant (Palmer's point).</p>
<p>If an injury is suspected, the bowel should be examined and a surgeon's opinion should be sought if in doubt. Unrecognized injuries present 2-4 days postoperatively with nausea, vomiting, abdominal pain and fever.</p>
<p>Veress needle injuries do not usually need to be repaired in the absence of bleeding or a tear. For punctures of the large intestine without tearing, meticulous irrigation of the peritoneal cavity and antibiotic treatment is important, as the large intestine contents have a high bacterial load. Intestinal injury should be repaired in two layers. In extended lacerations, a segmental resection is recommended. Thermal injuries require wide resection due to the risk of tissue necrosis, which may take days to manifest clinically.</p>
<p>Injury to the rectosigmoid colon may be detected by proctosigmoidoscopy.</p>
<p>A diverting colostomy is indicated in extensive colon injuries or injuries involving the mesentery.</p>
<p>Gastric perforation during laparoscopy may occur in cases with prior upper abdominal surgery and an inadvertently gas distended stomach following induction of anaesthesia. Small Veress needle punctures with no bleeding can be treated by irrigation. Larger defects such as trocar injuries require repair in two layers by a surgeon experienced in gastric surgery. The abdominal cavity should be irrigated to remove any gastric contents. Nasogastric suction usually is maintained postoperatively until normal bowel function returns.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="postoperative-care">POSTOPERATIVE CARE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#postoperative-care" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="analgesia">Analgesia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#analgesia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Analgesia should be planned preoperatively. Major abdominal surgery is likely to require an epidural or patient-controlled analgesia (PCA). This can then be gradually converted to regular paracetamol and a non-steroidal anti-inflammatory agent, with or without opioids for breakthrough pain. Anti-emetics and stool softeners should be prescribed with opioids.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fluid-and-electrolyte-balance">Fluid and electrolyte balance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fluid-and-electrolyte-balance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In the immediate postoperative period it is important to maintain fluid balance and monitor serum electrolyte levels whilst a patient is on intravenous fluids. The normal fluid intake of approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mn>24</mn></mrow><annotation encoding="application/x-tex">2.5 \mathrm{~L} / 24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span><span class="mord">/24</span></span></span></span></span> hours requires additional replacement of fluid deficit due to intraoperative blood loss and insensible water losses. In cases of hyperkalaemia, an electrocardiogram (ECG) is indicated for the assessment of cardiac rhythm, as well as calcium gluconate for prevention and management of arrhythmia and an insulin-dextrose infusion for the reduction of potassium levels. Hypokalaemia is treated by adding potassium in the intravenous fluids. Hyponatraemia is usually caused by excessive fluid intake and hypernatraemia by dehydration. A fall in the urine output below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.5 \mathrm{~mL} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mL</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> hour may indicate insufficient replacement. This can be confirmed with a fluid challenge of a colloid. Fluid challenges should be given with caution in elderly patients or those with cardiac disease as this may exacerbate pulmonary oedema. If no improvement in urine output is seen, an assessment of cardiac and renal function is required.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cardiovascular-stability">Cardiovascular stability<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-stability" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Epidural analgesia, dehydration and bleeding are common causes of postoperative hypotension. This in turn can result in reduced tissue perfusion and impaired healing, cerebral infarction, renal failure and multiple organ failure. Unless the patient is stable, orientated, with pulse <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">50-100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span> beats <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, warm peripheries, capillary refill <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">&lt;2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> seconds and a good urine output, further investigations to identify the cause are required.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="bladder-care">Bladder care<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bladder-care" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>An indwelling catheter in the postoperative period allows for accurate measurement of urine output and prevents from urinary retention secondary to the general anaesthetic or pain. The catheter should be removed when the patient is able to mobilize. The trial of void involves</p>
<p>measurement of the voided volume and estimation of the post-void residual volume using a portable bladder ultrasound scan. If greater than 150 mL , recatheterization for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>24</mn><mo>−</mo><mn>72</mn></mrow><annotation encoding="application/x-tex">24-72</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">24</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">72</span></span></span></span></span> hours is indicated. With persistent voiding difficulty the patient may need to go home with an indwelling catheter and return after <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">7-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> days for a trial without catheter or taught intermittent self-catheterization till bladder function is normal, i.e., she has control of micturition.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="oral-intake">Oral intake<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oral-intake" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Early postoperative oral hydration and feeding may reduce the length of patient stay without any increase in ileus. If there is vomiting, then feeding should be delayed. With persistent vomiting, bowel obstruction should be excluded. Other symptoms include abdominal pain and an absence of passage of flatus or faeces. Signs include abdominal distension and tenderness with pronounced bowel sounds. An abdominal X-ray would show dilated loops of bowel. Management involves nil by mouth, intravenous fluids and insertion of a nasogastric tube. If there is no improvement, further contrast imaging is required to identify the site of obstruction for surgical intervention. In cases at high risk of paralytic ileus (excessive bowel handling or bowel injury), a nasogastric tube should be inserted with slower introduction of diet.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="postoperative-complications">POSTOPERATIVE COMPLICATIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#postoperative-complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="postoperative-haemorrhage">Postoperative haemorrhage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#postoperative-haemorrhage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Signs of intra-abdominal bleeding include tachycardia, hypotension, abdominal distension, oliguria, confusion, sweating and abdominal pain. Minimal bleeding can be managed expectantly with monitoring, serial haemoglobin measurements and transfusion if indicated. Small retroperitoneal hematomas may eventually be reabsorbed. Patients with shock and increasing abdominal girth require immediate surgical exploration.</p>
<p>Pelvic arterial embolization can be considered for haemodynamically stable women with active arterial bleeding.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pyrexia">Pyrexia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pyrexia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>An isolated episode of pyrexia <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><msup><mn>38</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">&gt;38^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">3</span><span class="mord"><span class="mord">8</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span>, within the first 24 hours will usually resolve with conservative measures but persistent pyrexia or pyrexia after 24 hours is likely to represent infection. Identification of the source and early treatment aims to reduce morbidity. Examination of the chest, heart, abdomen, wound and legs should be followed by blood tests, including full blood count, C-reactive protein, urea and electrolytes and liver function tests. A
mid-stream urine or catheter specimen should be sent for microscopy, culture and sensitivity along with blood and sputum cultures.</p>
<p>A chest X-ray enables investigation for pneumonia or atelectasis. Regular paracetamol will reduce pyrexia and fluid administration is required to replace increased losses.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="surgical-site-infections">Surgical site infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#surgical-site-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Surgical site infections (SSIs) can be caused by endogenous flora of the skin or vagina. Common organisms in SSIs of abdominal incisions are Staphylococcus aureus, coagulasenegative staphylococci, Enterococcus spp. and Escherichia coli. SSIs of vaginal procedures include Gram-negative bacilli, enterococci, group B streptococci and anaerobes from the vagina and perineum. Postoperative pelvic abscesses are commonly associated with anaerobes.</p>
<p>Risk factors include diabetes, smoking, systemic steroid medication, radiotherapy, poor nutrition, obesity, prolonged hospitalization and blood transfusion. Surgical factors associated with SSIs include prolonged operating time, excessive blood loss, hypothermia, hair removal by shaving, and surgical drains.</p>
<p>SSIs can be superficial incisional, deep incisional, and involving organ or space, i.e., vaginal cuff cellulitis and pelvic abscess.</p>
<p>The most serious form of SSI is necrotizing fasciitis, often caused by a polymicrobial infection that can rapidly lead to necrosis of the surrounding tissue, sepsis and endorgan damage.</p>
<p>Laboratory investigations include a full blood count and culture from the incision or abscess discharge. When organ or space SSIs are suspected, computed tomography (CT) scan, magnetic resonance imaging (MRI) or ultrasonography is indicated to localize the site of infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment">Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Patients with wound cellulitis can be treated as outpatients with oral antibiotics. Admission and intravenous antibiotic treatment is indicated in cases of pyrexia, peritonitis, intra-abdominal or pelvic abscess, inability to tolerate oral antibiotics, or other signs of sepsis. In a localized wound infection, incision and drainage is indicated. In the absence of an abscess, cuff cellulitis can be treated with oral antibiotics.</p>
<p>In case of deep incisional or organ/space infections, intravenous broad-spectrum antibiotics should be continued until the patient is apyrexial and clinically well for at least 24 to 48 hours. If patients do not demonstrate systemic improvement and if there is no resolution of fever within 48 hours, repeat imaging and change of antibiotics following consultation with a microbiologist should be considered.</p>
<p>Septic pelvic thrombophlebitis should be ruled out in patients who are not responding to broad-spectrum</p>
<p>antibiotics, in the absence of an abscess or haematoma. Treatment includes antibiotics and intravenous heparin.</p>
<p>Superficial abscesses should be opened and drained. After debridement of necrotic tissue, wound healing may be facilitated with packing, wound vacuum, or secondary closure after regranulation. In deep incisional and organ/ space infections, debridement and drainage are occasionally required.</p>
<p>Necrotizing fasciitis is life-threatening and requires immediate wide local debridement and broad-spectrum intravenous antibiotics.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cardiovascular-and-respiratory-complications">Cardiovascular and respiratory complications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-and-respiratory-complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Surgery and general anaesthesia increase the risk of myocardial infarction, especially in those with risk factors. An ECG and cardiac enzymes should be considered in a patient with chest pain. In cases of arrhythmia, differential diagnosis includes sepsis, hypovolaemia, electrolyte abnormalities and drug toxicity.</p>
<p>Respiratory complications include respiratory tract infection, atelectasis, pulmonary oedema and pulmonary embolism. A blood gas on air is required to determine the severity and adjust oxygen therapy. Assisted ventilation and admission to intensive care unit should be considered for patients with oxygen saturations <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> or a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo>&lt;</mo><mn>8.0</mn><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{PO}_{2}&lt;8.0 \mathrm{kPa}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">8.0</span><span class="mord"><span class="mord mathrm">kPa</span></span></span></span></span></span>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="venous-thromboembolism">Venous thromboembolism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#venous-thromboembolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>If there is clinical suspicion of pulmonary embolism (PE), diagnostic imaging is required. If there is a delay in obtaining imaging then a treatment dose of low-molecular weight heparin (LMWH) should be administered.</p>
<p>If there is high clinical probability of a deep vein thrombosis (DVT) but a negative leg Doppler ultrasound it may be appropriate to continue with treatment and repeat the scan after 1 week.</p>
<p>Computerized tomography pulmonary angiogram (CTPA) or isotope lung scanning after a chest X-ray are the recommended imaging investigations. In a positive diagnosis, a treatment dose of LMWH should be commenced and converted to oral anti-coagulants once the patient is stable and the risk of bleeding is reduced. The patient should be referred to a haematologist and anticoagulation specialist.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="discharge-from-hospital">DISCHARGE FROM HOSPITAL<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#discharge-from-hospital" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A discharge summary should provide information of the perioperative events and the patient should be supplied with adequate analgesia and medications as well as contact information in case of complications or concerns.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="appendix">Appendix<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#appendix" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="governance-audit-and-research">Governance, audit and research<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#governance-audit-and-research" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Tahir Mahmood</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="learning-outcomes">Learning outcomes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#learning-outcomes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter you should be able to:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="knowledge-criteria">Knowledge criteria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#knowledge-criteria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Understand the principles of storage, retrieval, analysis and presentation of data</li>
<li>Discuss the range of uses of clinical data, its effective interpretation and associated confidentiality issues</li>
<li>List the basic principles of the Data Protection Act</li>
<li>Describe the audit cycle as applied to obstetrics and gynaecology locally and nationally (specifically related to maternal and perinatal mortality)</li>
<li>Discuss the role of guidelines, integrated care pathways and protocols, e.g., National Institute for Health and Clinical Excellence and the Royal College of Obstetricians and Gynaecologists guidelines</li>
<li>Describe the elements of clinical effectiveness, including evidence-based practice, types of clinical trial, evidence classification and grades of recommendation</li>
<li>Describe the principles of risk management, including incident reporting</li>
<li>Contrast the differences between audit and research</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="professional-skills-and-attitudes">Professional skills and attitudes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#professional-skills-and-attitudes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Consider the principles behind good research design and critical analysis of research, including statistics and ethical issues.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="data-collection-in-the-national-health-service">DATA COLLECTION IN THE NATIONAL HEALTH SERVICE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#data-collection-in-the-national-health-service" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Patients connect with their doctors either in the primary care or in the hospital settings. The first interface usually occurs in the primary care setting and that accounts for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of contact between the patient and the health system.</p>
<p>In the hospital setting, patients are seen either in outpatient clinics or as an emergency through acute admission units. A small proportion of patients will eventually be admitted to inpatient beds, either for further diagnostic work-up or requiring surgical or medical intervention. At each stage of the patient's journey, information is collected either in paper form (case notes) or entered into electronic data systems (paperless notes).</p>
<p>The challenge for healthcare planners is to ensure that the information collected at the primary and secondary interface can then be linked to national databases to define trends in disease patterns, population needs and future health service planning.</p>
<p>The data also helps in carrying out epidemiological studies such as maternal mortality rates. These data also allows international comparisons such as the WHO report on Maternal Mortality and regional comparisons in caesarean section and hysterectomy rates in England.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sources-of-data-collection-and-computing-systems">Sources of data collection and computing systems<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sources-of-data-collection-and-computing-systems" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="gp-consultations-and-registrations">GP consultations and registrations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gp-consultations-and-registrations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>All patient interfaces with primary care are captured so that a picture can evolve on why patients are making contact with their GPs such as diagnosis of depression,</p>
<p>upper respiratory tract infection, arthritis, minor injuries, vaginal bleeding, contraceptive requirements, etc. Furthermore these data can also be used to meet national quality targets by setting alert signals for example:</p>
<ul>
<li>That <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of women eligible for cervical cytology have been screened.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="registration-of-births-and-deaths">Registration of births and deaths<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#registration-of-births-and-deaths" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Since 1838 there has been in England and Wales an enforced system of registration of birth and deaths. As a junior doctor, you may be asked to complete a death certificate. It is important to follow the instructions carefully and make correct entries. A death certificate has two sections:</p>
<ol>
<li>A direct cause of death.</li>
<li>Contributory factors to the cause of death.</li>
</ol>
<p>It is a legal requirement to register all births irrespective of the place of birth. Therefore, it is possible to accurately know what proportion of babies have been born at home or in obstetric units.</p>
<p>Using this data it is also possible to study in detail the changes in birth rates and death rates per 1000 population. Subtraction of the death rates from the birth rates gives the annual growth rate of a population.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hospital-episode-statistics-hes">Hospital episode statistics (HES)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hospital-episode-statistics-hes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>HES collect inpatient administrative and clinical data transcribed from patients' case notes. The clinical data includes the principle condition causing admission, other relevant conditions and the description and date of any operation performed. The administrative data includes the date the patient was put on the waiting list, the source and date of admission, the specialty, the date of discharge or death and the destination on discharge or transfer. The data provides overall activity data such as number of operations performed such as hysterectomies, and caesarean sections, and this information can be used in the planning of hospital services such as local needs for maternity beds.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mortality-rates-statistics">Mortality rates statistics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mortality-rates-statistics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These are calculated from hospital admissions. The maternal mortality data in the UK has been reported through a triennial report since 1952. These reports tell us that major postpartum haemorrhage, hypertensive disease of pregnancy, infection and venous embolic disease remain the major causes for maternal deaths. The National Confidential Enquiry into Patient Outcome and Death (NCEPOD) annual report analyses data on perioperative deaths and has reported that only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>22</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">22 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">22%</span></span></span></span></span> of the high risk group were cared for in a critical care unit thus receiving suboptimal care leading to their deaths.</p>
<p>Data on Perinatal Mortality Rates (PNMR) are collected annually. It includes the number of stillbirths during
pregnancy and deaths in the first week of life per 1000 live births. It includes all fetuses after 20 weeks of gestation or 500 g . Preterm births are the most common cause of perinatal death, followed by birth defects and small for gestation babies. PNMR is a major marker used to compare the quality of healthcare delivery among maternity units within a country and also to compare quality of care worldwide.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="morbidity-rates-statistics">Morbidity rates statistics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#morbidity-rates-statistics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Hospital admissions data are utilized to look at the morbidity data related to specific diseases: for example, pregnancy-related morbidity data are captured by calculating the incidence of major postpartum haemorrhage (blood loss <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>2.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;2.5 \mathrm{~L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">2.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span></span></span></span></span> ), admission to intensive care unit following delivery, stroke during pregnancy, pulmonary embolism and deep vein thrombosis, etc. In Scotland all cases of severe maternal morbidity are reported to NHS Quality Improvement Scotland and an annual report (near miss survey) is published showing comparative data for all the obstetric units.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="research-and-data-linkage">Research and data linkage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#research-and-data-linkage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Linkage of records gives us a picture of the full course of illness and of the different illnesses occurring in the life of an individual. It is also possible to use record linkage between different databases to develop quality indicators such as patients' re-admission rates within 28 days with a diagnosis of deep vein thrombosis or the number of patients having a re-operation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="data-protection-act">Data Protection Act<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#data-protection-act" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The Data Protection Acts in the UK and Australia seek to strike a balance between the rights of the individual and the sometimes competing interests of those legitimate reasons for using personal information. Staff who hold or process personal data must abide by the following principles.</p>
<p>Personal information must be:</p>
<ul>
<li>Fairly and lawfully processed.</li>
<li>Processed for limited purposes.</li>
<li>Adequate, relevant and not excessive.</li>
<li>Accurate and up to date.</li>
<li>Not kept longer than necessary.</li>
<li>Processed in accordance with the individual's rights.</li>
<li>Kept secure at all times.</li>
<li>Not transferred to other countries unless the country has adequate protection for individuals.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="caldicott-principles">Caldicott principles<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#caldicott-principles" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In the UK the Caldicott Report (1997) recommended the appointment of a Caldicott Guardian in each NHS organization and that staff who handle patient identifiable</p>
<p>information ensure that the Caldicott principles are met whenever information is transferred, i.e., by word of mouth, written, by electronic or any other means.</p>
<p>When you consider undertaking a clinical audit which would require review of case notes, you must seek permission from the Caldicott Guardian of your hospital. This process ensures that you observe the principles of information governance and the data extracted is annonymised. You must not store data on your private computer. You can use authorized encrypted USB drives.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="evidence-based-healthcare">EVIDENCE-BASED HEALTHCARE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#evidence-based-healthcare" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Evidence-based practice is the process of systematically finding and using contemporaneous research findings as a basis for clinical decision making and is an integral part of clinical governance framework. In order to facilitate the development of evidence based practice the following processes need to be applied.</p>
<ul>
<li>Identify areas in practice from which clear clinical questions can be formulated.</li>
<li>Identify the best related evidence from available literature such as guidelines.</li>
<li>Critically appraise the evidence for validity and clinical usefulness.</li>
<li>Implement and incorporate relevant findings into practice.</li>
<li>Subsequently measure performance against expected outcomes or against peers.</li>
<li>Ensure staff are supported and developed through adequate resourcing of evidence-based practice, education and training programmes.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-audit">Clinical audit<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-audit" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Clinical audit is the systematic and critical analysis of the quality of clinical care, including the procedures used for diagnosis, treatment, the associated use of resources and the resulting outcome for the patient. Clinical audit should seek to improve the quality and outcome of patient care through clinicians examining and modifying their practice according to standards of what could be achieved based on the best available evidence (Box B.1).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="four-steps-of-clinical-audit">Four steps of clinical audit<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#four-steps-of-clinical-audit" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="defining-best-practice">Defining best practice<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#defining-best-practice" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The area identified must address important aspects of practice about quality of care such as high infection rates following caesarean section.</p>
<p>The next stage is to describe current practice to illustrate the problem and identify area for improvement. This can be done by looking at resources such as the RCOG Green Top Guidelines, Scottish Intercollegiate Guidelines</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-b-1-key-facts-about-clinical-audit">Box B. 1 Key facts about clinical audit<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-b-1-key-facts-about-clinical-audit" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Clinical audit is not research but is focused on improving patient care</li>
<li>Clinical audit takes time and requires multiprofessional involvement</li>
<li>Clinical audit should have a clearly defined question which needs to be addressed derived from the best evidence based practice</li>
<li>Clinical audit requires adequate time for planning, engagement with stakeholders, collecting reliable data, analysing and then presenting the results to the team</li>
<li>A clearly thought out strategy is important to disseminate the best practice, implement, monitor and to demonstrate improvement in clinical care</li>
</ul>
<p>Network (SIGN), National Institute of Health and Clinical Excellence (NICE), RANZCOG statements on women's health and the NHS evidence website.</p>
<p>Finally a particular area of interest is identified in the guideline that would help to define a 'standard' (a broad statement of good practice based on the best possible evidence) against which current practice can be measured (this is termed as 'criteria'). The criterion refers to resources used for the successful achievement of the standard (structure), the actions that must be undertaken (process) and the results (outcomes).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparing-to-monitor">Preparing to monitor<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparing-to-monitor" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The criteria should be easy to measure/collect data and the collected data are useful clinically. Baseline data are collected first which provides a starting point from which progress can be measured. The standard should be widely disseminated through newsletters and departmental meetings to the wards and the clinical staff.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="monitoring-your-achievement">Monitoring your achievement<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#monitoring-your-achievement" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is important to agree on a sample size and time frame with your clinical supervisor to complete the audit cycle. The hospital information system manager may have information about the number of patients with particular clinical conditions so that you can estimate how long it might take to collect your data. The next step would be to agree who will be collecting data and who will be recording it on an audit software package in order to generate timely feedback.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="planning-for-improvement">Planning for improvement<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#planning-for-improvement" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Once the audit data has been collected, the audit summary should be completed and the results be carefully looked at in order to provide constructive feedback to the clinical team. The results should be discussed with the professional groups to ask for their comments for the interpretation of results and action planning. Areas of good practice</p>
<p>are clearly highlighted and areas which need to be addressed are clearly documented. A named individual should be identified so that appropriate changes in the policy can be implemented and monitored.</p>
<p>It is important to remember that clinical audit is a continuing process and one clinical audit quite often leads to a second clinical audit to demonstrate that the first audit cycle has made measurable changes leading to redefining unit policy or adopting new ways of delivering care to meet national standards. Therefore it is the responsibility of the doctor undertaking a clinical audit to write a detailed report and to make appropriate recommendations on how the next group of foundation doctors could continue with the same theme in order to ensure that the second or third audit cycle is completed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="national-clinical-audits">National clinical audits<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#national-clinical-audits" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Maternal mortality and morbidity data are used as quality indicators for maternity services nationally and internationally. The maternal deaths are categorized as direct causes where there are obstetric causes and the death occurs during pregnancy or within the first 42 days following delivery. The commonest causes of direct maternal deaths are major postpartum haemorrhage, hypertensive disease of pregnancy, community acquired infection, and deep vein thrombosis. The indirect causes of death include non-obstetric causes such as suicide occurring within one year of childbirth. Every maternal death is analysed in depth by a panel of experts. Similarly, perinatal mortality data are also collected. Their analyses provide data and trends on causes of perinatal deaths and the main causes are unexplained stillbirths and deaths related to prematurity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-guidelines">Clinical guidelines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-guidelines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Clinical guidelines have been defined as systematically developed statements to assist practitioners in patient management decisions about appropriate healthcare for specific clinical circumstances. The Green Top Guidelines of the Royal College of Obstetricians &amp; Gynaecologists are an excellent resource.</p>
<p>The development of clinical guidelines is a fairly time consuming procedure and it can take between 18-24 months to develop the guideline from inception to completion of the task. At an earlier stage the clinical questions within a guideline are agreed. They provide the framework for the systematic review of the available evidence. The literature is synthesized and evidence is graded by using GRADE (Grading of Recommendations, Assessment, Development and Evaluation working group). It is also accepted that for many therapies, randomized controlled trials or systematic reviews of randomized controlled trials may not be available. In those instances observational data may provide better evidence, as is generally the case for their outcomes.</p>
<p>GRADE evidence levels: They are graded from level 1 (randomized controlled trials for a systematic review) to grade at level 4 (expert opinion): more details available at (<a href="http://www.sign.ac.uk" target="_blank" rel="noopener noreferrer">www.sign.ac.uk</a>). Once the evidence has been collated for each clinical question it is then appraised and reviewed.</p>
<p>Based on the level of evidence, recommendations are made within a clinical guideline.</p>
<p>Grading of recommendation: The Recommendations for guidelines based on evidence are graded as Grade A (based on meta-analysis, systematic reviews or randomized controlled trials) to Good Practice point where clinicians make a consensus recommendation (<a href="http://www.rcog.org.uk" target="_blank" rel="noopener noreferrer">www.rcog.org.uk</a>).</p>
<p>Integrated care pathways have been described as the journey of a patient through all interfaces within the healthcare system and should take care of all the steps of patient journey from primary care through to secondary and tertiary care. Each stage of an integrated care pathway should have a clearly defined checklist of recommended measures to ensure that the care providers have adhered to those recommendations and appropriate care has been provided.</p>
<p>The principles enshrined in a clinical guideline need to be adapted for local use (Local Protocol) so that a care pathway is developed for easy access to instructions on how to look after a patient within the local service provision and adherence to local protocol can be monitored.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="research">Research<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#research" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The primary aim of research is to drive generalizable new knowledge, whereas the aim of audit is to measure standards of care.</p>
<p>For clinical research, application is made for approval from a suitably constituted research ethics committee whereas no such approval is normally required for clinical audit.</p>
<p>There is a legal and a moral impetus to ensure that research is conducted with a maximum respect for participants and their privacy, even if the research is not linked to clinical care. It is generally believed that explicit consent should be obtained to use identifiable personal data for medical research, particularly for multicentre or secondary research where people who are not part of the clinical team need access to data. The skills, attitude and commitment of the people who manage and use a research database are important to protect the privacy of its data subjects.</p>
<p>Concern has been expressed regarding widespread misconduct in research. This dishonesty in publishing erroneous findings in order to promote careers or to get financial rewards has undermined public confidence in medical research.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="type-of-research-studies">Type of research studies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#type-of-research-studies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="descriptive-studies">Descriptive studies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#descriptive-studies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Descriptive studies provide information that can be used to test aetiological hypothesis generated by other research</p>
<p>methods. For example, long-term toxic effects of tobacco and development of lung cancer were first discovered by epidemiological studies. Quite often descriptive studies have been used to substantiate suspicions arising from other sources, e.g., vaginal carcinoma in childhood resulting from maternal stilboestriol therapy and pleural mesothelioma from asbestos exposure. Similarly, data on multiple sclerosis shows that it occurs with the same degree of frequency in African-Americans and Caucasians in the northern US states. This observation suggests that environmental influences are critically important in determining whether the disease is common or rare.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="analytical-studies">Analytical studies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#analytical-studies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are two kinds of epidemiological observations that are made in groups of individuals rather than populations and provide evidence that a particular event may be a cause of a particular disease. Case control studies compare people with the disease and those without it. Cohort studies compare people exposed to the suspected cause and those not exposed. The two types of study answer two different questions.</p>
<p>To explain this, suppose that investigation is required to determine whether delivery by forceps and the accompanying trauma to the infant's head can result in brain damage which can then manifest itself as childhood epilepsy.</p>
<p>A case control study would involve comparing the obstetric histories of a group of epileptic children with those of a control group of non-epileptic children. If it is found that the proportion of epileptic children with a history of forceps delivery exceeded the proportion of control children this would suggest that forceps delivery may be a cause of epilepsy; but there are many other determinants of epilepsy so that among the group of epileptics only a small percentage of cases may be attributed to forceps delivery. This proportion can be calculated by using a mathematical formula.</p>
<p>A cohort study of the same problem would compare a group of children delivered by forceps with a group of children delivered normally. If it is found that the proportion of forceps delivered children who developed epilepsy exceeded the proportion of normally developed children this would suggest that forceps delivery is associated and may be a cause of epilepsy. Forceps delivery does not invariably lead to epilepsy, which occurs in only a small percentage of children delivered in this way. By using mathematical calculations, it is possible to calculate the excess or attributable risk.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-trials">Clinical trials<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-trials" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Clinical trials are carried out in medical research and drug development to allow safety and efficacy data to be collected for health interventions. A clinical trial may be designed to:</p>
<ul>
<li>Assess the safety and effectiveness of new medication, e.g., antibiotics.</li>
<li>Assess the safety and effectiveness of different dosage of medication than is commonly used, e.g., 5 IU of oxytocin dose instead of 10 IU dose for third stage of labour.</li>
<li>Assess the safety and effectiveness of a surgical device, e.g., laparoscopic surgical instruments</li>
<li>Compare the effectiveness of two or more already approved interventions, e.g., comparing medication 1 against medication 2.
Clinical trials are usually conducted in three phases:</li>
<li>Phase 1 to test the treatment in a few healthy people to learn whether it is safe to take.</li>
<li>Phase 2 to test the treatment in a few patients to see if it is active against the disease in the short term.</li>
<li>Phase 3/4 trials to test the treatment on several hundred to several thousand patients, often at many different clinics or hospitals. These trials usually compare the new treatment with either a treatment already in use or occasionally with no treatment.
Randomized clinical trials can be:</li>
<li>Double blind: The subjects and the researchers involved in the study do not know which study treatment they receive. This blinding is to prevent bias so that the physician should not know which patient was getting the study treatment and which patient was getting the placebo or in a two drug comparison study whether it was drug A or drug B.</li>
<li>placebo controlled: The use of a placebo (fake treatment) allows the researchers to isolate the effects of the study treatment. It is important that the dummy treatment is closely matched to the active drug treatment. The patients in both study groups are monitored very closely for the impact of treatment and the side effects experienced by patients in both groups.
All clinical trials should be approved by the Ethics Committee and overseen by a panel of experts. It is important that before recruiting a patient into a clinical trial, an informed consent has been signed. The process of randomization is agreed before the start of a clinical trial.</li>
</ul>
<p>It is the responsibility of the clinical researcher to ensure that the safety of the subjects is closely monitored for any adverse outcomes. Therefore clinical trials of drugs are designed to exclude women of childbearing age, pregnant women, and/or women who become pregnant during the study.</p>
<p>The results of the drug trials are sent to the appropriate national licensing authority.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-b-2-key-attributes-associated-with-promotion-of-a-quality-organization">Box B. 2 Key attributes associated with promotion of a quality organization<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-b-2-key-attributes-associated-with-promotion-of-a-quality-organization" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>There is an integrated approach to quality improvement throughout the whole organization</li>
<li>Leadership skills are developed in line with professional and clinical needs</li>
<li>Infrastructures exist that foster the development of evidence based practices</li>
<li>Innovations are valued and good practices are shared within and without the organization</li>
<li>Risk management systems are in place</li>
<li>There is a pro-active approach to reporting, dealing with and learning from untoward incidents</li>
<li>Complaints are taken seriously and actions taken to prevent any recurrence</li>
<li>Poor clinical performance is recognized, thus preventing potential harm to patients or staff</li>
<li>Practice and professional development is aligned and integral to clinical governance framework</li>
<li>Clinical data are of best quality and can be used effectively to monitor patient care and clinical outcomes (White Paper The New NHS; Modern, Dependable (DH 1997))</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-governance">Clinical governance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-governance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Clinical governance has been defined as a framework for the continual improvement of patient care by minimizing clinical risks (Box B.2).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="risk-management">Risk management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#risk-management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Risk management simply means 'to develop good practice and reduce the occurrence of harmful or adverse incidents'. Clinical risk is defined as 'A clinical error to be at variance from intended treatment, care, therapeutic intervention or diagnostic result; there may be an untoward outcome or not'. For example, if patients in an obstetric unit develop wound infections following caesarean section this results in extended length of stay, increased patient discomfort and increased workload and cost for staff working in that unit. It is important to consider the broader issues surrounding this situation, such as ward cleanliness, lack of adherence to infection control policies, failure to follow national guidelines on sepsis prophylaxis, and addressing education and training needs of the staff. Each unit should have a clinical risk strategy and a system is in place for reporting, monitoring and evaluating clinical incidences
and near misses. Near misses have been described as, 'potentially harmful incident that could have adverse consequences for the patient/carer'. Similarly there should be a system in place for complaints reporting, monitoring and learning from these complaints to improve patient care.</p>
<p>The National Negligence Scheme for Trusts (CNST) was established in 1995. With CNST specifically in obstetrics, each unit pays a premium based on the size of the unit, level achieved through CNST standards and receives discount for managing clinical risks. There are three levels of CNST accreditation, the higher the level you achieve, higher the discount. It has been recognized that the CNST standards have done much to advance risk management and reduce clinical risks.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-incident-reporting">Clinical incident reporting<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-incident-reporting" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Clinical incident reporting is required for staff and patients in highlighting any areas where an individual or organization fails to deliver the appropriate standard of care. Incident reporting offers a framework for the detection of untoward incidents and near misses which enable actions to be taken and lessons to be learned, practices to be reviewed and information to be shared to prevent any recurrence. Let us take an example of monitoring third and fourth degree perineal tears in an obstetric unit. These incidents are reported and information is collated. Monthly reports will identify if the number of third or fourth degree tears are increasing following instrumental deliveries. That observation would call into question whether the doctors undertaking those procedures are appropriately skilled, trained and supervised.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="conclusion">CONCLUSION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#conclusion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is important to appreciate that clinical governance is about assuring sustained, continuous quality improvement that can only be achieved by determined and conscious efforts by the clinical and non-clinical staff who have the appropriate support of their organization to deliver best practice. Quality improvement is based around the following robust systems and processes:</p>
<ul>
<li>clinical risk management and clinical audit</li>
<li>continued practice and professional development</li>
<li>implementing and continuing professional development within NHS organization</li>
<li>research and development</li>
<li>evidence-based healthcare.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="medicolegal-aspects-of-obstetrics-and-gynaecology">Medicolegal aspects of obstetrics and gynaecology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medicolegal-aspects-of-obstetrics-and-gynaecology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Roger Pepperell</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="learning-outcomes">Learning outcomes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#learning-outcomes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter you should be able to:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="knowledge-criteria">Knowledge criteria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#knowledge-criteria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Discuss the issues of confidentiality and consent in under 16-year-olds (Fraser competency) and vulnerable adults</li>
<li>Outline the legal regulation of abortion, sexual offenders, assisted reproduction the relative legal status of the fetus and the mother</li>
<li>Describe the principles of child protection</li>
<li>Describe the principles and legal issues surrounding informed consent</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-competencies">Clinical competencies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-competencies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Obtain informed consent for the common procedures in obstetrics and gynaecology</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="professional-skills-and-attitudes">Professional skills and attitudes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#professional-skills-and-attitudes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Be aware of the legal rights of and provisions for pregnant women</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-and-legal-issues-around-informed-consent">PRINCIPLES AND LEGAL ISSUES AROUND INFORMED CONSENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-and-legal-issues-around-informed-consent" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When a woman agrees to a surgical procedure or a specific method of treatment, it is essential that the implications of benefits and risks are explained to her or informed consent to such treatment is not obtained. Indeed, it is a fundamental law of medical and legal practice that a doctor must obtain consent from the patient for any particular medical or surgical treatment and that without
appropriate consent a procedure may constitute an act of assault or trespass against the person.</p>
<p>Secondly, the patient must receive sufficient knowledge of any proposed treatment to make a valid choice about whether or not to consent. The consent form provides evidence that consent has been given for a particular procedure, but it only has meaning if it is evident that the patient did actually understand the nature and implications of the procedure.</p>
<p>In explaining the nature of a procedure to any woman, it is important to explain the purpose of the operation and the potential complications. Given that there may be a range of complications for any operation, the question arises as to how far it is necessary to go in explaining all the potential complications, given that this may induce disproportionate anxiety about a series of very remote risks.</p>
<p>In general terms, a risk in excess of a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> chance should be explained to the patient, although this is a guideline rather than an absolute figure. Where the risk is well under <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>, but is serious and would influence the quality of life subsequently if it occurred, this also needs to be explained in detail so that an informed decision can be made by the patient as to whether she wishes to proceed with that procedure. Where there are non-surgical methods of treatment that could be used instead of a surgical procedure, these also need to be explained to the patient.</p>
<p>A common example that addresses the issues of informed consent is the information given to patients before sterilization about potential failure rates. During the 1980s a substantial number of legal actions were based on alleged failure to inform patients that there was a significant risk of failure and that pregnancy could follow any of the commonly used sterilization procedures. The patient bringing a claim would generally allege that no advice was given about the risk of failure and subsequent</p>
<p>pregnancy and that, had such advice been given, either the woman would not have had the operation or she would have continued to use contraception after the sterilization procedure. It is now standard practice to advise all patients, both female and male, that there is a risk of failure and to record a statement to the effect that such advice has been given. In regard to sterilization, the character of the menstrual cycle also needs to be borne in mind. Where the periods have been particularly heavy or irregular, and have been controlled during treatment with the oral contraceptive pill (OCP), when the OCP is ceased after the sterilization the abnormal periods will almost certainly return. If the patient is made aware of this likelihood, she may well decide to just continue the OCP rather than having the sterilization performed.</p>
<p>The failure of a sterilization procedure in either sex may result from a method failure or recanalization. In the female, a clip may be applied to the wrong structure, may transect the tube during application, or not remain closed. In each of these instances, pregnancy usually occurs within 6 months of the procedure. The second cause of failure is recanalization of the Fallopian tubes or, in men, the vas deferens. This may result in a pregnancy many years later and is an unavoidable risk of the procedure. Despite the signing of a consent form that records the risk of failure, errors of technique are generally indefensible.</p>
<p>A consent form does not protect either the patient or the surgeon if performance of the procedure is faulty.</p>
<p>It is important that consent is obtained by a member of staff who is medically qualified and who signs the consent form with the patient after explaining both the nature of the procedure and the potential complications. Ideally the procedure should be performed in the follicular phase of the cycle or alternative contraception given in that cycle.</p>
<p>Ideally, consent should be obtained by the surgeon who is performing the procedure. There are limitations as to what can be reasonably included in a consent form and it is common practice to include a general statement, either in the text of the consent form or in the patient's records, that the risks and the intended purpose of the procedure have been explained to the patient. Such a general statement is often found to be inadequate when defending a medicolegal case, and it is much better if headings of the matters discussed are recorded on the consent form or within the medical record at the time the consent form is signed.</p>
<p>It is also important to ensure that the details concerning the patient's name and the description of the procedure to be performed are correct. For example, it is not sufficient to write 'sterilization' to describe the operation when the procedure may be tubal cautery, clip sterilization or tubal ligation. The actual procedure to be performed must be written on the consent form.</p>
<p>The consent from must always be available and must be checked at the time of admission to hospital and in theatre before any operation is commenced. The condition of the patient at that time, including the date and normality of the last menstrual period should also be checked, where the procedure is being done more than 4 weeks after the previous review. The patient may have conceived in the interim and wish a change in the treatment previously proposed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="litigation-in-obstetrics-and-gynaecology">LITIGATION IN OBSTETRICS AND GYNAECOLOGY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#litigation-in-obstetrics-and-gynaecology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Litigation in obstetrics and gynaecology has had a profound effect on the provision of maternity services. In the UK and Australia, the problem has been masked to some extent by Crown indemnity and its equivalent in Australia. The government provides insurance cover for all doctors and midwives practising within the public health services. However, in countries such as the US closure of maternity units and the reduction of maternity services are common events because of the risk of litigation and the size of the costs to defend a case or settle the damages awarded. The costs of insurance have to be passed on to the mothers or the services cannot survive. The reality of the situation is that, regardless of the issues of fault, unless damages are capped, maternity services are often commercially uninsurable. Indeed, in many parts of the US, obstetricians cannot actually purchase insurance cover as their specialty is considered to be too high risk.</p>
<p>When a patient decides to make a claim against her doctor, she will approach her solicitor. If the solicitor considers there is justification, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">s</mi><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">e</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{s} / \mathrm{he}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">s</span><span class="mord">/</span><span class="mord"><span class="mord mathrm">he</span></span></span></span></span></span> will advance the action by issuing a summons, seek access to the relevant case note records and then lodge an application for a hearing. If the case is to proceed, in England and Wales it will be heard in the High Court by Masters of the Queen's Bench Division. Cases may also be heard in the County Court if the costs are below a certain figure. In the UK, cases are heard before a judge and not a jury. In Australia, cases are usually heard before a judge and jury. The case usually commences with the Barrister for the plaintiff outlining their perceived problem and the care given. This is generally reported widely in the daily press, often in large type on the first or second pages of the paper, and often resulting in severe adverse publicity for the doctor or hospital concerned. If it is ultimately proven that the doctor or hospital was not</p>
<p>at fault, it is rare for the press to detail these findings as widely and the comments tend to be almost hidden in small type deep in the publication.</p>
<p>Medical litigation may occur soon after a problem has been perceived to have occurred by a patient, but may be delayed for some years. Where the problem does not involve a child, the litigation process must generally be submitted to the Court involved within 7 years of the 'adverse' event occurring. Where the condition of the child is the reason for the litigation, the case should reach the Court within 7 years of that child reaching 'maturity' - in other words the case can reach the Court any time in the 25 years after the 'adverse' event occurred. Because no-one can remember exactly what happened 12 months ago, let alone 25 years ago, the documentation about any adverse event must be extensive and detailed. There also tends to be a long time interval between the issuing of a summons and its hearing and between setting down a case for trial and the actual date of the trial.</p>
<p>Medical litigation is expensive and it is not therefore surprising that most plaintiffs in the UK are supported by Legal Aid. In Australia this is often not the case unless a large payout is expected. The Statement of Claim outlines the nature of the claim and it is up to the defendant to respond and either acknowledge or refute the allegations. The legally aided litigant has considerable advantages, as the Legal Aid fund meets all costs and there is usually no penalty for failure of a claim.</p>
<p>In an attempt to speed up the resolution of disputes in the UK and in Australia, new regulations have been introduced through the Civil Procedures Rules and were implemented as guidance to expert witnesses as recently as April 2002.</p>
<p>The rules specify that the primary responsibility of an expert is to the Court and that this responsibility overrides any obligation to any other person from whom the expert has received instructions or payment.</p>
<p>After providing a report, the format of which has now been standardized, the reports of the plaintiff's and defendant's experts are exchanged and some Courts advise the various parties to put one list of written questions to the experts. These questions must be put within 28 days of service of the report and the questions must be answered within a further 28 days.</p>
<p>It is now common practice for the Court to order that the experts should also meet to discuss a common agenda submitted by the solicitors of both parties and to prepare a joint report outlining the extent of agreement and disagreement. The joint report should outline the reasons for any disagreements and should enable many cases to be resolved out of court, resulting in a substantial reduction in the legal costs involved.</p>
<p>The trial itself is an adversarial process and the onus is on the plaintiff to prove that the staff failed to provide a reasonable level of care with the result that the patient suffered unnecessary injury.</p>
<p>During the course of any trial, the major evidence tends to be drawn from the case records. As a Resident Medical Officer, it is important to remember that case notes will be examined in great detail and constitute a legal document. It is therefore important to record facts properly and the following guidelines should be followed:</p>
<ul>
<li>Entries into case notes must be clear, concise and factual, and should detail the diagnosis, differential diagnoses, investigations arranged, and the plan of management to be instituted on that day.</li>
<li>The details written on the next day should include the progress over the previous 24 hours, the results of investigations that are to hand, further investigations arranged (if any) and any change in the diagnosis or treatment to be given.</li>
<li>All entries concerning intraoperative complications or problems should be detailed and preferably written by the most senior person in the operating theatre at the time.</li>
<li>Entries should always be initialed and dated, and preferably timed. Although initialing should allow identification of the writer in the future, if required, it is better if the identification of the writer is printed or stamped in, and the medical registration number included. Timing of the record writing is particularly important in the delivery suite, Intensive Care Unit and Emergency Department where emergencies are more likely and the rapidity of care needs to be assessed.</li>
<li>No attempt should be made to alter entries in case records without countersigning the alteration and indicating why it has been made. Retrospective information concerning an adverse event can be added to the medical record providing it is dated, appropriately signed and factual.</li>
</ul>
<p>If a letter is received from a solicitor asking for information with a view to initiating legal action, it is important to:</p>
<ul>
<li>Notify one's medical defence organization.</li>
<li>Notify the complaints officer in the Hospital concerned, who will usually then notify the solicitors who represent them.</li>
</ul>
<p>Litigation commonly ensues when there are complications following a surgical procedure or where there is a perinatal death or the birth of a child that has brain dysfunction or skeletal injuries such as an Erb's palsy.</p>
<p>All the evidence available in the literature suggests that less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of cases of cerebral palsy or mental retardation are related to the events that occur during labour. However, the difficulty that judges have is deciding whether, on the balance of probabilities, the adverse outcome could have been avoided or reduced in severity by more appropriate care during labour. If the judge decides in favour of the plaintiff, the quantum of the award will be assessed on the level of disability and the life expectancy of the child. This may amount to an award of several million pounds or dollars.</p>
<p>Shoulder dystocia resulting in damage to the brachial plexus is another common cause for litigation in obstetrics. The arguments proffered in such cases are that either the dystocia could have been avoided by predicting the likelihood of shoulder dystocia and delivering the child by caesarean section, or delivering vaginally but at an earlier gestation when the baby was smaller, or that the damage to the brachial plexus could have been avoided by not using excessive traction and by the use of changing the angle of entry of the pelvic brim by placing the patient in McRobert's position and exerting directed suprapubic pressure to deliver the anterior shoulder or using appropriate internal manoeuvres.
Other reasons for litigation against an obstetrician include:</p>
<ul>
<li>Inadequate screening for a possible fetal abnormality during the antenatal period, because the patient would have requested termination had the abnormality been defined.</li>
<li>Failure to recognize a baby was growth restricted, and defining why.</li>
<li>Failure to recognize a baby was going to die in utero and doing appropriate monitoring to prevent this.</li>
<li>Failure to adequately assess the significance of a fetal heart rate abnormality seen on the cardiotocographic record obtained during labour.</li>
<li>Allowing the second stage of labour to last too long resulting in sphincter injury leading to bowel incontinence problems.</li>
<li>Too long a delay between the time a decision was made to perform a Caesarean Section on the grounds of fetal distress and the actual time the baby was delivered resulting in adverse outcome to the new born.</li>
<li>Not adequately treating a post-partum haemorrhage, resulting in the patient requiring a hysterectomy to control the life-threatening bleeding.
Litigations in gynaecology are often related to sterilization or contraception failure, complications occurring during or after gynaecological surgery (particularly when this has
been performed laparoscopically), or failure or delay in diagnosing a malignancy in a patient.
The majority of obstetricians/gynaecologists will be the subject of a litigious claim during their professional careers but the risk can be minimized by:</li>
<li>Careful adherence to the principle of not undertaking procedures for which one is inadequately trained or supervised.</li>
<li>Careful and considerate provision of information to the patient before any surgical procedure concerning the nature of the procedure and the possible complications.</li>
<li>Prompt action if there are abnormal findings in any tests that necessitate intervention; for example, an abnormal fetal heart rate during labour demands a decision. The decision may be to continue observation, to take a scalp blood sample for pH measurement or to deliver the woman. It is not acceptable to ignore the recording. The findings must be recorded in the notes as well as the decision concerning the further plan of care.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-confidentiality-including-data-protection">PATIENT CONFIDENTIALITY (INCLUDING DATA PROTECTION)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-confidentiality-including-data-protection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The doctor normally has an ethical obligation to keep secret all details of a personal nature that may be revealed during consultation and treatment. The duty is not, however, absolute, as confidentiality may be breached under special circumstances. It must be remembered that unauthorized disclosure of information without the patient's consent is not a criminal offence but it does expose the doctor to disciplinary procedures by the Medical Board or Medical Council of the country concerned. Disclosure may involve matters of public interest, particularly where the patient may constitute a risk of violence or transmission of infections such as AIDS to the public or to the immediate relatives.</p>
<p>Human immunodeficiency virus infection is not notifiable by statute although, in the UK, the General Medical Council (GMC) advises that doctors 'should make every effort to persuade a patient of the need for their General Practitioners and sexual partners to be informed of a positive diagnosis'.</p>
<p>There are some acts of disclosure that are compulsory by law and these include:</p>
<ul>
<li>Notification of births and deaths.</li>
<li>Notification of the termination of a pregnancy.</li>
<li>Notification of a treatment cycle of in vitro fertilization.</li>
<li>Notification of artificial insemination by donor.</li>
</ul>
<p>In Australia there is no universal law concerning notification of AIDS in the various states, but doctors who</p>
<p>diagnose AIDs or HIV infection have a legal obligation in all States to notify their respective Health Departments, as do pathologists and pathology departments in some States.</p>
<p>Because of the time scales of possible legal action being taken against a doctor or hospital it is necessary for all medical records to be stored for at least 7 years, or 25 years if the record includes pregnancy care.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-rules-regarding-abortion">THE RULES REGARDING ABORTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-rules-regarding-abortion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The Abortion Act (1967) in the UK radically changed the availability of termination of pregnancy in the UK and had the effect of both legalizing and liberalizing abortion.</p>
<p>Under this law, termination of pregnancy can be performed under the following four conditions:</p>
<ul>
<li>That the pregnancy has not exceeded its 24th week and that continuance of the pregnancy would involve greater risk than if the pregnancy were terminated of injury to the physical or mental health of the pregnant woman or any existing children of her family.</li>
<li>That the termination is necessary to prevent grave permanent injury to the physical or mental health of the pregnant woman.</li>
<li>That the continuance of the pregnancy would involve risk to the life of the pregnant woman greater than if the pregnancy were terminated.</li>
<li>That there is a substantial risk that if the child were born it would suffer from physical or mental abnormalities so as to be seriously handicapped.
Under the conditions of the Act, the decision to terminate a pregnancy must be agreed by two practitioners unless the practitioner 'is of the opinion, formed in good faith, that the termination is immediately necessary to save life or to prevent grave permanent injury to the physical or mental health of the pregnant woman'.</li>
</ul>
<p>Termination of pregnancy must be carried out in a hospital vested by the Secretary of State for the purposes of his/her functions under the National Health Services Act 1977. In other words, premises must be licensed for the purpose of termination of pregnancy. In addition, the need to ensure the fetus will not be born alive is a requirement where the pregnancy is terminated after 22 weeks of gestation. This often necessitates the injection of potassium chloride or other substances into the fetal heart under ultrasonic guidance to result in fetal death.</p>
<p>Notification is also a statutory requirement, first of the intention to perform an abortion and second of the performance of the termination and any complications during or after the event. This is, perhaps, why so much emphasis is still laid on notification when the Act itself is very liberal and in a legal framework that does not require notification of conception or sterilization.</p>
<p>In other countries the rules concerning pregnancy termination and the availability of it vary dramatically. In some countries abortion is not allowed and any doctor performing an abortion or patient having an abortion can be convicted of a felony and punished appropriately. In Australia there is no universal rule concerning abortion although it is readily available in most, but not all of the States. Those States that allow it do so under similar rules to those defined above in the UK. In Victoria, for many years, the Menhennit ruling was applied, with this ruling being similar to the rules in the UK. Currently only the ACT and Victoria have decriminalized abortion.</p>
<p>Late term (third trimester) abortions are performed in some States in Australia, despite the existence of child destruction laws, presumably because they have satisfied the conditions necessary for legal abortion. In public hospitals performing such procedures, the appropriateness of such an abortion is usually assessed and the procedure approved by a special medical and legal committee before it can be performed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-use-of-assisted-reproduction-in-infertility-care">THE USE OF ASSISTED REPRODUCTION IN INFERTILITY CARE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-use-of-assisted-reproduction-in-infertility-care" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The Human Fertilisation and Embryology Act 1990 (which applies in the UK) provides the statutory authority that regulates all matters relating to assisted reproduction. The Act is long and complex and should be read by all personnel involved in these procedures. The Act is administered by the Human Fertilisation and Embryology Authority which consists of:</p>
<ul>
<li>a chairman and deputy chairman</li>
<li>such numbers of other members as the Secretary of State appoints.
The Authority has the following duties:</li>
<li>To keep under review information about embryos and any subsequent development of embryos and about the treatment services and activities governed by this Act, and advise the Secretary of State, if asked to do so, about these matters.</li>
<li>To publicize the services provided to the public by the Authority or provided in pursuance of licences.</li>
<li>To provide, to such extent as it considers appropriate, advice and information for persons to whom licences apply or who are receiving treatment services or providing gametes or embryos for use for the purpose of activities governed by this Act or may wish to do so.</li>
<li>To perform such other functions as may be specified in the regulations.
Overall, the Human Fertilisation and Embryology Authority has the power to license and supervise centres</li>
</ul>
<p>providing assisted reproduction and to decide which procedures are acceptable within the terms of reference of the Act. It also has wide-ranging powers under the clinical law, including, under warrant, the rights to enter premises 'using such force as is reasonably necessary' to take possession of whatever may be required as evidence of breach of the law and to take the necessary steps to preserve such evidence.</p>
<p>In other countries similar bodies and legislation exist and control not only the availability of this treatment to appropriate 'couples' but may include recommendations as to the number of embryos to be transferred to reduce the likelihood of multiple pregnancies, the place for preimplantation genetic diagnosis, and ensure that all patients having such treatment, whether donor gametes are required or not, and who conceive, are appropriately registered for subsequent assessment by any child so produced. Any such child has a right to know how they were conceived and whose gametes were involved.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-relevant-legal-status-of-the-fetus-the-pregnant-woman-the-child-and-the-pubertal-girl">THE RELEVANT LEGAL STATUS OF THE FETUS, THE PREGNANT WOMAN, THE CHILD AND THE PUBERTAL GIRL<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-relevant-legal-status-of-the-fetus-the-pregnant-woman-the-child-and-the-pubertal-girl" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Although in some countries the fetus has legal rights as soon as conception occurs, in most the fetus has no legal rights in any trimester of the pregnancy, but gets these as soon as it is born alive. It is therefore imperative that you are familiar with the law in the country in which you are working to understand what your responsibility is to the fetus when a woman is pregnant.</p>
<p>During the last few years in the US, some Courts have been asked to decide whether a woman can be forced to allow a caesarean section to be performed on the grounds of an identified problem within the fetus but where she has refused such treatment, and in some instances caesarean section has been ordered. In others the rights of the mother have been deemed to override those of the fetus and the pregnancy has been allowed to continue. In many other countries the rights of the pregnant woman have clearly overridden those of the fetus and Court applications allegedly on behalf of the fetus have not been made.</p>
<p>Once the child has been born a Court will usually approve treatment of the child which has been refused by the mother, where that treatment may be lifesaving (such as blood transfusion for blood group immunization) or would reduce the likelihood of significant morbidity.</p>
<p>During childhood consent for treatment is usually given by the parents with this generally accepted as being appropriate for most medical care including serious illnesses, emergency care and for necessary operative procedures but not for sterilization. If the child is mentally disabled, again parental consent is appropriate for most treatment
required. However, sterilization, abortion and the use of some forms of contraception such as an intrauterine device or depo-provera would usually require the approval of a Government Body, such as a Guardianship Board, which deals with the rights of a disabled child or adult.</p>
<p>Although by definition a child does not become an adult and achieve full adults rights until the age of 18 years in most countries, thereby obtaining the ability to consent to treatment or the performance of operative procedures, a child younger than 18 years has been deemed mature enough to make such decisions under certain circumstances. These circumstances define Gillick competency or satisfaction of the Fraser Guidelines, which refer to a case in the UK in 1982 where a woman took a case to Court in an attempt to prevent contraceptive advice or treatment being given to a child under the age of 16 years without parental consent. Ultimately this case was settled in the House of Lords as follows: 'whether or not a child is capable of giving the necessary consent will depend on the child's maturity and understanding and the nature of the consent required. The child must be capable of making a reasonable assessment of the advantages and disadvantages of the treatment proposed, so the consent, if given, can be properly and fairly described as true consent.' In order to satisfy the Fraser guidelines the doctor concerned must be satisfied that:</p>
<ul>
<li>The young person will understand the professional's advice.</li>
<li>The young person cannot be persuaded to inform their parents.</li>
<li>The young person is likely to begin, or to continue having, sexual intercourse with or without contraceptive treatment.</li>
<li>Unless the young person receives contraceptive treatment, their physical or mental health, or both, are likely to suffer.</li>
<li>The young person's best interests require them to receive contraceptive advice or treatment with or without parental consent.
The ramifications of this decision extend beyond that of the provision of contraception because, if the child is 'Gillick competent', he or she is able to prevent the parents from viewing their medical record.</li>
</ul>
<p>Many countries have accepted the UK decision on Gillick competence and this rule now applies in most developed countries.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-role-of-the-doctor-in-child-protection">THE ROLE OF THE DOCTOR IN CHILD PROTECTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-role-of-the-doctor-in-child-protection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>All doctors have a role in child protection when the possibility of child abuse or neglect is defined. This abuse can</p>
<p>be physical abuse, sexual abuse or the denial of appropriate and necessary therapy. Relevant information needs to be shared with other staff members of the institution concerned, including senior medical personnel and medical social workers, even where the child or her parent do not
consent, or it is not possible or it is inappropriate to ask for such consent. A decision should then be made concerning the need for referral to external agencies and an understanding of the roles, policies and practices of such agencies in the country concerned would be necessary.</p>
<p>This page intentionally left blank</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="self-assessment-questions">Self-assessment: Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#self-assessment-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-1">CHAPTER 1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Bartholin's glands:
A. Are located on either side of the urethra
B. Lead into ducts of length around 0.5 cm
C. Are commonly the site of cyst formation
D. Are drained by ducts opening between the labia minora and the vaginal introitus
E. Are endocrine glands</li>
<li>The vagina:
A. Is closely related anteriorly to the trigone of the bladder and the urethra
B. Has the rectum as its only direct relation posteriorly
C. Is composed of striated muscle
D. Has a pH in the sexually mature non-pregnant female of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.0</mn><mo>−</mo><mn>3.0</mn></mrow><annotation encoding="application/x-tex">2.0-3.0</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.0</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3.0</span></span></span></span></span>
E. Is lined by glandular epithelium</li>
<li>In regard to the uterus and its supporting structures, which one of the following statements is true?
A. Posteriorly, the uterosacral ligaments and their peritoneal covering form the lateral boundaries of the rectouterine pouch (of Douglas)
B. Laterally, the broad ligaments form an important supporting structure for the uterus
C. In about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of women, the uterus lies in a position of retroversion in the pouch of Douglas
D. In labour, the isthmus (lower segment) of the uterus plays a significant role in expulsion of the fetus
E. The anterior ligaments and utero-vesical folds play an important role in maintaining anteversion of the uterus</li>
<li>The ovary:
A. Lies in close relation to the internal iliac vessels
B. Derives its blood supply from the ovarian artery which arises from the internal iliac artery
C. Is covered by ciliated columnar epithelium
D. Is supported laterally by the suspensory ligament which lies in close relation to the ureter
E. Contains Graafian follicles which are found only in the central medulla of the organ</li>
<li>With regard to the uterus, which one of the following is correct?
A. Lymphatic drainage from the lower part of the uterus passes to the superficial inguinal and adjacent superficial femoral nodes
B. Uterine pain is mediated through sympathetic afferent nerves passing up to T11/T12 and L1/L2
C. The uterine artery lies beneath the ureter at the point where the ureter enters the bladder
D. The blood supply of the uterus is derived entirely from the uterine artery
E. The isthmus (lower segment) of the uterus is partly innervated by the pudendal nerve</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-2">CHAPTER 2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Which one of the following is the most likely reason for a premature menopause occurring at the age of 38 years in a woman previously delivered of two children?
A. Radiotherapy directed at the left breast following lumpectomy of a breast malignancy at the age of 36 years
B. Tamoxifen therapy given following the breast surgery
C. The six months of cytotoxic chemotherapy given following completion of the radiotherapy detailed above
D. Cytotoxic chemotherapy given following excision of a Wilm's tumour from her left kidney at the age of 10 years
E. Excision of an endometrioma from her right ovary five years ago</p>
</li>
<li>
<p>Which one of the following best describes normal follicular growth occurring in a 25 year-old woman?
A. About 100 ovarian follicles show obvious follicular growth in each menstrual cycle
B. In most women one follicle is selected to become the dominant follicle on about day 5-6 of that cycle
C. The dominant follicle grows by about 1 cm per day from days 6 to 14 of the cycle
D. The follicle ruptures when it reaches about 4 cm in diameter
E. A separate but adjacent follicle becomes the corpus luteum</p>
</li>
<li>
<p>Which one of the following statements about meiosis is correct?
A. Meiosis is the mechanism of production of the seven million germ cells found in the ovary at 6 months of fetal life
B. The first meiotic division is completed prior to birth of the baby concerned
C. The second meiotic division commences at the time of attachment of the sperm to the oocyte
D. Rearrangements of the genes within the chromosomes occurs after the male zygote chromosomes have entered the nucleus and combine with those of the female zygote
E. The delay between the end of the first meiotic division and the commencement of the second meiotic division is the cause of the increased chromosome abnormality rate seen in women who conceive after the age of 37 years</p>
</li>
<li>
<p>Which one of the following statements about the process of fertilization in the human female is correct?
A. It usually occurs within the outer end of the Fallopian tube
B. The female gamete determines the sex of a resulting fetus
C. A twin pregnancy is due to failure of the normal inhibitory process, where further sperm are prevented from entering the oocyte following attachment of the first sperm to the Zona pellucida
D. Fertilization can occur up to six days after ovulation
E. Sperm capacitation to facilitate fertilization occurs within the seminiferous epithelium of the testis</p>
</li>
<li>
<p>Which one of the following facts about implantation is correct?
A. Implantation usually occurs about two days after fertilization
B. At the time of implantation the embryo is usually at the eight-cell stage
C. hCG is produced by the implanting embryo soon after implantation has commenced
D. If the endometrial appearance at the time of implantation is proliferative, the pregnancy is lost as a spontaneous miscarriage
E. If implantation occurs, the period is always delayed and a urinary pregnancy test performed two to three days after the day the period was expected, will be positive</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-3">CHAPTER 3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Which one of the following facts about the human placenta is correct?
A. It is not very invasive
B. It contributes to the high levels of circulating oxytocin in the mother
C. It needs glucose and amino acids from the mother to grow
D. It does not help in excretory functions of the fetus
E. It is richly innervated</li>
<li>Regarding the rise in cardiac output, which one of the following is correct? It
A. occurs in late pregnancy
B. is entirely driven by a rise in stroke volume
C. is associated with a rise in afterload
D. can precipitate heart failure in women with heart disease
E. causes an increase in pulmonary arterial pressure</li>
<li>Considering respiratory function in pregnancy, which one of the following statements is correct?
A. Progesterone sensitizes the adrenal medulla to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>
B. Maternal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">P</mi><mi mathvariant="normal">n</mi></msub><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{P}_{\mathrm{n}} \mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">n</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> rises by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>∼</mo><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\sim 15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">∼</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span>
C. There is no increase in maternal 2,3-DPG
D. Maternal oxygen-carrying capacity rises by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>∼</mo><mn>18</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\sim 18 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">∼</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">18%</span></span></span></span></span>
E. There is an <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> increase in minute ventilation</li>
<li>Considering renal function in pregnancy, which one of the following statements is correct?
A. Most increase in renal size occurs in late pregnancy
B. The ureters are floppy and toneless
C. The rise in GFR activates the renin-angiotensin system
D. About 1800 mmol sodium are retained during pregnancy
E. Urinary tract infections are less common in pregnancy</li>
<li>In relation to endocrine function in pregnancy, which one of the following statements is correct?
A. Insulin resistance develops
B. Glycosuria is not common
C. The thyroid involutes
D. The gut absorbs more calcium but less is lost in the urine</li>
</ol>
<p>E. The increased skin pigmentation is caused by thyroid-stimulating hormone</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-4">CHAPTER 4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>In early placental development, which one of the following is correct?
A. The outer cytotrophoblast invades the endometrial cells and the myometrium
B. Decidual cells do not support the invading trophoblasts
C. With the placental invasion large lacunae are formed and are filled with fetal blood
D. Chorion frondosum forms the placenta
E. Chorion laevae forms the placenta</li>
<li>Which one of the following is correct regarding the umbilical cord?
A. It has two veins and one artery
B. The arterial blood has more oxygen
C. One artery and one vein is compatible with fetal growth and a live baby
D. Cord artery has a systolic pressure of 120 mmHg
E. Cord venous pressure is 70 mmHg</li>
<li>Which one of the following is correct regarding placental transfer?
A. Transfer of placental gases is by simple diffusion
B. Transfer of glucose is by simple diffusion
C. In active transport the concentration of the substrate transported in fetal blood is lower than on the maternal blood.
D. Low molecular weight substrates are transported by pinocytosis
E. Fetal cells do not get transferred to the maternal circulation</li>
<li>Placental function includes all of the following except:
A. Gaseous exchange
B. Fetal nutrition
C. Removal of waste products
D. Endocrine function
E. A barrier for infections</li>
<li>Regarding amniotic fluid, which one of the following is correct?
A. Polyhydramnios is associated with fetal anomaly
B. Amniocentesis for karyotyping carries no risk to the pregnancy
C. The only complication of long standing severe oligohydramnios is postural deformities
D. Most cases of intrauterine growth restriction have normal liquor volume
E. Amnio infusion is a standard procedure for variable decelerations observed on the cardiotocography</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-5">CHAPTER 5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Which one of the following statements is true of perinatal mortality?
A. Perinatal mortality is an indication of the wealth of the nation
B. Knowing the circumstances around perinatal mortality helps countries to build better maternity units
C. It is an important indication of maternal health and the standard of maternal and neonatal care
D. The World Health Organization has set targets of perinatal mortality for each country
E. The World Bank gives financial incentives to countries that have the best perinatal mortality rates</li>
<li>Which one of the following statements is true of stillbirth?
A. Stillbirth is an indication of the standard of intrapartum care
B. Using the Wigglesworth Classification, around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> are classified as of unknown antecedent
C. The most common cause of stillbirth is intrapartum stillbirth
D. The region with the highest stillbirth rate in the world is in the Caribbean
E. There was a statistically significant reduction in the stillbirth rate in the UK in 2008 compared to the year before</li>
<li>Which one of the following statements is true of neonatal deaths?
A. Low birth weight is a well-known direct cause
B. In low resource countries, tetanus remains one of the most important causes of neonatal deaths
C. The neonatal death rates related to prematurity in developing countries have shown a significant fall
D. The majority of deaths related to neonatal tetanus occur around the 3rd week of life
E. The best investment to improve the neonatal death rates is to build more neonatal intensive care units</li>
<li>Which one of the following statement most accurately describes maternal deaths?
A. Direct maternal deaths arise from complications or their management which are unique to pregnancy, occurring during the antenatal, intrapartum or postpartum periods
B. Coincidental causes occur when two or more causes are noted to cause a mother's death
C. The maternal mortality rate in the UK is defined as the number of direct and indirect deaths per 100000 live births</li>
</ol>
<p>D. Maternal mortality rates reflect the state of antenatal care of a country
E. Can be reduced by increasing the number of doctors and midwives
5. Which one of these statements is true of maternal mortality?
A. Group B Streptococcus is a major cause of maternal mortality
B. Cardiac disease is the leading cause of direct deaths in the UK
C. Group A Streptococcus sepsis is easily recognized and treated
D. Group A Streptococcus sepsis was the leading cause of maternal deaths in the UK between 2006 and 2008
E. Venous thromboembolism is now a rare cause of death</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-6">CHAPTER 6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Which of the following are not included in basic clinical skills in obstetrics?
A. Ensuring verbal and non-verbal communication in a logical sequence
B. Eliciting physical signs (general, systemic and obstetric examinations)
C. Differentiating normal pregnancy associated changes from abnormal deviation
D. Arriving at a provisional diagnosis
E. Performing a fetal anomaly scan at 22 weeks</li>
<li>In eliciting an obstetric history, which of the following is correct?
A. Previous obstetric history is relatively unimportant as management decisions are made on how the current pregnancy has progressed
B. The first date of the last menstrual period (LMP) is a reliable indicator of the expected date of delivery (EDD)
C. The pre-ovulatory period is fairly constant whereas the post-ovulatory period shows a wide variation in a typical menstrual cycle
D. Ultrasound scan in the third trimester accurately determines the gestational age
E. Hormonal contraception may be associated with a delay in ovulation in the first cycle after discontinuation</li>
<li>Regarding symptoms of pregnancy, which one of following statements is true?
A. Nausea and vomiting commonly occur 10 weeks after missing the first period
B. Increased frequency of micturition tends to worsen after the first 12 weeks of pregnancy, as the uterus rises above the symphysis pubis
C. Morning sickness persist throughout pregnancy in most women
D. Plasma osmolality gradually increases with advancing gestation
E. There is an increased diuretic response after water loading when the woman is sitting in the upright position</li>
<li>During pregnancy, which of the following statements is correct?
A. Blood pressure is recorded with the patient lying flat on her back to get the most accurate reading
B. Blood pressure should be recorded on different positions during each antenatal visit, alternating the blood pressure cuff on different arms
C. If inferior vena cava compression is not recognized for a prolonged period, fetal compromise may occur secondary to a reduction in utero-placental circulation
D. Diastolic pressure should be taken with the fourth Korotkoff sound (i.e. fading of the sound)
E. Benign 'flow murmurs' due to the hyperdynamic circulation are common and are of no significance</li>
<li>In pelvic examination during pregnancy, which of the following is correct?
A. Routine pelvic examination to confirm pregnancy and gestation at booking should be performed, even in settings where an ultrasound scan is freely available
B. Digital vaginal examination is contraindicated in later pregnancy in cases of antepartum haemorrhage until placenta praevia can be excluded
C. Routine antenatal radiological pelvimetry has been shown to be of value in predicting outcome of labour in primigravid women
D. In a normal female or gynaecoid pelvis, because the sacrum is evenly curved, maximum space for the fetal head is provided at the pelvic outlet
E. Diameter of the diagonal conjugate is approximately 3.5 cm greater than the obstetric diameter</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-7">CHAPTER 7<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Antenatal screening for infection is to provide the best outcome for the mother and the fetus/newborn. Which one of the following investigations is not recommended as part of routine antenatal care?
A. Hepatitis B
B. Cytomegalovirus
C. Syphilis</li>
</ol>
<p>D. Rubella
E. HIV/ AIDS
2. Which of the following statements is true of Group B streptococcus?
A. It is a gram negative bacteria
B. It is not a commensal organism
C. It is associated with an increased risk of preterm birth
D. Screening is routine in the antenatal period in all countries
E. If Group B streptococcus was found in urine culture there is no need to treat in labour
3. There is a risk of gestational diabetes in all of the following except:
A. Previous macrosomic baby weighing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>4.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;4.5 \mathrm{~kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">4.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>
B. Maternal BMI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>35</mn></mrow><annotation encoding="application/x-tex">&gt;35</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">35</span></span></span></span></span>
C. First degree relatives with Diabetes Mellitus
D. Gestational diabetes in previous pregnancy
E. Adolescent pregnancy
4. Extra folic acid supplementation is recommended in all the following except:
A. Previous child with neural tube defects
B. Women on anti-epileptic medication
C. Women with diabetes mellitus
D. Maternal obesity with a BMI&gt;35
E. Mothers who had a previous Down syndrome baby
5. Which one of the following statements are incorrect in pregnancy:
A. Mothers are encouraged to take reasonable exercise
B. Coitus in pregnancy is not contraindicated
C. Moderate alcohol consumption is not harmful in pregnancy
D. Smoking is harmful to the fetus
E. Paracetamol is a safe drug in pregnancy</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-8">CHAPTER 8<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>With regard to an antepartum haemorrhage at 36 weeks, the commonest cause is:
A. Placenta previa
B. Placental abruption
C. Idiopathic
D. A cervical lesion
E. Vasa previa</li>
<li>With regard to hypertension in pregnancy, which one of the following statements is correct?
A. The diastolic reading is taken as the fourth Korotkoff sound
B. A diastolic reading of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>90</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;90 \mathrm{mmHg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">90</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mmHg</span></span></span></span></span></span> is more significant than a systolic reading of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;150 \mathrm{mmHg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mmHg</span></span></span></span></span></span>
C. Pre-eclampsia is defined as the development of hypertension after 20 weeks
D. The most important regulatory factor of maternal blood pressure in pregnancy is a fall in peripheral resistance
E. The HELLP syndrome is a mild variant of pre-eclampsia</li>
<li>In twin pregnancy, which of the following statements is true?
A. The prevalence of identical (monozygotic) twins varies from country to country
B. The twin peak sign is most commonly seen on a first trimester ultrasound in dizygotic twins
C. Miscarriage is less common then in singleton pregnancies
D. Preterm delivery is increased by a factor of two with respect to a singleton pregnancy
E. The feto-fetal (twin-twin) transfusion syndrome presents only after 24 weeks gestation</li>
<li>The causes of an unstable lie include all of the following except:
A. Placenta previa
B. Polyhydramnios
C. Subseptate uterus
D. Primiparity
E. Twin pregnancy</li>
<li>In prolonged pregnancy, which one of the following statements is correct?
A. All babies show signs of the post-maturity syndrome
B. Can be accurately determined from the mother's last menstrual period in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of cases
C. May indicate the presence of a fetal anomaly
D. Is only associated with an increase in perinatal morbidity, not mortality
E. Is managed by induction of labour at 40 weeks gestation</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-9">CHAPTER 9<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-9" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Anaemia in pregnancy is most frequently caused by:
A. Sickle cell disease
B. Folate deficiency
C. B12 deficiency
D. Thalassaemia
E. Iron deficiency</li>
<li>Which of the following does not increase the risk of gestational diabetes?
A. South-East Asian ethnicity
B. A family history of diabetes
C. Age <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>18</mn></mrow><annotation encoding="application/x-tex">&lt;18</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">18</span></span></span></span></span> years
D. Polycystic ovarian syndrome
E. Obesity</li>
<li>In acute venous thromboembolism in pregnancy, which one of the following statements is true?
A. Is more likely to occur in the right leg compared to the left</li>
</ol>
<p>B. Can be diagnosed by the use of D-dimer measurements
C. Is two times more likely than in the nonpregnant state
D. Is a leading cause of maternal mortality in the developed world
E. Is treated by warfarin in the first instance
4. Compared to women with a normal body mass index, obesity in pregnancy is associated with:
A. An increased risk of pre-eclampsia
B. Similar pregnancy outcomes
C. A higher normal birth rate
D. A lower miscarriage rate
E. Similar efficacy of ultrasound screening
5. Concerning epilepsy and pregnancy, which of the following statements is true?
A. The majority of women will have an increase in seizure frequency in pregnancy
B. Women with epilepsy have a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4-5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> chance of having a child who develops epilepsy
C. Sodium valproate is the anti-epileptic of choice
D. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of folic acid should be taken preconceptually and throughout the first trimester
E. Breast-feeding should be avoided</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-10">CHAPTER 10<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-10" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Ultrasound of fetal anatomy at 20 weeks does not detect the majority of abnormalities in which of the following organ systems?
A. Cardiac
B. Central nervous system
C. Skeletal
D. Gastrointestinal
E. Urogenital</li>
<li>A woman aged 20 years (with a background risk of delivering a baby with Down's syndrome of 1:1500) has a first trimester screening test for Down's syndrome which reports a risk of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>150</mn></mrow><annotation encoding="application/x-tex">1: 150</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">150</span></span></span></span></span>. Which of the following statements is not true?
A. There is a high chance that her baby does not have Down's syndrome
B. Her chances of having a baby with Down's syndrome are approximately ten times greater than we would expect in someone of her age
C. Her baby has Down's syndrome
D. In the light of your increased risk of Down's syndrome she might want to consider having an invasive test (chorionic villus sampling, CVS) to rule out the diagnosis
E. If she has a CVS, she will have about a one in 100 chance of miscarrying from the procedure</li>
<li>Which one of the following statements about assessment of fetal growth in pregnancy is not correct?
A. Ultrasound measurement of fetal abdominal circumference is the best single parameter to record fetal growth
B. The relative size of fetal head and abdominal circumferences measured by ultrasound is a useful measure in clinical practice
C. Serial symphysio-fundal height measurements during pregnancy will detect over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of small-for-dates fetuses
D. Identification of a small-for-dates fetus on ultrasound is an indication to confirm that fetal anatomy is normal
E. Identification of a small-for-dates fetus on ultrasound is an indication to assess blood flow in the umbilical artery with Doppler ultrasound</li>
<li>Which of the following tests used in the management of women with high risk pregnancies have been shown to improve fetal outcome in randomized controlled trials?
A. Fetal cardiotocography
B. Umbilical artery blood flow recorded with Doppler ultrasound
C. Maternal fetal movement counting
D. Fetal biophysical profile testing
E. Ultrasound measurement of amniotic fluid volume</li>
<li>Which of the following fetal ultrasound parameters are surrogate measures of fetal anaemia?
A. Abdominal circumference
B. Umbilical artery blood flow
C. Amniotic fluid volume
D. Biophysical profile
E. Middle cerebral artery peak systolic blood flow</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-11">CHAPTER 11<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-11" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Which one of the following is diagnostic of labour?
A. The appearance of 'show'
B. Rupture of membranes
C. Painful uterine contractions with no cervical change
D. Regular painful uterine contractions with cervical change
E. Backache and abdominal pain</p>
</li>
<li>
<p>Slow labour progress in the first stage of labour is most likely to be due to which one of the following:
A. Fetal weight of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;4 \mathrm{~kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>
B. In-coordinate uterine contractions
C. Malposition of the fetal head
D. Gynaecoid pelvis
E. Primigravidity</p>
</li>
<li>
<p>Prolonged second stage of labour can be due to the following except:
A. Malposition of the fetal head
B. Asynclitism of the fetal head
C. Epidural analgesia
D. Maternal exhaustion
E. Fetal distress</p>
</li>
<li>
<p>The complications of epidural analgesia include all of the following except:
A. Blood stained tap
B. Accidental dural tap
C. Hypertension
D. Total spinal blockade
E. Accidental nerve injury</p>
</li>
<li>
<p>Electronic fetal monitoring features that are reassuring of the fetal state are:
A. Accelerations of the fetal heart rate
B. Absence of accelerations
C. Presence of variable decelerations
D. Absent baseline variability
E. Presence of late decelerations</p>
</li>
<li>
<p>Management of preterm labour involves all of the following except:
A. Tocolytic agents
B. Oxytocin
C. Corticosteroids
D. Antibiotics
E. Magnesium sulphate</p>
</li>
<li>
<p>Which one of the following is not an accepted indication for induction of labour:
A. Prolonged pregnancy
B. Diabetes in pregnancy
C. Macrosomic baby
D. Intrauterine growth restriction
E. Pre-eclampsia at term</p>
</li>
<li>
<p>The following are all known complications of induction of labour except:
A. Prematurity
B. Cord prolapse
C. Fetal distress
D. Uterine rupture
E. Less painful labour</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-12">CHAPTER 12<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-12" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>In normal delivery, which one of the following statements is correct?
A. The normal duration of the second stage of labour in a nulliparous woman who has received epidural analgesia is commonly regarded as lasting up to 2 hours
B. The fetal head is said to be engaged when the bony part of the vertex has descended to the level of the ischial spines
C. The mother experiences a sensation to bear down when the cervix becomes fully dilated
D. Continuous pushing throughout the duration of a contraction is the preferred method for maternal expulsion
E. The fetal head should be maintained in an attitude of flexion until it has passed through the introitus</li>
<li>In perineal injury and episiotomy, which one of the following statements is correct?
A. Mediolateral episiotomy compared to midline episiotomy is associated with more third and fourth degree perineal injuries
B. A third degree perineal tear is diagnosed when the external anal sphincter is completely torn
C. A fourth degree laceration has occurred when both the external and internal anal sphincters are disrupted
D. Instrumental delivery and persistent occipitoposterior (OP) position are risk factors for severe perineal tears
E. Failure to repair injury to the anal sphincter may result in short term, but not long term, incontinence of flatus and faeces</li>
<li>Regarding caesarean section, which one of the following statements is correct?
A. The rising caesarean section rate witnessed over recent years has resulted in a corresponding decrease in the instrumental delivery rate
B. Women who have had one previous lower segment caesarean section (LSCS) should not attempt vaginal delivery in a subsequent pregnancy
C. A previous LSCS carries a greater risk of scar dehiscence than a classical caesarean section because the lower segment is thinner
D. A persistent OP position of the fetus in the second stage of labour is a contraindication for forceps or vacuum-assisted delivery
E. Almost all babies with a face presentation in labour are delivered by caesarean section</li>
<li>Regarding operative vaginal delivery, which one of the following statements is correct?
A. McRobert's manoeuvre alone is successful in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of cases of shoulder dystocia
B. Elective caesarean delivery of all macrosomic infants ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>4500</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;4500 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4500</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> ) will eliminate the majority of cases of shoulder dystocia.
C. The vacuum extractor is just as successful as the obstetric forceps for assisted vaginal delivery
D. Forceps delivery compared with vacuum extraction is associated with more 3rd and 4th degree perineal lacerations</li>
</ol>
<p>E. Vacuum extraction, but not forceps delivery, may be attempted when the cervix is not completely dilated and the fetal head position is not certain
5. Regarding postpartum haemorrhage (PPH), which one of the following statements is correct?
A. Uterine atony is responsible for at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> of primary PPH obstetric cases
B. Active management of the third stage of labour does not reduce the risk of postpartum bleeding
C. No attempt should be made to deliver a retained placenta until blood is available for transfusion
D. Ergometrine should not be administered intravenously despite continuing PPH because of the risk of vasoconstriction
E. Intrauterine tamponade may increase postpartum bleeding by preventing effective contraction and retraction of the uterine muscle</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-13">CHAPTER 13<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-13" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Physiological changes in the puerperium include:
A. Increase in serum levels of oestrogen and progesterone
B. Increase in clotting factors
C. Decrease in prolactin levels in women who breastfeed
D. Drop in platelet count
E. Sudden decrease in cardiac output</li>
<li>Risk factors for anal sphincter injury include:
A. Occipito-anterior position
B. Second stage of an hour
C. Epidural analgesia
D. A baby weight less than 4 kg
E. Multiparous pregnancy</li>
<li>In the UK, the most common overall cause of maternal death (2006-2008) was:
A. Thromoboembolism
B. Cardiac disease
C. Haemorrhage
D. Sepsis
E. Amniotic fluid embolism</li>
<li>With regards to postnatal anticoagulation, which one of the following statements is correct?
A. Heparin is contraindicated in breastfeeding
B. Warfarin is contraindicated in breastfeeding
C. Warfarin can be commenced immediately postpartum
D. Anticoagulant therapy should be continued for a total of at least three months treatment
E. Postnatal review for women who develop VTE during pregnancy should be with the GP</li>
<li>In examination of the newborn, which one of the following statements is correct?
A. Includes ascertaining parental concerns and identifying risks
B. The ideal time for this is after 7 days of age
C. Jaundice in the first 24 hours is normal
D. Umbilical hernias carry a risk of strangulation and need referral to the surgeons
E. A high pitch cry is normal</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-14">CHAPTER 14<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-14" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Regarding psychiatric disorders of childbirth, which one of the following statements is true?
A. They are not that common in pregnancy
B. Psychiatric medication should be stopped in the first trimester
C. Pregnancy and childbirth does not precipitate psychiatric disorders
D. It is not a leading cause of maternal death
E. Elevated incidence of severe mood disorders is associated with increased risk of suicide</li>
<li>Depressive illness in pregnancy - all the following statements are true except:
A. Stopping medication will cause relapse in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of mothers
B. Anxiety is a prominent feature
C. Counseling and cognitive behavioral therapy are more effective than medication for mild to moderate depression and anxiety
D. Commonly used anti-depressants are selective serotonin reuptake inhibitors (SSRIs)
E. Most women will need to continue with anti-depressant therapy</li>
<li>In serious mental illness in pregnancy, which of the following statements is true?
A. The overall incidence is greater in the antenatal period
B. It is seen more in the postpartum period
C. Relapse in the antenatal period is more likely if the mother has had no illness for two years without medication
D. Relapse in the postnatal period is less likely if the mother had no illness for two years without medication
E. Relapse in the antenatal period is less likely if the mother had the illness within two years of conception</li>
<li>Selective serotonin reuptake inhibitors (SSRIs) are associated with all of the following except:
A. No increase in congenital malformation in the fetus</li>
</ol>
<p>B. Increased pregnancy loss
C. Intrauterine growth restriction
D. Pulmonary hypertension in the newborn
E. Neonatal hypoglycaemia
5. Use of lithium for psychiatric conditions in pregnancy. Which statement is incorrect?
A. Is used for the management of bipolar disorders
B. Has an increased risk of fetal cardiac malformations
C. May be associated with neonatal hypothyroidism
D. Mother needs to be induced 10 days after stopping the lithium
E. If mother starts labour whilst on lithium caesarean section is indicated</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-15">CHAPTER 15<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-15" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>In which of the following circumstances is it reasonable for a chaperone not to be present during vaginal examination?
A. If the doctor performing the examination is known to the patient
B. If the doctor is female
C. If the examination is performed in the clinic with a nurse outside the room
D. Where the patient has indicated that they do not wish a third person to be present
E. If the patient is elderly</li>
<li>You are performing a pelvic examination on a 26 -year-old woman who has presented with abnormal bleeding. Having explained the procedure and obtained verbal consent you perform the examination, but as you insert the speculum the patient becomes distressed and asks you to stop. In addition to acknowledging her distress and apologizing for the discomfort which of the following would be the most appropriate response:
A. Withdraw the speculum and proceed with bimanual pelvic examination
B. Change to smaller speculum and try again
C. Explain that without being to do the examination you will be unable to make a diagnosis and retry the examination again after a few minutes
D. Stop the examination, allow the patient to get dressed and discuss alternatives
E. Explain that the examination will only take a few more seconds and complete the examination</li>
<li>On performing a speculum examination for a routine Pap smear for a 30-year-old multiparous woman on the contraceptive pill, you notice an area of epithelium surrounding the cervical os that
appears darker red than the pink epithelium covering the rest of the cervix. There is no abnormal discharge, ulceration or contact bleeding. The Pap smear result is normal. You see her two weeks later to discuss the results. Which of the following would be the most appropriate action to take?
A. Refer for urgent colposcopic examination
B. Ask her to return for a further Pap smear in two years
C. Take a punch biopsy from the area
D. Request a first pass urine sample for Chlamydia PCR
E. Organize for cryotherapy to the affected area</li>
<li>Which of the following findings on bimanual pelvic examination can be considered normal?
A. Increased discomfort on movement of the cervix
B. A 10 cm palpable mass in the right adnexal region
C. A mobile retroverted uterus
D. Nodularity in the posterior formix
E. A uterus equivalent in size to a 12 week pregnancy in a non pregnant patient.</li>
<li>For which of the following is a Sims speculum normally used in outpatient vaginal examinations?
A. Taking a cervical smear
B. Taking vaginal swabs
C. Assessment of anterior vaginal wall prolapse
D. Assessment of pelvic floor tone
E. Insertion of and intrauterine device</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-16">CHAPTER 16<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-16" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>A 50-year-old premenopausal woman is referred to the Gynaecology clinic following an ultrasound which indicates the presence of a 7 cm solitary leiomyoma in the posterior uterine wall. She is asymptomatic. Which one of the following would be the most appropriate management?
A. Reassure her that no treatment is necessary unless she develops symptoms
B. Uterine artery embolization (UAE)
C. Laparoscopic myomectomy
D. A six month course of gonadotrophin-releasing hormone (GnRH) analogues
E. Hysterectomy</li>
<li>A 45-year-old multiparous woman presents with regular heavy periods. Pelvic examination and recent Pap smear are normal. She is sexually active but has completed her family and is using condoms for contraception. A full blood count shows that she is anaemic with a haemoglobin of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>104</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">104 \mathrm{~g} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">104</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> and an iron deficient picture. She smokes ten cigarettes a day but is otherwise in good health with no significant past medical or family history. Which of the following</li>
</ol>
<p>would be the most appropriate management for her symptoms?
A. Tranexamic acid 1 g tds during her periods
B. Norethisterone 5 mg bd day <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>−</mo><mn>26</mn></mrow><annotation encoding="application/x-tex">12-26</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">26</span></span></span></span></span> of each cycle
C. Insertion of Mirena <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> IUS
D. Endometrial resection
E. Laparoscopically assisted vaginal hysterectomy
3. A 22-year-old woman presents with a 2-year history of oligo-amenorrhoea and a negative pregnancy test. Examination is normal except that she has a BMI of 30. Pelvic ultrasound is normal. A day 21 serum progesterone level is consistent with anovulation. Results of other initial blood investigations are normal except for a marginally raised prolactin level and an increased free androgen index. Which one of the following would be the most likely cause for her symptoms?
A. Pituitary adenoma
B. Premature ovarian failure
C. Turners syndrome
D. Polycystic ovarian syndrome
E. Functional hypothalamic amenorrhea
4. An 8-year-old girl is brought to her GP after having had her first period. On examination she is on the 95 th centile for her age in height, has stage 2 breast development and some axillary and pubic hair development. Which of the following would be the most likely diagnosis?
A. Idiopathic
B. CNS Tumour
C. Congenital adrenal hyperplasia (non-classical)
D. Neurofibromatosis
E. Follicular cysts of the ovary
5. A 49-year-old woman with no significant past medical history except for a hysterectomy for heavy menstrual bleeding 2 years ago is requesting hormone replacement therapy (HRT) for hot flushes. Which of the following conditions would she be at increased risk of developing if she takes HRT?
A. Ischaemic heart disease
B. Colonic carcinoma
C. Osteoporosis
D. Endometrial cancer
E. Cholelithiasis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-17">CHAPTER 17<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-17" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Which of the following does not provide an assessment of the uterine cavity?
A. Hysterosonocontrast sonography
B. Laparoscopy
C. Hysteroscopy
D. Hysterosalpingogram
E. Transvaginal ultrasound</li>
<li>Match the following:</li>
<li>Elevated FSH, elevated LH, suppressed oestradiol</li>
<li>Suppressed FSH, suppressed LH, suppressed oestradiol</li>
<li>Normal FSH, elevated LH, normal oestradiol</li>
<li>Suppressed FSH, suppressed LH, normal oestradiol.</li>
<li>Which of the following is not a recognized cause of oligospermia?
A. Sulphasalazine
B. Mesalazine
C. Cyclophosphamide
D. Nandrolone
E. Cannabis</li>
<li>Regarding in vitro fertilization, which one of the following statements is correct?
A. The natural LH surge is used to induce final oocyte maturation
B. The chance of a live birth after a single cycle of treatment at age 40 years is approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span>
C. Gonadotropin medications are given from the start of the luteal phase of the cycle
D. Embryos reach the blastocyst stage two days after fertilization
E. Endometrial thickness on day of embryo transfer should exceed 5 mm in order to give a good chance of implantation</li>
<li>Which of the following is not a feature of IVF ovarian hyperstimulation (OHSS)?
A. Decreased capillary permeability
B. Elevated serum oestradiol
C. Pleural effusion
D. Pericardial effusion
E. Ascites</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-18">CHAPTER 18<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-18" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>A 45-year-old woman has a miscarriage in her first pregnancy at 11 weeks gestation. She has no other family or medical history of note. Which one of the following would be the most likely cause for the loss of her pregnancy?
A. Isoimmunization
B. Antiphospholipid antibody syndrome
C. Cervical incompetence
D. Bicornuate uterus
E. Fetal chromosomal abnormality</p>
</li>
<li>
<p>A 26-year-old is admitted to the emergency department of a small local hospital with a 12- hour history of lower abdominal pain and vaginal bleeding. Her last period was eight weeks ago and she has a positive urinary pregnancy test. On examination she pale and sweaty with a blood pressure of 70/40 and a pulse of 50 . Her abdomen is soft on palpation with no evidence of guarding or rebound. After obtaining intravenous access and starting resuscitation which of the following would be the most appropriate next step in treatment?
A. Arrange an ultrasound scan to check for an intrauterine pregnancy
B. Take her to theatre for laparoscopy to exclude ectopic pregnancy
C. Perform a speculum examination to check for products of conception
D. Prescribe misoprostol and arrange ultrasound scan for two days' time
E. Arrange for transfer to the nearest hospital with a gynaecology department</p>
</li>
<li>
<p>A 20-year-old woman is found to have had a missed miscarriage whilst having an ultrasound at eight weeks' gestation. She wishes to discuss conservative management. Which one of the following statements is true?
A. The risk of infection would be lower than for surgical treatment
B. The success rate is more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span>
C. The time for resolution of her bleeding is likely to be shorter than following surgical treatment
D. It is less painful than surgical management
E. Reported patient satisfaction rates are higher than for surgical treatment</p>
</li>
<li>
<p>A 20-year-old woman has been admitted to the emergency department with a history of right iliac fossa pain, with sudden onset pain which has been continuing for two hours and is worse when she moves. She has had no nausea, fever or change in bowel habit and no urinary symptoms. Her last period was three weeks ago but lighter than normal for her and she is using condoms for contraception. On examination her pulse is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mo separator="true">,</mo><mrow><mi mathvariant="normal">B</mi><mi mathvariant="normal">P</mi></mrow><mn>120</mn><mi mathvariant="normal">/</mi><mn>80</mn></mrow><annotation encoding="application/x-tex">90, \mathrm{BP} 120 / 80</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">90</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">BP</span></span><span class="mord">120/80</span></span></span></span></span> and she is tender on palpation in the right lower quadrant of the abdomen. Which one of the following should be the first investigation?
A. Full blood count
B. Urinalysis for blood or protein
C. Urinary pregnancy test
D. Midstream urinary culture
E. Pelvic ultrasound</p>
</li>
<li>
<p>A 23-year-old woman of South-East Asian origin is in the late first trimester of pregnancy. She has noted a small amount of vaginal bleeding for the past few days and has had marked nausea and vomiting for several weeks. The uterus measures large for dates
and ultrasound shows intrauterine contents with a 'snowstorm' appearance and no fetus is identified. Which of the following is most likely diagnosis?
A. Cervical carcinoma
B. Endometrial carcinoma
C. Adenomyosis
D. Leiomyoma
E. Hydatidiform mole</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-19">CHAPTER 19<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-19" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>A 19-year-old girl attends her GP because she is concerned she may have contracted a sexually transmitted infection (STI) following recent unprotected sexual intercourse. She has no vulval or abdominal pain, no vaginal discharge and is afebrile. Vulval, speculum and PV examination are all normal. Which one of the following would be the most appropriate investigation to arrange to exclude the most common STI?
A. Low vaginal swab for bacteriologic and viral culture
B. Upper vaginal swab for bacteriologic and viral culture
C. IgM antibody testing for gonorrhea
D. IgG antibody testing for gonorrhoea
E. Polymerase chain reaction (PCR) testing of a urine specimen for Chlamydia</li>
<li>A 25-year-old woman comes for advice about the effectiveness of various contraceptive methods, as she is about to start an occasional sexual relationship. Clinical assessment reveals no reason why any of the available methods would not be applicable. Which one of the following would be most appropriate to recommend on the grounds of the best efficacy in preventing an unwanted pregnancy?
A. The combined oestrogen/progestogen oral contraceptive pill
B. The Nuva <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> vaginal contraceptive ring
C. A norgestrel post-coital pill
D. Three monthly injections of Depo-Provera <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span>
E. The Implanon <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> contraceptive rod</li>
<li>A 26-year-old woman, who has always had irregular periods, presents for contraceptive advice as she is about to marry and must not conceive for the next five years. Her BMI is 32 , blood pressure is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mi mathvariant="normal">/</mi><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">120 / 80 \mathrm{mmHg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">120/80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mmHg</span></span></span></span></span></span>, and clinical examination is normal apart from the presence of a male-appearing escutcheon. Which one of the following oral contraceptive pills (OCP) would be most appropriate to prescribe?
A. An OCP containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of ethinyl oestradiol and levonorgestrel
B. An OCP containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of ethinyl oestradiol and levonorgestrel</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="self-assessment">Self-assessment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#self-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>C. An OCP containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of ethinyl oestradiol and levonorgestrel
D. An OCP containing ethinyl oestradiol and cyproterone acetate
E. An OCP containing low dose levonorgestrel only
4. A 28 year-old woman presents to a doctor in Melbourne, Australia requesting a termination of an unwanted pregnancy. Her first child was delivered only eight months ago, she has not been able to return to work yet because she is still breastfeeding, and her husband has just lost his job. She has not had a period since her delivery but ultrasound examination today has shown she is 12 weeks pregnant and the baby is alive and with no apparently abnormalities. Which one of the following would be the most appropriate advice to give her?
A. Termination of the pregnancy would be completely inappropriate
B. If termination was to be performed it would require written opinions from at least two specialist gynaecologists and a psychiatrist
C. A termination would be best achieved by the administration of a progesterone antagonist such as mifepristone, followed by the administration of a prostaglandin 48 hours later
D. The safest method of termination would be to use pre-operative vaginal prostaglandin and then perform a suction curettage
E. It would be safest just to induce labour in the next week or so, using vaginal prostaglandins
5. A 52-year-old woman presents because she is having problems of pain in her vaginal region when she has sexual intercourse with her husband. She has had four children who are now aged 30, 26, 22 and 18 years, an episiotomy was performed during each delivery, but she had no problems with sex, except when she was breastfeeding, until the last 12 months. She is not diabetic. Her periods have always been irregular, occurring every two to three months, but her last one was 18 months ago. She has had regular smear tests every year or so, and has been told she has a cervical eversion. Which one of the following is the most likely cause for her current symptoms?
A. Her repaired episiotomy wound
B. Endometriosis
C. Atrophic vaginitis
D. Monilial vaginal infection
E. The cervical eversion</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-20">CHAPTER 20<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-20" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Which of the following is commonly found with vulval cancer?
A. Vulval intraepithelial neoplasia (VIN)
B. Differentiated VIN
C. Paget's disease
D. Condyloma
E. Herpes simplex infection</li>
<li>A 30 year-old-woman with a stage IIB squamous cell carcinoma of the cervix. Which of the following treatments is best for her?
A. Cone biopsy
B. Radical trachelectomy and pelvic node dissection
C. Radical hysterectomy and pelvic node dissection
D. Radiotherapy
E. Chemoradiotherapy</li>
<li>Which of the following is a predisposing factor for endometrial cancer?
A. Oral contraceptive pills
B. Multiparity
C. Human paillomovirus infection
D. Obesity
E. BRCA carrier</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-21">CHAPTER 21<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-21" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>The uterosacral ligaments provide support to:
A. The urinary bladder
B. Rectum
C. Upper vagina and cervix (level 1)
D. Urethra
E. All of the above</li>
<li>A patient with a cystocele may present with symptoms of:
A. A 'lump'sensation
B. Sexual dysfunction
C. Incomplete bladder emptying
D. Recurrent UTIs
E. All of the above</li>
<li>A 22-year-old para 1 has symptoms of stress urinary incontinence. Which of the following would be the first step in management?
A. Pelvic floor physiotherapy
B. Advise a mid-urethral sling
C. Arrange bladder pressure studies
D. Oxbutynin
E. Anterior colporrhaphy</li>
<li>A 29-year-old G1P1 presents with uterovaginal prolapse. She is planning to have further pregnancies. Which of the following would be the most appropriate management?
A. Vaginal pessaries
B. Manchester repair
C. Fascial repairs of the vagina
D. Graft (mesh) repairs of the vagina</li>
</ol>
<p>E. Arrange pelvic floor physiotherapy and advise her to delay surgery until her family is completed
5. Which of the following is least likely to be a cause of acute retention of urine in women?
A. Vaginal tears during childbirth
B. Impacted retroverted gravid uterus
C. Inflammatory lesions of the vulva
D. Vaginal repair of prolapse
E. Radiotherapy for cervical cancer</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="appendix-a">APPENDIX A<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#appendix-a" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Which of the following is not a routine preoperative investigation?
A. Full blood count in an otherwise healthy patient
B. Pregnancy test in a reproductive age woman
C. Coagulation screen in an otherwise healthy patient
D. Electrocardiogram in patients of advanced age
E. Urea and electrolytes in a woman on loop diuretics</li>
<li>How long before surgery should Aspirin be discontinued?
A. 8 days
B. 2 days
C. 24 hours
D. 12 hours
E. 2 hours</li>
<li>Which of the following medications should be avoided before surgery?
A. Iron for anaemic patients
B. Lithium
C. Combined OCP for young women
D. GnRH agonists for abnormal uterine bleeding
E. Antibiotic prophylaxis before the start of the procedure</li>
<li>Which of the following complications could be caused by inappropriate lithotomy position?
A. Gas embolization
B. Skin necrosis
C. Femoral hernia
D. Ankle pain
E. Acute compartment syndrome</li>
<li>Which of the following factors do not increase the risk of urinary tract injuries?
A. Endometriosis
B. Bladder overdistension
C. Advanced age
D. Suprapubic trocar insertion
E. Urinary infection</li>
<li>Which of the following is not a common cause of postoperative hypotension?
A. Dehydration
B. Bleeding
C. Renal failure
D. Heart failure
E. Epidural analgesia</li>
<li>Which one of the following statements is correct?
A. Klebsiella is a common microorganism in surgical site injuries
B. Postoperative pelvic abscesses are frequently caused by aerobic flora
C. Diabetes is a risk factor for surgical site infections while smoking is protective
D. Hair removal by shaving is a protective factor
E. Surgical drains are a risk factor for surgical site infections</li>
<li>Concerning venous thromboembolism after surgery, which one of the following statements is correct?
A. For suspicion of pulmonary embolism, diagnostic imaging is required
B. Doppler ultrasound has a poor sensitivity for deep vein thrombosis
C. Anticoagulant therapy should not be started until confirmation of diagnosis
D. In a positive diagnosis of pulmonary embolism, oral anticoagulants are the initial treatment of choice
E. Anticoagulation should not be started because of the risk of postoperative bleeding</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="appendix-b">APPENDIX B<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#appendix-b" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Routinely collected data by Hospital Episodes Statistics (HES) includes which of the following?
A. Clinical trials data
B. Height and weight data for all patients
C. Cancer staging data
D. Blood pressure data
E. Used for health service planning</p>
</li>
<li>
<p>Regarding data protection, which of the following statements is correct?
A. Individual patient data is readily available for clinical research for doctors in the National Health Service
B. Junior doctors must seek permission from Caldicott Guardian of their Trust/hospital before using patient identifiable data for clinical audit
C. Individual patients' named data can be readily made available to junior doctors for clinical audit
D. Ethics Committee approval is required for audit
E. Data from UK can be transferred across other countries for comparative analysis</p>
</li>
<li>
<p>Regarding research and clinical audit, which of the following statements is correct?
A. Clinical audit and clinical research address similar questions in order to improve patient care
B. Clinical audit seeks to improve the quality of patient care against agreed standards
C. Clinical research critically appraises routine clinical practice to identify gaps in service provision
D. Clinical audit should only be done if there is a national guideline
E. Clinical research is usually funded by the pharmaceutical companies to test their drugs</p>
</li>
<li>
<p>Regarding clinical guidelines, which of the following statements is correct?
A. Clinical guidelines are evidence-based statements to assist clinicians to make appropriate clinical decisions in order to improve patient care
B. It is mandatory for all organisations to implement all clinical guidelines once they are published
C. Guidelines are usually developed by clinicians working in the hospitals
D. Different organizations developing clinical guidelines regularly consult each other and follow similar methodology
E. The clinical guidelines recommendations are based on cost-effectiveness data</p>
</li>
<li>
<p>In research, which one of the following statements is correct?
A. Descriptive studies provide information on disease prevalence in a population
B. Case control and cohort studies compare people with the disease and those without it
C. Randomized clinical trials involve allocation of different treatments (interventions) on good faith of the clinicians
D. Clinicians are usually aware of whether their patients are being treated with an active or a dummy preparation
E. Clinical trials of new drugs must exclude pregnant women and those who wish to become pregnant during the study</p>
</li>
<li>
<p>Regarding evidence-based healthcare, which of the following statements is correct?
A. Evidence-based healthcare should ensure that risk management strategies are in place to reduce risk to all patients
B. Clinical risk management strategies should only focus on cases of maternal and neonatal mortality
C. Clinical incident reporting involves setting up investigation panels against all those involved in the care of a specific patient
D. Patients should be encouraged to complain against staff as it helps to improve care
E. The investigations of near misses within an organization should be privately conducted to reduce risk to the organization</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="appendix-c">APPENDIX C<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#appendix-c" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>A 49-year-old woman is admitted to hospital for the performance of a total abdominal hysterectomy and bilateral salpingo-oophorectomy. She has been fully investigated as an outpatient of the hospital and diagnosed with severe anaemia due to dysfunctional uterine bleeding (DUB). A blood transfusion has been given. You are the Surgical Registrar who will be performing the surgery, but you have not seen this patient previously. You have available a written document concerning the risks of such surgery; this has been produced by the College of Obstetrics and Gynaecology of the country concerned. Which one of the following statements regarding the obtaining of informed consent is correct?
A. The consent form must have been discussed and witnessed by the consultant of the surgical unit
B. Because she has been evaluated in the Outpatient Clinic there is no need to discuss the care further
C. There is no need for you to discuss any potential complications where the risk of these is under <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>
D. You must discuss the possible alternatives to the proposed surgery, the complications which might occur during the surgery, the care required if such a complication occurred, and the postoperative complications and care
E. You must provide the written College Statement concerning the possible complications of the surgery proposed to the patient</p>
</li>
<li>
<p>A 46-year-old woman had a total abdominal hysterectomy for uterine fibroids 10 days ago. The operation itself was apparently uncomplicated; however, a deep vein thrombosis occurred during the postoperative period. She is currently on treatment with warfarin and this is planned to continue for at least 6 months. Which of the following rules regarding retention of the medical records of the woman should apply?
A. Retention for 5 years
B. Retention for 7 years
C. Retention for 10 years
D. Retention for 15 years
E. Retention for 25 years.</p>
</li>
<li>
<p>Which one of the following methods of evaluating the adequacy of a particular method of treatment of a specific condition is best?
A. Expert opinion from a specialist in the field
B. Occasional case reports
C. Multiple case reports
D. Retrospective case/control studies
E. Randomized controlled clinical trials</p>
</li>
<li>
<p>A 34 year-old woman has just been delivered of a 4500 g baby. The head was delivered by a midwife but when shoulder dystocia was defined, you were requested to complete the delivery and did so. Unfortunately the baby has an Erb's palsy. Which one of the following pieces of information must be included in the medical record you are completing immediately after the delivery, in case the Erb's palsy does not resolve and litigation occurs against you or the hospital?
A. The exact date and time the baby's head was delivered, and by whom
B. Detailed information of all of the techniques you and others used to effect delivery of the shoulders and the remainder of the baby, and signed by you
C. The exact time the remainder of the baby was delivered
D. The Apgar score of the baby at the time of birth
E. All of the above</p>
</li>
<li>
<p>A 15-year-old girl attends your surgery because she wishes a prescription for the oral contraceptive pill (OCP) so that she can commence a sexual relationship with a 'wonderful man'. She has not been sexually active previously. He has indicated to her that he is not prepared to use condoms. She indicates that she doesn't wish her parents to be informed, as they would not allow such sexual activity. Which one of the following would be the most appropriate advice to give her?
A. It is illegal to give her the contraceptive pill, because of her age
B. To give her the pill, she would need to give consent for her parents to be informed
C. To give her the pill she would need to give consent for the appropriate Health Department to be informed
D. To give her the pill more information about the male involved would need to be obtained
E. She should just get her partner to use condoms.</p>
</li>
</ol>
<p>Answers see pages 393-408</p>
<p>This page intentionally left blank</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="self-assessment-answers">Self-assessment: Answers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#self-assessment-answers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-1">CHAPTER 1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Bartholin's glands:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. Bartholin's glands are located at either side of the vaginal introitus at approximately the junction of the anterior two-thirds and posterior one-third of the vulva. They produce mucus that is drained by the Bartholin's ducts, which are approximately 2 cm in length and open between the labia minora and the vaginal orifice. Cyst formation is relatively common, but is the result of occlusion of the duct with accumulation of mucus in the duct and not in the gland.</li>
<li>The vagina:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> is correct. The vagina is a tube of smooth muscle lined by non-cornified squamous epithelium. Anteriorly, it is intimately related to the trigone of the urinary bladder and the urethra. Posteriorly, the lower third is separated from the anal canal by the perineal body, the middle third is related to the rectum and the upper third to the rectouterine pouch (pouch of Douglas). The pH of the vagina in the sexually mature non-pregnant female is between 4.0 and 5.0 , which has an important antibacterial function in reducing the risk of pelvic infection.</li>
<li>Uterus and its supporting structures:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> is correct. The anterior ligament is a fascial condensation which with the adjacent peritoneal uterovesical fold extends from the anterior aspect of the cervix across the superior surface of the bladder to the peritoneal peritoneum of the anterior abdominal wall. It has a weak supporting role. Likewise, the broad ligament plays only a minor supportive role. Posteriorly, the uterosacral ligaments play a major role in supporting the uterus and the vaginal vault, and these ligaments and their peritoneal covering form the lateral boundaries of the rectouterine pouch (of Douglas).
In pregnancy, the isthmus of the uterus enlarges to form the lower segment of the uterus, which in labour becomes a part of the birth canal but does not contribute greatly to
the expulsion of the fetus. (The incidence of uterine retroversion is about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span>.</li>
<li>The ovary:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. The ovary lies on the posterior surface of the broad ligament in close proximity to the external iliac vessels and the ureter on the lateral pelvic wall. It is attached to the pelvic brim by the suspensory ligament of the ovary. The surface of the ovary is covered by a cuboidal or low columnar type of germinal epithelium. The blood supply is derived from the ovarian artery which arises directly from the aorta. The follicles are found in both the cortex and medulla of the organ.</li>
<li>Uterus:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is correct. The blood supply to the uterus comes largely from the uterine artery but branches of this anastomose with branches of the ovarian vessels in the upper part of the broad ligament, assuring adequate collateral supply to the uterus even following internal iliac ligation. Lymphatic drainage follows the blood vessels. Uterine pain is mediated through sympathetic afferent nerves passing up to T11/T12 and L1/L2. The pudendal nerve (somatic nerve) supplies the vulva and pelvic floor.)</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-2">CHAPTER 2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Premature menopause:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> is correct. Radiotherapy given in the chest region is unlikely to adversely affect ovarian function (A is therefore incorrect); tamoxifen does not result in ovarian failure, although its use is associated with the development of hot flushes (therefore B is incorrect); cytotoxic chemotherapy given to a child is unlikely to result in ovarian failure and she certainly did not develop this following the treatment of her Wilm's tumour as she has two children (therefore D is incorrect); and surgery to one ovary is also unlikely to cause a premature menopause ( E is therefore incorrect). The cytotoxic chemotherapy given at the age of 36 years is the most likely cause.</p>
</li>
<li>
<p>Normal follicular growth:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is correct. In a normal ovulatory menstrual cycle, one follicle is selected to become the dominant follicle on day <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">5-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> of the cycle ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is therefore correct); however, up to ten show obvious but lesser growth than the dominant follicle (A is therefore incorrect). The dominant follicle grows by 2 mm per day thereafter ( C is therefore incorrect), ruptures at about 2 cm in diameter ( D is incorrect) and this ruptured follicle becomes the corpus luteum after release of the oocyte ( E is therefore incorrect).</p>
</li>
<li>
<p>Meiosis:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> is correct. The seven million germ cells produced during fetal life are produced by mitosis, not meiosis (A is therefore incorrect). The first meiotic division commences in utero in the fetus but ceases in prophase. It does not recommence its division until the luteinizing hormone surge occurs in the particular menstrual cycle and this first meiotic division is completed just prior to fertilization of the oocyte by the sperm ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is therefore incorrect). The attachment of the sperm results in the commencement of the second meiotic division ( C is therefore correct). The crossover process between adjacent copies of the same chromosome occurs during prophase of meiosis I, not after meiosis I has been completed ( D is therefore incorrect). The long delay between the cessation of prophase I in fetal life and the time when it recommences in the cycle concerned (which can be 40-45 years later) is the reason for the increased incidence of chromosomal abnormalities associated with advanced maternal age ( E is therefore incorrect).</p>
</li>
<li>
<p>Regarding the process of fertilization in the human female:
A is correct. The female gametes only contains an X chromosome therefore cannot determine the sex of the resulting fetus. This is determined by the male gamete which will contain either an X or Y chromosome ( B is therefore incorrect). Twin pregnancies occur due to division of the embryo (identical or monochorionic twin pregnancy), or if two separate oocytes are fertilized by two separate sperm (a dichorionic twin pregnancy; therefore C is incorrect). The exact time during which the oocyte can be fertilized after ovulation is uncertain, but it is believed fertilization does not occur if this time interval is in excess of 36 hours ( D is therefore incorrect). Sperm capacitation to facilitate fertilization generally occurs within the genital tract of the woman ( E is therefore incorrect).</p>
</li>
<li>
<p>Implantation:
C is correct. Implantation generally occurs five to six days after ovulation and fertilization ( A is incorrect) at which time the embryo is at the blastocyst stage ( B is therefore incorrect). hCG is produced soon after the implantation process commences ( C is therefore correct) and then the plasma levels double every 48 hours if the pregnancy is progressing normally. The endometrium must be secretory in type to allow implantation ( D is therefore incorrect)
and is then converted to the appearance of decidua. Implantation will not occur if the endometrium is proliferative in type so a pregnancy will not result. Implantation and hCG production can occur even where the embryo is very abnormal, under which circumstances the period occurs at the expected time and the woman concerned never knows she was actually pregnant in that cycle (E is therefore incorrect). A urinary pregnancy test performed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> days after the period commenced will be negative.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-3">CHAPTER 3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Human placenta:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> is correct. The blastocyst embeds into the decidua and part of it becomes the placenta which invades into the decidua and into the myometrium and 'erodes' into the spiral arterioles to convert them into large lakes to allow maximal perfusion of the placenta. Oxytocin causes uterine contractions and may cause placental separation and hence it does not produce oxytocin but instead it produces oestrogens and progesterones. The placenta is an active organ that produces a number of hormones and needs glucose and amino acids to grow. The placenta helps to transfer the excretory products from the fetal compartment to the mother. It is not richly innervated as there is no specific purpose with such innervation.</p>
</li>
<li>
<p>Regarding the rise in cardiac output:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. The rise in cardiac output is seen from early pregnancy. The increase in cardiac output is brought about by increase in the stroke volume and the heart rate. It is associated with a fall in the after load. The heart is already strained due to the need to pump an extra <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of blood volume and in those with heart disease it can tip the balance and cause heart failure especially if they are anemic or if they contract an infection. The pulmonary vasculature in a mother is able to accommodate the increased blood flow without causing pulmonary hypertension.</p>
</li>
<li>
<p>Considering respiratory function in pregnancy:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. Progesterone sensitizes the medulla oblongata and not the adrenal medulla to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. This causes some over-breathing which reduces the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> level that allows the fetus to offload its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> to the maternal side. Not the maternal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> but the oxygen carrying capacity of blood increases by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>18</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">18 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">18%</span></span></span></span></span>. There is an increase in maternal 2,3-DPG that shifts the maternal oxygen dissociation curve to the right, thus facilitating the down-loading of oxygen to the fetus. There is a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> increase in minute ventilation due to increase in tidal volume from 500 to 700 ml .</p>
</li>
<li>
<p>Considering renal function in pregnancy:</p>
</li>
</ol>
<p>C is correct. There is increase in renal size of up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> due to increase in size of the parenchyma in addition to the enlargement of the pelvicalyceal system and the ureter, but the increase is seen from early pregnancy. The ureters increase in size due to the influence of progesterone and increased urinary output but they are not floppy and have good tone. Because of an increase in blood volume there is a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> increase in GFR that activates the renin angiotensin system. About 900 and not 1800 mmol of sodium are retained during pregnancy. Because of ureteric dilatation and reflux of urine due to lack of sphincteric action at the point entry of ureter into the bladder and higher incidence of urinary stasis there is higher incidence of urinary tract infection in pregnancy.
5. In relation to endocrine function in pregnancy:</p>
<p>A is correct. Insulin resistance develops with progress of pregnancy due to the change in the hormonal milieu. There is a significant increase in human placental lactogen after 28 weeks as a result of which some women develop gestational diabetes. Due to increased glomerular filtration rate, more glucose is presented to the kidneys and in some mothers the quantity of glucose exposed for absorption exceeds the tubular maximal absorption capacity and hence presents as 'renal' glycosuria without a high blood glucose level. Because of increased metabolism, the thyroid increases in size. The gut absorbs more calcium but more is also lost in the urine and in areas of dietary deficiency, calcium supplementation becomes necessary. Skin pigmentation is caused by an increase in melanocyte secreting hormone.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-4">CHAPTER 4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>In early placental development:</li>
</ol>
<p>D is correct. The villi have inner cyto and outer syncytiotrophoblast that invades the endometrium and myometrial layers. Decidual cells provide the initial nutrition for the invading trophoblasts. The spiral arterioles are invaded by the trophoblasts making large lacunae that are full of maternal blood and the tertiary villi bathe in these lacunae to accomplish the respiratory, nutrition and excretory functions. Chorion frondosum forms the placenta. Chorion laevae is the layer surrounding the membranes and it fuses with the uterine cavity.
2. Regarding the umbilical cord:</p>
<p>C is correct. The umbilical cord has two arteries and one vein. The fetus pumps the blood through these arteries to the placenta to get more oxygen and excrete the carbon dioxide and hence arterial blood has less oxygen compared with the vein. One in 200 babies has only one artery and one vein and they grow normally and live birth is achieved. Cord arterial pressure is 70 mmHg and the venous pressure is 25 mmHg . The relative venous pressure
is higher to maintain good venous circulation that is vital to bring oxygen and nutrition to the fetus.
3. Placental transfer:</p>
<p>A is correct. Simple diffusion is according to the concentration gradients and this facilitates transfer of oxygen and carbon dioxide in the right direction for the fetus. Glucose is transferred according to the gradient but it needs energy i.e. facilitated diffusion. Active transport needs energy for transport and to drive the substances against the gradient and hence there could be cases where the concentration may be already higher in the fetal blood. Higher molecular weight substrates are transferred by pinocytosis. Fetal cells escape into the maternal circulation due to the higher pressure on the fetal side and due to breaches in the fetomaternal barrier.
4. Placental function:</p>
<p>E is correct. The placenta has multiple functions. It helps with gas exchange and is an important organ for transferring nutrition to the fetus and excretion of waste products from the fetus. It produces a number of hormones; initially human chorionic gonadotrophin and later oestrogens and progesterones, which are all essential for maintenance of pregnancy. But it is a poor barrier against infections thus the fetus is affected by malaria, syphilis, HIV, CMV and toxoplasmosis.
5. Amniotic fluid:</p>
<p>A is correct. Polyhydramnios may suggest fetal anomaly such as neural tube defects, anencephaly, gut atresia and several other known pathologies. Aminocentesis carries a risk of miscarriage, pre-labour rupture of membranes, infection and preterm labour although these are less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>. Postural deformities are one of the complications of long-standing severe oligohydramnios. A major problem with this situation is pulmonary hypoplasia. Adequate fluid is needed to push the alveoli and bronchioles to expand; if not it results in lung hypoplasia. Most cases of intrauterine growth restriction would be associated with reduced amniotic fluid due to less urine production caused by less renal perfusion. Amnio-infusion may abolish the variable decelerations but trials have shown no improvement in clinical outcome and hence it is not a standard procedure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-5">CHAPTER 5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Perinatal mortality:</li>
</ol>
<p>C is correct. Perinatal mortality rate describes the number of stillbirths and early neonatal deaths per 1000 total births (live births and stillbirths). This gives a picture of maternal health and the standard of care provided to mothers and their newborn babies. By improving socioeconomic conditions, the quality of obstetric and neonatal care and an active screening programme for common</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="self-assessment">Self-assessment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#self-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>congenital abnormalities, perinatal mortality rates can be significantly improved. The World Health Organization has two targets for assessing progress in improving maternal health (MDG 5). These are reducing maternal mortality ratio by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> between 1990 and 2015, and achieving universal access to reproductive health by 2015.
2. Regarding stillbirths:</p>
<p>E is correct. Until 2011, the Centre for Maternal and Child Enquiries has published annual perinatal reports for the UK. The report showed a significant reduction in both stillbirth rates and early neonatal deaths. Stillbirth rates indicate the quality of antenatal care and screening programmes and are the largest contributors to perinatal mortality. Most stillbirths occur antenatally. The traditionally used systems such as the Wigglesworth and the Aberdeen (Obstetric) classifications consistently reported up to twothirds of stillbirths as being from unexplained causes. The sub-Saharan regions of central Africa have the highest stillbirth rates.
3. Regarding neonatal deaths:</p>
<p>B is correct. Birth weight is no doubt an indication of maternal health and nutrition. Neonatal tetanus remains a common cause of neonatal death in settings where lack of hygiene and inadequate cord care are prevalent, as many women are not immunized against tetanus. The majority of deaths from neonatal tetanus occur between the tenth day of life. Prematurity remains a significant contributor to perinatal mortality rates in developing countries and improving maternal health and obstetric care are more important steps to improving the outcome than to provide for more neonatal intensive care units.
4. Regarding the description of maternal deaths:</p>
<p>A is correct. Direct maternal deaths are defined as those resulting from conditions or complications or their management that are unique to pregnancy, occurring during the antenatal, intrapartum or postpartum periods. Coincidental (fortuitous) deaths occur from unrelated causes which happen to occur in pregnancy or the puerperium. Definitions of maternal death can vary across the regions and between countries. As the UK has the advantage of accurate denominator data, including both live births and stillbirths, it has defined its maternal mortality rate as the number of direct and indirect deaths per 100,000 maternities as a more accurate denominator to indicate the number of women at risk. Maternities are defined as the number of pregnancies that result in a live birth at any gestation or stillbirths occurring at or after 24 completed weeks of gestation and are required to be notified by law. Improving the socioeconomic status of women coupled with improved maternal health and antenatal care are key to the improvement of maternal mortality rates.
5. Maternal mortality:</p>
<p>D is correct. In the 2006-2008 UK Confidential Enquiry into Maternal Deaths Report, the leading cause of
direct deaths was sepsis, particularly from Group A Streptococcus. This infection can occur at any time during the antenatal or postpartum period and the onset can be insidious and non-specific. Cardiac diseases remained the leading cause of indirect deaths. The reduction in the number of deaths from venous thromboembolism is due mainly to improved screening and thromboprophylaxis guidelines adopted by all maternity units in the UK. However, it remains an important and avoidable cause of death.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-6">CHAPTER 6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Basic clinical skills in obstetrics:</li>
</ol>
<p>E is correct. Correct, compassionate verbal and non-verbal communication is an essential skill in clinical medicine. This includes introduction of the care provider, proper identification of the woman, expression of the purpose of the clinical examination and detailed history taking. This is followed by good general, systemic and obstetric examination. Any deviation from the norm should be noted and discussed with the woman including a diagnosis or differential diagnosis. Performing a fetal anomaly scan is an advanced skill and is practiced only by who had sufficient training.
2. In eliciting an obstetric history:</p>
<p>E is correct. Past obstetric history is pivotal to managing the index pregnancy, e.g., past history of diabetes, hypertensive or psychiatric illness would help us to plan management better. Many women do not remember the LMP accurately and when facilities permit the gestation is assessed by ultrasound in the first trimester and EDD is calculated based on the early scan. Post-ovulatory period is fairly constant and is about 14 days whether the cycle is long or short. Ultrasound for dating can be three weeks + or - if it is based on third trimester scans, while its + or - 1 week if it is based on a first trimester scan. Hormonal contraception may delay the first ovulatory cycle after discontinuation of the method.
3. Regarding symptoms of pregnancy:</p>
<p>E is correct. Nausea and vomiting can start within two weeks of missed period and it is believed to be secondary to the rise of human chorionic gonadotrophin (hCG). The frequency of micturition is due to the increased urine production due to increased glomerular filtration rate following <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> expansion of the blood volume in addition to the pressure on the bladder by the gravid uterus. This pressure is relieved after 12 weeks when the uterus becomes an intra-abdominal organ hence the frequency lessens. Morning sickness fades away when the pregnancy progresses to the second trimester and only in a minority of cases it may continue throughout pregnancy. Plasma</p>
<p>osmolality reduces with advancing gestation due to increased intravascular volume and reduced plasma proteins. There is increased diuresis after water loading when the woman is sitting in an upright position, perhaps due to increased perfusion.
4. During pregnancy:</p>
<p>C is correct. Blood pressure (BP) is recorded when the patient is sitting up or lying at a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>45</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">45^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">4</span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span> incline and not whilst she is lying on her back because the venous return may be reduced, affecting the cardiac output and the reading. BP should be recorded in the same position during each visit using an appropriate size cuff - obese women would need a larger cuff. If inferior venacaval compression is prolonged it is likely to affect the cardiac output of the mother and hence the uterine circulation, which could compromise the baby. Current recommendation is to consider the Korotokoff fifth sound and if the point at which the sound disappears cannot be identified, then use the Koratokoff fourth sound. The flow murmurs are of no significance and should be differentiated from any murmur due to a cardiac pathology.
5. In pelvic examination during pregnancy:</p>
<p>B is correct. With the availability of first trimester scanning, it is not essential to perform a routine pelvic examination. When there is painless bleeding in late pregnancy, placenta praevia should be excluded. Digital vaginal examination in cases of placenta praevia may cause torrential haemorrhage and require an emergency caesarean section, hence it is contraindicated. Radiological examination of the pelvis is of little value in predicting labour outcome as labour is a dynamic process with changes in dimensions occuring with flexion of the baby's head and moulding and pelvic give. The gynaecoid pelvis is 'roomy' at all levels of the pelvis to allow cephalic descent. The diagonal conjugate is only 1.5 cm longer than the obstetric diameter.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-7">CHAPTER 7<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Regarding antenatal screening for infection:</li>
</ol>
<p>B is correct. Screening for Hepatitis B is routinely carried out. Hepatitis B is easily transmitted to the fetus and newborn whist it traverses the birth canal. If the mother has hepatitis B antibodies, further testing is required to confirm if they are positive for surface (s) antigens or core (e) antigens. Those who are positive for core antigens are considered to have active viruses and may have a high transmission rate of up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">85 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">85%</span></span></span></span></span> to the fetus. In most countries newborns are given gamma globulins and the active vaccine if e positive and only the vaccine if they are s positive. If the infection is transmitted there is a high possibility of liver cirrhosis followed by hepatocellular cancer,
hence the need to actively immunize the newborn. No routine screening is done for cytomegalovirus (CMV) as reinfection is not uncommon and no preventive action can be taken based on the test. General advice should be given to avoid child nurseries where children have coughs, colds and influenza and may harbour CMV infection that is easily transmitted. Syphilis is uncommon but if detected it is eminently treatable to avoid infection of the fetus and its sequelae. Checking the husband/partner and contact tracing is important. Rubella infection causes major congenital malformations in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25-50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>, if the mother is infected in the first trimester of pregnancy. If the mother is not immune she should be immunised postpartum. HIV/ AIDS screening is not universal but it is advisable to make it as a routine screening. If found positive, antiretroviral therapy, elective caesarean delivery and avoidance of breast feeding has reduced the incidence of vertical transmission from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>45</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">45 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">45%</span></span></span></span></span> to less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span>.
2. Group B streptococcus:</p>
<p>C is correct. Group B streptococcus is a Gram-positive bacterium and is a commensal organism found in the nose, oropharynx, nasopharynx, anal canal and vagina. Group B streptococcal colonization of the genito-urinary tract is associated with higher incidence of preterm labour and pre-labour rupture of membranes. Screening is not routine in all the countries. In the UK screening is not performed but should there be a high risk history, then suitable precautions are taken, especially intrapartum penicillin therapy if the mother had streptococcal colonization in the vaginal or rectal swab or growth in urine culture.
3. Gestational diabetes:</p>
<p>E is correct. Gestational diabetes predisposes to macrosomic babies and those who had higher birth weight babies in the previous pregnancy are more prone to gestational diabetes. The cut off value of when to consider the baby to be macrosomic, i.e., <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">&gt;4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> or 4.5 kg varies with population studied. Maternal BMI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>35</mn></mrow><annotation encoding="application/x-tex">&gt;35</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">35</span></span></span></span></span> has a known association with gestational diabetes mellitus in pregnancy. Gestational diabetes in previous pregnancy identifies those who are likely to develop early onset type II diabetes in their life and they also indicate a higher chance of getting gestational diabetes in subsequent pregnancies. Older mothers <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>35</mn></mrow><annotation encoding="application/x-tex">&gt;35</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">35</span></span></span></span></span> years of age are more prone to gestational diabetes and not younger mothers.
4. Extra folic acid supplementation:</p>
<p>E is correct. Folic acid is well known to reduce the overall incidence of congenital malformations. Folic acid facilitates cell division and is an important vitamin in any growth or reparative process. Extra folic acid supplementation ( 5 mg per day) reduces neural tube defects and hence it is important to take prior to and in early pregnancy in mothers who had a previous child with neural tube defects. Mothers who have epilepsy, especially those who are on anti-epileptic medication, have a higher chance of</p>
<p>having children with neural tube defects and they should be advised on higher dose folic acid supplementation. This also applies to mothers with diabetes and those with a high BMI, e.g., <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>35</mn></mrow><annotation encoding="application/x-tex">&gt;35</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">35</span></span></span></span></span>. Downs syndrome is a chromosomal problem, commonly trisomy 21, and the incidence cannot be reduced by taking extra folic acid.
5. Regarding pregnancy:</p>
<p>C is correct. Moderate exercise for recreation, including swimming, is harmless and is encouraged. Strenuous exercise and competitive sports with active movements are contraindicated. Coitus does not do any harm although there may be release of prostaglandins with the semen. If the mother has threatened miscarriage, abdominal pain, bleeding, short cervix or threatened preterm labour it may be unwise to participate in coitus. There is controversy about minimal alcohol consumption and its effects on the fetus. Moderate alcohol consumption may be harmful to the fetus and severe alcohol consumption is associated with fetal alcohol syndrome associated with microcephaly and mental retardation. Smoking is harmful to the pregnancy and is well known to be associated with intrauterine growth restriction. Paracetamol is safe in pregnancy. Non-steroidal anti-inflammatory drugs taken in significant amounts in the third trimester may cause oligohydramnios and premature closure of the ductus arteriosus.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-8">CHAPTER 8<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Antepartum haemorrhage at 36 weeks:</li>
</ol>
<p>C is correct. Although placental abruption (separation of normally situated placenta) and placenta praevia (low lying placenta) are major causes of maternal and perinatal morbidity and mortality the incidence of each of these conditions is less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>. The commonest reason is idiopathic. Clinical examination both general, abdominal and a speculum examination (to exclude cervical or vaginal lesion and to visualize whether blood is emerging via the cervical os) and an ultrasound examination (to check the placental position and to visualize the fetal lie and presentation and liquor volume) are vital to identify the other causes and to come to the diagnosis by exclusion of 'idiopathic'.
2. Hypertension in pregnancy:</p>
<p>D is correct. In modern practice the fifth Korotkoff sound is used to determine diastolic blood pressure. More emphasis is now paid on systolic reading especially that <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>160</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;160 \mathrm{mmHg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">160</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mmHg</span></span></span></span></span></span> as there is a greater tendency for cerebral hemorrhage and there is strong recommendation to immediately treat and bring the systolic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">B</mi><mi mathvariant="normal">P</mi></mrow><mo>&lt;</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{BP}&lt;150 \mathrm{mmHg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7224em; vertical-align: -0.0391em;"></span><span class="mord"><span class="mord mathrm">BP</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mmHg</span></span></span></span></span></span> and preferably <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>140</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;140 \mathrm{mmHg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">140</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mmHg</span></span></span></span></span></span>. Hypertension after 20 weeks is gestational in the absence of proteinuria and
the diagnosis would be pre-eclampsia in the presence of significant proteinuria. There are several factors that may be contributory to a rise in blood pressure although it is known that there is a fall in peripheral resistance due to vasodilatory hormones including oestrogen and progesterone. In pre-eclampsia the vasoconstrictor thromboxane and vasodilatory prostacyclin mainly liberated by the platelets and endothelial cells of blood vessels play a major role. HELLP syndrome stands for haemolysis, elevated liver enzymes and low platelets and it signifies a serious form of the pre-eclamptic process which has affected several systems. It has a poor prognosis and careful management and early delivery is advised.
3. Twin pregnancy:</p>
<p>B is correct. The prevalence of identical twins appear to be uniformly similar in many countries. Twin peak sign or lambda sign at the attachment of the membranes to the uterus signifies additional chorionic layers in-between the amniotic membranes and the diagnosis of dizygotic twins. All complications of pregnancy are increased in twins and miscarriage is not an exception. Preterm delivery in twins is twice that of singleton pregnancy and the average gestational age of delivery of the fetuses are much less than singletons. Twin-to-twin transfusion can appear as early as 18 weeks and many centres would scan at this stage and decide on the date of the next scan. Earlier diagnosis and treatment by laser transection of anastomotic vessels is associated with better outcome.
4. The causes of an unstable lie:</p>
<p>D is correct. Placenta praevia occupies the lower segment and prevents the head or breech from settling down in the pelvis. Polyhydramnios allows the fetus to 'float' around instead of binding the fetus to a longitudinal lie by the uterine muscular tone and normal amount of amniotic fluid volume. Subseptate uterus limits the space of the uterine cavity and some fetuses may present with transverse or oblique lie. Primiparity is generally associated with good uterine and abdominal muscle tone and should favour a stable longitudinal lie. In twin pregnancy the first twin usually presents in the longitudinal lie but the second twin can be in an abnormal lie and the incidence is made greater if it is associated with polyhydramnios.
5. Prolonged pregnancy:</p>
<p>C is correct. Post-maturity syndrome has no direct link to prolonged pregnancy. Post-maturity syndrome describes a newborn which is growth retarded, has an anxious look, is stained with meconium, and has overgrown nails and peeling skin on the palm and sole. Mother's recollection of menstrual period is shown to be incorrect in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of cases. There is a possibility of fetal anomaly like anencephaly and this should be excluded. Prolonged pregnancy is associated with perinatal morbidity and mortality. The guidelines from most recognized professional bodies suggest induction by 41 weeks and three days to avoid morbidity and</p>
<p>mortality based on the evidence from randomized controlled studies.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-9">CHAPTER 9<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-9" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Anaemia in pregnancy:</li>
</ol>
<p>E is correct. Pregnancy causes an increase in both plasma volume and red cell mass. This requires an increase in iron and folate which is not always met by maternal diet. In addition there are fetal requirements for both these nutrients. The increased requirement for iron is greater than that for folate. Whilst sickle cell disease and thalassaemia can cause anaemia in pregnancy, this is much less common than iron deficiency.
2. Risk of gestational diabetes:</p>
<p>C is correct answer. Risk factors for gestational diabetes are the same as those for type 2 diabetes. Older mothers are more at risk of developing gestational diabetes; gestational diabetes in a woman less than 18 years old is unusual.
3. Acute venous thromboembolism in pregnancy:</p>
<p>D is correct. Venous thromboembolism is a leading cause of maternal mortality in the developed world. It is ten times more likely to occur in pregnancy compared to when a woman is not pregnant. Deep vein thrombosis occurs more frequently in the left leg due to compression of the left common iliac vein. D-Dimer measurements are of limited use in pregnancy as false positive results are common. Heparin is the first line treatment, warfarin use in pregnancy is associated with an embryopathy and with fetal bleeding problems.
4. Obesity in pregnancy:</p>
<p>A is correct. Obesity in pregnancy is associated with poorer obstetric outcomes than women with a normal body mass index. These include a higher risk of miscarriage and preeclampsia. The chance of requiring a caesarean section is greater. Ultrasound scanning is more difficult in obese women and thus the efficacy of screening for anomalies using ultrasound is reduced.
5. Epilepsy and pregnancy:</p>
<p>B is correct. The effect of pregnancy on epilepsy is variable. Usually the seizure frequency is unchanged, but a minority of women will have increased seizures. Different antiepileptics confer different risks to the fetus; however, sodium valproate has the greatest risks and should be avoided in women of reproductive age. There is an increased risk if neural tube defects and so a higher 5 mg dose of folic acid is recommended. Children of women with epilepsy have a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4-5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> chance of developing the condition themselves; this increases to up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> if their father is also affected. Breast-feeding is safe for women on most anti-epileptic medications.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-10">CHAPTER 10<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-10" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Abnormalities detected by ultrasound at 20 weeks. A is correct. Only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of cardiac anomalies are detected. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of the CNS malformations are picked up. More than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> skeletal malformations are identified. Depending on the specific gastrointestinal anomaly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> is diagnosed. In most series about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">85 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">85%</span></span></span></span></span> of urogenital anomalies are detected.</li>
<li>First trimester screening test for Down's syndrome: C is the only answer which is not true. The test gives a possibility and hence it is not true that the baby has Down's syndrome. There is over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>99</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">99 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">99%</span></span></span></span></span> chance (149/150) that the baby does NOT have the diagnosis. The back ground incidence is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>1500</mn></mrow><annotation encoding="application/x-tex">1: 1500</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1500</span></span></span></span></span> but the test has placed the chance to be <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>150</mn></mrow><annotation encoding="application/x-tex">1: 150</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">150</span></span></span></span></span>. At this stage of pregnancy chorionic villus sampling is an option for this woman but this procedure has a one in hundred chance of leading to a procedure related miscarriage.</li>
<li>Assessment of fetal growth in pregnancy:</li>
</ol>
<p>C is the only answer which is not correct. Progressive abdominal circumference measurement provides the best measure of fetal growth. If the abdominal and head circumference are on the same centile in a fetus that is small or large, it is more likely that the extreme of size is constitutional/ genetic; if they are divergent (e.g., with head larger than abdomen in a small fetus, or head smaller than abdomen in a large fetus) then it is more likely that there is pathological fetal growth. Serial symphysial fundal height measurements detect as few as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of small- or large-for-dates fetuses. Fetal abnormality is associated with growth pathology and that can have been missed at the 20 week detailed scan and it is important to exclude fetal anomaly on cases of IUGR. In cases where the fetus is growth restricted the UA Doppler recording will indicate its severity and inform management decisions.
4. Tests in high risk pregnancies which improve fetal outcome:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is correct. The only antenatal fetal function test that has shown to improve fetal outcome is the umbilical artery Doppler measurements.
5. Surrogate measures of fetal anaemia:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> is correct. When a fetus is significantly anaemic there is a redirection of blood to the brain to maintain oxygen and nutrient supply and an increase in the blood flow in the middle cerebral artery.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-11">CHAPTER 11<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-11" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Diagnosis of labour:</li>
</ol>
<p>D is correct. 'Show', which is the discharge of the blood stained mucus plug or rupture of membranes, may be associated with the onset of labour but can take place</p>
<p>independently without progressing to labour. Some mothers have 'show' or rupture of membranes and will take days before going into labour. The painful contractions should be associated with cervical effacement and dilatation or both on two consecutive vaginal examinations to diagnose labour. Painful contractions may persist for several hours without cervical changes and the pain may subside only to restart in a few days' time. Backache and abdominal pain are not sufficient indicators to diagnose labour.
2. Slow labour progress in first stages of labour:</p>
<p>C is correct. Fetal weight of 4 kg or even more may have no association to abnormal labour progress. Incoordinate uterine contractions are just the description of how the contraction patterns appear, i.e., two or three together and then one and again two or three together at varying intervals. Incoordinate contractions do not mean inefficient contractions as progressive cervical dilatation can take place with incoordinate contractions. Malposition of the head presents a larger diameter to the pelvis and can cause relative disproportion and lead to slow progress of labour.</p>
<p>A gynaecoid pelvis is roomy and so should not cause slow progress. The labour is slower in primigravid compared with multigravida but is not abnormally slow in most cases.
3. Prolonged second stage of labour:</p>
<p>E is correct. Malposition and asynclitism of the fetal head present larger diameters to the pelvis and may cause delay in the second stage of labour. Epidural analgesia abolishes the 'Ferguson reflex' and reflex release of oxytocin due to distension of cervix and upper vagina and associated increased uterine activity and hence may cause prolonged second stage. Maternal exhaustion can be a cause and this should be avoided by preventing early encouragement for the mother to bear down - one should ideally wait till the head descends to the perineal phase. Fetal distress does not cause delay in the second stage and on the contrary the delayed second stage may cause fetal distress.
4. Complications of epidural analgesia</p>
<p>C is correct. Complications include blood stained tap, accidental dural tap and if the medication is injected without realizing this may lead to total spinal blockade. Extremely rarely nerve injury may take place. It causes hypotension due to vaso dilatation and not hypertension.
5. Electronic fetal monitoring:</p>
<p>A is correct. Accelerations of the fetal heart rate indicate good fetal health and the fetus is unlikely to be acidotic. Absence of accelerations may be due to infection, fetal sleep phase, administration of sedatives and analgesics and rarely intracranial pathology or previous injury. Presence of variable decelerations suggestive of cord compression and late decelerations suggestive of placental
insufficiency are of concern and need to be observed for additional features of concern such as rising baseline rate and reduction in baseline variability. Absent fetal heart rate variability may suggest that the fetus is already hypoxic or has suffered injury.
6. Management of preterm labour:</p>
<p>B is correct. Hylaine membrane disease and respiratory distress syndrome are the major concerns with prematurity in addition to concern about other organ maturation. The severity of hyaline membrane disease is reduced by the administration of corticosteroids (dexa- or betamethasone 12 mg 12 or 24 hours apart). In order to have the time to bring about this maturity the labour has to be delayed for at least 48 hours in the absence of contraindications such as infections and this is achieved by the use of tocoytics. Antibiotics are shown to be of value in cases of preterm labour associated with pre-labour rupture of membranes. Magnesium sulphate has been found to be neuroprotective or preterm babies and increasing number of units are administering a bolus dose of 4 g of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">g</mi><mi mathvariant="normal">S</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{MgSO}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9275em; vertical-align: -0.2441em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">MgSO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.207em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span></span></span></span></span> or a bolus followed by 1 g per hour for 24 hours; both appear to be effective in neuroprotection.
7. Accepted indication for induction of labour:</p>
<p>C is correct. There is increased morbidity and mortality in high risk pregnancies associated with diabetes, prolonged pregnancy, pre-eclampsia and intrauterine growth restriction. There is no evidence to suggest that there is maternal, fetal or neonatal advantage by induction for macrosomia.
8. Complications of induction of labour:</p>
<p>E is correct. Prematurity is a known complication of induction if the gestation is not checked correctly. In modern practice this is less of a problem with the ultrasound estimation of gestational age in the first trimester. Cord prolapse is a possibility and is less due to wider use of prostaglandins instead of depending on artificial rupture of membranes. However, one needs to exclude cord presentation prior to rupture and should be cautious when rupture is carried out with a high head. The use of oxytocin or prostaglandin may hyperstimulate the uterus and cause iatrogenic fetal distress. Uterine rupture is rare with induction but is a possibility in women with previous CS and in grand multiparous women. Induced labour is usually longer than spontaneous labour and may be associated with more contractions and naturally is likely to be more painful.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-12">CHAPTER 12<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-12" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Normal delivery:</li>
</ol>
<p>B is correct. Provided there are no adverse clinical factors present, a normal duration of the second stage of labour</p>
<p>is commonly regarded as lasting up to three hours in a nulliparous woman who has received epidural analgesia. Engagement is considered to have occurred when the fetal head has descended to or beyond the level of the ischial spines. During the descent phase of the second stage of labour, the mother does not normally experience the sensation of bearing down until the head has reached the pelvic floor and perineal phase. Maternal expulsive effort should combine short pushing spells with periods of panting to allow vaginal and perineal tissues to relax and stretch over the advancing head. As part of the mechanism of normal labour, the fetal head is delivered by extension when 'crowning' of the head occurs.
2. Perineal injury and episiotomy:</p>
<p>D is correct. Where episiotomy is performed, the recommended technique is a mediolateral incision to reduce the risk of extension involving the external sphincter and anus. Third-degree injury to the perineum is classified into three sub-categories according to whether the damage to the external sphincter is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>50</mn><mi mathvariant="normal">%</mi><mo stretchy="false">(</mo><mn>3</mn><mi mathvariant="normal">a</mi><mo stretchy="false">)</mo><mo separator="true">,</mo><mo>&gt;</mo><mn>50</mn><mi mathvariant="normal">%</mi><mo stretchy="false">(</mo><mn>3</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">b</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">&lt;50 \%(3 \mathrm{a}),&gt;50 \%(3 \mathrm{~b})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50%</span><span class="mopen">(</span><span class="mord">3</span><span class="mord mathrm">a</span><span class="mclose">)</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50%</span><span class="mopen">(</span><span class="mord">3</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">b</span></span><span class="mclose">)</span></span></span></span></span> or complete (3c). A fourth degree laceration involves the ano/rectal mucosa as well as the external and internal sphincter complex. Instrumental delivery, especially forceps delivery, and delivery of a deflexed fetal head in the OP position may result in over-distension of the perineum resulting in perineal injury. Obstetric anal sphincter injuries may lead to long term incontinence of flatus and faeces especially if the injury was not recognized and adequately repaired.
3. Caesarian section:</p>
<p>E is correct. Despite incidences of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25-30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> or greater for caesarean deliveries in most developed countries, the instrumental vaginal delivery rates have remained around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> for several years. Women who have had one uncomplicated previous lower segment caesarean section for a non-recurrent indication may attempt a vaginal delivery in a subsequent labour provided there are no other adverse clinical factors present. The risk of scar dehiscence or rupture is much greater with a previous classical caesarean section and may occur before the onset of labour. Provided the operator has been adequately trained, most occipitoposterior and transverse positions of the fetal head can be managed safely by forceps or vacuum delivery. Although some babies with a mento-anterior face presentation may deliver vaginally, most obstetricians will perform a caesarean delivery because of the risks associated with this malpresentation.
4. Operative vaginal delivery:</p>
<p>D is correct. McRobert's manoeuvre is successful in the majority of cases of shoulder dystocia. Only a minority of macrosomic infants will experience shoulder dystocia and the majority of cases will occur in normal labours with infants weighing less than 4000 g . In almost all reports comparing forceps and vacuum delivery, more infants are successfully delivered with forceps than vacuum extractor.</p>
<p>Significantly more severe perineal lacerations are associated with forceps delivery than vacuum extraction. The prerequisites for vacuum delivery are the same as for the forceps, namely, there should be full dilatation of the cervix and known position and attitude of the fetal head.
5. Postpartum haemorrhage:</p>
<p>A is correct. A number of important obstetric factors predispose to atonic uterus making it the most common cause of postpartum haemorrhage (PPH). Nevertheless, uterine hypotonia may occur following normal delivery. There is little doubt that active management of the third stage of labour reduces postpartum bleeding and should be recommended as preferred management of the third stage. If the placenta is retained and the mother is experiencing a PPH, the uterus should be massaged to stimulate a contraction and an attempt made to deliver the placenta by controlled cord traction. If the placenta has been expelled and the haemorrhage continues despite the administration of intravenous oxytocin, ergometrine should be administered intravenously provided the mother does not have hypertension or a cardiac condition. Recently, uterine tamponade with balloon catheters has become a relatively simple and usually effective management for persisting PPH.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-13">CHAPTER 13<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-13" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Physiological changes in the puerperium:</li>
</ol>
<p>B is correct. With the delivery of the fetus and placenta the hormone producing fetoplacental unit is detached from the mother. This causes a reduction of these hormones that gradually come to non-pregnant levels by six weeks. There is an increase in clotting factors in the third stage of labour and immediate puerperium as a defense mechanism to prevent excessive bleeding which in some women at risk may cause thromboembolism. Prolactin increases with lactation. Platelet counts are stable or increase slightly unless there is increased consumption. Cardiac output remains stable but gradually comes down with diuresis and return of the blood volume to normal.
2. Risk factors for anal sphincter:</p>
<p>C is correct. Occipitoanterior position presents the smallest diameter and has less association with third degree tears compared with a direct occipitoposterior delivery when a larger diameter is presented. Normal duration of second stage of labour is not known to increase the incidence of anal sphincter injury. Use of epidural is associated with a slight increase in anal sphincter injury. Babies that weigh greater than 4.5 kg and not less than 4.0 kg are linked to third degree tears. Multiparous pregnancies are not independent risk factor for anal sphincter injury.</p>
<ol start="3">
<li>UK's most common overall cause of maternal death (2006-2008):
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is correct. Sepsis was the leading cause of direct maternal deaths whilst cardiac disease was the main cause of indirect deaths but these numbers outweigh that due to sepsis. Acquired heart disease due to old age, obesity, hypertension, smoking and diabetes are on the increase in addition to those contributed by migrant population with mitral valve disease. Hypertensive disease is the second leading cause of direct maternal deaths, followed by thromboembolic disease, early pregnancy deaths and amniotic fluid embolism.</li>
<li>Regarding postnatal anticoagulation:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. Heparin and warfarin are not contraindicated with breastfeeding. Use of warfarin is discouraged in the antenatal period due to fear of 'warfarin embryopathy'. Those who were on heparin are converted to warfarin after an interval of 2-3 days due to ease of administration and better effectiveness. Generally three months of treatment is advised for those who had thromboembolism for full resolution of the clots and for the coagulopathy status to have completely abated. Postnatal follow up is best done by the haematologist who will be able to control the dosage based on the test results and will also be able to give advice on the long term follow up.</li>
<li>Examination of the newborn:
A is correct. Examination of the newborn is to assure normality to the parents by excluding any abnormal signs on general, cardiovascular, respiratory, abdominal and musculoskeletal systems. The best time is within 24 hours of delivery and certainly before the mother and baby are discharged from the hospital. Jaundice is not a normal feature of all babies - it needs to be observed and infection and other causes should be ruled out. Umbilical hernia in a newborn may be small and should regress by the end of one to two years. Follow up by the paediatrician is needed and there is no need for immediate referral or surgical repair unless there is a large defect. High pitched cry is not normal - possible sepsis, meningeal irritation should be checked for and additional tests may be needed if the baby develops symptoms of vomiting, fever or fits.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-14">CHAPTER 14<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-14" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Psychiatric disorders of childbirth:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> is correct. Psychiatric disorders are common in pregnancy as pregnancy precipitates the condition. If the mother is on psychiatric medication, the risks and benefits should be analyzed; stopping the drug may cause relapse of the psychiatric condition and certain drugs can be more teratogenic. Psychiatric disorder is the third commonest single cause of indirect maternal deaths. Elevated severe mood disorders (affective) are linked to increased risk of suicide.</li>
<li>Depressive illness in pregnancy:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> is correct. Depressive illness is likely to recur in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of mothers when medication is stopped. Anxiety is a prominent feature in depression. Counseling and cognitive behavioral therapy works well for mild to moderate depression associated with anxiety compared with medication. SSRIs are the commonest anti-depressant drug that is used and is continued in pregnancy. Only some women will need continuation of anti-depressant therapy after the pregnancy.</li>
<li>Serious mental illness in pregnancy:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is correct. The overall incidence of serious illness of schizophrenia, episodic psychosis and bipolar disorders are less during the antenatal period. Serious mental illness is more common in the postnatal period but is not higher than the general population. If the mother has had no illness for the preceding two years prior to conception and was not on medication the risk of relapse in the antenatal period is minimal whilst it is commoner in the postnatal period. The chance of relapse is high if the mother was on medication within the last two years prior to conception.</li>
<li>Selective serotonin reuptake inhibitors (SSRIs):
A is correct. SSRIs are associated with congenital malformation especially ventricular septal defects. There is increased pregnancy loss and intrauterine growth restriction. There is also increased incidence of hypothermia, hypoglycemia and pulmonary hypertension.</li>
<li>Use of lithium for psychiatric conditions in pregnancy: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> is correct. Lithium is a popular medication used for bipolar disorders. The side-effects are high and the drug level is monitored at intervals to avoid toxicity. Lithium is associated with increase in incidence of fetal cardiac malformations - the fetus of one in ten mothers on medication may be affected and the common condition is the Ebstein's anomaly. Hypothyroidism and polyhydramnios are known associations with the use of the drug. In order to avoid toxic effects on the neonate, lithium is stopped and elective induction undertaken about ten days after cessation of the drug and caesarean section is not required if mother goes into labour whilst on the drug. Instead the drug should be stopped and hydration maintained with an intravenous line.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-15">CHAPTER 15<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-15" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Chaperone during vaginal examination:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. A chaperone should always be present, even if the doctor is female. If the patient does not want a chaperone, you should record that the offer was made and declined. If a chaperone is present, you should record that fact and make a note of the chaperone's identity. If for justifiable practical reasons you cannot offer a chaperone, you should explain to the patient and, if possible, offer to delay the examination to a later date.</p>
</li>
<li>
<p>Pelvic examination:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. If a patient indicates during an examination that they have withdrawn their consent you must cease the examination immediately. Although it may be possible to discuss a further attempt at examination, for example, with another instrument it should be clear that the patient has consented to this and, given the position the patient is in, there could be some question over whether the patient is truly giving consent freely. A better alternative would be to abandon the examination at that time. Alternatives might include scheduling the examination for another appointment and/or discussing alternative methods.</p>
</li>
<li>
<p>Pap smear:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is correct. The appearance is typical of a cervical ectropion which is the presence of columnar epithelium on the ectocervix and is normal, especially in reproductive women on the contraceptive pill. There is no indication to offer STI testing in a woman of this age who is asymptomatic unless there is a history of contact. Although ectropions can be treated with cryotherapy this is not indicated if the patient is asymptomatic.</p>
</li>
<li>
<p>Bimanual pelvic examination:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> is correct. Uterine retroversion is a normal anatomical variant found in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of women. It may be associated with pathology in the pouch of Douglas but this is less likely if the uterus is fixed in retroversion rather than mobile. Nodularity in the pouch of Douglas is typical of endometriosis. Although in a thin woman the ovary may be palpable in the adnexal region this should normally be less than 5 cm in size. Pain on cervical movement (cervical excitation) is associated with peritoneal irritations form blood or inflammation.</p>
</li>
<li>
<p>Sims speculum:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> is correct. Examination of the cervix and taking swabs is performed by most doctors using a bivalve speculum. Pelvic floor tone is normally assessed by digital examination. Movement of the anterior vaginal wall can only be seen using the Sims speculum inserted along the posterior vaginal wall.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-16">CHAPTER 16<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-16" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Treatment of 7 cm solitary leiomyoma in the posterior uterine wall:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> is correct. Most fibroids are asymptomatic and do not require treatment. In symptomatic women the choice of approach may be dictated by factors such as the patient's desire for future fertility, the importance of uterine preservation, symptom severity, and tumor characteristics. Although all the treatments are effective none would be indicated in the absence of symptoms. There is a small risk of malignant change but this would not normally be considered an indication for treatment unless the fibroid
began to enlarge rapidly or cause pain. In the normal course of events the fibroid will regress after the menopause. Fertility is not an issue here so UAE would not be indicated. GnRh treatment would be limited by its effect on bone density.</li>
<li>Treatment of regular heavy periods:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> is correct. When there is regular heavy bleeding with no underlying structural lesion, HMB is usually the result of a primary endometrial disorder where the mechanisms regulating local endometrial 'hemostasis' are disturbed. The levonorgestrel-releasing intrauterine system is widely recommended as the first choice for medical therapy of HMB in those women who do not have contraindications to its use.</li>
<li>Oligo-amenorrhoea and a negative pregnancy test: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. The diagnostic criteria for PCOS are any two of the following three are sufficient to confirm the diagnosis:</li>
</ol>
<ul>
<li>oligo- or anovulation</li>
<li>hyperandrogenism (biochemical or clinical) and</li>
<li>polycystic ovaries on ultrasound examination.</li>
</ul>
<p>Prolactin levels are increased in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> of cases.
4. Precocious puberty:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> is correct. In girls precocious puberty is defined as the development of the physical signs of puberty before the age of 8 years. It usually progresses from premature thelarche to menarche because breast tissue responds faster to oestrogen than the endometrium. The majority of cases do not have a pathological basis. In girls older than 4 years old specific causes are less likely to be found with the majority being idiopathic ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> ).
5. HRT:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> is correct. As she has had a hysterectomy she would require oestrogen-only treatment and obviously cannot develop endometrial cancer. Although studies in older women on combined HRT showed an increase in cardiovascular disease this was not seen in younger women or with oestrogen-only treatment. HRT is associated with a reduced risk of carcinoma of the colon and osteoporosis. Oestrogen-only treatment is associated with an increased in breast cancer, venous thrombosis and cholelithiasis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-17">CHAPTER 17<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-17" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Imaging of the uterine cavity:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is correct. Laparoscopy only visualizes the serosal surface of the uterus.</li>
<li>Matches are: 1, c; 2, a; 3, b; 4, d. These are the characteristic clinical and hormone profiles of disorders of ovulation: (1) type III - hypergonaodropic hypogonadism, due to ovarian failure; (2) type I hypogonadal hypogonadism resulting from failure of</li>
</ol>
<p>pulsatile gonadotropin secretion from the pituitary; (3) type II - normogonadotropic anovulation, most commonly caused by polycystic ovary syndrome ; and (4) suppression of FSH LH by exogenous oestradiol in the pill.
3. Causes of oligospermia</p>
<p>B is correct. Spermatogenesis and sperm function may be affected by a wide range of toxins and therapeutic agents. Various toxins and drugs may act on the seminiferous tubules and the epididymis to inhibit spermatogenesis. Chemotherapeutic agents, particularly alkylating agents, depress sperm function and sulphasalazine, which is frequently used to treat Crohn's disease, reduces sperm motility and density, and anabolic steroids used for bodybuilding may produce profound hypospermatogenesis.
4. In vitro fertilization:</p>
<p>E is correct. The chance of a live birth after a single cycle of treatment at age 40 is approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">12 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">12%</span></span></span></span></span>. Embryos reach the blastocyst stage five days after fertilization. IVF involves stimulation of multiple ovarian follicle development using recombinant or urinary derived gonadotropins, with concurrent use of a GnRH agonist or antagonist to prevent a premature LH surge and ovulation before oocytes are harvested.
5. IVF ovarian hyperstimulation (OHSS):</p>
<p>A is correct. OHSS results in marked ovarian enlargement with fluid shift from the intravascular compartment into the third space, leading to ascites, pleural effusion, sodium retention and oliguria. Patients may become hypovolaemic and hypotensive and may develop renal failure as well as thromboembolic phenomena and adult respiratory distress syndrome. The pathophysiology of this condition appears to be associated with an increase in capillary vascular permeability.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-18">CHAPTER 18<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-18" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Miscarriage:</li>
</ol>
<p>C is correct. Fifty per cent of spontaneous miscarriages are associated with chromosome abnormality. This was her first pregnancy so the causes of recurrent miscarriage are less likely to apply. Cervical incompetence normally presents with painless cervical dilation later in pregnancy.
2. Bleeding in early pregnancy:</p>
<p>C is correct. Haemodynamic shock associated with bleeding in early pregnancy is usually due either to ruptured ectopic pregnancy or incomplete miscarriage. In this case the low pulse rate suggests vagal stimulation from products of conception distending the cervix and the absence of abdominal signs of peritonism is against ruptured ectopic. The immediate priority would be to look for products of conception and remove tissue from the cervix. This will
confirm a diagnosis of miscarriage and delay in doing this will cause ongoing blood loss as the uterus will not be able to contract properly, even with the administration of ergometrine.
3. Missed miscarriage:</p>
<p>A is true. Infection is more likely than after surgical evacuation of the uterus, but the drawback is that the time for symptoms to resolve is longer and that the chances of avoiding further treatment are lower in missed miscarriage.
4. Sudden onset and continuing right iliac fossa pain:</p>
<p>C is correct. Ectopic pregnancy is the most likely cause of her symptoms and the first step would be a pregnancy test. All the other tests are reasonable alternatives and may well also be indicated at some point but a negative pregnancy test will exclude ectopic pregnancy in more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>97</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">97 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">97%</span></span></span></span></span> of cases and a positive test will be essential in interpreting the results of any ultrasound scan. The absence of any GI or urinary symptoms make the other leading differentials of appendicitis and urinary tract infection (which might have suggested FBC or urinalysis should be done first) less likely.
5. Small amount of vaginal bleeding for the past few days and marked nausea and vomiting for several weeks:
E is correct. Molar pregnancy typically presents with symptoms of miscarriage. Other pregnancy symptoms such as vomiting are often worse because of the very hCG levels. The diagnosis can be suggested by ultrasound appearances of multiple echoluscent areas in the uterine cavity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-19">CHAPTER 19<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-19" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Screeening for STI:</li>
</ol>
<p>E is correct. The most common STI organism in the developed world is Chlamydia trachomatis. This is best defined by PCR testing of urine (E). It is most unlikely to be found in low vaginal or upper vaginal swabs, which are also inadequate for testing for gonococcal infection, and antibody testing for gonorrhea is not very accurate nor is this the most common STI. Vaginal swabs are useful for screening for bacterial vaginosis such as gardnerella infection, Candida infection and for GBS screening, but a urinary PCR for chlamydia is best able to define this STI (E is therefore correct).
2. Contraceptive efficacy:</p>
<p>E is correct. The Implanon <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> contraceptive rod has the lowest failure rate whether assessed overall or just with perfect use ( E is therefore correct), although the periods in the three to six months after insertion are often very irregular and unpredictable. Of the other methods given A, B and D have similar failure rates, but the failure rate of the post-coital pill (E) is much higher.</p>
<ol start="3">
<li>Choice of the appropriate contraceptive to prescribe: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. This woman has the clinical features of polycystic ovarian syndrome (PCOS) and thus should not be given a pill containing a progestogen-derived from testosterone (A, B, and C), but should be given the one containing the anti-androgen cyproterone acetate. The failure rate of the low dose progestogen pill (E) is too high to be validly considered in view of her reproductive desires.</li>
<li>Therapeutic abortion:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. In Australia and the UK a maximum of two opinions from appropriate doctors is all that is necessary ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is incorrect) and not even two such opinions are always required. Termination is certainly acceptable for the reasons she explained (therefore A is incorrect). Of the remaining three options, D is certainly the most applicable, most likely to be successful and safest.</li>
<li>Causes of dyspareunia:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> is correct. This woman is almost certainly menopausal, at which time the reduced oestrogen production from the ovaries results in the occurrence of atrophic vaginitis (thus C is correct). The episiotomy would not be the cause as it has not been a problem in the past, except when breastfeeding. The problems when she was breastfeeding could have been due to the episiotomy healing, or due to the atrophic vagina consequent on the low oestrogen levels at that time. Endometriosis would be a most unlikely cause after the menopause, monilial infection is rare after the menopause unless the woman is diabetic, and a cervical eversion does not cause dyspareunia and is likely to be less evident after the menopause as well.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-20">CHAPTER 20<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-20" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Vulvar cancer:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is correct. Vulvar cancer has two distinct histological patterns with two different risk factors. The more common basoloid/warty types occur mainly in younger women and are associated with usual VIN and HPV infection sharing similar risk factors as cervical cancer. The keratinizing types occur in older women and are associated with lichen sclerosus. VIN is categorized into usual VIN (classic VIN or Bowen's disease) and differentiated VIN based on the distinctive pathological features.</li>
<li>Treatment of stage IIB squamous cell carcinoma of the cervix:
E is correct. Stage IIB cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina. Local excision carried out by cone biopsy is an option for patients with stage Ia lesions who wish to preserve fertility. Simple hysterectomy suffices for stage 1a1 disease for those who have completed family.
Extended hysterectomy or radiotherapy can be used to treat stage Ib-IIa. The cure rate is similar for both surgery
and radiotherapy but the former is generally associated with less long-term morbidity from vaginal stenosis. Surgery can also preserve ovarian function for those pre-menopausal women. Stage II-IV disease is usually treated with chemoradiation with weekly platinum based chemotherapy and intracavity and external beam radiotherapy.</li>
<li>Predisposing factor for endometrial cancer:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. There are specific factors associated with an increased risk of corpus carcinoma, such as nulliparity, late menopause, diabetes and hypertension. It can also be hereditary. Women with Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome have increased risk of endometrial cancer and ovarian cancer, as well as colorectal cancer. However, the most important risk factors associated with hyper-oestrogen state are:</li>
</ol>
<ul>
<li>obesity</li>
<li>exogenous oestrogens</li>
<li>endogenous oestrogens</li>
<li>oestrogen-producing ovarian tumours</li>
<li>tamoxifen in breast cancer</li>
<li>endometrial hyperplasia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-21">CHAPTER 21<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-21" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Uterosacral ligaments:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> is correct. The uterosacral ligaments are responsible for providing level 1 support to the upper vagina and the cervix and the uterus.</li>
<li>Cystocele:
E is correct. Typically patients complain of 'something coming down' per vaginum. At times there may be incomplete emptying of the bladder and this will be associated with double micturition, the desire to repeat micturition immediately after apparent completion of voiding. The patient may give a history of having to manually replace the prolapse into the vagina to void. Some patients may get recurrent urinary tract infections as a result of incomplete emptying of the bladder.</li>
<li>Stress urinary incontinence:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> is correct. Stress incontinence should be managed initially by pelvic floor physiotherapy. Surgical treatment is indicated where there is a failure to respond to conservative management.</li>
<li>Uterovaginal prolapse:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> is correct. Surgical repair may have to be repeated if vaginal delivery occurs later.</li>
<li>Acute retention of urine:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> is correct. Radiotherapy is more often associated with urinary frequency or incontinence from fistula formation.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="self-assessment">Self-assessment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#self-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="appendix-a">APPENDIX A<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#appendix-a" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Routine preoperative investigations:</li>
</ol>
<p>C is correct. Preoperative blood investigations include full blood count; urea and electrolytes for screening for renal disease in patients with hypertension, diabetes and in women on diuretics; liver function test for patients with alcohol abuse or liver disease; group and save prior to procedures with risk of bleeding and cross match if heavy bleeding is suspected or antibodies are present.
Routine coagulation screen is not necessary unless the patient has a known bleeding disorder, or has been on medication that causes anticoagulation.
2. Aspirin prior to surgery:</p>
<p>A is correct. Aspirin should be discontinued 7-10 days before surgery as it inhibits platelet cyclooxygenase irreversibly, so platelet aggregation studies can be abnormal for up to 10 days.
3. Contraindications prior to surgery:</p>
<p>C is correct. The combined oral contraceptive pill should be stopped <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> weeks prior to major surgery to minimize the risk of VTE.
4. Intraoperative/postoperative complications:</p>
<p>E is correct. Compartment syndrome in the legs may occur due to lithotomy position when the pressure in the muscle of an osteofascial compartment is increased, causing ischaemia followed by reperfusion, capillary leakage from the ischaemic tissue, and further increase in tissue oedema resulting in neuromuscular compromise and rhabdomyolysis. Leg holders, pneumatic compression stockings, high body mass index and prolonged surgical time are risk factors.
Femoral neuropathy occurs secondary to excessive hip flexion, abduction, and external hip rotation, which contribute to nerve compression.
5. Risk factors for urinary tract injuries:</p>
<p>C is correct. Risk factors for bladder injury include endometriosis, infection, bladder overdistension, and adhesions. Lateral rather than suprapubic trocar insertion will reduce the risk of bladder injury.
6. Postoperative care:</p>
<p>C is correct. Epidural analgesia, dehydration and bleeding are common causes of postoperative hypotension.
7. Postoperative complications:</p>
<p>E is correct. Common organisms in SSIs of abdominal incisions are Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus spp., and Escherichia coli. Postoperative pelvic abscesses are commonly associated with anaerobes. Risk factors include diabetes, smoking, systemic steroid medication, radiotherapy, poor nutrition, obesity, prolonged hospitalization and blood transfusion. Surgical factors associated with SSIs include prolonged operating
time, excessive blood loss, hypothermia, hair removal by shaving, and surgical drains.
8. Venous thromboembolism post-surgery:</p>
<p>A is correct. If there is clinical suspicion of pulmonary embolism, diagnostic imaging is required. If there is a delay in obtaining imaging then a treatment dose of lowmolecular weight heparin (LMWH) should be administered. In a positive diagnosis, a treatment dose of LMWH should be commenced and converted to oral anticoagulants once the patient is stable and the risk of bleeding is reduced.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="appendix-b">APPENDIX B<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#appendix-b" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Routinely collected data by Hospital Episodes Statistics (HES):
E is correct. In England and Wales, HES collects data for in-patient administration, and records outcomes such as any procedure performed. However, these data do not record details at patient level. The data provides information on overall hospital in-patient activity so that service can be planned according to the local needs.</li>
<li>Data protection:</li>
</ol>
<p>B is correct. Data governance is overseen by Caldicott Principles. Every organization has clearly defined rules about data accessibility and how it should be used. Data should be kept secured at all times and should not be transferred to countries outside the EU. Named data should not be used and where identifiable data is being used for audit or research, approval should be sought from Caldicott Guardian. The principle of data protection clearly enshrines the principle of privacy and confidentiality. It is not a prerequisite to have a clinical guideline before undertaking a clinical audit but it does help if a guideline exist in that particular area of interest.
3. Research and clinical audit:</p>
<p>B is correct. One complete cycle of clinical audit demonstrates improvement in patient care and that includes procedures used for diagnosis, treatment, associated use of resources and resulting outcome for the patient, whereas the primary aim of research is to drive generalizable new knowledge. For clinical research application is made for approval from Research Ethics Committee whereas no such approval is required for clinical audit. It is important that the first cycle of clinical audit is followed by further audit cycles in order to demonstrate continuing improvement process. This may require several cycles of clinical audit to demonstrate significant improvement in patient outcomes. There are clearly laid out principles around research funding. There are several organisations which provide funding for research.</p>
<ol start="4">
<li>Clinical guidelines:</li>
</ol>
<p>A is correct. Clinical guidelines are developed by a large number of organizations such as WHO, NICE, SIGN and Royal Colleges, to cite a few. Although guidelines are evidence-based and derived from level 1 evidence base, not all organizations follow similar methodology. The guideline developers usually consult previously published guidelines from other organizations but they do not necessarily follow their methodology. Guidelines production is a very intense, time-consuming process taking between 18-24 months. Guidelines recommendations are based on clinical effectiveness. Guidelines published by NICE take account of cost-effectiveness of the recommendation as well.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5-research">5. Research:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-research" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> is correct. Descriptive studies test an aetiological hypothesis - such as excessive smoking increases the risk of cancer of the lung. Case control studies compare people with disease and those without it whereas cohort studies compare people exposed to the suspected causative agent and those not exposed to it. It is unethical for patients to be randomized without Ethics Committee approval. Furthermore, patients should give valid, informed consent before they can be entered into a clinical trial. If patients do not wish to be randomized to a clinical trial, then they should be treated with standard treatment for that condition. Clinicians should not be aware of whether their patients are being treated with an active drug or a dummy preparation, and should be treated in a similar way. All side-effects should be reported accurately. However, if any patient experience an undesirable side-effect, then they should be withdrawn from the trial irrespective of their allocation in the trial immediately. Thereafter they should be treated following the best practice guidelines. Finally, pregnant women or those who desire to become pregnant should not be exposed to new drugs or new interventions as data may not be available on the safety of these drugs on embryonic development.
6. Evidence-based healthcare:</p>
<p>A is correct. The risk management strategy should be in place in each organization in order to not only improve care of women but also to minimize risk to patients and to the organization. Clinical risk management strategy involves collection of data on all aspects of patient care and that involves elements of process, treatment and outcome. Therefore the focus should not only be on serious outcomes such as maternal and neonatal mortality. By reducing risk to women and to their babies, care can be improved. The focus should be to minimize risk and to learn from errors. This can only be done by learning from near misses and by implementation of guidelines. Successful implementation of guidelines is always supported by regular clinical audits to ensure that level of adherence to guidelines is above <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>. When clinical
incidents are reported, they should be investigated in a positive and constructive way involving all members of a care team. Lessons should be learned and action plan be implemented to reduce the risk of recurrence of similar incidences in the future. When patients do complain against staff, it is important to investigate their complaints in an open and transparent way to ensure that issues identified by the patient have been investigated fully. Lessons should be learned and organizations should respond to the issues identified in the patient's complaints.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="appendix-c">APPENDIX C<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#appendix-c" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Informed consent:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. As the operating surgeon it is your responsibility to obtain informed consent (A is therefore incorrect). You can never be sure exactly what was discussed by other individuals ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is therefore incorrect), therefore you must discuss the other treatment options available to this patient and the potential complications which could occur if the planned surgery was performed and the further treatment which might then be necessary. She may well decide against the planned surgery when given all of this information especially if complications of the surgery, although most unlikely and even at a risk of less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>, would distress her considerably ( C is therefore incorrect). Provision of the College Statement on the risks of surgery would be incomplete information and, even if provided, would not cover the requirements of Informed Consent unless time was given for these matters to be discussed in detail (E is incorrect).</li>
<li>Legal requirements regarding retention of medical records:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is correct. For a problem unrelated to pregnancy, medical records must be retained for at least seven years, and can then be destroyed. For a pregnancy related record, these need to be retained for seven years after the child has reached it 'maturity' at the age of 18 years. Both the maternal medical record and that of the child must therefore be retained for 25 years. As this case does not involve a pregnancy, the correct response is therefore B.</li>
<li>Levels of evidence:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> is correct. By far the best level of evidence is provided by randomized controlled clinical trials. The remaining options are less valuable in defining the adequacy and accuracy of the evidence given, with these progressively declining in efficacy from D to A .</li>
<li>Requirements of an adequate medical record:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> is correct. All of these matters need to be documented in detail. The adequacy of care can only be assessed and the possible cause of any long-term problem in the baby defined with all of this information.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="self-assessment">Self-assessment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#self-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol start="5">
<li>Appropriate care of a 15 -year-old girl requesting contraception:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> is correct. If he is less than three years older than her, and is not a relative, a teacher or other responsible person, then sex would be legal. If he is older, is a close relative, a teacher or youth leader etc., any sexual relationship would be illegal and is potentially reportable to the Police if the actual relationship is confirmed. It is not illegal to give her
the pill providing she understands the implications (A is therefore incorrect). Advising the parents or Department of Health is not necessary to give her the pill (B and C are therefore incorrect). Use of condoms would remove the doctor from the problem, but less than adequate contraception would be provided since her partner has indicated he is not prepared to use such methods ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> is therefore incorrect).</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="further-reading">Further reading<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#further-reading" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Papers marked * indicates those the editors consider landmark studies in the development of obstetrics and gynaecology over the last 40 years. These are mainly clinical trials or meta-analyses that have influenced contemporary practice. They are also beloved of the setters of short answer questions in postgraduate examinations. Although highly cited, many of these studies have been the source of much debate and do not necessarily represent the 'final word' in evidence-based practice. We are sure that readers of this book will have suggestions of their own as to other studies that should be included (or indeed should be excluded from this list).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-2">CHAPTER 2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Johnson MH (2008) Essential Reproduction, 6th edn. John Wiley, Chichester
Moore K (1988) The Developing Human: Clinically Oriented Embryology. WB Saunders, London
Philipp EE, Setchell M (ed) (1991) Scientific Foundations of Obstetrics and Gynaecology. Heinemann, London</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-3">CHAPTER 3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Broughton Pipkin F (2001) Maternal physiology. In: Chamberlain GV, Steer P (eds) Turnbull's Obstetrics, 3rd edn. Churchill Livingstone, Edinburgh
Broughton Pipkin F (2007) Maternal physiology. In: Edmonds DK (ed) Dewhurst's Textbook of Obstetrics and Gynaecology, 8th edn. Blackwell, Oxford
Cartwright JE, Duncan WC, Critchley HO et al (2010) Remodelling at the maternal-fetal interface: relevance to human pregnancy disorders. Reproduction 140:803-813
James D, Steer P, Weiner C et al (2011) High Risk Pregnancy: Management Options. Elsevier Saunders, London</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-4">CHAPTER 4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>De Swiet M, Chamberlain GVP (1992) Basic Science in Obstetrics and Gynaecology. Churchill Livingstone, Edinburgh</p>
<p>Erikson PS, Secher NJ, Weis-Bentson M (1985) Normal growth of the fetal biparietal diameter and the abdominal diameter in a longitudinal study. Acta Obstetricia et Gynaecologica Scandinavica 64:65-70
Gardosi J, Chang A, Kalyan B et al (1992) Customised antenatal growth charts. Lancet 339:283-287
Thorburn GD, Harding R (1994) Textbook of Fetal Physiology. Oxford University Press, Oxford</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-5">CHAPTER 5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Centre for Maternal and Child Enquiries (CMACE) (2010) Perinatal Mortality 2008 United Kingdom. CMACE, London
Centre for Maternal and Child Enquiries (CMACE) (2011) Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006-08. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. British Journal of Obstetrics and Gynaecology 118 (Suppl. 1):1-203.
Flenady V, King J, Charles A et al for the Perinatal Society of Australia and New Zealand (PSANZ) Perinatal Mortality Group (2009). PSANZ Clinical Practice Guideline for Perinatal Mortality. Version 2.2 April. Available: <a href="http://www" target="_blank" rel="noopener noreferrer">www</a>. stillbirthalliance.org.au/doc/Section_1_Version_2.2_ April_2009.pdf
Gardosi J, Kady SM, McGeown P et al (2005) Classification of stillbirth by relevant condition at death (ReCoDe): population based cohort study. British Medical Journal 331:1113-1117
World Health Organization (2004) Beyond the Numbers: Reviewing Maternal Deaths and Complications to Make Pregnancy Safer. WHO Press, Geneva
World Health Organization (2006) Neonatal and Perinatal Mortality: Country, Regional and Global Estimates. WHO Press, Geneva
World Health Organization (2007) Neonatal and Perinatal Mortality: Country, Regional and Global Estimates 2004 /Elisabeth Åhman and Jelka Zupan. WHO Press, Geneva</p>
<p>World Health Organization (2010) Trends in Maternal Mortality: 1990 to 2008. Estimates Developed by WHO, UNICEF, UNFPA and The World Bank. WHO Press, Geneva</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-6">CHAPTER 6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chandraharan E, Arulkumaran S (2005) Female pelvis and details of operative delivery; shoulder dystocia and episiotomy. In: Arulkumaran S, Penna LK, Rao Basker (eds) Management of Labour. Orient Longman, India</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-7">CHAPTER 7<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Australian Institute of Health and Welfare, Australian Government, Canberra. Australian Red Cross Blood Service. Transfusion Available: <a href="http://www.transfusion.com.au" target="_blank" rel="noopener noreferrer">www.transfusion.com.au</a>
Laws PJ, Li Z, Sullivan EA (2010) Australia's mothers and babies 2008. Perinatal statistics series no. 24. Cat. no. PER 50. Canberra: AIHW.
National Collaborating Centre for Women's and Children's Health March (2008) Antenatal Care Routine Care for the Healthy Pregnant Woman. RCOG Press, London. Available: <a href="http://www.nice.org.uk/nicemedia/" target="_blank" rel="noopener noreferrer">http://www.nice.org.uk/nicemedia/</a> live/11947/40145/40145.pdf
National Health and Medical Research Council Immunization Handbook. Available: <a href="http://www.health" target="_blank" rel="noopener noreferrer">http://www.health</a>. gov.au/internet/immunise/publishing.nsf/Content/ Handbook-home
National Health and Medical Research Council (2003) Guidelines on the Prophylactic Use of Rh D Immunoglobulin (anti-D) in Obstetrics. NHMRC, Australian Government, Canberra. Available: <a href="http://www" target="_blank" rel="noopener noreferrer">http://www</a>. nhmrc.gov.au/guidelines/publications/wh33
National Organisation for Fetal Alcohol Syndrome and Related Disorders (NOFASARD). Available: <a href="http://www" target="_blank" rel="noopener noreferrer">http://www</a>. nofasard.org.au/
Royal Australian and New Zealand College of Obstetrics and Gynaecology. Statement C-Obs 6 Guidelines for the use of Rh (D) Immunoglobulin (anti-D) in Obstetrics in Australia. Available: <a href="http://www.ranzcog.edu.au/womens-health/" target="_blank" rel="noopener noreferrer">http://www.ranzcog.edu.au/womens-health/</a> statements-a-guidelines/college-statements-andguidelines.html?showall=&amp;limitstart=
Royal Australian and New Zealand College of Obstetricians and Gynaecologists College guidelines. Available: http:// <a href="http://www.ranzcog.edu.au/womens-health/statements-a-guidelines/college-statements-and-guidelines.html" target="_blank" rel="noopener noreferrer">www.ranzcog.edu.au/womens-health/statements-a-guidelines/college-statements-and-guidelines.html</a>? showall=&amp;limitstart=
Royal College of Obstetricians and Gynaecologists Greentop guideline No 22. (March 2011) The Use of Anti-D immunoglobulin for Rhesus D Prophylaxis. Available: <a href="http://www.rcog.org.uk/files/rcog-corp/GTG22AntiD.pdf" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/GTG22AntiD.pdf</a>
The Royal Women's Hospital (Victoria, Australia) A-Z Fact Sheets. Available: <a href="http://www.thewomens.org.au/" target="_blank" rel="noopener noreferrer">http://www.thewomens.org.au/</a> Amphetamines</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-8">CHAPTER 8<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>*CLASP collaborative group (1994) CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>343</mn><mo>:</mo><mn>619</mn><mo>−</mo><mn>29</mn></mrow><annotation encoding="application/x-tex">343: 619-29</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">343</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">619</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">29</span></span></span></span></span>
*Hannah ME, Hannah WJ, Hellman J et al (1992) Induction of labour as compared with serial antenatal monitoring in post-term pregnancy. New England Journal of Medicine 326:1587-1592
*Hannah ME, Hannah WJ, Hewson SA et al (2000) Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial (Term Breech Trial). Lancet 356:1375-1383
*Hilder L, Costeloe K, Thilaganathan B (1998) Prolonged pregnancy: evaluating gestation-specific risks of fetal and infant mortality. British Journal of Obstetrics and Gynaecology 105:169-173 29
*Magpie Trial Follow-Up Study Collaborative Group (2007) The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. British Journal of Obstetrics and Gynaecology 114:289-299
National Institute for Health and Clinical Excellence (2010) The Management of Hypertensive Disorders in Pregnancy. Available: <a href="http://www.nice.org.uk/cg107" target="_blank" rel="noopener noreferrer">http://www.nice.org.uk/cg107</a>
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 63 Antepartum Haemorrhage. Available: <a href="http://www.rcog.org.uk/files/rcog-corp/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/</a> GTG63_05122011APH.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 20b The Management of Breech Presentation. Available: <a href="http://www.rcog.org.uk/files/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/</a> rcog-corp/GtG%20no%2020b%20Breech%20 presentation.pdf
Royal College of Obstetricians and Gynaecologists Green-top Guideline No. 27 Placenta Praevia, Placenta Praevia Accreta and Vasa Praevia: Diagnosis and Management. Available: <a href="http://www.rcog.org.uk/files/rcog-corp/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/</a> GTG27PlacentaPraeviaJanuary2011.pdf
Royal College of Obstetricians and Gynaecologists Green-top Guidelines no. 51 Management of Monochorionic Twin Pregnancy. Available: <a href="http://www.rcog.org.uk/files/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/</a> rcog-corp/uploaded-files/T51ManagementMonochorionicTwinPregnancy2008a.pdf
Smith GC, Pell JP, Dobbie R (2002) Birth order, gestational age, and risk of delivery related perinatal death in twins: retrospective cohort study. British Medical Journal 325:1004</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-9">CHAPTER 9<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-9" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Centre for Maternal and Child Enquiries/RCOG Joint Guideline (2010) Management of Women with Obesity in Pregnancy. Available: <a href="http://www" target="_blank" rel="noopener noreferrer">http://www</a>. rcog.org.uk/files/ rcog-corp/CMACERCOGJointGuidelineManagement WomenObesityPregnancya.pdf
*Crowther CA, Hiller JE, Moss RJ et al (2005) Effect of treatment of gestational diabetes mellitus on pregnancy outcomes (ACHOIS). New England Journal of Medicine 352:2477-2486
*HAPO Study Cooperative Research Group (2008) Hyperglycaemia and adverse pregnancy outcomes. New England Journal of Medicine 358:1991-2002
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 37b (Feb 2007, reviewed 2010) The Acute Management of Thrombosis and Embolism During</p>
<p>Pregnancy and the Puerperium. Available: <a href="http://www" target="_blank" rel="noopener noreferrer">http://www</a>. rcog.org.uk/files/rcog-corp/GTG37b_230611.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 30 (Sept 2007) Management of Genital Herpes in Pregnancy. Available: <a href="http://www.rcog" target="_blank" rel="noopener noreferrer">http://www.rcog</a>. org.uk/files/rcog-corp/uploaded-files/ GT30GenitalHerpes2007.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 13 (Sept 2007) Chickenpox in Pregnancy. Available: <a href="http://www.rcog.org.uk/files/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/</a> rcog-corp/uploaded-files/ GT13ChickenpoxinPregnancy2007.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 39 (June 2010) Management of HIV in Pregnancy. Available: <a href="http://www.rcog.org.uk/files/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/</a> rcog-corp/uploaded-files/GtG_no_39_HIV_in_pregnancy_ June_2010_v2011.pdf</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-10">CHAPTER 10<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-10" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Baschat AA (2004) Pathophysiology of fetal growth restriction: implications for diagnosis and surveillance. Obstetrical and Gynecological Survey 59:617-627
Bottomley C, Bourne T (2009) Dating and growth in the first trimester. Best Practice in Research in Clinical Obstetrics and Gynaecology 23:439-452
Cosmi E, Ambrosini G, D'Antona D et al (2005) Doppler, cardiotocography, and biophysical profile changes in growth-restricted fetuses. Obstetrics &amp; Gynecology 106:1240-1245
Devoe LD (2008) Antenatal fetal assessment: Contraction stress test, nonstress test, vibroacoustic stimulation, amniotic fluid volume, biophysical profile, and modified biophysical profile - An overview. Seminars in Perinatology 32:247-252
Johnstone FD (1992) Clinical Obstetrics and Gynaecology. Baillière Tindall, London
Langford KS (2002) Infectious disease and pregnancy. Current Obstetrics and Gynaecology 12:125-130
*Malone FD, Canick J, Ball R et al (2003) First-trimester or second-trimester screening, or both, for Down's syndrome (FASTER). New England Journal of Medicine 353:2001-2011
National Collaborating Centre for Women's and Children's Health (2008) Induction of Labour Clinical Guideline. RCOG Press, London. Available: <a href="http://www.nice.org.uk/" target="_blank" rel="noopener noreferrer">http://www.nice.org.uk/</a> nicemedia/live/12012/41255/41255.pdf
Reed GB, Claireaux AE, Bain AD (1989) Diseases of the Fetus and Newborn. Chapman and Hall, London
Royal College of Obstetricians and Gynaecologists Greentop Guidelines No. 31 (Nov 2002) The Investigation and Management of the Small-for-Gestational-Age Fetus. Available: <a href="http://www.rcog.org.uk/files/rcog-corp/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/</a> uploaded-files/GT31SmallGestationalAgeFetus.pdf
Spencer K, Spencer CE, Power M et al (2003) Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. British Journal of Obstetrics and Gynaecology <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>110</mn><mo>:</mo><mn>281</mn><mo>−</mo><mn>286</mn></mrow><annotation encoding="application/x-tex">110: 281-286</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">110</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">281</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">286</span></span></span></span></span>
*The GRIT study group (2003) A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretation. British Journal of Obstetrics and Gynaecology 110:27-32
Timor-Tritsch IE, Fuchs KM, Monteagudo A et al (2009) Performing a fetal anatomy scan at the time of firsttrimester screening. Obstetrics &amp; Gynecology 113:402-407
*Van Bulck B et al (2004) Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial. Lancet 364:513-520</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-11">CHAPTER 11<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-11" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Baskett TF, Arulkumaran S (2001) Intrapartum Care for the MRCOG and Beyond. RCOG Press, London
*Doyle LW, Crowther CA, Middleton P et al (2009) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews, Issue 1. Art No: CD004661
Fonseca EB, Celik E, Parra M et al (2007) Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine 357:462-469
*Kenyon SL, Taylor DJ, Tarnow-Mordi W; ORACLE Collaborative Group ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋆</mo><mo>⋆</mo></mrow><annotation encoding="application/x-tex">\star \star</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4653em;"></span><span class="mord">⋆</span><span class="mord">⋆</span></span></span></span></span> ) Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. Lancet 357:979-988
*Kenyon SL, Taylor DJ, Tarnow-Mordi W; ORACLE Collaborative Group (2001) Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. Lancet 357:989-994
*MacDonald D, Grant A, Sheridan-Pereira M et al (1985) The Dublin randomised controlled trial of intrapartum fetal heart rate monitoring. Americal Journal of Obstetrics and Gynecology 152:524-539
Mahmood T, Owen P, Arulkumaran S, Dhillon C (eds) (2010) Models of Care in Maternity Services. RCOG Press, London
National Centre for Clinical Excellence (2007) Clinical Guideline 55. Intrapartum Care. Available: <a href="http://www.nice.org.uk/nicemedia/" target="_blank" rel="noopener noreferrer">http://www.nice.org.uk/nicemedia/</a> live/11837/36280/36280.pdf
*O'Driscoll K, Stronge JM, Minogue M et al (1973) Active management of labour. British Medical Journal 3:135-137
Royal College of Obstetricians and Gynaecologists Green-top Guideline No. 50 (April 2008) Umbilical Cord Prolapse. Available: <a href="http://www.rcog.org.uk/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/</a> files/rcog-corp/uploaded-files/ GT50UmbilicalCordProlapse2008.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 7 (Oct 2010) Antenatal Corticosteroids to Reduce Neonatal Morbidity. Available: <a href="http://www.rcog.org.uk/files/rcog-corp/GTG%5C%207.pdf" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/GTG\%207.pdf</a>
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 1b (Feb 2011) Tocolysis for Women in Preterm Labour. Available: <a href="http://www.rcog.org.uk/files/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/</a> rcog-corp/GTG1b26072011.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 42 (March 2012) Shoulder Dystocia. Avaialble: <a href="http://www.rcog.org.uk/files/rcog-corp/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/</a></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="further-reading">Further reading<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#further-reading" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>GTG%2042_Shoulder%20dystocia%202nd%20 edition%202012.pdf</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-12">CHAPTER 12<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-12" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>*Landon MB, Hauth JC, Leveno KJ et al (2004) Maternal and perinatal outcomes associated with a trial of labour after prior caesarean delivery. New England Journal of Medicine 351:2581-2589
Robson S, Higgs P (2011) Third- and fourth- degree injuries. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists 13 (2):20-22
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 52 (May 2009) Prevention and Management of Postpartum Haemorrhage. Available: <a href="http://www.rcog.org.uk/files/rcog-corp/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/</a> GT52PostpartumHaemorrhage0411.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guidelines No. 26 (Jan 2011) Operative vaginal delivery. Available: <a href="http://www.rcog.org.uk/files/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/</a> rcog-corp/GTG26.pdf</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-13">CHAPTER 13<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-13" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Benn C (2011) Milk of humankind: best. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists 13 (2):40-41
Coker A, Oliver R (2006) Definitions and Classifications in a Textbook of Postpartum Hemorrhage. Sapiens Publishing, pp 11-16
Kumarasamy R (2011) Infection in the peuperium. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists 13 (2):17
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 37b (Feb 2007, reviewed 2010) The Acute Management of Thrombosis and Embolism During Pregnancy and the Puerperium. Available: <a href="http://www" target="_blank" rel="noopener noreferrer">http://www</a>. rcog.org.uk/files/rcog-corp/GTG37b_230611.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 29 (March 2007) The Management of Third and Fourth Degree Perineal Tears. Available: http:// <a href="http://www.rcog.org.uk/files/rcog-corp/GTG2911022011.pdf" target="_blank" rel="noopener noreferrer">www.rcog.org.uk/files/rcog-corp/GTG2911022011.pdf</a>
Royal College of Obstetricians and Gynaecologists Green-top Guideline No. 47 (Dec 2007) Blood Transfusions in Obstetrics. Available: <a href="http://www.rcog" target="_blank" rel="noopener noreferrer">http://www.rcog</a>. org.uk/files/rcog-corp/uploaded-files/ GT47BloodTransfusions1207amended.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 56 (Jan 2011) Maternal Collapse in Pregnancy and the Peurperium. Available: <a href="http://www.rcog.org.uk/files/rcog-corp/GTG56.pdf" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/GTG56.pdf</a>
Thakkar (2004) Guidelines on neonatal examination. CGCHealth005-1; Milton Keynes NHS Trust</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-14">CHAPTER 14<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-14" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Cox JL, Holden JM, Sagovshy R (1987) Detection of postnatal depression: development of the 10-item Edinburgh postnatal depression scale (EPDS). British Journal of Psychiatry 150:782-786
Holden JM, Sagovsky R, Cox JL (1989) Counselling in a general practice setting: a controlled study of health
visitors; intervention in treatment of postnatal depression. British Medical Journal 298:223-226
Oates M, ed (1998) Risk and childbirth in psychiatry. In: Lee A (ed) Advances in Psychiatric Treatment: Acute Psychosis, Schizophrenia and Comorbid Disorder, Recent Topics. Gaskell, London, vol 1, pp 116-123
Oates M, Cantwell R (2011) Deaths psychiatric causes. Chapter 11 In: Saving Mothers Lives. Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom Centre for Maternal and Child Enquiries. British Journal of Obstetrics and Gynaecology 118 (suppl 1):134-144.
RANZCOG College Statement C-Gen 18 (2012) Perinatal Anxiety and Depression. Available: http:// <a href="http://www.ranzcog.edu.au/component/docman/doc_view/897-c-gen-18-perinatal-anxiety-and-depression" target="_blank" rel="noopener noreferrer">www.ranzcog.edu.au/component/docman/doc_view/897-c-gen-18-perinatal-anxiety-and-depression</a>. html?Itemid=341
Ruben PC (1987) Prescribing in Pregnancy. British Medical Association, London
Stewart DE, Klompenhouwer JL, Kendell RE et al (1991) Prophylactic lithium in puerperal psychosis: the experience of three centres. British Journal of Psychiatry 158:393-397
Wieck A, Kumar R, Hirst AD et al (1991) Increased sensitivity of dopamine receptors and recurrence of affective psychosis after childbirth. British Medical Journal 303:613-616</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-15">CHAPTER 15<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-15" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Critchley HOD, Munro MG, Broder M et al (2011) A five-year international review process concerning terminologies, definitions and related issues around abnormal uterine bleeding. Seminars in Reproductive Medicine 29:377-382</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-16">CHAPTER 16<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-16" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>*Garry R, Fountain J, Mason S et al (2004) The eVALuate study: two parallel randomised trials, one comparing laparoscopic with abdominal hysterectomy, the other comparing laparoscopic with vaginal hysterectomy. British Medical Journal 328:129
*Hulley S, Grady D, Bush T et al (1998) Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women (HERS). Journal of the Americal Medical Association 280:605-613
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 48 (Dec 2007) Management of Premenstrual Syndrome. Available: <a href="http://www.rcog.org" target="_blank" rel="noopener noreferrer">http://www.rcog.org</a>. uk/files/rcog-corp/uploaded-files/ GT48ManagementPremensturalSyndrome.pdf
Royal College of Obstetricians and Gynaecologists Greentop guideline No. 32 (Nov 2008) Pelvic Inflammatory Disease. Available: <a href="http://www.rcog.org.uk/files/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/</a> rcog-corp/uploaded-files/ T32PelvicInflamatoryDisease2008MinorRevision.pdf
Royal College of Obstetricians and Gynaecologists Greentop guidelines No. 58 (Feb 2011) The Management of Vulval Skin Disorders. Available: <a href="http://www.rcog.org.uk/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/</a> files/rcog-corp/GTG58Vulval22022011.pdf</p>
<p>Royal College of Obstetricians and Gynaecologists Greentop guidelines No. 19 (May 2011) Venous Thromboembolism and Hormone Replacement Therapy. Available: <a href="http://www.rcog.org.uk/files/rcog-corp/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/</a> GTG19VTEHRT310511.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 41 (May 2012) The Initial Management of chronic Pelvic Pain. Available: http:// <a href="http://www.rcog.org.uk/files/rcog-corp/CPP" target="_blank" rel="noopener noreferrer">www.rcog.org.uk/files/rcog-corp/CPP</a>_ GTG2ndEdition230512.pdf
RANZCOG College Statement C-Gyn 9 (March 2011) Management of the Menopause. Available: <a href="http://www" target="_blank" rel="noopener noreferrer">http://www</a>. ranzcog.edu.au/component/docman/doc_view/915-c-gyn-09-management-of-the-menopause.html?Itemid=341
RANZCOG College Statement C-Gyn 6 (March 2012) Investigation of Intermenstrual and Postcoital Bleeding. Available: <a href="http://www.ranzcog.edu.au/component/" target="_blank" rel="noopener noreferrer">http://www.ranzcog.edu.au/component/</a> docman/doc_view/907-c-gyn-06-investigation-of-intermenstrual-and-postcoital-bleeding.html?Itemid=341
Sampson JA (1921) Perforating hemorrhagic (chocolate) cysts of the ovary. Their importance and especially their relation to pelvic adenomas of the endometrial type ('adenomyoma' of the uterus, rectovaginal septum, sigmoid, etc.). Archives of Surgery 3:245-323.
*The Women's Health Initiative steering committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the WHI randomised controlled trial. Journal of the American Medical Association 291:1701-1712
*Writing group for the Women's Health Initiative (WHI) randomised controlled trial (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results the WHI randomised controlled trial. Journal of the American Medical Association 288:321-333</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-17">CHAPTER 17<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-17" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Bhattacharya S, Porter M, Amalraj E et al (2009) The epidemiology of infertility in the North East of Scotland. Human Reproduction 24 (12):3096-3107
Brosens J, Gordon A (1990) Tubal Infertility. J B Lippincott, Philadelphia
Insler V, Lunenfeld B (1986) Infertility, Male and Female. Churchill Livingstone, Edinburgh
Lashen H (2001) Investigations for infertility. Current Obstetrics and Gynaecology 11:239-244
Ledger WL (2002) In vitro fertilization. Current Obstetrics and Gynaecology 12:269-275
National Collaborating Centre for Womens and Childrens Health (2004) Fertility Assessment and Treatment for People with Fertility Problems. RCOG press Availalable: <a href="http://www.rcog.org.uk/files/rcog-corp/uploaded-files/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/uploaded-files/</a> NEBFertilityFull.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guidelines No. 24 (Oct 2006) The Investigation and Management of Endomtreiosis. Available: <a href="http://www" target="_blank" rel="noopener noreferrer">http://www</a>. rcog.org.uk/files/rcog-corp/GTG2410022011.pdf
Taylor A (2001) The subfertile couple. Current Obstetrics and Gynaecology 11:115-125</p>
<p>Wakley G (2002) Sexual dysfunction. Current Obstetrics and Gynaecology 12:35-40</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-18">CHAPTER 18<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-18" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Abortion Act (1967) HMSO, London
Ankum A (2000) Diagnosing suspected ectopic pregnancy. British Medical Journal 321:1235-1236
*Clark P, Walker ID, Langhorne P et al (2010) Scottish pregnancy intervention (SPIN) study: a multicentre, randomised controlled trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage. Blood 115:4162-4167
Demetroulis C, Saridogan E, Kunde D et al (2001) A prospective RCT comparing medical and surgical treatment for early pregnancy failure. Human Reproduction 16:365-369
Department of Health, Department for Education and Employment, Home Office (2001) The Removal, Retention and Use of Human Organs and Tissue Post-Mortem Examination. Advice from the Chief Medical Officer. Stationery Office, London
Eliakim R, Abulafia O, Sherer DM (2000) Hyperemesis: a current review. American Journal of Perinatology 17 (4):207-218</p>
<p>Graziosi GC, Moi BW, Ankum WM et al (2001) Management of early pregnancy loss - a systematic review. Internation Journal of Gynaecology and Obstetrics 86:337-346
Regan L, Rai R (2000) Epidemiology and the medical causes of miscarriage. Best Practice and Research in Clinical Obstetrics and Gynaecology 14 (5):839-854
Royal College of Obstetricians and Gynaecologists Greentop guideline No. 21 (May 2004) The Management of Tubal Pregnancy. Available: <a href="http://www.rcog.org.uk/files/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/</a> rcog-corp/GTG21_230611.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 25 (Oct 2006) The Management of Early Pregnancy Loss. Available: <a href="http://www.rcog.org.uk/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/</a> files/rcog-corp/uploaded-files/ GT25ManagementofEarlyPregnancyLoss2006.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 38 (Feb 2010) Management of Gestational Trophoblastic Disease. Available: <a href="http://www.rcog.org.uk/files/rcog-corp/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/</a> GT38ManagementGestational0210.pdf
Royal College of Obstetricians and Gynaecologists Greentop Guideline No. 17 (April 2011) The Investigation and Treatment of Couples with Recurrent First-trimester and Second-trimester Miscarriage. Available: <a href="http://www" target="_blank" rel="noopener noreferrer">http://www</a>. rcog.org.uk/files/rcog-corp/GTG17recurrentmiscarriage. pdf
Speroff L, Glass RH, Kase NG (1994) Ectopic pregnancy. In: Speroff L, Glass RH, Kase NG (eds) Clinical Gynecologic Endocrinology and Infertility. Williams and Wilkins, Baltimore, 32:pp. 947-964
*Trinder J, Brocklehurst P, Porter R et al (2006) Management of miscarriage: expectant, medical or surgical? Results of randomised controlled trial (MIST). British Medical Journal 332:1235-1240</p>
<p>Zhang J, Gilles JM, Barnhart K et al (2005) A comparison of medical management with misoprostol and surgical management for early pregnancy failure. New England Journal of Medicine 353:761-769</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-19">CHAPTER 19<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-19" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Adaikan PG, Chong YS, Chew SSL et al (2000) Male sexual dysfunction. Current Obstetrics and Gynaecology <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>:</mo><mn>23</mn><mo>−</mo><mn>28</mn></mrow><annotation encoding="application/x-tex">10: 23-28</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">23</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">28</span></span></span></span></span>
Barton SE (2000) Classification, general principles of vulval infections. Current Obstetrics and Gynaecology <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>:</mo><mn>2</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">10: 2-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span>
Berek JS (2007) Berek and Novak's Gynecology, 14th edn. Lippincott, Williams &amp; Wilkins, Philadelphia
Breen KJ, Cordner SM, Thomson CJH et al (2010) Good Medical Practice: Professionalism, Ethics and Law. Cambridge University Press, Melbourne
Bignell CJ (1997) Chlamydial infections in obstetrics and gynaecology. Current Obstetrics and Gynaecology 7:104-109
Denman M (1999) Gynaecological aspects of female sexual dysfunction. Current Obstetrics and Gynaecology 9:88-92
Department of Health (1990) Handbook of Contraceptive Practice. HMSO, London
Hampton N (2001) Choice of contraception. Current Obstetrics and Gynaecology 11:50-53
Hamoda H, Bignell C (2002) Pelvic infections. Current Obstetrics and Gynaecology 12:185-190
Johnstone FD (1992) Clinical Obstetrics and Gynaecology. Baillière Tindall, London
Ledger WJ, Witkin SS (2007) Vulvovaginal Infections. Manson Publishing, London
Loudon N (1991) Handbook of Family Planning, 2nd edn. Churchill Livingstone, Edinburgh
Masters T, Everett S (2002) Intrauterine and barrier contraception. Current Obstetrics and Gynaecology <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>:</mo><mn>28</mn><mo>−</mo><mn>34</mn></mrow><annotation encoding="application/x-tex">12: 28-34</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">28</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">34</span></span></span></span></span>
Robinson C, Kubba AA (1997) Medical problems and oral contraceptives. Current Obstetrics and Gynaecology 7:173-179
Royal Australian and New Zealand College of Obstetrics and Gynaecology College Statement C-Gyn 11 (Jul 2012) Emergency Contraception. Available: <a href="http://www.ranzcog" target="_blank" rel="noopener noreferrer">http://www.ranzcog</a>. edu.au/component/docman/doc_view/1001-c-gyn-11-emergency-contraception.html?Itemid=341
Royal College of Obstetricians and Gynaecologists (2004) Evidence-based Guideline 4: Male and Female Sterilisation. RCOG Press, London. Available: http:// <a href="http://www.rcog.org.uk/files/rcog-corp/uploaded-files/" target="_blank" rel="noopener noreferrer">www.rcog.org.uk/files/rcog-corp/uploaded-files/</a> NEBSterilisationFull060607.pdf
Royal College of Obstetricians and Gynaecologists (2011) Evidence-based guideline 7: The Care of Women Requesting Induced Abortion. RCOG Press, London. Available: <a href="http://www.rcog.org.uk/files/rcog-corp/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/</a> Abortion%20guideline_web_1.pdf
Stewart P, Fletcher J (2002) Therapeutic termination of pregnancy. Current Obstetrics and Gynaecology <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>:</mo><mn>22</mn><mo>−</mo><mn>27</mn></mrow><annotation encoding="application/x-tex">12: 22-27</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">22</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">27</span></span></span></span></span></p>
<p>Spagne VA, Prior RB (1985) Sexually Transmitted Diseases. Marcel Dekker, New York
Szarciwski A, Guillebaud J (1994) Contraception. Oxford University Press, Oxford
Walters WAW (1991) Clinical Obstetrics and Gynaecology. Baillière Tindall, London</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-20">CHAPTER 20<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-20" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Berek JS, Neville F, Hacker NF (2009) Berek and Hacker's Gynecologic Oncology, 5th edn. Lippincott, William &amp; Wilkins, Philadelphia
Brown V, Sridhar T, Symonds RP (2011) Principles of chemotherapy and radiotherapy. Obstetrics, Gynaecology and Reproductive Medicine 21 (12):339-345
*Buys SS, Partridge E, Black A et al (2011) Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian cancer screening randomised controlled trial. Journal of the American Medical Association 305:2295-2303
Freeman S, Hampson F, Addley H et al (2009) Imaging of the female pelvis. Obstetrics, Gynaecology and Reproductive Medicine 19 (10):271-281
Hannemann MH, Alexander HM, Cope NJ et al (2010) Endometrial hyperplasia: a clinician's review. Obstetrics, Gynaecology and Reproductive Medicine 20 (4):116-120</p>
<p>Holland C (2010) Endometrial cancer. Obstetrics, Gynaecology and Reproductive Medicine 20 (12):347-352</p>
<p>Iyengar S, Acheson N (2008) Premalignant vulval conditions. Obstetrics, Gynaecology and Reproductive Medicine 18 (3):60-63
Kyrgiou M, Shafi MI (2010) Colposcopy and cervical intra-epithelial neoplasia. Obstetrics, Gynaecology and Reproductive Medicine 20 (5):38-46
Kyrgiou M, Shafi MI (2010) Invasive cancer of the cervix. Obstetrics, Gynaecology and Reproductive Medicine 20 (5):47-54</p>
<p>Palmer J, Gillespie A (2012) Palliative care in gynaecological oncology. Obstetrics, Gynaecology and Reproductive Medicine 22 (5):123-128
Peevor R, Fiander AN (2010) Human papillomavirus (including vaccination). Obstetrics, Gynaecology and Reproductive Medicine 20 (10):295-299
Robinson Z, Edey K, Murdoch J (2011) Invasive vulval cancer. Obstetrics, Gynaecology and Reproductive Medicine 21 (5):129-136
Royal Australian and New Zealand College of Obstetrics and Gynaecology College Statement C-Gyn 5 (Jul 2010) Screening for the Prevention of Cervical Cancer. Available: <a href="http://www.ranzcog.edu.au/component/" target="_blank" rel="noopener noreferrer">http://www.ranzcog.edu.au/component/</a> docman/doc_view/908-c-gyn-05-screening-for-the-prevention-of-cervical-cancer.html?Itemid=341
Shafi MI, Earl H, Tan LT (2010) Gynaecological Oncology. Cambridge University Press, Cambridge
Symonds IM (2012) Screening for gynaecological conditions, Obstetrics, Gynaecology and Reproductive Medicine. Available: <a href="http://dx.doi.org/10.1016/" target="_blank" rel="noopener noreferrer">http://dx.doi.org/10.1016/</a> j.ogrm.2012.11.005</p>
<p>Taylor SE, Kirwan JM (2012) Ovarian cancer: current management and future directions. Obstetrics, Gynaecology and Reproductive Medicine 22 (2):33-37</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-21">CHAPTER 21<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-21" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>*Altman D, Väyrynen T, Engh ME et al; Nordic Transvaginal Mesh Group (2011) Anterior colporrhaphy versus transvaginal mesh for pelvic-organ prolapse. New England Journal of Medicine 364:1826-1836
DeLancey JO (1992) Anatomic aspects of vaginal eversion after hysterectomy. American Journal of Obstetrics and Gynecology 166:1717
National Institutes for Health and Clinical Excellence Clinical Guideline 40. (Oct 2006) Urinary Incontinence. The Management of Urinary Incontinence in Women. Available: <a href="http://www.nice.org.uk/nicemedia/pdf/" target="_blank" rel="noopener noreferrer">http://www.nice.org.uk/nicemedia/pdf/</a> CG40NICEguideline.pdf
*Ward K, Hilton P; United Kingdom and Ireland Tensionfree Vaginal Tape Trial Group (2002) Prospective multicentre randomised trial of tension-free vaginal tape and colposuspension as primary treatment for stress incontinence. British Medical Journal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>325</mn><mo>:</mo><mn>67</mn><mo>−</mo><mn>70</mn></mrow><annotation encoding="application/x-tex">325: 67-70</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">325</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">67</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">70</span></span></span></span></span></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="appendix-a">APPENDIX A<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#appendix-a" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Croissant K, Shafi MI (2009) Preoperative and postoperative care in gynaecology. Obstetrics, Gynaecology and Reproductive Medicine (3):68-74
National Institute for Clinical Excellence (NICE) Clinical Guidline 46. (Jan 2010) Venous Thromboembolism: Reducing the Risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Inpatients Undergoing Surgery. Available: http:// publications.nice.org.uk/ venous-thromboembolism-reducing-the-risk-cg92
Royal College of Obstetricians and Gynaecologists Clinical Governance Advice no. 6 (Dec 2008) Obtaining Valid Consent. Available: <a href="http://www.rcog.org.uk/files/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/</a> rcog-corp/CGA6-15072010.pdf
Scottish Intercollegiate Guidelines Network (SIGN) (2004) Postoperative Management in Adults. A Practical Guide to Postoperative Care for Clinical Staff. SIGN, Edinburgh
Sharp HT (2010) Prevention and management of complications from gynecologic surgery. Obstetrics &amp; Gynecology Clinics of North America 37 (3):461-467</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="appendix-b">APPENDIX B<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#appendix-b" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>General Medical Council Confidentiality: Supplementary Guidance Available: <a href="http://www.gmc-uk.org" target="_blank" rel="noopener noreferrer">www.gmc-uk.org</a>
General Medical Council: Research: The Role and Responsibilities of Doctors. Available: <a href="http://www.gmc-uk.org" target="_blank" rel="noopener noreferrer">www.gmc-uk.org</a></p>
<p>McSherry R, Pearce P (eds) (2007) Clinical Governance: A Guide to Implementation for Healthcare Professionals, 2nd edn. Blackwell, Oxford
Royal College of Obstetricians &amp; Gynaecologists Clinical Governance Advice No. 5 (Oct 2003) Understanding Audit. Available: <a href="http://www.rcog.org.uk/files/rcog-corp/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/</a> uploaded-files/ClinGov5UnderstandingAudit2003.pdf
Royal College of Obstetricians and Gynaecologists (2006) Guideline Compendium: A Compendium of College Guidelines Available. RCOG Press, London
Royal College of Obstetricians and Gynaecologists Clinical Governance Advice No. 2 (Sep 2009) Improving Patient Safety: Risk Management for Maternity and Gynaecology. Available: <a href="http://www.rcog.org.uk/files/rcog-corp/" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/files/rcog-corp/</a> CGA2ImprovingPatientSafety2009.pdf
Scottish Intercollegiate Guidelines Network. SIGN 50: A Guideline Developer's Handbook. Scottish Intercollegiate Guidelines Network. (2011); pp 23-27. Available: http:// <a href="http://www.sign.ac.uk/guidelines/fulltext/50/" target="_blank" rel="noopener noreferrer">www.sign.ac.uk/guidelines/fulltext/50/</a></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="appendix-c">APPENDIX C<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#appendix-c" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Breen KJ, Cordner SM, Thomson CJH et al (2010) Good Medical Practice: Professionalism, Ethics and Law. Cambridge University Press, Melbourne
Chamberlain GVP (ed) (1992) How to Avoid Medico-legal Problems in Obstetrics and Gynaecology, 2nd edn. RCOG, London
Clements RV (1994) Safe Practice in Obstetrics and Gynaecology. A Medico-legal Handbook. Churchill Livingstone, Edinburgh</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="further-websites">FURTHER WEBSITES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#further-websites" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Since the publication of the last edition, the availability of online resources has expanded exponentially. Many of these are open source and the issue is no longer whether there is information the reader can access online but which information is reliable and detailed enough for the the student who wants to study an area in greater detail but concise enough not to overwhelm them. We have included a number of online resources within the relevant sections but it should be noted that both the Royal College of Obstetrics and Gynaecology (RCOG) in the UK and the Royal Australian and New Zealand College of Obstetrics and Gynaecology (RANZCOG) and the National Institute for Health and Clinical Excellence publish statements and guidelines about clinical practice. These not only provide a summary of what is considered best practice in each country, but often themselves contain further links to other material and reference original evidence. They have the added advantage of being more regularly updated than most textbooks. It should be noted that as documents are updated the URL may change. If you are unable to access the relevant webpage using the URLs listed in the chapters you can copy the URL into your search engine for the relevant contents webpage given below and search by name for the information.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-national-institute-for-clinical-excellence-guidelines">The National Institute for Clinical Excellence guidelines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-national-institute-for-clinical-excellence-guidelines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><a href="http://www.nice.org.uk/guidance/index.jsp?action=byTopic" target="_blank" rel="noopener noreferrer">http://www.nice.org.uk/guidance/index.jsp?action=byTopic</a> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">&amp;</mi><mn>0</mn><mo>=</mo><mn>7252</mn></mrow><annotation encoding="application/x-tex">\&amp; 0=7252</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">&amp;0</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7252</span></span></span></span></span></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-royal-college-of-obstetrics-and-gynaecology-rcog">The Royal College of Obstetrics and Gynaecology (RCOG)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-royal-college-of-obstetrics-and-gynaecology-rcog" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="green-top-guidelines">Green-top Guidelines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#green-top-guidelines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><a href="http://www.rcog.org.uk/guidelines?filter0%5C%5B%5C%5D=10" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/guidelines?filter0\%5B\%5D=10</a></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-governance-advice">Clinical Governance Advice<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-governance-advice" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><a href="http://www.rcog.org.uk/guidelines?filter0%5C%5B%5C%5D=6" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/guidelines?filter0\%5B\%5D=6</a></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="joint-guidelines">Joint Guidelines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#joint-guidelines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><a href="http://www.rcog.org.uk/guidelines?filter0%5C%5B%5C%5D=11" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/guidelines?filter0\%5B\%5D=11</a></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="national-evidence-based-guidelines">National Evidence Based Guidelines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#national-evidence-based-guidelines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><a href="http://www.rcog.org.uk/guidelines?filter0%5C%5B%5C%5D=12" target="_blank" rel="noopener noreferrer">http://www.rcog.org.uk/guidelines?filter0\%5B\%5D=12</a></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="royal-australian-and-new-zealand-college-of-obstetrics-and-gynaecology-ranzcog-statements-on-women-s-health">Royal Australian and New Zealand College of Obstetrics and Gynaecology (RANZCOG) statements on women's health<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#royal-australian-and-new-zealand-college-of-obstetrics-and-gynaecology-ranzcog-statements-on-women-s-health" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="obstetrics">Obstetrics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#obstetrics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><a href="http://www.ranzcog.edu.au/womens-health/statements-a-guidelines/college-statements-and-guidelines" target="_blank" rel="noopener noreferrer">http://www.ranzcog.edu.au/womens-health/statements-a-guidelines/college-statements-and-guidelines</a>. html?showall=&amp;start=1</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="gynaecology">Gynaecology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gynaecology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><a href="http://www.ranzcog.edu.au/womens-health/statements-a-guidelines/college-statements-and-guidelines" target="_blank" rel="noopener noreferrer">http://www.ranzcog.edu.au/womens-health/statements-a-guidelines/college-statements-and-guidelines</a>. html?showall=&amp;start=2</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="general">General<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#general" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><a href="http://www.ranzcog.edu.au/womens-health/statements-a-guidelines/college-statements-and-guidelines.html?sho" target="_blank" rel="noopener noreferrer">http://www.ranzcog.edu.au/womens-health/statements-a-guidelines/college-statements-and-guidelines.html?sho</a> wall=&amp;start=3</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-websites">Other websites<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-websites" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The National electronic library for Health has links to guidelines for both the UK and USA on: <a href="http://www" target="_blank" rel="noopener noreferrer">http://www</a>. evidence.nhs.uk</p>
<p>The most recent version of the Confidential Enquiry into Maternal Deaths in the United Kingdom: http:// onlinelibrary.wiley.com/doi/10.1111/bjo.2011.118.issue-s1/ issuetoc</p>
<p>The most recent report on maternal deaths in Asutralia the Australian Insititue of Health and Welfare: <a href="http://www.aihw.gov.au/WorkArea/DownloadAsset" target="_blank" rel="noopener noreferrer">http://www.aihw.gov.au/WorkArea/DownloadAsset</a>. aspx?id=10737421514</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="index">Index<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#index" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Page numbers followed by ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>f</mi></mrow><annotation encoding="application/x-tex">f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span> ' indicate figures, ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>t</mi></mrow><annotation encoding="application/x-tex">t</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6151em;"></span><span class="mord mathnormal">t</span></span></span></span></span> ' indicate tables, and ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>b</mi></mrow><annotation encoding="application/x-tex">b</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal">b</span></span></span></span></span> ' indicate boxes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a">A<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>ABC therapy, maternal postpartum collapse, 204-205
Abdominal examination, 69, 225, 226 f
placenta praevia diagnosis, 100
Abdominal girth, 73
Abdominal hysterectomy, 245
Abdominal pain, 120
acute, 262
history taking, 224
Abdominal palpation, 73
abdominal girth, 73
symphysial-fundus height, 73, 73b, 73 f
uterine fundus, 73
Abdominal pregnancy management, 286
Abdominal wall, congenital abnormalities, 142
Abnormal movements, fetal abnormalities, 145
Abnormal uterine bleeding (AUB), 241-242
history taking, 224
intermenstrual bleeding, 241
intrauterine contraceptive devices, 296
myometrial benign tumours, 236
postcoital bleeding, 242
postmenopausal bleeding, 242
Abortion see Termination of pregnancy
Abortion Act (1967), 373
Abruptio placentae, 101-104
aetiology, 101
case study, 102b
clinical assessment, 103
clinical types, 102-103
complications, 104, 104f
differential diagnosis, 103
incidence, 101
management, 103-104, 103f
mortality rate, 101
presentation, 102-103, 102f
prognosis, 103
Acceleration, fetal heart rate, 167
Acetabulum, 4f
Acid-base balance
fetal monitoring, 169
placental gas transfer, 46
see also pH
aCL see Anticardiolipin antibodies (aCL)
Acquired dysmenorrhoea, 249-250
ACTH (adrenocorticotrophic hormone), 38
Activated partial thromboplastin time (APTT), 31
Active transport, placental transfer, 45
Acute abdominal pain, 262
Acute appendicitis, 262
upper genital tract infection vs., 311
Acute cervicitis treatment, 309
Acute compartment syndrome, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>358</mn><mo>−</mo><mn>359</mn></mrow><annotation encoding="application/x-tex">358-359</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">358</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">359</span></span></span></span></span>
Acute fatty liver of pregnancy (AFLP), <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>129</mn><mo>−</mo><mn>130</mn></mrow><annotation encoding="application/x-tex">129-130</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">129</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">130</span></span></span></span></span>
Acute polyhydramnios, 52
Acute pyelonephritis, 127-128
Acute salpingitis, 311f
Acute urinary tract infections, upper genital tract infection <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>v</mi><mi>s</mi><mi mathvariant="normal">.</mi><mo separator="true">,</mo><mn>311</mn></mrow><annotation encoding="application/x-tex">v s ., 311</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.03588em;">v</span><span class="mord mathnormal">s</span><span class="mord">.</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">311</span></span></span></span></span>
Acute viral hepatitis, 126-128
Adenocarcinoma, vagina, 321
Adenomyosis, 238, 238f
female infertility, 268
heavy menstrual bleeding, 242-243
Adjuvant radiotherapy, endometrial carcinoma, 330
Adrenal glands, 39
Adrenaline (epinephrine), 44</p>
<p>Adrenarche, 252
premature, 254
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-adrenergic agonists, 171-172
Adrenocorticotrophic hormone (ACTH), 38
AFC (antral follicle count), 269
AFE see Amniotic fluid embolism (AFE)
AFI (amniotic fluid index), 112
Afibrinogenaemia, 104
AFLP (acute fatty liver of pregnancy), <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>129</mn><mo>−</mo><mn>130</mn></mrow><annotation encoding="application/x-tex">129-130</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">129</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">130</span></span></span></span></span>
AFV see Amniotic fluid volume (AFV)
Age, congenital abnormalities, 144
Albumin synthesis, 34
Alcohol intake, 81
Aldosterone, 39
Alloimmune factors, miscarriage, 279
Amenorrhoea
history taking, 224
lactation, 301
questions and answers, 386, 403
secondary see Secondary amenorrhoea
Amino acids, 35
Ammonia, placenta, 47
Amniocentesis, 52-53, 53f, 147f
biochemical screening, 146
indications, 53
Amniotic fluid, 51-52
formation, 51, 51f
questions and answers, 379, 395
tests, 52
volume, 51
Amniotic fluid embolism (AFE), 197
maternal postpartum collapse, 204
Amniotic fluid index (AFI), 112
Amniotic fluid volume (AFV)
fetal abnormalities, 145
fetal assessment, 152-153
Amniotomy hook, 161
Amphetamine, 81
Ampulla, Fallopian tube, 7
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-Amylase, capacitation, 19</p>
<p>Anaemia, 121-123
aetiology, 121
clinical features, 122
diagnosis, 122
implications in pregnancy, 122
management, 122, 358
multiple pregnancy, 107
postpartum complications, 203
prophylaxis, 122-123
questions and answers, 381-382, 399
risk factors, 121-122
Anaesthesia
regional, 358
spinal, 165
Analgesia
combined oral contraceptive pill interactions, 299t
epidural see Epidural analgesia
inefficient uterine activity, 177
inhalational, 164
labour see Labour
narcotic, 164
occipitoposterior presentation, 188
postoperative care, 360
regional, 164-166, 164f-165f
Anal sphincter injury, questions and answers, 384, 401
Analytical studies, research, 367
Anaphylaxis, maternal postpartum collapse, 204
Androblastomas, 334
Anencephaly, 142 f
Angiotensin II
pre-eclampsia, 91
uteroplacental blood flow, 44
Anovulation
heavy menstrual bleeding, 243
investigations, 269
nongonadotropic, 267
treatment, 272-273
Antenatal cardiotocography, 95
Antenatal care, 79-88, 86t
aims of, 79-80
booking visit, 82
breast care, 87-88
carbohydrate intake, 86-87
coitus, 87
cultural awareness, 88
dietary advice, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mo>−</mo><mn>87</mn><mo separator="true">,</mo><mn>87</mn><mi mathvariant="normal">t</mi></mrow><annotation encoding="application/x-tex">85-87,87 \mathrm{t}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">85</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">87</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">87</span><span class="mord mathrm">t</span></span></span></span></span>
education, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mo>−</mo><mn>87</mn></mrow><annotation encoding="application/x-tex">85-87</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">85</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">87</span></span></span></span></span>
energy intake, 86
exercise, 87
fat intake, 86
frequency of, 79
historical aspects, 79
mineral intake, 87
patterns, 79-80
protein intake, 86
provision of, 79-80
questions and answers, 380-381, 397-398
recommended tests, 82-85
see also specific tests
schedules, 85
social awareness, 88
subsequent visits, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mo separator="true">,</mo><mn>86</mn><mi mathvariant="normal">t</mi></mrow><annotation encoding="application/x-tex">85,86 \mathrm{t}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">85</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">86</span><span class="mord mathrm">t</span></span></span></span></span>
vitamins, 87
Antenatal classes, 161
Antenatal psychiatric disorders, 208-209
Antepartum haemorrhage, 98-105
causes, 104-105, 104f
definition, 98
multiple pregnancy, 108
questions and answers, 381, 403
Anterior arm and leg presentation, 116 f
Anterior arm presentation, 116 f
Anterior colporrhaphy, 347, 347f
Anterior ligament, uterus, 6
Anterior superior iliac spine, 4 f
Antiasthmatic drugs, 299t
Antibiotic(s)
combined oral contraceptive pill interactions, 299t
prophylaxis, 358
upper genital tract infections, 312
see also specific types
Anticardiolipin antibodies (aCL)
miscarriage, 279
recurrent miscarriage, 282
Anticholinergic drugs, 210
see also specific types
Anticoagulant drugs, 299t
postnatal anticoagulation, 202-203
see also specific types
Anticonvulsant drugs
combined oral contraceptive pill interactions, 299t
congenital abnormalities, 144
see also specific types
Antidepressant medications, 209-210
antenatal psychiatric disorders, 208
breastfeeding, 215
miscarriage, 278
severe postnatal depression, 214
see also specific types
Anti-D immunoglobulin, 83, 83f, 281
Anti-emetic therapy, 289
see also specific types
Anti-epileptic drugs (AEDs), 135, 211
antenatal psychiatric disorders, 209
breastfeeding, 215
see also specific types</p>
<p>Antihistamine drugs
combined oral contraceptive pill interactions, 299 t
nausea and vomiting, 289
see also specific types
Antihypertensive drugs, 94
eclampsia management, 98
see also specific types
Antipsychotic medications, 210-211
breastfeeding, 215
see also specific types
Antral follicle count (AFC), 269
Anus, 5 f
Anxiety, postnatal period, 217, 217b
Aortic lymph node, 8 f
Apareunia, 314
Appendicitis
acute see Acute appendicitis
female infertility, 267-268
APTT (activated partial thromboplastin time), 31
Arcus tendineus fasciae ani, 342 f
Arcus tendineus fasciae pelvis (ATFP), 341
Arcus tendineus levator ani, 342 f
Arginine vasopressin (AVP), 38
Arrhenoblastomas, 334
Arterial blood pressure, 29-30
Arterial disease, contraceptive pill side effects, 298
ARTs see Assisted reproduction technologies (ARTs)
Ascorbic acid supplements, 87
Asherman's syndrome, 268
Asphyxia, neonatal diseases/disorders, 205
Aspirin
diabetes mellitus, 131-132
preoperative assessment, 358
questions and answers, 389, 406
Assessments, preoperative see Preoperative assessment
Assisted reproduction technologies (ARTs), 82
legislation, 373-374
Asthma, 137
ATFP (arcus tendineus fasciae pelvis), 341
At-risk infants, fetal assessment, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>148</mn><mo>−</mo><mn>153</mn><mo separator="true">,</mo><mn>149</mn><mi mathvariant="normal">t</mi></mrow><annotation encoding="application/x-tex">148-153,149 \mathrm{t}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">148</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">153</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">149</span><span class="mord mathrm">t</span></span></span></span></span>
Atypical antipsychotic drugs, 209-211
AUB see Abnormal uterine bleeding (AUB)
Auscultation, 75-77, 77f, 225
fetal heart, 148
intermittent, 166, 166t</p>
<p>Autoimmune diseases/disorders, 138
miscarriage, 279
see also specific diseases/disorders
Autonomic innervation, pelvic anatomy, 9
AVP (arginine vasopressin), 38</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b">B<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Backache, 120-121
Bacterial vaginosis, 308, 308f
Baker-Walker halfway system, 345, 345f, 345 t
Bandl's ring, 157-158
Barrier contraception see Contraception
Bartholin's glands, 4-5, 10f
abscess/cysts, 261-262
infections, 307, 310f
treatment, 309
questions and answers, 377, 393
Basal heart rate, fetal monitoring, 167, 170 f
Basal zone (zona basalis), endometrial cycle, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>17</mn><mo>−</mo><mn>18</mn></mrow><annotation encoding="application/x-tex">17-18</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">17</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">18</span></span></span></span></span>
Bed-wetting, 350
Benzalkonium, 294
Benzodiazepines, 215
Betamethasone, 173
Bicornis bicollis, 278 f
Bicornis unicornis, 278 f
Bimanual vaginal examination, 228, 229 f
questions and answers, 385, 403
Biochemical screening, 85, 146
fetal assessment, 143-144
pre-test counselling, 146
secondary amenorrhoea, 247
Biofeedback therapy, overactive bladder syndrome, 354
Biophysical measurements, fetal assessment, 152-153
Biopsy, vulval intraepithelial neoplasia, 318, 318 f
Bipolar illness management, 211
Birth weight, fetal development, 48, 48 f
Bladder outlet obstruction, 354
Blastocysts
early placental development, 41
fertilization, 19-20, 20 f
Bleeding see Haemorrhage/bleeding
Bleeding time, 31
Blood, changes in pregnancy, 30-32
nutrients, 34-35
see also specific components
Blood group testing, 83
Blood pressure
arterial, 29-30
control/management, 93
eclampsia management, 97-98
measurement, 68b, 68f
in pregnancy, 28 f
umbilical cord, 43
see also Hypertension
Blood supply
pelvic anatomy, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mo>−</mo><mn>8</mn><mo separator="true">,</mo><mn>7</mn><mi mathvariant="normal">f</mi></mrow><annotation encoding="application/x-tex">7-8,7 \mathrm{f}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">8</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">7</span><span class="mord mathrm" style="margin-right: 0.07778em;">f</span></span></span></span></span>
uterus in pregnancy, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo separator="true">,</mo><mn>25</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">25,25 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
The blues, 212
BMI (body mass index), 68
Body mass index (BMI), 68
Bohr effect, 45, 46f
Bone pain, post-menopause, 257
Bones
pelvic anatomy, 3, 4f
post-menopause, 257
Bony pelvis, 70-71, 71f
Borderline ovarian malignancies, 337
Brandt-Andrews technique, 184, 185f
Braxton Hicks contractions, 27
Breast(s)
antenatal care, 87-88
changes in pregnancy, 37, 37f
examination, 69, 69f, 225, 226f
Breast abscess, postpartum complications, 202
Breast cancer, 69
contraceptive pill side effects, 298
Breastfeeding, 200-201, 200f
colostrum, 200
personal hygiene, 200-201
psychiatric medication, 215
see also Lactation
Breast tenderness, history taking, 67
Breech presentation, 112-116
causes, 113, 113b
complications, 113-114
delivery, 114-116
fetal abnormalities, 145
hazards, 113
management, 113
types, 112-113, 112 f
vaginal delivery, 114, 115 f
Brenner (transitional) cell cystadenocarcinomas, 335
Brenner cell tumours, 334
Broad ligaments, 6, 343
Bromocriptine, 315
Brow presentation, 188, 188f</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="c">C<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>CA-125, 338
Cabergoline, 273
Caesarean section, 191-193, 194f
classification, 192
complications, 193
indications, 191-193
multiple pregnancy, 109
postpartum infections, 202
preterm delivery, 173
questions and answers, 383, 401
vaginal delivery, 115-116
Calcitonin, 39
Calcium
changes in pregnancy, 35
placental transfer, 45
supplements, 87
Calcium channel blockers (CCBs), 94
preterm delivery treatment, 172-173
Calcium reabsorption, 34
Caldicott principles, 364-365
Candida infections see Candidiasis
Candidiasis, 307
vulval pruritus, 259 t
Capacitation, fertilization, 19
Carbohydrate intake, antenatal care, 86-87
Carbohydrate metabolism
changes in pregnancy, 34-35, 34f
placenta, 46
Carbon dioxide
changes in pregnancy, 32
placental transfer, 45-46
Carbon monoxide, smoking, 80
Carcinosarcomas (mixed müllerian tumours), 331, 331f
Cardiac disease, 136-137
maternal postpartum collapse, 204
Cardiac output
postpartum changes, 199
in pregnancy, 28t, 29
questions and answers, 378, 394
Cardiac position, 28-29
Cardiac size, 28-29
Cardinal ligament, 6
Cardiotocography (CTG)
antenatal, 95
fetal assessment, 152-153
fetal monitoring, 166-169, 167f
first stage of labour, 161-163
Cardiovascular system
changes in pregnancy, 28-30, 28f, 28 t
examination, 68, 68f
fetal development, 49-50, 50f
post-menopause, 257
postoperative complications, 362
postpartum changes, 199
stability in postoperative care, 360
see also specific features
Carpal tunnel syndrome, 121
Case control studies, 367
CBT (cognitive behavioural therapy), 251</p>
<p>CCBs see Calcium channel blockers (CCBs)
CD4 cell count, HIV infection, 126
Cell-mediated immune response, hypertension, 93
Centre for Maternal and Child Enquiries (CMACE), 56-57
neonatal death, 58-59
stillbirth causes, 58
Cephalopelvic disproportion, 178
Cervical assessment, labour induction, 175
Cervical caps, 293
Cervical carcinoma, 321-328
antepartum haemorrhage, 105
classification, 321-323, 322f, 322t
clinical features, 326-327
colposcopy, 323-324, 323f-324f
contraceptive pill side effects, 298
cytology, 321, 322f
FIGO classification, 326t
follow-up, 325-326
human papilloma virus, 324
investigations, 327
pathology, 326
pathophysiology, 323-324
prognosis, 327-328
screening, 321
treatment, 325, 327
tumour spread, 326
Cervical cerclage, recurrent miscarriage, 282
Cervical glandular intraepithelial neoplasia (CGIN), 325-326
Cervical intraepithelial neoplasia, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>324</mn><mo>−</mo><mn>326</mn><mo separator="true">,</mo><mn>324</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">324-326,324 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">324</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">326</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">324</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
Cervical pregnancy management, 286
Cervical smears, 227b
Cervicitis, 306-307
acute, treatment, 309
chronic, 307
Cervix, 5-6, 5f, 342 f
carcinoma see Cervical carcinoma
changes in pregnancy, 24-25, 25 f
dilatation, 163
examination, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo separator="true">,</mo><mn>70</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">70,70 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">70</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">70</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
female infertility, 268
incompetence, miscarriage, 279
integrity, labour initiation, 156
lesions, antepartum haemorrhage, 105
polyps, 260
squamous cell carcinoma, 388, 405
Chemoradiotherapy, cervical cancer treatment, 327
Chemotherapy, ovarian malignancies, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>336</mn><mo>−</mo><mn>337</mn></mrow><annotation encoding="application/x-tex">336-337</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">336</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">337</span></span></span></span></span>
Chicken pox, 125</p>
<p>Child protection, 374-375
psychiatric disorders, 218
Children, legal status of, 374
Chlamydia trachomatis infection, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>310</mn><mo>−</mo><mn>311</mn></mrow><annotation encoding="application/x-tex">310-311</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">310</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">311</span></span></span></span></span>
female infertility, 267
vulvovaginitis, 308
Chloasma, 68-69, 69f
Chloroquine, 126
Cholestasis, obstetric, 129
Chorion frondosum, 41
Chorionic gonadotrophin, placenta, 47
Chorionic villus sampling, 147 f
Chromosomal abnormalities
amniocentesis, 53
congenital abnormalities, 142-143, 145 t
Chronic cervicitis, 307
Chronic hypertensive disease, classification, 90
Chronic pelvic infections, 312
management, 312
symptoms and signs, 312
Chronic polyhydramnios, 52
Chronic renal disease, 130t
Cisterna chyli, 8 f
Clear-cell cystadenocarcinomas, 335
Clinical audit, 365-366, 365b
defining best practice, 365
monitoring, 365
planning for improvement, 365-366
preparing to monitor, 365
questions and answers, 390, 406
Clinical governance, 368
Clinical guidelines, 366
questions and answers, 390, 407
Clinical history
premenstrual syndrome, 251
preoperative assessment, 357
see also History-taking
Clinical incident reporting, 368
Clinical pelvimetry, 70
Clinical skills, 223-230
questions and answers, 380, 385, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo separator="true">,</mo><mn>402</mn><mo>−</mo><mn>403</mn></mrow><annotation encoding="application/x-tex">400,402-403</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">402</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">403</span></span></span></span></span>
see also specific skills
Clinical trials, 367
Clitoris, 4, 4f-5f, 10f
Clomipramine, 209
Clonidine, 258
Clopidogrel, 358
Clotrimazole, 309
Clotting factors, changes in pregnancy, 23b, 31-32
CMAC see Centre for Maternal and Child Enquiries (CMACE)
Coagulation diathermy, cervical cancer, 325</p>
<p>Cocaine, 81
Coccygeus muscle, 342 f
Coccyx, 3, 4f-5f, 342 f
Cognitive behavioural therapy (CBT), 251
Cohort studies, 367
Coincident (fortuitous) deaths, 59
Coitus, 20-21
antenatal care, 87
Coitus interruptus, 301
Colostrum, 200
Colporrhaphy, anterior, 347, 347f
Colposcopy, cervical cancer, 323-324, 323f-324f
Combined oral contraceptive pill, 296-297, 298b-299b
commencement, 298
drug interactions, 299-300, 299t
dysmenorrhoea management, 250
efficacy, 299
failure rate, 299
future review, 299
heavy menstrual bleeding, 244, 244f
lactation, 299
nausea and vomiting, 299
premenstrual syndrome, 251
side effects, 299
surgery, 299
Common iliac artery, 7 f
Communication, psychiatric disorders, 218
Compartment syndrome, acute, 358-359
Complete miscarriage, 280
Complications
intraoperative see Intraoperative complications
postpartum see Postpartum complications
Condoms
female, 293
male, 293
Condylomata acuminata see Genital warts
Cone biopsies
cervical cancer, 325
complications, 325
Confidential Enquiry Into Maternal Deaths (2006-2008), 119
Confidentiality, HIV infection, 126
Congenital abnormalities, 141-143
abdominal wall, 142
cardiac defects, 142, 143f
chromosomal abnormalities, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>142</mn><mo>−</mo><mn>143</mn><mo separator="true">,</mo><mn>145</mn><mi>t</mi></mrow><annotation encoding="application/x-tex">142-143,145 t</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">142</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">143</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">145</span><span class="mord mathnormal">t</span></span></span></span></span>
diabetes mellitus, 132
early pregnancy risk factors, 144-145
incidence, 141</p>
<p>late pregnancy risk factors, 145
neural tube defects, 141-142, 142f
see also specific diseases/disorders
Congenital cardiac defects, 142, 143f
Congenital heart disease, 145
Congenital vaginal cysts, 261
Conjoined twinning, 108, 111
Conjugated equine oestrogen, 257-258
Consent see Informed consent
Constipation, 120
Contraception, 291-305, 292t
barrier methods, 291-294
cervical caps, 293
diaphragm, 293, 293f
female condoms, 293
intrauterine devices see Intrauterine contraceptive devices (IUDs)
male condoms, 293
spermicides, 294
sponges, 294
emergency, 300
history taking, 66
hormonal, 296-305
contraceptive pill see Contraceptive pill
injectable compounds, 300
newer methods, 300
non-medical methods, 300-301
postnatal period, 205
questions and answers, 387-388, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>404</mn><mo>−</mo><mn>405</mn></mrow><annotation encoding="application/x-tex">404-405</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">404</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">405</span></span></span></span></span>
Contraceptive pill, 296-305
beneficial effects, 298-299
contraindications, 297
mode of action, 297
side effects, 297-298, 297t
see also specific methods
Cord presentation, labour, 178
Cord prolapse, 176, 178, 179f
Corona radiata, 15
Corpus albicans, 15
Corpus luteum
development, 15 f
ovulation, 15 f
Corpus uteri, 5
changes in pregnancy, 25-27, 26f
Corticosteroids
combined oral contraceptive pill interactions, 299t
placenta, 48
preterm delivery treatment, 173
Corticotrophin-releasing hormone (CRH)
hypothalamus, 38
labour initiation, 156
placenta, 48</p>
<p>Cortisol, 39
Counselling
fetal screening results, 146
preconception see Preconception counselling
preoperative care, 357
Couvelaire uterus, 102
CRH see Corticotrophin-releasing hormone (CRH)
CRL (crown rump length), 145
Crown rump length (CRL), 145
Cryocautery, cervical cancer, 325
Cryptomenorrhoea, 248
CTG see Cardiotocography (CTG)
Cultural awareness
antenatal care, 88
pelvic examination, 228-229
Cystadenocarcinomas, mucinous, 335, 336 f
Cystadenomas
mucinous, 333-334
serous, 333, 335
Cystic fibrosis, 137-138
Cystocele, 344
questions and answers, 388, 405
Cystometrograms, urinary incontinence, 350-352, 351f
Cytology
cervical cancer, 321, 322f
male infertility, 272
Cytotoxic agents, congenital abnormalities, 144
Cytotrophoblasts, stem villus, 42</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="d">D<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Darifenacin, 353t
Data collection, 363-365
GP consultation, 363-364
questions and answers, 389-390, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>406</mn><mo>−</mo><mn>407</mn></mrow><annotation encoding="application/x-tex">406-407</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">406</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">407</span></span></span></span></span>
research and data linkage, 364
Data protection, 372-373
questions and answers, 389, 406
Data Protection Act (1998), 364-365
D&amp;C (dilatation and curettage), 236
Deceleration, fetal heart rate, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>167</mn><mo>−</mo><mn>168</mn></mrow><annotation encoding="application/x-tex">167-168</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">167</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">168</span></span></span></span></span>
Decidual basalis, 41
Decidual capsularis, 41
Decidual reaction, 20
Deep dyspareunia, 313-314
Deep inguinal lymph node, 8 f
Deep transverse arrest, head malposition, 189
Deep vaginal wall haematomas, 197
Deep vein thrombosis (DVT), 128
postpartum complications, 202</p>
<p>Defining best practice, clinical audit, 365
Deflexed head, labour, 158-159
Dehydroepiandrosterone (DHEA)
labour initiation, 156
menopause, 255
placenta, 47-48
Delayed puberty, 254-255, 255t
Delivery, 183-197
breech presentation, 114-116
fetal abnormalities, 148
gestational diabetes management, 123
instrumental see Instrumental delivery
multiple pregnancy, 109-110
preterm see Preterm delivery
questions and answers, 377-378, 383-384, 393-394, 400-401
shoulder dystonia, 184b, 193-194, 194 f
see also Caesarean section; Vaginal delivery
Demographics, 82
Dennonviller's fascia, 342
Deprivation, perinatal death, 57, 57t
Dermatitis, vulval pruritus, 259 t
Dermoid cysts, 334, 335f
Descent
first stage of labour, 163
labour mechanism, 159
Descriptive research studies, 366-367
Detrusor instability, 350-352
overactive bladder syndrome, 353
Developed countries
maternal mortality rates, 59
perinatal mortality, 56-57
Dexamethasone, 173
DHEA see Dehydroepiandrosterone (DHEA)
Diabetes mellitus, 131-132
congenital abnormalities, 145
gestational see Gestational diabetes management, 132
preoperative preparation, 358
pregnancy implications, 131-132, 131 t
see also Gestational diabetes
Diaphragm
changes in pregnancy, 32
contraception, 293, 293f
Diastolic blood pressure, 28t
Diathermy
haemorrhage management, 359
laparoscopic ovarian diathermy, 273
DIC (disseminated intravascular coagulation), 92-93</p>
<p>Diet
antenatal care, 85-87, 87t
overactive bladder syndrome, 354
premenstrual syndrome, 251
Dilatation and curettage (D&amp;C), 236
Direct deaths, 59
Disseminated intravascular coagulation (DIC), 92-93
Diuretics, 251
DNA fragmentation index (DH), 271
Donor insemination, 275
Doppler flow studies, gestational hypertension, 95
Double blind clinical trials, 367
Double uterus, 234
Down's syndrome see Trisomy 21
Drew-Smythe catheter, 175, 176f
Drug history, miscarriage, 278
Drug toxicity/overdose, maternal postpartum collapse, 204
DVT see Deep vein thrombosis (DVT)
Dye insufflation, tubal patency, 269-270, 270f
Dysgerminomas, ovarian malignancies, 336
Dysmenorrhoea, 249-250
investigations, 250
management, 250
primary, 249
secondary (acquired), 249-250
Dyspareunia, 313-314
deep, 313-314
questions and answers, 388, 405
superficial, 313
Dysuria, 350</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="e">E<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#e" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Early deceleration, fetal heart rate, 168
Early neonatal rate, 56t
Early pregnancy assessment units (EPAU), 281
Early pregnancy care, 277-289
bleeding, 277
questions and answers, 387, 404
questions and answers, 386-387, 404
Eclampsia, 96-97
case study, 97b-98b
classification, 90
delivery, 98
management, 97-98
after delivery, 98
maternal postpartum collapse, 204
pathogenesis, 90-93
pathology, 90-93, 91f
superimposed, 90
symptoms, 95-96
see also Pre-eclampsia</p>
<p>Ectopic pregnancy, 282-286
acute presentation, 283, 283b
clinical presentation, 283-284
diagnosis, 284
intrauterine contraceptive devices, 296
management, 286
pathology, 284, 284f
predisposing factors, 283, 283t
sites of implantation, 283f
subacute presentation, 283-284, 284b
Ectropion, pelvic examination, 227
ECV (external cardiac version), breech presentation, 113, 114f
EDD (estimated date of delivery), 66, 66 f
Edinburgh Postnatal Depression Scale (EPDS), 212
Ejaculatory problems, 315
Elective delivery, 153
Electrical stimulation, overactive bladder syndrome, 354
Electrocardiogram, fetal monitoring, 169
Electrolytes
placental transfer, 45
postoperative care, 360
Electronic fetal monitoring, questions and answers, 383, 400
ELISAs (enzyme-linked immunoassays), 311
Embryonic loss, 280, 280f
Embryo transfer, female infertility treatment, 273-274
Emergency contraception, 300
Emergency gynaecology, 261-262
acute abdominal pain, 262
acute appendicitis, 262
Bartholin's abscess/cysts, 261-262
heavy vaginal bleeding, 262
pelvic infection, 261
vaginal trauma, 262
vulval trauma, 262
Emotional symptoms, menopause, 256
Empty gestation sac, 280, 280f
Endocrine analysis, male infertility, 272
Endocrine system
changes in pregnancy, 37-39
menopause, 255
miscarriage, 278
postpartum changes, 200
questions and answers, 378-379, 395
uterovaginal prolapse, 346
see also specific hormones</p>
<p>Endodermal sinus tumours, ovarian malignancies, 336
Endogenous oestrogens, endometrial carcinoma, 328
Endometrial carcinoma, 328-330
heavy menstrual bleeding, 242-243
investigations, 329-330
pathology, 329, 329f
prognosis, 330, 330t
risk factors, 328-329
questions and answers, 388, 405
symptoms, 329
treatment, 330
Endometrial cycle, 17-18, 17f
Endometrial cystadenocarcinomas, ovarian malignancies, 335
Endometrial hyperplasia
endometrial carcinoma, 328-329
heavy menstrual bleeding, 242-243
Endometrial resection/ablation, heavy menstrual bleeding, 244-245, 244 f
Endometriosis, 239-241, 261
deep dyspareunia, 314
diagnosis, 241
endometriomas, 240, 240f
female infertility, 268
management, 241
microscopic features, 240, 240f
pathology, 239-240
postpartum complications, 201
sites, 239-240, 239f-240f
Endometriotic cysts, 335, 335f
Endometrium, 5
aspirate, endometrial carcinoma, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>329</mn><mo>−</mo><mn>330</mn></mrow><annotation encoding="application/x-tex">329-330</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">329</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">330</span></span></span></span></span>
biopsy, heavy menstrual bleeding, 243
carcinoma see Endometrial carcinoma
cavity, 5
hyperplasia see Endometrial hyperplasia
polyps, 235-236, 235f
Endopelvic fascia, 342 f
Endoscopic resection, myometrial benign tumours, 237-238
Endothelial dysfunction, pre-eclampsia, 91
Energy intake, antenatal care, 86
Engagement, fetal palpation, 75
Enterocele, 343, 345
management, 347-348
Enzyme-linked immunoassays (ELISAs), 311
EPAU (early pregnancy assessment units), 281</p>
<p>EPDS (Edinburgh Postnatal Depression Scale), 212
Epididymal biopsy, male infertility, 272
Epidural analgesia, 164, 164f
eclampsia management, 98
questions and answers, 383, 400
Epilepsy, 135-136
management, 211
questions and answers, 382, 399
Epinephrine (adrenaline), 44
Episiotomy repair
questions and answers, 383, 401
vaginal delivery, 185-187, 186b
Erectile dysfunction, 315
Erythrocytes, changes in pregnancy, 30
Essure <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">®</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\circledR}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8476em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8476em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord amsrm mtight">®</span></span></span></span></span></span></span></span></span></span></span></span></span> procedure, 303
Estimated date of delivery (EDD), 66, 66 f
Estradiol, 258
Ethinylestradiol, 257-258
Ethnicity, perinatal death, 57, 57t
Evening primrose oil, 251
Evidence-based healthcare, 365-368
questions and answers, 390, 407
see also Clinical audit
Examination, 68-73, 225-229
abdomen, 69, 225, 226f
breasts, 69, 69f, 225, 226f
general examination, 68-70
head and neck, 68-69
heart and lungs, 68
labour, 161
limbs, 69-70
posture, 70 f
preoperative assessment, 357
rectal examination, 229
skeleton, 69-70
systemic examination, 68-70
see also specific tests
Excessive lassitude, history taking, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>66</mn><mo>−</mo><mn>67</mn></mrow><annotation encoding="application/x-tex">66-67</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">66</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">67</span></span></span></span></span>
Exercise, antenatal care, 87
Exogenous oestrogens, endometrial carcinoma, 328
Exomphalos, 142, 143f
Extended hysterectomy, cervical cancer treatment, 327
Extension, labour mechanism, 159
External anal sphincter, 5f, 10f
External cardiac version (ECV), breech presentation, 113, 114f
External ear, fetal development, 51
External genitalia, pelvic anatomy, 3-5, 4 f
External iliac artery, 7 f
External rotation, labour mechanism, 159
External urethral orifice, 4</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="f">F<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#f" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Face presentation, 75, 187-188, 187f
Facilitated diffusion, placental transfer, 44
Fallopian tubes, 5f, 6-7, 7f
ectopic pregnancy, 282
False pelvis, 3
Family history, 67
dizygotic twins, 106
history taking, 225
psychiatric disorders, 212
FAS (fetal alcohol syndrome), 81
Fascial repairs, uterovaginal prolapse management, 347-348
Fascial supports, vagina, 341
Fat intake, antenatal care, 86
Fat metabolism, placenta, 46
FDPs (fibrinogen/fibrin degeneration products), 31
Female condoms, 293
Female sexual function disorders, 313-315
see also specific diseases/disorders
Ferguson's reflex, 26-27
Fertility, ovarian malignancies, 335
Fertilization, 19-20
capacitation, 19
implantation, 19-20, 20f
questions and answers, 394, 399
sperm transport, 19
Fetal alcohol syndrome (FAS), 81
Fetal assessment, 143-148
amniotic fluid volume, 152
at-risk infants, 148-153, 149t
biophysical measurements, 152-153
fetal growth, 151-152
interventions, 153
normal infants, 148-153
screening, 143-146
counselling, 146-148
delivery issues, 148
interventions, 147
positive tests, 146-148
questions and answers, 382, 399
surveillance, 148
umbilical artery Doppler blood flow, 150
Fetal cotyledon, 42
Fetal death, 55
Fetal development, 48-51
cardiovascular system, 49-50, 50f
external ear, 51
gastrointestinal tract, 50
growth, 48-49, 48f-49f
renal system, 50
respiratory system, 50
vision, 51</p>
<p>Fetal growth, 151-152, 151f-152f
questions and answers, 382, 399
Fetal growth restriction, 145
Fetal haemoglobin (HbF), 45
Fetal heart rate (FHR)
acceleration, 167
deceleration, 167-168
early deceleration, 168
fetal assessment, 152-153
fetal monitoring, 167-169, 168t
variable deceleration, 168-169
Fetal macrosomia
diabetes mellitus, 132
obesity, 133
Fetal monitoring, 166-169, 167f
acid-base balance, 169
cardiotocography, 166-169, 167f
electrocardiogram, 169
fetal heart rate see Fetal heart rate (FHR)
intermittent auscultation, 166, 166t
Fetal nuchal translucency (FNT), 145, 145 f
Fetal palpation, 73-77, 74f
engagement, 75
lie, 73-74, 74f
position, 75
presentation, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>74</mn><mo>−</mo><mn>75</mn><mo separator="true">,</mo><mn>74</mn><mi mathvariant="normal">t</mi><mo separator="true">,</mo><mn>75</mn><mi mathvariant="normal">f</mi></mrow><annotation encoding="application/x-tex">74-75,74 \mathrm{t}, 75 \mathrm{f}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">74</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">75</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">74</span><span class="mord mathrm">t</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">75</span><span class="mord mathrm" style="margin-right: 0.07778em;">f</span></span></span></span></span>
station, 75
Fetal tissue disposal, miscarriage, 282
Fetoplacental blood flow regulation, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>43</mn><mo>−</mo><mn>44</mn></mrow><annotation encoding="application/x-tex">43-44</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">43</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">44</span></span></span></span></span>
Fetus
anomaly screening, 85
assessment see Fetal assessment
bradycardia, breech presentation, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>113</mn><mo>−</mo><mn>114</mn></mrow><annotation encoding="application/x-tex">113-114</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">113</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">114</span></span></span></span></span>
breathing, 153
breech presentation, 114
development see Fetal development
growth see Fetal growth
heart rate see Fetal heart rate (FHR)
legal status of, 374
1 tone, 153
lung maturity estimation, 53
monitoring see Fetal monitoring movements, 153
palpation see Fetal palpation
FHA (functional hypothalamic amenorrhoea), 246
FHR see Fetal heart rate (FHR)
Fibrin degeneration products (FDPs), 31
Fibrinogen
changes in pregnancy, 31-32
degradation products, 31
estimation, 31
synthesis, 34</p>
<p>Fibromas, ovaries, 335
FIGO (International Federation of Gynaecology and Obstetrics) abnormal uterine bleeding, 241, 242 t cervical cancer, 326 t
heavy vaginal bleeding, 262
vulval cancer, 319, 320t
Finding presentation, 229-230, 230b
First stage of labour see Labour
Fit control, eclampsia management, 97
Flexed breech, 112
Flexion of head, labour mechanism, 159
Fluconazole, 309
Fluid balance
eclampsia management, 98
first stage of labour, 163
postoperative care, 360
Fluid replacement therapy
inefficient uterine activity, 177
occipitoposterior presentation, 188
upper genital tract infections, 312
FNT (fetal nuchal translucency), 145, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>145</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">145 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">145</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
Folic acid supplementation, 87
cystic fibrosis, 137
neural tube defects, 141-142
preconception, 80
questions and answers, 381, 397-398
sickle cell syndromes, 138-139
Follicle-stimulating hormone (FSH)
actions, 16
male infertility, 272
menopause, 255
ovulation, 15
spermatogenesis, 18
Follicular cysts, ovaries, 332-333, 332 f
Follicular development
oogenesis, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>14</mn><mo>−</mo><mn>15</mn></mrow><annotation encoding="application/x-tex">14-15</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">14</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">15</span></span></span></span></span>
questions and answers, 394, 398
Follicular (proliferative) phase, endometrial cycle, 17-18
Footling presentation, 112
Forced expiratory volume in 1 second <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">V</mi></mrow><mn>1</mn></msub><mo fence="true">)</mo></mrow><mo separator="true">,</mo><mn>32</mn></mrow><annotation encoding="application/x-tex">\left(\mathrm{FEV}_{1}\right), 32</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">FEV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">32</span></span></span></span></span>
Foreign bodies, deep dyspareunia, 314
Forewater rupture, labour induction, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>175</mn><mo separator="true">,</mo><mn>175</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">175,175 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">175</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">175</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
Fothergill repair, 348
Frank breech, 112
FSH see Follicle-stimulating hormone (FSH)
Full blood count (FBC), heavy menstrual bleeding, 243</p>
<p>Functional hypothalamic amenorrhoea (FHA), 246
Fundal dominance, labour, 157-158
Fundal height measurement, 148, 152f</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="g">G<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#g" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Gallstones, contraceptive pill side effects, 298
Gardnerella infections, 308
Gaseous exchange, placental transfer, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>45</mn><mo>−</mo><mn>46</mn></mrow><annotation encoding="application/x-tex">45-46</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">45</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">46</span></span></span></span></span>
Gastrointestinal system
changes in pregnancy, 34
fetal development, 50
intraoperative complications, 360
Gastro-oesophageal reflux, 120
Gastroschisis, 142
Gelder's forewater amniotomy forceps, 161
Gelhorn pessary, 347, 347f
General anaesthesia, intraoperative complications, 358
General examination see Examination
Genetics
miscarriage, 278
ovarian malignancies, 335
Genital herpes, 307-308, 308f
treatment, 309
Genital tract infections, 305-313
lower genital tract see Lower genital tract infections
preterm delivery, 170
upper see Upper genital tract infections
see also specific infections
Genital tract, postpartum changes, 199
Genital warts, 308, 309f
treatment, 309
Germ cell tumours
management, 337
ovarian malignancies, 336
Gestational diabetes, 84-85, 123-125
diagnostic criteria, 124b, 124t
effects on pregnancy, 124 t
olanzapine, 210
questions and answers, 381, 397, 399
risk factors, 123 b
see also Diabetes mellitus
Gestational hypertension, 89-98
anti-hypertensive drugs, 94
case study, 94b
cell-mediated immune response, 93
classification, 90
complications, 96
definition, 89-90
fetoplacental investigations, 94-95
incidence, 89
induction of labour, 96
laboratory investigations, 94
management, 95 f
maternal investigations, 94
GFR (glomerular filtration rate), 33
GH (growth hormone), 46
Glibenclamide, 123
Globulin synthesis, 34
Glomerular filtration rate (GFR), 33
Glucose
changes in pregnancy, 34
gestational diabetes management, 123
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-Glucuronidase, capacitation, 19
Gluteus maximus, 10f
Glycogen storage, placenta, 46
GnRH see Gonadotrophin-releasing hormone (GnRH)
Gonadotrophin(s)
actions, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>16</mn><mo>−</mo><mn>17</mn></mrow><annotation encoding="application/x-tex">16-17</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">16</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">17</span></span></span></span></span>
ovulation, 16 f
see also specific hormones
Gonadotrophin-releasing hormone (GnRH)
myometrial benign tumours, 237
ovulation, 15
Gonadotropin-releasing hormone agonists, 251
Gonococcal vulvovaginitis, 308
Gonorrhoea, 311, 311f
female infertility, 267
GP consultation, data collection, 363-364
Graafian follicle development, 14f
GRADE evidence levels, 366
Graft repairs, uterovaginal prolapse, 348, 348f
Granulosa cells, 14-15, 14f
Granulosa cell tumours, 334, 334f, 336
Granulosa lutein cysts, ovaries, 333
Gravidity, 77
Green Top Guidelines, 366
Group B Streptococcus
questions and answers, 381, 397
screening, 84
Growth hormone (GH), 46
Growth spurt, puberty, 252
Gynaecological disorders, 233-262
lower genital tract, 259-261
questions and answers, 385-386, 403
upper genital tract, 233-238
see also specific diseases/disorders
Gynaecological history, history taking, 225</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="h">H<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#h" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>HAART (highly active antiretroviral therapy), 125-126
Haematocrit, 30, 122t
Haematological investigations, 82-83
Haemoglobin, 30, 122t
Haemoglobinopathies, 138-139
see also specific diseases/disorders
Haemorrhage/bleeding
abruption placentae, 102-103
antepartum see Antepartum haemorrhage
early pregnancy care, 277
ectopic pregnancy diagnosis, 284
intraoperative complications, 359
maternal postpartum collapse, 203-204
ovarian lesions, 239, 331
postmenopausal see Postmenopausal bleeding
postoperative complications, 361
postpartum see Postpartum haemorrhage
Haemostasis, topical, 359
Haldane effect, 45
HbF (fetal haemoglobin), 45
hCG see Human chorionic gonadotrophin (hCG)
Headache, post-menopause, 257
Head entrapment, breech presentation, 113
Head examination, 68-69
Head malposition
deep transverse arrest, 189
vaginal delivery, 188-189
see also specific positions
Heart
position, 28-29
size, 28-29
Heartburn, 120
Heart disease, congenital, 145
Heart palpations, post-menopause, 256
Heart rate, 28f, 28t, 29
Heavy menstrual bleeding see Menstrual bleeding, heavy
Heavy vaginal bleeding, 262
Helicobacter pylori infection, 288
HELLP syndrome, 93
Hepatitis
acute viral, 126-128
screening, 84
Hepatitis B
reactivation, 126
screening, 127
Hepatitis C, 126
screening, 127</p>
<p>Herbal therapies, menopause therapy, 258-259
Heroin, 81
Herpes simplex virus (HSV) infections see Genital herpes
HES (hospital episode statistics), 364
HFEA (Human Fertilization and Embryology Authority), 273-274
Highly active antiretroviral therapy (HAART), 125-126
Hirsutism, 249
History-taking, 65, 223-225
family history, 225
infertility, 266-267
medical history, 225
menstrual history, 224-225
presenting complaint, 224
previous gynaecological history, 225
social history, 225
see also Clinical history
HIV infection, 125-126, 313
screening, 84
HLA (human leucocyte antigen), 23
HMD (hyaline membrane disease), 171
Hodge pessary, 347, 347f
Hofbauer cells, stem villus, 42
Home births, 161
Hormonal contraception see Contraception
Hormone(s)
ovulation, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>17</mn><mo separator="true">,</mo><mn>16</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">15-17,16 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">17</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">16</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
postnatal depression, 215
see also Endocrine system; specific hormones
Hormone replacement therapy (HRT), 257-258
questions and answers, 386, 403
uterovaginal prolapse, 346, 347f
Hormone-secreting tumours, ovarian lesions, 239, 332
Hospital care, obesity management, 134
Hospital discharge, 362
Hospital episode statistics (HES), 364
Hot flushes, menopause, 256
HPA see Human papilloma virus (HPV) infections
HRT see Hormone replacement therapy (HRT)
Human chorionic gonadotrophin (hCG)
biochemical screening, 146
ectopic pregnancy diagnosis, 284
miscarriage, 277
oogenesis, 15
Human Fertilization and Embryology Authority (HFEA), 273-274</p>
<p>Human leucocyte antigen (HLA), 23
Human papilloma virus (HPV) infections, 308
cervical cancer, 324
see also Genital warts; Vulval intraepithelial neoplasia (VIN)
Human placental lactogen, 46-47
Hyaline membrane disease (HMD), 171
Hydatidiform mole, 286, 287f-288f
Hydralazine, 94
Hymen, 4 f
Hyperemesis gravidarum, 282
Hypergonadotropic hypogonadism, 267
Hyperlipidaemia, 35
Hyperprolactinaemia
drug causes, 247b
female infertility, 267
male infertility, 272
Hyperstimulation, labour induction, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>175</mn><mo>−</mo><mn>176</mn></mrow><annotation encoding="application/x-tex">175-176</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">175</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">176</span></span></span></span></span>
Hypertension
chronic classification, 90
gestational see Gestational hypertension
questions and answers, 381, 398
unclassified, 90
Hyperthyroidism, 133
Hypertonic uterine activity, 177
case study, 178b
Hypogastric lymph node, 8 f
Hypoglycaemic agents, 299t
Hypogonadal hypogonadism, 267
Hypothalamus, 38
disorders, 246
Hypothyroidism, 132-133
Hypoxia, 205
Hysterectomy
abdominal, 245
extended, cervical cancer treatment, 327
heavy menstrual bleeding, 245
laparoscopic, 245
myometrial benign tumours, 237-238
radical, 327, 328f
vaginal, 245
Hysterosalpingography, 269, 269f
Hysteroscopy, 243
Hysterosonocontrast sonography, 269</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i">I<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>ICD (International Classification of Diseases), 55-56, 59
ICSI (intracytoplasmic sperm injection), 271-272, 275</p>
<p>Iliac lymph node, 8 f
Iliococcygeus muscle, 10, 342 f
Iliopectineal line, 71f
Ilium, 3, 4f
Illicit drug use, 81
IMB (intermenstrual bleeding), 241
Imipramine hydrochloride, 353 t
Immunosuppression, 24
Implantation, 42 f
ectopic pregnancy pathology, 284
fertilization, 19-20, 20f
questions and answers, 378, 394, 400
Indirect deaths, 59
Indocid (indomethacin), 172
Indomethacin, 172
Inevitable/incomplete miscarriage, 279, 279f, 280b
Infections, 125-126
chronic pelvic infections see Chronic pelvic infections
intermenstrual bleeding, 241
labour induction, 176
lower genital tract see Lower genital tract infections
management, 125
maternal postpartum collapse, 204
miscarriage, 280
post-caesarean section, 202
postoperative complications, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>361</mn><mo>−</mo><mn>362</mn></mrow><annotation encoding="application/x-tex">361-362</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">361</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">362</span></span></span></span></span>
pregnancy implications, 125
prelabour rupture of the membranes, 174
risk factors, 125
superficial dyspareunia, 313
upper general tract see Upper genital tract infections
see also specific infections
Infection screening, 83-85
questions and answers, 380-381, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>388</mn><mo separator="true">,</mo><mn>402</mn><mo separator="true">,</mo><mn>404</mn><mo>−</mo><mn>405</mn></mrow><annotation encoding="application/x-tex">388,402,404-405</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">388</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">402</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">404</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">405</span></span></span></span></span>
Infertility, 265-275
causes, 266 t
definition, 265
examination, 266-267
female see below
history-taking, 266-267
investigations, 268-272
male see below
myometrial benign tumours, 237
partner investigations, 265-266
prevalence, 265
primary, 265
questions and answers, 386, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>403</mn><mo>−</mo><mn>404</mn></mrow><annotation encoding="application/x-tex">403-404</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">403</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">404</span></span></span></span></span>
secondary, 265
Infertility, female, 267-268
cervical factors, 268, 270
endometriosis, 268
investigations, 268-270
ovulation detection, 268-269
ovulation disorders, 267
treatment, 272-274
anovulation, 272-273
embryo transfer, 273-274
intrauterine insemination, 273
tubal pathology, 273
in vitro fertilization, 273-274
tubal factors, 267-268, 267f
tubal patency, 269-270
uterine factors, 268
Infertility, male
cytogenic studies, 272
endocrine analysis, 272
epididymal biopsy, 272
immunological tests, 272
investigations, 265b, 270-272, 270t
retrograde ejaculation, 272
sperm DNA analysis, 271-272
testicular biopsy, 272
treatment, 274-275
Inflammatory conditions, female infertility, 267-268
Influenza H1N1 infection, 125
Influenza vaccine, 80
Informed consent, 369-370
preoperative care, 357
questions and answers, 390-391, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>407</mn><mo>−</mo><mn>408</mn></mrow><annotation encoding="application/x-tex">407-408</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">407</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">408</span></span></span></span></span>
Infundibulum, Fallopian tube, 7
Inhalational analgesia, 164
Inhibin A, 146
Innominate bones, 3, 4f
Instrumental delivery, 189-191, 191f
indications, 190
methods, 190-191, 190f-191f
prerequisites, 190
trial of, 191
Insulin, 46
Intact cells, placental transfer, 45
Interferential therapy, overactive bladder syndrome, 354
Interiliac lymph node, 8 f
Intermenstrual bleeding (IMB), 241
Intermittent auscultation, 166, 166 t
Internal anal sphincter, 5 f
Internal genital organs, pelvic anatomy, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>7</mn><mo separator="true">,</mo><mn>5</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">5-7,5 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">7</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
Internal iliac artery, 7-8, 7f
anterior branch, 7f, 8
posterior division, 8
Internal rotation, labour mechanism, 159
International Classification of Diseases (ICD), 55-56, 59</p>
<p>International Federation of Gynaecology and Obstetrics see FIGO (International Federation of Gynaecology and Obstetrics)
Interpreters, pelvic examination, 228-229
Interstitial portion, Fallopian tube, 7
Intertuberous diameter, 71f
Intracytoplasmic sperm injection (ICSI), 271-272, 275
Intraoperative complications, 358-360
general anaesthesia, 358
local anaesthesia, 358
patient positioning, 358-359
regional anaesthesia, 358
Intrapartum stillbirth, 58
Intrauterine contraceptive devices (IUDs), 294-296
complications, 295-296, 295f
inert devices, 294
insertion, 295
life span, 295
pharmacologically active devices, 294
progestogen-containing, 294-295, 294f
types, 294-295, 294f
Intra-uterine growth restriction (IUGR), multiple pregnancy, 108
Intrauterine insemination, female infertility treatment, 273
Introitus narrowing, superficial dyspareunia, 313
In vitro fertilization (IVF)
female age vs., 266 t
female infertility treatment, 273-274
multiple pregnancies, 274, 274t
questions and answers, 386, 404
Iodine deficiency, 132
Iodine supplements, 87
Iron deficiency anaemia, 122
Iron supplements, 203
anaemia prophylaxis, 122-123
Ischial bone, 4 f
Ischial space, 342 f
Ischial spine, 342 f
Ischial tuberosity, 4f, 10f, 342 f
Ischiocavernous muscle, 10 f
Ischiopubic ramus, 342 f
Ischiorectal fossa, 10
Ischium, 3, 4f
Isthmus
changes in pregnancy, 25
Fallopian tube, 7
uterus, 6
IUDs see Intrauterine contraceptive devices (IUDs)</p>
<p>IUGR (intra-uterine growth restriction), multiple pregnancy, 108
IVF see In vitro fertilization (IVF)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="j">J<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#j" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Joint pain, post-menopause, 257</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="k">K<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#k" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Kidneys, 33
Killer immunoglobulin-like receptors (KIRs), 23-24
KIRs (killer immunoglobulin-like receptors), 23-24
Knee chest position, cord prolapse, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>179</mn><mo separator="true">,</mo><mn>179</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">179,179 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">179</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">179</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
Knee presentation, 112
Kocher's forceps, forewater rupture, 161
Korotkoff sounds, 29-30</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="l">L<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#l" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>LA (lupus anticoagulant), 279, 282
Labetalol, 94
Labia majora, 4, 4f-5f
Labia minora, 4, 4f-5f
pelvic examination, 227
Labour, 155-179
analgesia, 163-166
inhalational analgesia, 164
narcotic analgesia, 164
non-pharmacological methods, 164
regional analgesia, 164-166, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>164</mn><mi mathvariant="normal">f</mi><mo>−</mo><mn>165</mn><mi mathvariant="normal">f</mi></mrow><annotation encoding="application/x-tex">164 \mathrm{f}-165 \mathrm{f}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord">164</span><span class="mord mathrm" style="margin-right: 0.07778em;">f</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">165</span><span class="mord mathrm" style="margin-right: 0.07778em;">f</span></span></span></span></span>
cephalopelvic disproportion, 178
cord presentation, 178
cord prolapse, 178, 179 f
definition, 155
delays, 177
duration, 156
examination, 161
fetal monitoring see Fetal monitoring
first stage, 155, 161-163
fetal condition, 161-163
fluid balance, 163
nutrition, 163
partograms, 161, 162 f
progress assessment, 163, 382, 400
induction see below
inefficient uterine activity, 177-178
initiation, 156-157
management, 160-163
mechanism of, 158-160, 159 f
multiple pregnancy, 109-110
onset, 156-157
onset of, 156-157
pain, 160
analgesia see above
passages, 158
posture, 166
precipitate, 176-177
preterm, multiple pregnancy, 108, 108 t
questions and answers, 382-383, 399-400
second stage, 155-156, 183
duration, 183
questions and answers, 383, 400
stages, 155-156
see also specific stages
third stage, 156, 160, 160 f
abnormalities, 195-197
see also specific disorders
management, 184
uterine activity, 157-158, 157f-158f
Labour induction, 174-176
cervical assessment, 175
indications, 174-175
methods, 175-176
forewater rupture, 175, 175f
hindwater rupture, 175, 176f
medical induction, 176
post-amniotomy, 175-176
questions and answers, 383, 400
Lactation, 37
amenorrhoea, 301
combined oral contraceptive pill, 299
see also Breastfeeding
Langerhans cells, 41
Laparoscopic Burch colposuspension, 352-353
Laparoscopic hysterectomy, 245
Laparoscopic ovarian diathermy (LOD), 273
Laparoscopic sterilization, 301-302
Laparoscopy, tubal patency, 269-270, 270 f
LASER ablation, cervical cancer, 325
Last menstrual period (LMP), 66
Late death, 59
Late deceleration, fetal heart rate, 168
Left mento-anterior (LMA) position, 76 f
Left occipito-anterior (LOA) position, 76 f
Left occipitoposterior (LOP) position, 76 f
Left occipitotransverse (LOT) position, 76 f
Leiomyomas
heavy menstrual bleeding, 242-243
questions and answers, 380, 386</p>
<p>Leiomyosarcomas, uterus, 331
Levator ani, 342 f
Levator ani pubococcygeus iliococcygeus muscle, 10 f
Levonorgestrel, 294-295, 294f
Leydig cells, spermatogenesis, 18
LH see Luteinising hormone (LH)
Libido, loss of, 314-315
drugs, 314b
Lichen planus, 259 t
Lichen sclerosis, 259 t
Lichen simplex, 259 t
Lie of fetus, 73-74, 74f
longitudinal see Longitudinal lie
transverse see Transverse lie
unstable see Unstable lie
Ligaments, vagina, 341, 342f
Limbs, examination, 69-70
Lipid peroxides, pre-eclampsia, 91
Lipids, 35
Listeria monocytogenes infection, 278
Lithium carbonate, 211
breastfeeding, 215
questions and answers, 385, 402
Litigation, 370-372
Live birth, 55
Liver disease, 129-130
LMA (left mento-anterior) position, 76 f
LMP (last menstrual period), 66
LMWH (low molecular weight heparin), 128, 135
LOA (left occipito-anterior) position, 76 f
Local anaesthesia, 358
Lochia, 199
Locked twins, multiple pregnancy, 111
LOD (laparoscopic ovarian diathermy), 273
Longitudinal lie
fetus, 74
presentation, 74
LOP (left occipitoposterior) position, 76 f
LOT (left occipitotransverse) position, 76 f
Loveset's manouvre, 114
Low birth rate, neonatal death, 58
Lower genital tract infections, 306-309
signs, 307
see also specific infections
symptoms, 306-307
treatment, 309
Low molecular weight heparin (LMWH), 128, 135
Lung examination, 68
Lupus anticoagulant (LA), 279, 282
Luteal (secretory phase), endometrial cycle, 18</p>
<p>Lutein cysts, ovaries, 333
Luteinising hormone (LH)
actions, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi>f</mi><mo separator="true">,</mo><mn>17</mn></mrow><annotation encoding="application/x-tex">15 f, 17</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">17</span></span></span></span></span>
male infertility, 272
menopause, 255
oogenesis, 13
ovulation, 15
spermatogenesis, 18
Lymphatic system
pelvic anatomy, 8-9, 8f
vulval cancer spread, 319, 319f
see also specific lymph nodes</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="m">M<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#m" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Madlinger procedure, 301-302
Magnesium sulphate
eclampsia management, 97
preterm delivery treatment, 173
Magnetic resonance imaging (MRI), 100
Malaria, 127
Male condoms, 293
Male sexual function disorders, 315
Malignant melanoma, vulva, 318-319
Malignant mesenchymal tumours, uterus, 330-331
Malpresentation, 187-188
brow presentation, 188, 188f
face presentation, 187-188, 187f
Manchester repair, 348
MAOIs (monoamine oxidase inhibitors), 209
Marijuana, 81
Mastitis, postpartum complications, 202
Maternal age
dizygotic twins, 106
perinatal death, 57, 57t
Maternal antibodies, 24
Maternal collapse, postpartum complications, 203-205, 203t
Maternal death
case studies, 217b
questions and answers, 379-380, 384, 396, 402
UK confidential enquires, 215-217
Maternal illnesses, miscarriage, 278
Maternal lifestyle, miscarriage, 278
Maternal medicine, 119-139, 120f
definition, 119
minor complaints, 119-121
pre-existing medical conditions, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>130</mn><mo>−</mo><mn>139</mn></mrow><annotation encoding="application/x-tex">130-139</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">130</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">139</span></span></span></span></span>
in pregnancy, 121-130
questions and answers, 381-382, 399
see also specific diseases/disorders</p>
<p>Maternal mortality, 59-60
causes, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo separator="true">,</mo><mn>60</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">60,60 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">60</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">60</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
definitions, 59
questions and answers, 380, 396
Maternal mortality rates (MMR), 59-60, 59t, 60f
developed countries, 59
Maternal weight gain, 35-36, 35f
Maternity services, psychiatric disorders, 218
Mature cystic teratomas, 334, 335f
Maximum urethral closure pressure (MUCP), 352
McCall's culdoplasty, 347-348
MCH (mean cell haemoglobin), 122t
MCV (mean cell volume), 122t
MDG (Millennium Development Goals), maternal mortality rates, 59
Mean cell haemoglobin (MCH), 122t
Mean cell volume (MCV), 122t
Mechanical cervical ripening, labour induction, 176
Medical history, 67
family history, 67
history taking, 225
Medications, preoperative assessment, 358
Meiosis
oogenesis, 13-14, 14f
questions and answers, 394, 399
Melanocyte-stimulating hormone (MSH)
pituitary gland, 38
skin changes, 37
Menarche, 252
premature, 254
Menopause, 255-259
consequences of, 257
hormonal changes, 255
hormone replacement therapy, 257-258
premature, 377-378, 393-394
superficial dyspareunia, 313
symptoms and signs, 256-257
treatment, 257-259, 257t
Menopause transition, 255
Menstrual bleeding, heavy, 242-245
causes, 242-243
examination, 243
history, 243
hormonal treatments, 244, 244f
investigations, 243
management, 244-245
medical treatment, 244
non-hormonal treatments, 244
questions and answers, 385-386, 403
surgery, 244-245</p>
<p>Menstrual cycle length, history taking, 224
Menstrual disorders, history taking, 224
Menstrual history taking, 224-225
Menstrual phase, endometrial cycle, 17
Mesosalpinx, Fallopian tube, 6
Metabolic disorders, amniocentesis, 53
Metformin
gestational diabetes management, 123
secondary amenorrhoea, 249
Methyldopa, 94
Metroplasty, 234-235, 235f
Micturition, 349
history taking, 66
Mifepristone, 304
Migraine, 136
Mild postnatal depression, 214, 214b
Millennium Development Goals (MDG), maternal mortality rates, 59
Mineral intake, antenatal care, 87
Minute ventilation, changes in pregnancy, 32
Miscarriage, 277-282
aetiology, 278-279
alloimmune factors, 279
autoimmune factors, 279
cervical incompetence, 279
clinical types, 279-280
see also specific types
complete, 280
drug history, 278
endocrine factors, 278
fetal tissue disposal, 282
genetic abnormalities, 278
inevitable/incomplete, 279, 279f, 280b
with infection, 280
management, 281-282
maternal illness, 278
maternal lifestyle, 278
missed see Missed miscarriage
multiple pregnancy, 107
psychological aspects, 282b
questions and answers, 381, 387
recurrent, 280, 282
spontaneous second trimester loss, 280
threatened, 279, 279f
thrombophilic defects, 279
uterus abnormalities, 278-279, 278f
Missed miscarriage, 280, 280f
questions and answers, 387, 404
Mixed müllerian tumours
(carcinosarcomas), 331, 331f</p>
<p>Mixed urge and stress incontinence, 349
MMR see Maternal mortality rates (MMR)
Moderate postnatal depression, 214
Monitoring, clinical audit, 365
Monoamine oxidase inhibitors (MAOIs), 209
Monoamniotic twinning, 108
Mons pubis (mons veneris), 3, 4f
Mons veneris (mons pubis), 3, 4f
Montgomery's tubercles, 37
Mood stabilizers, 211
antenatal psychiatric disorders, 209
breastfeeding, 215
Morbidity rates, 364
Mortality rates, 364
perinatal death, 56
Morula
early placental development, 41
fertilization, 19-20
MRI (magnetic resonance imaging), 100
MSH see Melanocyte-stimulating hormone (MSH)
Mucinous cystadenocarcinomas, 335, 336 f
Mucinous cystadenomas, 333-334
MUCP (maximum urethral closure pressure), 352
Multiple pregnancies, 105-111, 109f
complications, 107-108
conjoined twinning, 111
delivery, 109-110
dizygotic twins, 106-107
labour, 109-110
labour complications, 110-111
locked twins, 111
management, 109
monozygotic twins, 105-106, 106 f
perinatal mortality, 111
prenatal diagnosis, 108
presentation, 109, 110f
prevalence, 105
questions and answers, 381, 398
risks, 107 t
types, 105-107, 106f
in vitro fertilization, 274, 274t
Muscle decussation, 24, 24f
Mycoplasma infection, 278
Myometrial benign tumours, 236-238
histopathology, 236
management, 237-238
medical treatment, 237
pathology, 236
surgery, 237
symptoms and signs, 236-237
uterine artery embolization, 237</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="n">N<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#n" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Nabothian follicles, 6
Narcotic analgesia, 164
National clinical audits, 366
National Confidential Enquiry into Patient Outcome and Death (NCEPOD), 364
National Institute for Health and Clinical Excellence (NICE), 79-80
Natural killer (NK) cells, 23-24
Nausea and vomiting, 287-289
combined oral contraceptive pill, 299
history taking, 66
multiple pregnancy, 107
NCEPOD (National Confidential Enquiry into Patient Outcome and Death), 364
Neck examination, 68-69
Neisseria gonorrhoea infection see Gonorrhoea
Neonatal death
causes, 58-59, 59f
definition, 56
questions and answers, 379, 396
Neonatal diseases/disorders, 205
asphyxia, 205
hypoxia, 205
see also specific diseases/disorders
Neonatal examination, 206b
questions and answers, 384, 402
Neonatal mortality rate (NMR), 56, 56 t
UK, 57 f
Neonatal period, 56
Neonatal screening, HIV infection, 126
Neoplasia
deep dyspareunia, 314
palliative care, 338-339
vaginal epithelium, 261
see also specific types
Nerve supply
pelvic anatomy, 9, 9f
uterus in pregnancy, 26-27
Neural tube defects (NTDs), 141-142, 142 f
Neurological injury, intraoperative complications, 359
Neuropathic bladder, 354-355
New York Heart Association (NYHA), 136-137, 137b
NICE (National Institute for Health and Clinical Excellence), 79-80</p>
<p>Nicotine, 80
Nifedipine, 173
Nitrous oxide, labour analgesia, 164
NK (natural killer) cells, 23-24
NMR see Neonatal mortality rate (NMR)
Nocturnal enuresis, 350
Nongonadotropic anovulation, 267
Nonoxynol-9, 294
Non-rotational instrumental delivery, 190-191
Non-sensitized Rhesus (Rh) negative women, 281
Non-steroidal anti-inflammatory drugs (NSAIDs)
dysmenorrhoea management, 250
miscarriage, 278
Non-stress test (NST), 174
Noradrenaline, 44
Norepinephrine, 44
Norethisterone, 262
NSAIDs see Non-steroidal antiinflammatory drugs (NSAIDs)
NST (non-stress test), 174
NTDs (neural tube defects), 141-142, 142 f
Nuchal translucency, 85
Nutrition, first stage of labour, 163
NYHA (New York Heart Association), 136-137, 137b</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="0">0<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#0" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>OAB see Overactive bladder syndrome (OAB)
OA (occipitoanterior) position, 188
Obesity, 133-134
endometrial carcinoma, 328-329
management, 134
perinatal death, 57-58
pregnancy implications, 133-134, 134 t
questions and answers, 382, 399
Obstetrical examination, labour, 161
Obstetric cholestasis, 129
Obstetric diseases/disorders, 89-117
questions and answers, 381, 398-399
see also specific diseases/disorders
Obstetric forceps, 189-190, 190f, 192 f
Obstetric history, 65-67, 82
pregnancy symptoms, 66-67
present pregnancy, 66-67
previous, 67
questions and answers, 380, 396
Obstetric vacuum extractor, 189-191, 191f, 193f</p>
<p>Obturator foramen, 4 f
Obturator internus muscle, 342 f
Obturator lymph node, 8 f
Occipitoanterior (OA) position, 188
Occipitoposterior (OP) presentation, 158-159, 188-189, 189f
Occipitotransverse (OT) position, 188
Oedema
definition, 90, 90f
maternal weight gain, 36
Oestradiol
menopause, 255
ovulation, 16 f
placenta, 48
Oestriol, unconjugated, 146
Oestrogens
endogenous, 328
exogenous, 328
labour initiation, 156
menopause, 255
ovulation, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>16</mn></mrow><annotation encoding="application/x-tex">15-16</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">16</span></span></span></span></span>
placenta, 47-48
see also specific types
Oestrone, 48
OHSS see Ovarian hyperstimulation syndrome (OHSS)
Olanzapine, 210
Oligohydramnios, 52
Oligomenorrhoea, secondary, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>245</mn><mo>−</mo><mn>249</mn></mrow><annotation encoding="application/x-tex">245-249</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">245</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">249</span></span></span></span></span>
Oligospermia, questions and answers, 386, 404
Oncology, 317-339
questions and answers, 388, 405
see also Neoplasia; specific diseases/ disorders
Oogenesis, 13-15, 14f
follicular development, 14-15
meiosis, 13-14, 14f
Opportunistic infections, HIV infection, 313
OP (occipitoposterior) presentation, 158-159, 188-189, 189f
Orgasmic dysfunction, 315
Orgasmic phase, coitus, 20-21
Orgasmic platform, coitus, 21
Osteoporosis, post-menopause, 257
OT (occipitotransverse) position, 188
Ovarian artery, 7 f
Ovarian failure, secondary amenorrhoea, 247
Ovarian hyperstimulation syndrome (OHSS), 273-274
questions and answers, 386, 404
Ovarian lesions, 238-239, 239f, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>331</mn><mo>−</mo><mn>332</mn></mrow><annotation encoding="application/x-tex">331-332</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">331</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">332</span></span></span></span></span>
benign, 332-335
epithelial tumours, 333-334
functional cysts, 332-333
germ cell tumours, 334
neoplastic cysts, 333-335
sex cord stromal tumours, 334
malignancies see Ovarian malignancies
signs, 332
symptoms, 331-332
Ovarian ligament, 7
Ovarian malignancies, 335-338
aetiology, 335
diagnosis, 336, 337f
epithelial type, 335-336
fertility, 335
germ cell tumours, 336
management, 336-338
borderline tumours, 337
chemotherapy, 336-337
follow-up, 337-338
germ cell tumours, 337
pathology, 335-336
primary, 335-336
prognosis, 338, 338t
screening, 338
secondary, 336
sex-cord stromal tumours, 336
staging, 336, 337t
see also specific diseases/disorders
Ovarian reserve assessment, 269
Ovaries, 5f, 7
blood vessels, 8
prolapsed, 314
questions and answers, 377, 393
Overactive bladder syndrome (OAB), 353-354
biofeedback therapy, 354
detrusor instability, 353
dietary modification, 354
drug treatment, 353, 353t
electrical stimulation, 354
pelvic floor physiotherapy, 354
timed voiding, 354
vaginal oestrogen, 354
Overflow incontinence, 349
Ovulation
corpus luteum, 15 f
detection in infertility, 268-269
disorders, female infertility, 267
heavy menstrual bleeding, 243
hormones, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>17</mn><mo separator="true">,</mo><mn>16</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">15-17,16 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">17</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">16</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
suppression, endometriosis management, 241
Ovulation induction, dizygotic twins, 107
Ovulation method of contraception, 300
Oxybutynin, 353t
Oxygen, placental transfer, 45
Oxytocin, 38</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="p-mathbf-p-p"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold">P</mi></mrow><annotation encoding="application/x-tex">\mathbf{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6861em;"></span><span class="mord mathbf">P</span></span></span></span></span><span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#p-mathbf-p-p" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Pain
abdominal see Abdominal pain
intrauterine contraceptive devices, 296
labour, 160
myometrial benign tumours, 236-237
Painkillers see Analgesia
Palliative care, neoplasia, 338-339
Palpation, abdominal see Abdominal palpation
Pap smear, questions and answers, 385, 403
Paracervical blockade, labour analgesia, 165
Paracolpium, 342 f
Parametrial lymph node, 8 f
Parametrium, 342 f
Parasympathetic innervation, pelvic anatomy, 9
Parathyroid glands, 39
Parathyroid hormone (PTH), 39
Parenteral therapy, hormone replacement therapy, 258
Parity
definition, 77
dizygotic twins, 106
ovarian malignancies, 335
Paroxetine, 210
Partograms, first stage of labour, 161, 162 f
Parturition see Labour
Parvovirus B19 infection, 125
Patient confidentiality, 372-373
Patient positioning, intraoperative complications, 358-359
PCB (postcoital bleeding), 242
PCOS see Polycystic ovary syndrome (PCOS)
PCR (polymerase chain reaction), upper genital tract infections, 311
PE (pulmonary embolism), 128
Peak expiratory flow rate (PEFR), 32
Pearl index, 292t
Pelvic anatomy, 3-10
blood supply, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mo>−</mo><mn>8</mn><mo separator="true">,</mo><mn>7</mn><mi mathvariant="normal">f</mi></mrow><annotation encoding="application/x-tex">7-8,7 \mathrm{f}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">8</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">7</span><span class="mord mathrm" style="margin-right: 0.07778em;">f</span></span></span></span></span>
bones, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo separator="true">,</mo><mn>4</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">3,4 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">3</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">4</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
external genitalia, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn><mo separator="true">,</mo><mn>4</mn><mi mathvariant="normal">f</mi></mrow><annotation encoding="application/x-tex">3-5,4 \mathrm{f}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">4</span><span class="mord mathrm" style="margin-right: 0.07778em;">f</span></span></span></span></span>
internal genital organs, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>7</mn><mo separator="true">,</mo><mn>5</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">5-7,5 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">7</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
lymphatic system, 8-9, 8f
nerves, 9
perineum, 10
questions and answers, 377, 393
see also specific anatomical structures
Pelvic brim, 3
Pelvic diaphragm, 342f</p>
<p>Pelvic examination, 70-73, 226-229, 226 f
bimanual examination, 228, 229 f
bony pelvis, 70-71, 71f
cervix, 70, 70f
dysmenorrhoea, 250
ectropion, 227
labia minora, 227
pelvis outlet, 72
planes of the pelvis, 71-72
questions and answers, 380, 385, 397, 403
speculum examination, 70, 227, 227 f
vaginal wall prolapse, 227, 227f
vaginal walls, 70
vulva, 70
Pelvic floor, 9-10
muscles, 10f, 342 f
Pelvic floor physiotherapy, 354
Pelvic girdle dysfunction, 121
Pelvic infections, 261
chronic see Chronic pelvic infections
Pelvic inflammatory disease (PID), 310
barrier contraception, 291
deep dyspareunia, 314
intrauterine contraceptive devices, 295-296
Pelvic inlet, planes of, 71, 72 f
Pelvic lymph node dissection, cervical cancer treatment, 327
Pelvimetry, 70
Perinatal death
definition, 56
incidence, 56-57, 56t
mortality rates, 56
questions and answers, 379-380, 399
sociodemography, 57-58, 57t
Perinatal mortality, 55-59
definitions, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>55</mn><mo>−</mo><mn>56</mn></mrow><annotation encoding="application/x-tex">55-56</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">55</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">56</span></span></span></span></span>
smoking, 80
Perinatal Mortality Rates (PNMR), 56, 56t, 364
UK, 57 f
Perinatal period, 55
Perinatal psychiatry, 208
Perineal body, 10f, 342
Perineal injury repair
questions and answers, 383, 401
vaginal delivery, 185-187
Perineal tissue infiltration, labour analgesia, 165-166
Perineal wound breakdown, 197
Perineum, 10
Personal hygiene, breastfeeding, 200-201</p>
<p>Pethidine, 164
pH
vagina, 5
see also Acid-base balance
Phase of repair, endometrial cycle, 17
Phlebothrombosis, 202
PID see Pelvic inflammatory disease (PID)
Pinocytosis, placental transfer, 45
Pipelle sampler, endometrial carcinoma, 329-330
Piriformis muscle, 342 f
Pituitary gland, 38
Placebo controlled clinical trials, 367
Placenta
ammonia, 47
carbohydrate metabolism, 46
development see Placental development
fat metabolism, 46
functions, 45-48
questions and answers, 379, 395
hormone production, 47-48
hormones, 38
nutrient metabolism, 46-47
protein metabolism, 46-47
questions and answers, 378, 396
transport function see Placental transfer
urea, 47
Placental development, 41-53
early, 41, 42 f
questions and answers, 379, 395
stem villus, 42
Placental pathology, pre-eclampsia, 92, 92f-93f
Placental transfer, 44-45, 44f
active transport, 45
calcium, 45
electrolytes, 45
facilitated diffusion, 44
gaseous exchange, 45-46
intact cells, 45
nutrients, 46-47
pinocytosis, 45
potassium, 45
questions and answers, 379, 395
simple diffusion, 44
sodium, 45
water, 45
Placenta praevia, 99-101
aetiology, 99
case study, 100b
classification, 99-100, 99f
diagnosis, 99-100
incidence, 99
management, 100-101
symptoms and signs, 100</p>
<p>Plane of the greatest pelvic dimensions, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>71</mn><mo>−</mo><mn>72</mn></mrow><annotation encoding="application/x-tex">71-72</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">71</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">72</span></span></span></span></span>
Plane of the least pelvic dimensions, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>72</mn><mo separator="true">,</mo><mn>72</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">72,72 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">72</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">72</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
Planiform uterus, 278 f
Planning for improvement, clinical audit, 365-366
Plasma proteins, 35
Plasma transfusion, haemorrhage management, 359
Plasma volume, 33
postpartum changes, 199
Plateau phase, coitus, 20-21
Platelet(s), 31
Platelet count, 31
heavy menstrual bleeding, 243
PMS (premenstrual syndrome), 250-251, 250t
Pneumonia, varicella, 125
PNMR see Perinatal Mortality Rates (PNMR)
Polycystic ovary syndrome (PCOS), 247b
miscarriage, 278
myometrial tumours, 236
secondary amenorrhoea, 247-248
Polyhydramnios, 52
acute, 52
chronic, 52
Polymerase chain reaction (PCR), upper genital tract infections, 311
Pomeroy technique, 302
Position, fetal palpation, 75, 76f
Post-amniotomy, labour induction, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>175</mn><mo>−</mo><mn>176</mn></mrow><annotation encoding="application/x-tex">175-176</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">175</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">176</span></span></span></span></span>
Postcoital bleeding (PCB), 242
Post-date pregnancy see Prolonged pregnancy
Posterior commissure, 4
Postmenopausal bleeding, 242
history taking, 225
Postnatal anticoagulation, postpartum complications, 202-203
Postnatal depression (PND), 217b
aetiology, 212
moderate, 214
questions and answers, 384, 402
screening, 212
severe, 213-214, 214b
Postnatal depressive illness, 213-215
Postnatal gestational diabetes management, 123-124
Postnatal period
anxiety, 217, 217b
clinical review, 206
contraception, 205
unexplained physical symptoms, 217, 217b</p>
<p>Postnatal psychiatric disorders, 212-215
aetiology, 213
see also specific diseases/disorders
Postoperative care, 360-361
analgesia, 360
bladder care, 360-361
cardiovascular stability, 360
electrolyte balance, 360
fluid balance, 360
oral intake, 361
Postoperative complications, 361-362
cardiovascular system, 362
haemorrhage, 361
infections, 361-362
pyrexia, 361
questions and answers, 389, 406
respiratory disorders, 362
venous thromboembolism, 362
see also specific complications
Postoperative scarring, deep
dyspareunia, 314
Postpartum complications, 201-205, 201b
anaemia, 203
breast abscess, 202
endometriosis, 201
mastitis, 202
maternal collapse, 203-205, 203t
phlebothrombosis, 202
postnatal anticoagulation, 202-203
puerperal infections, 201, 201f
thromboembolism, 202-203
thrombophlebitis, 202
urinary tract infections, 201-202
Postpartum haemorrhage, 195-196
primary, 195-196, 195f-196f
questions and answers, 384, 401
secondary, 195-196
Postpartum infections, caesarean section, 202
Postpartum period, 199
physiological changes, 199-200
Postpartum psychosis, 213, 213b
aetiology, 212
Postpartum weight, 36
Post-term pregnancy see Prolonged pregnancy
Posture
blood pressure effects, 29-30, 30f
examination, 70 f
Potassium, 45
Precipitate labour, 176-177
Precocious puberty, 253-254
evaluation, 253, 253f
investigations, 253-254
questions and answers, 386, 403</p>
<p>Preconception care, 80
Preconception counselling
cystic fibrosis, 137
diabetes mellitus, 132
epilepsy, 135-136
psychiatric disorders, 217
Pre-eclampsia
classification, 90
management, 93-94
multiple pregnancy, 108
pathogenesis, 90-93
pathology, 90-93, 91f
placental pathology, 92, 92f-93f
prevention, 95
renal lesions, 92, 92 f
superimposed, 90
symptoms, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mo>−</mo><mn>96</mn></mrow><annotation encoding="application/x-tex">95-96</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">95</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">96</span></span></span></span></span>
see also Eclampsia
Pregnancies
early care see Early pregnancy care
ectopic see Ectopic pregnancy
immunology, 23-24
intrauterine contraceptive devices, 295
multiple see Multiple pregnancies
physiological changes, 23-39
questions and answers, 378-379, 394-395
prescription drugs, 88
prolonged see Prolonged pregnancy
teenage, 82
termination of see Termination of pregnancy
of unknown location, 286
Pregnancy associated plasma protein-A, 146
Pregnancy tests, secondary
amenorrhoea/oligomenorrhoea, 248-249
Pregnant women, legal status of, 374
Prelabour rupture of the membranes (PROM), 173-174
management, 174
pathogenesis, 174
Premature adrenarche, 254
Premature menarche, 254
Premature menopause, 377-378, 393-394
Premature thelarche, 254
Premenstrual syndrome (PMS), 250-251, 250t
Preoperative assessment, 357-358
clinical history, 357
examination, 357
investigations, 357-358
questions and answers, 389, 406
medications, 358</p>
<p>Preoperative care, 357-358
counselling, 357
informed consent, 357
Preoperative preparation, 358
anaemia management, 358
antibiotic prophylaxis, 358
diabetes mellitus management, 358
Preparing to monitor, clinical audit, 365
Prepuce, 4 f
Prescription drugs, pregnancy, 88
Presentation
abruption placentae, 102-103, 102f
anterior arm and leg presentation, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>116</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">116 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">116</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
anterior arm presentation, 116 f
breech see Breech presentation
brow presentation, 188, 188f
face presentation, 75, 187-188, 187 f
fetal palpation, 74-75, 74t, 75f
finding presentation, 229-230, 230b
footling presentation, 112
knee presentation, 112
multiple pregnancy, 109, 110f
occipitoposterior see
Occipitoposterior (OP) presentation
shoulder presentation, 116-117, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>116</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">116 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">116</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
vertex presentation, 75, 158-159
Presenting complaint, history taking, 224
Pressure symptoms, myometrial benign tumours, 237
Preterm delivery, 169-173
complications, 171
delivery methods, 173
genital tract infection, 170
management, 171-173, 172f
prevention, 171
questions and answers, 383, 400
risk factors, 170 f
social factors, 170 b
spontaneous, 169-170
survival, 170, 170f
treatment, 171-173, 171b
Preterm labour, multiple pregnancy, 108, 108 t
Primary dysmenorrhoea, 249
Primary infertility, 265
Primary postpartum haemorrhage, 195-196, 195f-196f
Primary villi, 41
Progesterone
intrauterine contraceptive devices, 294-295, 294f
labour initiation, 156
miscarriage, 278</p>
<p>ovulation, 15-16, 16f
placenta, 47
uterus in pregnancy, 25
Progesterone challenge test, 249
Progesterone-only contraceptive pill, 296-297
Progress assessment, first stage of labour, 163
Prolactin
lactation, 37
ovulation, 16
secondary amenorrhoea, 246
Prolapsed ovaries, 314
Prolonged pregnancy, 89b, 111-112
aetiology, 112
diagnosis, 111-112
labour management, 112
management, 112
questions and answers, 381, 398-399
PROM see Prelabour rupture of the membranes (PROM)
Prostaglandins
erectile dysfunction, 315
labour initiation, 156, 176
miscarriage management, 281
Prostaglandin synthetase inhibitors, 172
Protein
antenatal care, 86
fetal development, 48
placenta, 46-47
Protein hormones, placenta, 47
Proteinuria, 90
Prothrombin time, 31
Psammoma bodies, 333
Pseudocyesis, 67
Psoriasis, 259t
Psychiatric disorders, 207-218
antenatal, 208-209
child safeguarding, 218
communication, 218
maternity services, 218
postnatal see Postnatal psychiatric disorders
preconception counselling, 217
prevalence, 207
questions and answers, 384-385, 402
relevance, 207-208, 207b
screening, 211-212
substance abuse, 218
termination of pregnancy, 304-305
Psychiatric medications
breastfeeding, 215
in pregnancy, 209-211
see also specific types
Psychological symptoms, menopause, 256</p>
<p>Psychosis, postpartum see Postpartum psychosis
PTH (parathyroid hormone), 39
Puberty, 248f, 251-255, 252 f
age of onset, 252
delayed, 254-255, 255t
disorders, 251-259
growth spurt, 252
legal status of, 374
normal development, 251
precocious see Precocious puberty
timing of, 252
variations, 254
Pubic hair, 3
Pubic symphysis, 71f, 342 f
labour, 158
Pubis, 3, 4f
Pubococcygeus muscle, 342 f
Puborectalis muscle, 10, 342 f
Pubourethral ligaments, 342
Pubovesicocervical fascia, 342-343
Pudendal nerves, 9-10
blockade, 165, 165 f
Pudendal vessels, 10 f
Puerperal infections, 201, 201f
Puerperal psychosis see Postpartum psychosis
Pulmonary embolism (PE), 128
Punch biopsy, vulval pruritus, 260
Pyelonephritis, acute, 127-128
Pyrexia, postoperative complications, 361
Pyrimethamine, malaria, 126</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="q">Q<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#q" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Quadruple test, 146</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="r-mathbf-r-r"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold">R</mi></mrow><annotation encoding="application/x-tex">\mathbf{R}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6861em;"></span><span class="mord mathbf">R</span></span></span></span></span><span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#r-mathbf-r-r" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Radical hysterectomy, 327, 328f
Radiotherapy
adjuvant, 330
cervical cancer treatment, 327
endometrial carcinoma, 330
Raised intra-abdominal pressure, uterovaginal prolapse, 346
Ranitidine, 289
Rapid plasma reagin (RPR) test, 83-84
RAS (renin-angiotensin system), 39
RBF (renal blood flow), 33
RDS (respiratory distress syndrome), 171, 172 f
Rectocele, 345
Rectovaginal fistulas, 350
Rectum, 5 f
examination, 229
Recurrent miscarriage, 280, 282
Red blood cell count, 122t</p>
<p>Regional anaesthesia, 358
Regional analgesia, 164-166, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>164</mn><mi mathvariant="normal">f</mi><mo>−</mo><mn>165</mn><mi mathvariant="normal">f</mi></mrow><annotation encoding="application/x-tex">164 \mathrm{f}-165 \mathrm{f}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord">164</span><span class="mord mathrm" style="margin-right: 0.07778em;">f</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">165</span><span class="mord mathrm" style="margin-right: 0.07778em;">f</span></span></span></span></span>
Registration of births and deaths, 364
Remifentanil, 164
Renal blood flow (RBF), 33
Renal calculi, 131
Renal cortical necrosis, abruption placentae, 104
Renal disease, 130-131, 130t
disease implications, 130
pregnancy implications, 130
see also specific diseases/disorders
Renal function, 33-34, 33f
questions and answers, 378, 395
Renal lesions, pre-eclampsia, 92, 92f
Renal system, fetal development, 50
Renal tubular function, 34
Renal tubular necrosis, 104
Renin-angiotensin system (RAS), 39
Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom in the Triennium 2006-2008, 60
Reproductive health, 291-315
questions and answers, 387-388, 404-405
Research, 366-367
analytical studies, 367
descriptive studies, 366-367
questions and answers, 390, 406-407
Resolution phase, coitus, 21
Respiration, 32-33, 32f
questions and answers, 394, 402
Respiratory disorders, 137-138
postoperative complications, 362
see also specific diseases/disorders
Respiratory distress syndrome (RDS), 171, 172 f
Respiratory rate, 32
Respiratory system, fetal development, 50
Restitution, labour mechanism, 159
Retrocele management, 347
Retrograde ejaculation, 272
Retroverted uterus, deep dyspareunia, 314
Rhythm method of contraception, 300
Ridge pessary, uterovaginal prolapse, 346
Right mento-anterior (RMA) position, 76 f
Right mentoposterior (RMP) position, 76 f
Right occipito-anterior (ROA) position, 76 f</p>
<p>Right occipitoposterior (ROP) position, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>76</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">76 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">76</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
Right occipitotransverse (ROT) position, 76 f
Risk management, 368
RMA (right mento-anterior) position, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>76</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">76 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">76</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
RMP (right mentoposterior) position, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>76</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">76 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">76</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
ROA (right occipito-anterior) position, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>76</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">76 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">76</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
ROP (right occipitoposterior) position, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>76</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">76 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">76</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
Rotational instrumental delivery, 191
ROT (right occipitotransverse) position, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>76</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">76 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">76</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
Round ligaments, 7f, 343
uterus, 6
RPR (rapid plasma reagin) test, 83-84
Rubella screening, 83
Rupture, ovarian lesions, 239, 331</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="s">S<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#s" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Sacral ala, 4 f
Sacral lymph node, 8 f
Sacral promontory, 4 f
Sacrocolpopexy, 348
Sacroiliac joint, 4 f
Sacroiliac ligament, 158
Sacrospinous muscle, 342 f
Sacrotuberous ligament, 342 f
Sacrum, 3, 4f-5f
Salpingectomy, 286
Salpingitis
acute, 311 f
female infertility, 267
Salpingolysis, 273
Salpingotomy, 286
SBR see Stillbirth rate (SBR)
SCC see Squamous cell carcinoma (SCC)
Schiller's test, 323-324
SCSA (sperm chromatin structure assay), 271
Secondary amenorrhoea, 245-249
aetiology, 245-248, 246f
cryptomenorrhoea, 248
hirsutism, 249
history taking, 66
hypothalamic disorders, 246
investigations, 248-249
management, 249
ovarian disorders, 247-248
pathology, 246, 246f
pituitary disorders, 233b, 246-247
uterine causes, 248
Secondary (acquired) dysmenorrhoea, 249-250
Secondary infertility, 265
Secondary oligomenorrhoea, 245-249
see also Secondary amenorrhoea
Secondary postpartum haemorrhage, 195-196
Second stage of labour see Labour
Selective oestrogen receptor modulators (SERMs), 258
Selective serotonin reuptake inhibitors (SSRIs), 210
breastfeeding, 215
premenstrual syndrome, 251
questions and answers, 384-385, 402
Seminal plasma, 19
Septic pelvic thrombophlebitis, 361-362
SERMs (selective oestrogen receptor modulators), 258
Serotonin-norepinephrine reuptake inhibitors (SNRIs), 210
premenstrual syndrome, 251
Serous cystadenomas, 333, 335
Sertoli-Leydig cell tumours, 336
Severe postnatal depression, 213-214, 214b
Sex-cord stromal tumours, 336
Sex-hormone binding globulin (SHBG), 39
Sex-linked diseases, amniocentesis, 53
Sexual function disorders, male, 315
Sexual health, 291-315
questions and answers, 387-388, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>404</mn><mo>−</mo><mn>405</mn></mrow><annotation encoding="application/x-tex">404-405</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">404</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">405</span></span></span></span></span>
Sexual history, 306b
history taking, 224
Sexually-transmitted infections (STIs)
barrier contraception, 291
questions and answers, 381, 388
see also specific infections
SHBG (sex-hormone binding globulin), 39
Shelf pessary, 347, 347f
Shoulder delivery, labour mechanism, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>159</mn><mo>−</mo><mn>160</mn></mrow><annotation encoding="application/x-tex">159-160</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">159</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">160</span></span></span></span></span>
Shoulder dystonia, 184b, 193-194, 194f
Shoulder presentation, 116-117, 116f
Sickle cell syndromes, 138-139
Sildenafil (Viagra), 315
Simple diffusion, placental transfer, 44
Sims speculum, 385, 403
Skeleton examination, 69-70
Skene's ducts, 4</p>
<p>Skin
changes in pregnancy, 37
post-menopause, 256
SLE (systemic lupus erythematosus), 138
Smoking, 80, 81f
perinatal death, 57-58
SNRIs see Serotonin-norepinephrine reuptake inhibitors (SNRIs)
Social awareness, 88
Social history, 225
Sodium, placental transfer, 45
Sodium valproate, 135, 211
Solifenacin, 353t
Somatic innervation, pelvic anatomy, 9
SPD (symphyseal pelvis dysfunction), 121
Speculum examination, 70, 227, 227 f
Sperm
concentration, 271
DNA analysis, 271-272
male infertility, 271-272
morphology, 271
motility, 271
transport in fertilization, 19
Spermatogenesis, 18, 18f
Spermatozoon, 18, 19f
Sperm chromatin structure assay (SCSA), 271
Spermicides, 294
Spina bifida, 142 f
Spinal anaesthesia, 165
Sponges, contraception, 294
Spontaneous second trimester loss, 280
Squamous cell carcinoma (SCC)
cervix, 388, 405
vagina, 321
vulva, 318 f
SSRIs see Selective serotonin reuptake inhibitors (SSRIs)
Station, fetal palpation, 75
Stem villus, 42
Sterilization, 301-303
counselling, 301
female, 301-303
psychological implications, 303
techniques, 301-303
timing of, 301
Steroids, 94
placenta, 47-48
Stillbirth
causes, 58, 58f
definition, 55-56
intrapartum, 58
questions and answers, 379, 396</p>
<p>Stillbirth rate (SBR), 56, 56t
UK, 57 f
STIs see Sexually-transmitted infections (STIs)
Stress incontinence, 349
management, 352-353, 352f
questions and answers, 388, 405
Stretch marks, 37, 69, 69f
Striae gravidarum, 37, 69, 69f
Stroke volume, 28f, 28t, 29
Stromal sarcomas, uterus, 330-331
Subseptate uterus, miscarriage, 278f
Substance abuse, 80-81
maternal death, 216
psychiatric disorders, 212, 218
Suckling, lactation, 37
Suction curettage, trophoblastic disease management, 287
Suicide, maternal death, 215-216
Superficial dyspareunia, 313
Superficial inguinal lymph node, 8 f
Superficial inguinal node, 8
Superficial transverse perineal muscle, 10 f
Superficial vaginal wall haematomas, 197
Superimposed eclampsia, 90
Superimposed pre-eclampsia, 90
Superior vesical artery, 7 f
Supine hypotension syndrome, 30
Surgery
cervical cancer treatment, 327
combined oral contraceptive pill, 299
ectopic pregnancy management, 286
endometriosis management, 241
miscarriage management, 281, 281f
uterovaginal prolapse management, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>347</mn><mo>−</mo><mn>348</mn></mrow><annotation encoding="application/x-tex">347-348</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">347</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">348</span></span></span></span></span>
see also specific surgical techniques
Symphyseal pelvis dysfunction (SPD), 121
Symphysial-fundus height, abdominal palpation, 73, 73b, 73f
Symphysis, 5 f
Symphysis pubis, 4 f
Syncope, 121
Syncytiotrophoblasts, stem villus, 42
Syngamy, implantation, 19
Syntocinon infusion, labour induction, 176
Syphilis, 308
screening, 83-84
treatment, 309
Systemic lupus erythematosus (SLE), 138
Systolic blood pressure, 28t</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="t">T<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#t" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Tamoxifen, endometrial carcinoma, 328
TCAs see Tricyclic antidepressants (TCAs)
Teenage pregnancy, 82
TENS (transcutaneous electrical nerve stimulation), 164
Tension-free vaginal tape (TVT), 352
Teratomas, ovarian malignancies, 336
Termination of pregnancy, 303-305
complications, 304
contraception following, 305
criminal abortion, 305
indications, 304b
late termination, 305
legislation, 373
medical methods, 304
methods, 304
psychological problems, 304-305
risk factor, 305
surgical methods, 304
Testicular biopsy, male infertility, 272
Thalassaemias, 139
Theca lutein cysts, ovaries, 333
Thelarche, 252
premature, 254
Third stage of labour see Labour
Thoracic duct, 8 f
Threatened miscarriage, 279, 279f
Thromboembolic disease, 128-129
Thromboembolism
maternal postpartum collapse, 204
postpartum complications, 202-203
Thrombophilia, 134-135
Thrombophilic defects, miscarriage, 279
Thrombophlebitis, postpartum complications, 202
Thymus, 24
Thyroid disease, 132-133
hyperthyroidism, 133
hypothyroidism, 132-133
see also specific diseases/disorders
Thyroid gland, 38-39, 39f
enlargement, 69
Thyroxine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub><mo fence="true">)</mo></mrow><mo separator="true">,</mo><mn>38</mn><mo>−</mo><mn>39</mn></mrow><annotation encoding="application/x-tex">\left(\mathrm{T}_{4}\right), 38-39</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">38</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">39</span></span></span></span></span>
Tibolone, 258
Timed voiding, overactive bladder syndrome, 354
Tolterodine, 353 t
Topical haemostasis, haemorrhage management, 359
Topical hormone replacement therapy, 258
Torsion, ovarian lesions, 239, 331</p>
<p>Total hysterectomy and bilateral salpingo-oophorectomy, 330
Total peripheral resistance, 28t, 29
Toxins, male infertility, 271
Toxoplasma gondii infection, 278
TPHA (Treponema pallidum haemagglutination) test, 84
Transcutaneous electrical nerve stimulation (TENS), 164
Transdermal hormonal contraception, 300
Transferase mediated dUTP neck cord labeling (TUNEL), 271
Transurethral injections, stress incontinence management, 353
Transvaginal ultrasound
endometrial carcinoma, 329-330
endometrial polyps, 235, 235f
heavy menstrual bleeding, 243
ovarian malignancy screening, 338
Transverse lie, 116-117
labour, 158-159
Trends in Maternal Mortality 1990-2008, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>59</mn><mo>−</mo><mn>60</mn></mrow><annotation encoding="application/x-tex">59-60</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">59</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">60</span></span></span></span></span>
Treponema pallidum haemagglutination (TPHA) test, 84
Treponema pallidum immobilization antibody (FIA) test, 84
Treponema pallidum infections see Syphilis
Trichomoniasis, 307, 307f
treatment, 309
Tricyclic antidepressants (TCAs), 209-210
breastfeeding, 215
combined oral contraceptive pill interactions, 299 t
Tri-iodothyronine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub><mo fence="true">)</mo></mrow><mo separator="true">,</mo><mn>38</mn><mo>−</mo><mn>39</mn></mrow><annotation encoding="application/x-tex">\left(\mathrm{T}_{3}\right), 38-39</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">38</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">39</span></span></span></span></span>
Trisomy 21, 143, 143f
age risk, 144 t
karyotype, 144 f
screening, 85
questions and answers, 382, 399
Trophoblast cells, ectopic pregnancy pathology, 285
Trophoblastic disease, 286-287, 288b
clinical presentation, 287
incidence, 286
management, 287
pathology, 287
Trophoblasts, early placental development, 41
True pelvis, 3
True urinary incontinence, 349
TTTS (twin-to-twin transfusion syndrome), 108
Tubal clips, laparoscopic sterilization, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>301</mn><mo>−</mo><mn>302</mn><mo separator="true">,</mo><mn>302</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">301-302,302 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">301</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">302</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">302</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span></p>
<p>Tubal coagulation, laparoscopic sterilization, 302
Tubal ectopic pregnancy, upper genital tract infection <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>v</mi><mi>s</mi><mi mathvariant="normal">.</mi><mo separator="true">,</mo><mn>311</mn></mrow><annotation encoding="application/x-tex">v s ., 311</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.03588em;">v</span><span class="mord mathnormal">s</span><span class="mord">.</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">311</span></span></span></span></span>
Tubal factors, female infertility, 267-268, 267f
Tubal ligation, laparoscopic sterilization, 302, 302f
Tubal pathology, female infertility treatment, 273
Tuberculosis, 127
TUNEL (transferase mediated dUTP neck cord labeling), 271
TVT (tension-free vaginal tape), 352
Twin-to-twin transfusion syndrome (TTTS), 108</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="u">U<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#u" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>UAEs (uterine artery embolization), 237
Ultrasound
abruptio placentae, 103
anovulation treatment, 272
ectopic pregnancy diagnosis, 284, 285f, 285t
fetal assessment, 143-146
ovulation detection, 268
placenta praevia diagnosis, 100
transvaginal see Transvaginal ultrasound
Umbilical artery Doppler blood flow, 150, 150 f
Umbilical cord, 43, 43f
compression, 113
questions and answers, 379, 395
Unclassified hypertension, 90
Unconjugated oestriol, 146
Unstable lie, 116-117
complications, 116
management, 116-117, 117b
questions and answers, 381, 398
Upper genital tract infections, 309-312
differential diagnosis, 311
investigations, 311
management, 312
organisms, 310-311
see also specific organisms
secondary, 309-310
surgery indications, 312
symptoms and signs, 310
Urea, placenta, 47
Ureter, 7 f
anatomy, 349
injury, 359-360
Ureteral lymph node, 8 f
Urethra, 5 f
anatomy, 349</p>
<p>Urethral orifice, 4 f
Urethral pressure profile, urinary incontinence, 352
Urethrocele, 344
Urge incontinence, 349
Urinary bladder, 5f, 7f
anatomy, 348
function disorders, 349-350
innervation, 348
postoperative care, 360-361
trauma, 359-360
Urinary frequency, 350
Urinary incontinence, 349
diagnosis, 350-352
management, 352-353
stress see Stress incontinence
true, 349
see also specific types
Urinary pregnancy tests, 285b
Urinary retention, 350
questions and answers, 389, 405
Urinary tract
anatomy, 348-349
fistulae management, 352
physiology, 348-349
Urinary tract disorders, 348-355
questions and answers, 389, 406
see also specific diseases/disorders
Urinary tract infections (UTIs), <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>127</mn><mo>−</mo><mn>128</mn></mrow><annotation encoding="application/x-tex">127-128</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">127</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">128</span></span></span></span></span>
postpartum complications, 201-202
screening, 84
upper genital tract infection <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>v</mi><mi>s</mi><mi mathvariant="normal">.</mi><mo separator="true">,</mo><mn>311</mn></mrow><annotation encoding="application/x-tex">v s ., 311</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.03588em;">v</span><span class="mord mathnormal">s</span><span class="mord">.</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">311</span></span></span></span></span>
uterine prolapse, 345
Uroflowmetry, 350
Urogenital tract, menopause, 256
Urterovaginal fistula, 350
Uterine artery, 7f, 8
Uterine artery embolization (UAE), 237
Uterine diseases/disorders, 233-235
abnormal bleeding see Abnormal uterine bleeding (AUB)
diagnosis, 234
female infertility, 268
hyperstimulation, precipitate labour, 177
inversion, 197
malignant disease, 328-331
endometrial carcinoma see Endometrial carcinoma
malignant mesenchymal tumours, 330-331
management, 234
perforation, intrauterine contraceptive devices, 295
prolapse see Uterine prolapse
secondary amenorrhoea, 248
surgery, 234-235
symptoms and signs, 233-234
Uterine fibroids (myomas), 236, 236f
Uterine fundus, abdominal palpation, 73
Uterine prolapse
definitions, 343, 345
history taking, 224
Uteroplacental blood flow, 43-44, 43f
Uterosacral ligament, 343
questions and answers, 381, 388
uterus, 6
Uterovaginal prolapse, 341-348
complications, 348
definitions, 343
management, 346-348
conservative management, 346-347
surgery, 347-348
pathogenesis, 346
prevention, 346
questions and answers, 388-389, 405
staging/grading, 345
symptoms and signs, 343-345, 344t
Uterus, 5-6, 5f
activity in labour, 157-158, 157f-158f
anatomy, 233, 234f
changes in pregnancy, 24-27
blood vessels, 25
contractility, 27
corpus uteri, 25-27, 26f
isthmus, 25
muscle decussation, 24, 24f
myometrial activity development, 27, 27 f
nerve supply, 26-27
diseases/disorders see Uterine diseases/disorders; specific diseases/disorders
endometrial cavity, 5
isthmus, 6
postpartum changes, 199, 200f
questions and answers, 377, 393
supports and ligaments, 6
Uterus bicornis unicollis, 234, 234f
UTIs see Urinary tract infections (UTIs)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="v">V<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Vagina, 5, 10f, 342 f
adenosis, 261, 320-321
benign tumours, 260-261
bleeding
fetal abnormalities, 145
heavy, 262
candidiasis, 307
changes in pregnancy, 28</p>
<p>cysts, 261
congenital, 261
discharge, 260, 260 t
history taking, 224
intrauterine contraceptive devices, 296
epithelium, neoplastic lesions, 261, 319-321
see also specific diseases/disorders
examination see Vaginal examination
fascial supports, 341
inclusion cysts, 261
infections, 105
ligaments, 341, 342f
malignancy, 321
orifice, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo separator="true">,</mo><mn>5</mn><mi>f</mi></mrow><annotation encoding="application/x-tex">4,5 f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span>
prolapse, 343 f
definitions, 343
history taking, 224
questions and answers, 377, 393
solid benign tumours, 261
swabs, 228b
trauma, 262
Vaginal contraceptive ring, 300
Vaginal delivery, 183, 184b, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>184</mn><mi mathvariant="normal">f</mi><mo>−</mo><mn>185</mn><mi mathvariant="normal">f</mi></mrow><annotation encoding="application/x-tex">184 \mathrm{f}-185 \mathrm{f}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord">184</span><span class="mord mathrm" style="margin-right: 0.07778em;">f</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">185</span><span class="mord mathrm" style="margin-right: 0.07778em;">f</span></span></span></span></span>
breech presentation, 114, 115f
Caesarean section, 115-116
episiotomy repair, 185-187, 186b
questions and answers, 383, 401
head malposition, 188-189
see also specific positions
malpresentation see Malpresentation
multiple pregnancy, 109-110
perineal injury repair, 185-187
fourth degree, 186-187
questions and answers, 383, 401
third degree, 186-187
positions, 183
questions and answers, 383-384, 401, 407
Vaginal examination
bimanual see Bimanual vaginal examination
labour, 161
questions and answers, 380, 385
Vaginal hysterectomy, 245
Vaginal intraepithelial neoplasia (VAIN), 261, 319-320
Vaginal oestrogen, overactive bladder syndrome, 354</p>
<p>Vaginal walls
examination, 70
haematomas, 197
deep, 197
post-menopause, 256
prolapse, 227, 227 f
Vaginismus, 314
Vaginosis, bacterial, 308, 308f
VAIN (vaginal intraepithelial neoplasia), 261, 319-320
Variable deceleration, fetal heart rate, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>168</mn><mo>−</mo><mn>169</mn></mrow><annotation encoding="application/x-tex">168-169</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">168</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">169</span></span></span></span></span>
Varicella pneumonia, 125
Varicosities, 121
Vasa praevia, 104
Vascular disturbances, menopause, 256
Vasectomy, 303
VDRL (venereal disease research laboratory test), 83-84
Venereal disease research laboratory test (VDRL), 83-84
Venous thromboembolism (VTE), 128
contraceptive pill side effects, 297
postoperative complications, 362
questions and answers, 381-382, 389, 399, 406
Vertex presentation, 75, 158-159
Vertical transmission
HIV infection, 126
viral hepatitis, 127
Very low density lipoproteins (VLDL), 35
Vesical neck, 342 f
Vesicovaginal fistula, urinary incontinence, 350
Vestibule, 4
Viagra, 315
VIN see Vulval intraepithelial neoplasia (VIN)
Viral hepatitis, acute, 126-128
Viral load, HIV infection, 126
Visceral trauma, breech presentation, 113
Vision, fetal development, 51
Vital capacity, 32
Vitamin(s), antenatal care, 87
Vitamin A supplements, 87
Vitamin B supplements, 87
Vitamin C supplements, 87
Vitamin D supplements, 87</p>
<p>Vitamin supplementation, 80
nausea and vomiting, 289
VLDL (very low density lipoproteins), 35
Vomiting see Nausea and vomiting
VTE see Venous thromboembolism (VTE)
Vulva
benign tumours, 260-261
examination, 70
neoplasia, 260
questions and answers, 388, 405
oncology, 317-319
malignant melanoma, 318-319
squamous cell carcinoma, 318 f
treatment, 319, 320f
see also specific diseases/disorders
pruritus, 259-260, 259t
trauma, 262
Vulval intraepithelial neoplasia (VIN), 317-318
biopsy, 318
classification, 317, 317b
Vulvodynia, superficial dyspareunia, 313</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="w">W<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#w" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Warfarin
congenital abnormalities, 144
thromboembolic disease, 128-129
Wasserman reaction, 83-84
Water births, 166
Water, placental transfer, 45
Water retention
changes in pregnancy, 33
maternal weight gain, 36
Weight gain during pregnancy, 73
White blood cells
changes in pregnancy, 30-31, 31f
ectopic pregnancy diagnosis, 284
World Health Organisation (WHO), 55
Wound cellulitis treatment, 361</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="y">Y<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#y" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Yolk sac tumours, 336</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="z">Z<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#z" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Zona pellucida, 15
Zoster immunoglobulin, 125</p>
<p>This page intentionally left blank</p>
<section data-footnotes="true" class="footnotes"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 class="sr-only" level="2" id="footnotes">Footnotes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#footnotes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li id="user-content-fn-0">
<p>1 Overly rapid rehydration with 5% dextrose can results in water intoxication or central pontine myelinosis. <a href="#user-content-fnref-0" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩</a> <a href="#user-content-fnref-0-2" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>2</sup></a></p>
</li>
</ol>
</section></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>